NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF ISOBUTENE

(CAS NO. 115-11-7)

IN F344/N RATS AND B6C3F1 MICE

(INHALATION STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

December 1998

NTP TR 487

NIH Publication No. 99-3977

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. The interpretive conclusions presented in this Technical Report are based only on the results of these NTP studies. Extrapolation of these results to other species and quantitative risk analyses for humans require wider analyses beyond the purview of these studies. Selection *per se* is not an indicator of a chemical's carcinogenic potential.

Listings of all published NTP reports and ongoing studies are available from NTP Central Data Management, NIEHS, P.O. Box 12233, MD E1-02, Research Triangle Park, NC 27709 (919-541-3419). The Abstracts and other study information for 2-year studies are also available at the NTP's World Wide Web site: http://ntp-server.niehs.nih.gov.

NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF ISOBUTENE

(CAS NO. 115-11-7)

IN F344/N RATS AND B6C3F1 MICE

(INHALATION STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

December 1998

NTP TR 487

NIH Publication No. 99-3977

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

CONTRIBUTORS

National Toxicology Program

Evaluated and interpreted results and reported findings

J.H. Roycroft, Ph.D., Study Scientist D.A. Bridge, B.S. J.R. Bucher, Ph.D. R.E. Chapin, Ph.D. J.R. Hailey, D.V.M. J.K. Haseman, Ph.D. R.A. Herbert, D.V.M., Ph.D. R.R. Maronpot, D.V.M. G.N. Rao, D.V.M., Ph.D. C.S. Smith, Ph.D. G.S. Travlos, D.V.M. D.B. Walters, Ph.D. K.L. Witt, M.S., Integrated Laboratory Systems

Battelle Pacific Northwest Laboratory

Conducted studies, evaluated pathology findings for 14-week and 2-year studies in rats and mice

B.J. Chou, D.V.M., Ph.D., Principal Investigator
J.A. Dill, Ph.D.
S.L. Grumbein, D.V.M., Ph.D.
R.A. Miller, D.V.M., Ph.D.
E.W. Morgan, D.V.M.
H.A. Ragan, D.V.M.
R.A. Renne, D.V.M.
S.E. Rowe, D.V.M., M.S.
R.B. Westerberg, Ph.D.

Experimental Pathology Laboratories, Inc.

Provided pathology quality assurance

J.F. Hardisty, D.V.M., Principal Investigator C.C. Shackelford, D.V.M., M.S., Ph.D.

Dynamac Corporation

Prepared quality assurance audits

S. Brecher, Ph.D., Principal Investigator

NTP Pathology Working Group

Evaluated slides, prepared pathology report on rats (20 March 1997)

- P.K. Hildebrandt, D.V.M., Chairperson PATHCO, Inc.
- S. Ching, D.V.M., Ph.D. Glaxo-Wellcome
- J. Dillberger, D.V.M., Ph.D., Observer Glaxo-Wellcome
- J.R. Hailey, D.V.M. National Toxicology Program
- R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
- J.R. Leininger, D.V.M., Ph.D. National Toxicology Program
- J. Nold, D.V.M., Ph.D., Observer Pathology Associates International
- C.C. Shackelford, D.V.M., M.S., Ph.D. Experimental Pathology Laboratories, Inc.

Evaluated slides, prepared pathology report on mice (8 April 1997)

- D.G. Goodman, V.M.D., Chairperson PATHCO, Inc.
- J. Everitt, D.V.M. Chemistry Industry Institute of Toxicology
- V. Geiss, D.V.M., Observer National Toxicology Program
- J.R. Hailey, D.V.M. National Toxicology Program
- R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
- J.R. Leininger, D.V.M., Ph.D. National Toxicology Program
- A. Radovsky, D.V.M., Ph.D. National Toxicology Program
- C.C. Shackelford, D.V.M., M.S., Ph.D. Experimental Pathology Laboratories, Inc.

Analytical Sciences, Inc.

Provided statistical analyses

R.W. Morris, M.S., Principal Investigator S.R. Lloyd, M.S. N.G. Mintz, B.S.

Biotechnical Services, Inc.


Prepared Technical Report

S.R. Gunnels, M.A., Principal Investigator L.M. Harper, B.S. A.M. Macri-Hanson, M.A., M.F.A.

CONTENTS

ABSTRACT .	• • • • • • • • • • • • • • • • • • • •	5
EXPLANATION	N OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	8
TECHNICAL R	EPORTS REVIEW SUBCOMMITTEE	9
SUMMARY OF	TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS	10
INTRODUCTIO	DN	11
MATERIALS A	ND METHODS	17
RESULTS		29
DISCUSSION A	ND CONCLUSIONS	51
REFERENCES		53
Appendix A	Summary of Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene \ldots .	59
Appendix B	Summary of Lesions in Female Rats in the 2-Year Inhalation Study of Isobutene \ldots	95
Appendix C	Summary of Lesions in Male Mice in the 2-Year Inhalation Study of Isobutene \ldots	125
Appendix D	Summary of Lesions in Female Mice in the 2-Year Inhalation Study of Isobutene \ldots	153
Appendix E	Genetic Toxicology	187
Appendix F	Hematology and Clinical Chemistry Results	193
Appendix G	Organ Weights and Organ-Weight-to-Body-Weight Ratios	199
Appendix H	Reproductive Tissue Evaluations and Estrous Cycle Characterization	203
Appendix I	2-Hydroxyisobutyric Acid — Biomarker of Exposure	207
Appendix J	Chemical Characterization and Generation of Chamber Concentrations	211
Appendix K	Ingredients, Nutrient Composition, and Contaminant Levels in NIH-07 Rat and Mouse Ration	223
Appendix L	Sentinel Animal Program	227

ABSTRACT



ISOBUTENE

CAS No. 115-11-7

Chemical Formula: C₄H₈ Molecular Weight: 56.10

Synonyms: γ-butylene, isobutylene, liquified petroleum gas, 2-methylpropene

Isobutene is produced during the fractionation of refinery gases or through the catalytic cracking of methyl-t-butyl ether. Isobutene is primarily used to produce diisobutylene, trimers, butyl rubber, and other polymers. In addition, it is used in the production of isooctane, high-octane aviation gasoline, methyl-t-butyl ether, and copolymer resins with butadiene and acrylonitrile. Isobutene was selected for evaluation because of the potential for human exposure due to its large production volume and the lack of adequate data on its carcinogenic potential. The toxicity and carcinogenicity of isobutene were determined in male and female F344/N rats and B6C3F₁ mice exposed to isobutene (greater than 98% pure) by inhalation for 14 weeks or 2 years. The mutagenicity of isobutene was assessed in Salmonella typhimurium, and the frequency of micronuclei was determined in the peripheral blood of mice exposed by inhalation for 14 weeks.

14-WEEK STUDIES

Groups of 10 male and 10 female F344/N rats and B6C3F₁ mice were exposed to isobutene at concentrations of 0, 500, 1,000, 2,000, 4,000, or 8,000 ppm 6 hours per day, 5 days per week, for 14 weeks. Concentrations greater than 8,000 ppm isobutene were not used because of the danger of explosion. All rats and mice survived to the end of the study. The final

mean body weights and body weight gains of all exposed groups were similar to those of the chamber controls. No exposure-related gross lesions were observed in male or female rats or mice at necropsy. Microscopically, minimal hypertrophy of goblet cells lining the nasopharyngeal duct in the most caudal nose section was observed in some rats in each exposed group of males and females.

2-YEAR STUDIES

Based on the lack of significant exposure-related toxicologic effects in the 14-week rat and mouse studies, 8,000 ppm was selected as the highest exposure concentration in the 2-year studies. Concentrations of 0, 500, 2,000, and 8,000 ppm were selected for rats and mice with the 500 and 2,000 ppm selection based on published metabolic elimination rates for Sprague-Dawley rats and B6C3F₁ mice.

Rats

Groups of 50 male and 50 female F344/N rats were exposed to isobutene at concentrations of 0, 500, 2,000, or 8,000 ppm 6 hours per day, 5 days per week, for 105 weeks. Survival of exposed males and females was similar to that of the chamber controls. Mean body weights of exposed groups were generally similar to those of the chamber controls throughout the study.

2-Hydroxyisobutyric acid (HIBA), the major urinary metabolite of isobutene, was measured in the urine of male and female rats as an indicator of isobutene exposure at 6, 12, and 18 months. The amount of HIBA excreted increased with increasing exposure concentration. However, when HIBA concentration was normalized to isobutene exposure concentration, the relative amount of HIBA excreted decreased with increasing exposure concentration, implying nonlinear kinetics.

Pathology Findings

The incidence of thyroid gland follicular cell carcinoma in male rats exposed to 8,000 ppm was increased compared to the chamber control group and exceeded the historical control range. The incidences of hyaline degeneration of the olfactory epithelium were marginally increased in exposed rats; however, the severities of hyaline degeneration increased with increasing exposure concentration in males and females.

Mice

Groups of 50 male and 50 female $B6C3F_1$ mice were exposed to isobutene at concentrations of 0, 500, 2,000, or 8,000 ppm 6 hours per day, 5 days per week, for 105 weeks. Survival of exposed males and females was similar to that of the chamber controls. Mean body weights of exposed mice were generally similar to those of the chamber controls throughout the study except for female mice exposed to 2,000 or 8,000 ppm, which weighed slightly less than chamber controls from about week 52 until week 92.

2-Hydroxyisobutyric Acid — Biomarker of Exposure

HIBA was measured in the urine of male and female mice as an indicator of isobutene exposure at 6, 12, and 18 months. The amount of HIBA excreted However, when HIBA concentration was normalized to isobutene exposure concentration, the relative amount of HIBA excreted decreased with increasing exposure concentration, implying nonlinear kinetics.

Pathology Findings

The incidences of hyaline degeneration of the respiratory epithelium in all groups of exposed males and females were significantly greater than those in the chamber control groups. The incidences of hyaline degeneration of the olfactory epithelium in 2,000 and 8,000 ppm mice were greater than those in the chamber controls.

GENETIC TOXICOLOGY

Isobutene was not mutagenic in any of four strains of *S. typhimurium*, with or without S9 metabolic activation, and no increase in the frequency of micro-nucleated erythrocytes was seen in peripheral blood of male or female mice treated with isobutene by inhalation for 14 weeks.

CONCLUSIONS

Under the conditions of these 2-year inhalation studies, there was *some evidence of carcinogenic activity*^{*} of isobutene in male F344/N rats based on an increased incidence of follicular cell carcinoma of the thyroid gland. There was *no evidence of carcinogenic activity* of isobutene in female F344/N rats or male or female B6C3F₁ mice exposed to 500, 2,000, or 8,000 ppm.

Exposure to isobutene by inhalation for 2 years resulted in increased incidences and/or severities of nasal lesions including hyaline degeneration of the olfactory epithelium in male and female rats and mice and hyaline degeneration of the respiratory epithelium in male and female mice.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 8. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 10.

	Male F344/N Rats	Female F344/N Rats	Male B6C3F ₁ Mice	Female B6C3F ₁ Mice	
Concentrations in air 0, 500, 2,000, or 8,000 ppm 0, 500, 2,000, or 8,000 ppm		0, 500, 2,000, or 8,000 ppm	0, 500, 2,000, or 8,000 ppm		
Body weights	Exposed groups similar to chamber control group	Exposed groups similar to chamber control group	Exposed groups similar to chamber control group	2,000 and 8,000 ppm groups slightly less than chamber control group	
Survival rates	7/50, 5/50, 6/50, 8/50	23/50, 19/50, 33/50, 22/50	28/50, 32/50, 27/50, 28/50	32/50, 31/50, 39/50, 33/50	
Nonneoplastic effects Nose: severity of ol- epithelial hyaline degeneration (1.3, 1. 2.6)		Nose: severity of olfactory epithelial hyaline degeneration (1.5, 2.4, 2.8, 2.8)	<u>Nose</u> : respiratory epithelial hyaline degeneration (6/50, 19/49, 29/50, 39/48); olfactory epithelial hyaline degeneration (6/50, 7/49, 16/50, 17/48)	Nose: respiratory epithelial hyaline degeneration (21/47, 39/50, 41/49, 48/50); olfactory epithelial hyaline degeneration (17/47, 19/50, 24/49, 27/50)	
Neoplastic effects	Thyroid gland: follicular cell carcinoma (1/48, 0/48, 0/48, 5/50)	None	None	None	
Level of Some evidence evidence of carcinogenic activity		No evidence	No evidence	No evidence	
Micronucleated e	<i>murium</i> gene mutations:	Negative in strains TA9 Negative in male and fer	7, TA98, TA100, and TA1535, nale mice	with and without S9	

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Isobutene

EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (**clear evidence** and **some evidence**); one category for uncertain findings (**equivocal evidence**); one category for no observable effects (**no evidence**); and one category for experiments that cannot be evaluated because of major flaws (**inadequate study**). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- **Clear evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- **Some evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- **Equivocal evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemical related.
- No evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
- **Inadequate study** of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- adequacy of the experimental design and conduct;
- occurrence of common versus uncommon neoplasia;
- progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is
 impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to
 assume that benign neoplasms of those types have the potential to become malignant;
- · combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
- latency in tumor induction;
- multiplicity in site-specific neoplasia;
- metastases;
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- presence or absence of dose relationships;
- statistical significance of the observed tumor increase;
- · concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- survival-adjusted analyses and false positive or false negative concerns;
- · structure-activity correlations; and
- in some cases, genetic toxicology.

NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on isobutene on 10 December 1997 are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing the NTP studies:

- · to ascertain that all relevant literature data have been adequately cited and interpreted,
- to determine if the design and conditions of the NTP studies were appropriate,
- · to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- · to judge the significance of the experimental results by scientific criteria, and
- to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

Gary P. Carlson, Ph.D., Chairperson School of Health Sciences Purdue University West Lafayette, IN

- A. John Bailer, Ph.D., Principal Reviewer Department of Mathematics and Statistics Miami University Oxford, OH
- Steven A. Belinsky, Ph.D., Principal Reviewer Inhalation Toxicology Research Institute Kirkland Air Force Base Albuquerque, NM

James S. Bus, Ph.D. Health and Environmental Sciences Dow Chemical Company Midland, MI

Linda A. Chatman, D.V.M. Pfizer, Inc. Groton, CT

Special Reviewers

Stephen S. Hecht, Ph.D. University of Minnesota Cancer Centers Minneapolis, MN

Michele Medinsky, Ph.D., Principal Reviewer Chemical Industry Institute of Toxicology Research Triangle Park, NC John M. Cullen, Ph.D., V.M.D. Department of Microbiology, Parasitology, and Pathology College of Veterinary Medicine North Carolina State University Raleigh, NC

Susan M. Fischer, Ph.D. M.D. Anderson Cancer Center University of Texas Smithville, TX

Thomas L. Goldsworthy, Ph.D. Integrated Laboratory Systems Research Triangle Park, NC

Irma Russo, M.D. Fox Chase Cancer Center Philadelphia, PA

Jose Russo, M.D. Fox Chase Cancer Center Philadelphia, PA

SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS

On 10 December 1997, the draft Technical Report on the toxicology and carcinogenesis studies of isobutene received public review by the National Toxicology Program's Board of Scientific Counselors' Technical Reports Review Subcommittee. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Dr. J.H. Roycroft, NIEHS, introduced the toxicology and carcinogenesis studies of isobutene by discussing the uses of the chemical and the rationale for study, describing the experimental design, reporting on survival and body weight effects, and commenting on compound-related neoplastic and nonneoplastic lesions in rats and mice. The proposed conclusions for the 2-year studies were *some evidence of carcinogenic activity* in male F344/N rats and *no evidence of carcinogenic activity* in female F344/N rats or male or female B6C3F₁ mice.

Dr. Bailer, a principal reviewer, agreed in principle with the proposed conclusions. He said that because there were neoplasms at only one site in the 8,000 ppm group in just one species, he would be comfortable as well with equivocal evidence of carcinogenic activity in male rats. Dr. Bailer said that he would like to see information on typical levels of human exposure for the potentially exposed workers. Dr. Roycroft responded that there were no human exposure data, and only a limited amount of data in the literature provides even a hint of how people might be exposed to isobutene; for example, 1% of gasoline may be isobutene. Dr. G.W. Lucier, NIEHS, reported that the NIEHS/NTP has recently established an interagency agreement with the Centers for Disease Control and Prevention, to provide


information on exposure assessment for chemicals of interest to the NTP, including those evaluated by this Subcommittee.

Dr. Medinsky, the second principal reviewer, agreed with the proposed conclusions. She complimented the NTP for the use of pharmacokinetic data. Dr. Medinsky said it would be useful to include a metabolic scheme for isobutene so that the reader could readily see where the biomarker, 3-hydroxyisobutyric acid, fits in the metabolic fate of isobutene relative to what in fact might be the toxic metabolite for this chemical. Dr. Roycroft said that a metabolic scheme could be included, that the monoepoxide is a putative metabolite, and that a metabolic modeling effort has been started on isobutene to predict some blood concentrations of the epoxide.

Dr. Belinsky, the third principal reviewer, agreed with the proposed conclusions. He thought it interesting that there was no apparent precursor lesion, hyperplasia, for the thyroid gland neoplasms. Dr. R.A. Herbert, NIEHS, commented that hyperplasia can be considered a preneoplastic lesion for thyroid gland neoplasms and that this has been seen in other studies; however, in this study, the incidences of follicular cell hyperplasia were not significantly increased.

Dr. Bailer moved that the Technical Report on isobutene be accepted with the revisions discussed and the conclusions as written for male rats, *some evidence of carcinogenic activity*, and for female rats and male and female mice, *no evidence of carcinogenic activity*. Dr. Medinsky seconded the motion, which was accepted unanimously with eight votes.

INTRODUCTION



ISOBUTENE

CAS No. 115-11-7

Chemical Formula: C₄H₈ Molecular Weight: 56.10

Synonyms: γ-butylene, isobutylene, liquified petroleum gas, 2-methylpropene

CHEMICAL AND PHYSICAL PROPERTIES

Isobutene is a colorless, volatile liquid or easily liquified gas with a coal-gas odor. Isobutene has a melting point of -139° C, a boiling point of -6.9° C, a density of 0.5942, a vapor density of 2.01, and a vapor pressure of 400 mm Hg at 21.6° C. It is insoluble in water but very soluble in alcohol, benzene, ether, and sulfuric acid. Isobutene is highly flammable with a flash point of -76.11° C and an explosion limit range of 1.8% to 9.6%. Isobutene reacts vigorously with oxidizing materials and polymerizes easily (*Material Safety Data Sheet*, 1988; *Merck Index*, 1989; *Sax's*, 1992; *Hawley's*, 1993; *Patty's*, 1994).

PRODUCTION, USE, AND HUMAN EXPOSURE

Isobutene is produced during the fractionation of refinery gases or through the catalytic cracking of methyl-*t*-butyl ether. Isobutene is primarily used to produce diisobutylene, trimers, butyl rubber, and other polymers. In addition, it is used in the production of isooctane, high-octane aviation gasoline, methyl-*t*-butyl ether, and copolymer resins with butadiene and acrylonitrile (*Merck Index*, 1989; *Hawley's*, 1993; *Patty's*, 1994). It was estimated that approximately 1.3 billion pounds of isobutene were produced in the United States in 1992 (HSDB, 1997).

Although isobutene has been detected in urban atmosphere at low concentrations (*Patty's*, 1994), human exposure occurs primarily in the workplace. According to the National Occupational Exposure Survey, approximately 7,000 employees were potentially exposed to isobutene from 1981 until 1983 (NIOSH, 1990). Currently, no occupational exposure limits have been established. Although isobutene is a component of petroleum and natural gas, there are no reports of the detection of this water-insoluble, volatile gas in drinking water or wastewater.

Absorption, Distribution, Metabolism, and Excretion

Frank *et al.* (1980) detected isobutene in exhaled breath of fasted Sprague-Dawley rats given 5 g ethanol/kg body weight intraperitoneally. In addition, using a closed inhalation exposure system with Sprague-Dawley rats, Frank *et al.* (1980) determined that the isobutene elimination half-life (at an initial concentration of 5,000 ppm) was 1.3 hours.

Csanády *et al.* (1991), also using a closed inhalation exposure system, investigated the metabolism and elimination of isobutene over a 5-hour period by male Sprague-Dawley rats and $B6C3F_1$ mice exposed to isobutene concentrations of 100 to 12,000 ppm. The metabolism of isobutene in both species followed Michaelis-Menten kinetics. At concentrations up to


500 ppm isobutene, the metabolic elimination in rats and mice was directly proportional to exposure concentration. Maximum metabolic elimination rates (V_{max}) were determined as 340 µmol/kg per hour for rats and 560 µmol/kg per hour for mice. The atmospheric concentration at which $V_{max}/2$ was reached was 1,200 ppm for rats and 1,800 ppm for mice. The higher V_{max} for mice can be explained by the higher microsomal monooxygenase activity in mice. These investigations also demonstrated that the epoxide 1,1-dimethyloxirane (2-methyl-1,2-epoxypropane) was formed as the primary reactive intermediate during the metabolism of isobutene in rats and was detected in exhaled air of these rats at a maximum concentration of about 0.05 ppm. Under conditions of saturation, the epoxide was only about 7% of that observed for ethene oxide (epoxide of ethene) and about 1% of that observed for 1,2-epoxy-3-butene (epoxide of 1,3-butadiene). In another study, these authors showed that isobutene was metabolized to the epoxide 1,1-dimethyloxirane with mouse liver homogenates (Cornet et al., 1991), and this epoxidation was cytochrome P_{450} dependent. Accumulation of the epoxide was not linear with time and reached a maximum after 20 minutes. This kinetic behavior was explained by the immediate actions of epoxide hydrolase and glutathione-S-transferase converting the epoxide to 2-methyl-1,2-propanediol and to a glutathione conjugate, respectively. These enzymes are the most important epoxide detoxification mechanisms present in liver tissue (Figure 1).

Cornet *et al.* (1995a) compared the biotransformation of isobutene to the epoxide in lung and liver homogenates taken from male Sprague-Dawley rats. Lung homogenates produced less epoxide than liver homogenates (15% to 20%) in the first 30 minutes of incubation, and lung epoxide concentrations at 1 hour were about 40% of those in the liver. Over the course of incubation, lung production of epoxide was relatively constant while that of the liver rose sharply and declined steadily after 30 minutes. The liver cytochrome $P_{450}2E1$ (CYP2E1) content was 25 times that of the lung, and glutathione-S-transferase and epoxide hydrolase activities were about 10 times greater in the liver than the lung. These factors may explain the relatively slow formation and persistence of epoxide

in the lung and the rapid formation and disappearance in the liver.

Henderson et al. (1993) investigated the disposition of isobutene in male Sprague-Dawley rats exposed to 0, 40, 400, or 4,000 ppm isobutene by nose-only inhalation for 2 hours. Blood levels of isobutene were linearly related to exposure concentration between 40 and 400 ppm but increased in a supralinear fashion at the highest concentration, suggesting that in the rat, metabolism of isobutene may become saturated at exposure concentrations between 400 and 4,000 ppm. These investigators also studied the total uptake, excretion patterns, and metabolism of isobutene in rats exposed to 0, 2, 40, 400, or 4,000 ppm [¹⁴C]-isobutene by inhalation for up to 6 hours. Based on the recovered dose of radioactivity, isobutene absorption was linear up to an exposure concentration of 40 ppm with approximately 8% of the inhaled dose being absorbed. However, absorption dropped to approximately 5% at 400 ppm and 2% at 4,000 ppm. The amount of isobutene metabolized was also linear up to an exposure concentration of 40 ppm but decreased at higher concentrations; over 90% of the absorbed isobutene was metabolized at concentrations up to 400 ppm, but at 4,000 ppm, approximately 20% of the absorbed dose was exhaled as unmetabolized isobutene. In addition, rat urinary metabolites of isobutene were identified as isobutenediol and 2-hydroxyisobutyric acid. Two other urinary metabolites were tentatively identified as sulfate conjugates of isobutanediol.

Peter et al. (1987) investigated the inhalation pharmacokinetics of isoprene, which is structurally related to isobutene, in male Wistar rats and male B6C3F₁ mice in closed desiccator jars equipped with an oxygen supply and soda lime for carbon dioxide absorption. Metabolism of isoprene was linear in rats and mice up to an atmospheric concentration of about 300 ppm. Saturation of isoprene metabolism was nearly complete at about 1,000 ppm in rats and at about 2,000 ppm in mice (Peter et al., 1990). The maximal metabolic elimination rate of inhaled isoprene in mice (400 µmol/hr per kg body weight) was about three times greater than that in rats (130 µmol/hr per kg body weight). The half-life of isoprene was 6.8 minutes in rats and 4.4 minutes in mice.



Biotransformation of Isobutene

Cornet *et al.* (1995b) investigated the *in vitro* metabolism of isobutene in human liver as well as livers from rats and mice and showed that all three formed the epoxide 2-methyl-1,2-epoxypropane in liver homogenates. However, there were quantitative differences in epoxide formation with the highest concentrations being found with the mouse tissue,followed by rat (one-half that of the mouse) and human (one-tenth that of the mouse). Conversion of isobutene to its epoxide was mediated by CYP2E1 in each of these species. The concentration of

CYP2E1 in the liver of humans, rats, and mice showed a pattern similar to that of the interspecies epoxide concentrations in that mice had the highest activity of this enzyme. Human liver, however, contained higher concentrations of the microsomal epoxide-detoxifying enzyme epoxide hydrolase, and rat liver had about one-third the concentration observed in humans. The mouse liver had a very low activity of only 5% of that in human liver but had three times as much glutathione-S-transferase activity as rat and human livers. No other studies on the absorption, distribution, metabolism, or excretion of isobutene in humans were found in the available literature (National Library of Medicine, 1997).

Isoprene is metabolized to the epoxides 3,4-epoxy-3-methyl-1-butene and 3,4-epoxy-2-methyl-1-butene by liver microsomal cytochrome P₄₅₀-dependent monooxygenases (primarily CYP2E1) obtained from Swiss mice, Wistar rats, New Zealand rabbits, Syrian golden hamsters, and human cell lines (Del Monte et al., 1985; Longo et al., 1985; Gervasi and Longo, 1990; Bogaards et al., 1996). The 2-methyl epoxide is produced at about 20% to 25% the rate of the 3-methyl epoxide. The epoxide intermediates of isoprene biotransformation may undergo hydrolysis to form vicinal diols (catalyzed by epoxide hydrolase). may be conjugated with glutathione (catalyzed by glutathione-S-transferase), or may be further oxidized to isoprene diepoxide (2-methyl-1,2:3,4diepoxybutane) (Wistuba et al., 1994). Both isoprene monoepoxides are further oxidized to isoprene diepoxide by rat, mouse, and human liver microsomes (Wistuba et al., 1994; Bogaards et al., 1996). The V_{max} value for isoprene oxidation to the 3-methyl epoxide in mice is about seven times that in rats, whereas the apparent K_m values are similar in these two species. Inhibition of epoxide hydrolase activity results in nearly similar rates of monoepoxide formation by rat, mouse, and human liver microsomes (Bogaards et al., 1996). The biotransformation of isoprene is similar to that of 1,3-butadiene, which involves initial oxidation to 1,2-epoxy-3-butene followed by hydrolysis to 3-butene-1,2-diol, conjugation with glutathione, or further oxidation to diepoxybutane (Malvoisin et al., 1979; Malvoisin and Roberfroid, 1982; Csanády et al., 1992). As with isobutene, CYP2E1 is the major enzyme involved in the hepatic metabolism of isoprene and 1,3-butadiene.

Τοχιςιτά

Experimental Animals

There is little information in the literature on the toxicity of isobutene in animals. The 4-hour LC_{50} in rats is 620 g/m³ (270,000 ppm), and the 2-hour LC_{50} in mice is 415 g/m³ (180,000 ppm) (*Sax's*, 1992).

Humans

No epidemiological studies or reports of health effects related to exposure to isobutene were found in the literature (National Library of Medicine, 1997).

CARCINOGENICITY Experimental Animals

No information on the carcinogenicity of isobutene in experimental animals was found in a search of the available literature (National Library of Medicine, 1997).

Several structurally similar compounds which, like isobutene, form epoxide intermediates have been tested in rodent bioassays. There was no evidence of carcinogenicity in male or female F344/N rats or $B6C3F_1$ mice exposed by inhalation for 2 years to 5,000 or 10,000 ppm propylene (NTP, 1985a). However, male and female F344/N rats exposed to 400 ppm propylene oxide for 2 years had increased incidences of papillary adenoma of the nasal turbinates, and male and female B6C3F1 mice exposed to 400 ppm had increased incidences of hemangioma or hemangiosarcoma of the nasal turbinates (NTP, 1985b). A marginal increase in the incidence of interstitial cell adenoma of the testis was observed in male F344/N rats exposed to 700, 2,200, or 7,000 ppm isoprene vapor 6 hours per day, 5 days per week for 6 months and then allowed to recover for 6 months without exposure to isoprene (Melnick et al., 1994; NTP, 1995). In addition, increased incidences of neoplasms of the liver, lung, forestomach, and harderian gland were observed in male B6C3F₁ mice exposed by inhalation to 700 ppm or higher concentrations of isoprene for 6 months followed by a 6-month recovery period. Exposurerelated increased incidences of liver, lung, harderian gland, and forestomach neoplasms were also observed in male $B6C3F_1$ mice exposed to isoprene vapor at concentrations ranging from 10 to 2,200 ppm for 4 or 8 hours per day, 5 days per week, for 20, 40, or 80 weeks followed by a recovery period until week 105 (Placke et al., 1996). Increased incidences of hemangiosarcoma of the spleen and heart and of histiocytic sarcoma were also detected in exposed mice. Male and female F344/N rats exposed to 220, 700, or 7,000 ppm isoprene for 2 years had increased

incidences of mammary gland fibroadenoma (males and females) and carcinoma (males), renal tubule adenoma (males), and testicular adenoma (NTP, 1998).

Male and female Sprague-Dawley rats exposed to 1,000 or 8,000 ppm 1,3-butadiene for 2 years had dose-related neoplasms at multiple sites (Owen et al., Male rats had increased incidences of 1987). pancreatic exocrine neoplasms and Leydig cell tumors of the testis. Female rats exposed to 1,3-butadiene had uterine stromal sarcomas, Zymbal's gland carcinomas, mammary gland fibroadenomas and and thyroid gland follicular carcinomas. cell neoplasms. Exposure to 6.25, 20, 62.5, 200, or 625 ppm 1,3-butadiene for 2 years produced dose-related neoplasms at multiple sites in male and female $B6C3F_1$ mice (NTP, 1993). Exposed mice had increased incidences of neoplasms of the hematopoietic system, brain (males), forestomach, harderian gland, heart, kidney (males), liver, lung, mammary gland (females), ovary, and preputial gland.

Humans

No epidemiology studies of isobutene in humans were found in the available literature (National Library of Medicine, 1997).

GENETIC TOXICITY

Little information is available on the mutagenicity of isobutene. Because it is a gaseous substance, modifications to standard testing protocols are necessary to achieve adequate and accurate exposure. An early abstract reported negative results in genetic toxicity tests with isobutene in several strains of *Salmonella typhimurium* and in L5178Y mouse lymphoma cells, with and without rat liver S9 metabolic activation enzymes (Staab and Sarginson, 1984). It was not stated whether experimental controls for volatility

were employed in these experiments. However, two recent investigations which employed airtight exposure systems also found no mutagenicity in S. typhimurium strain TA100, TA102, or TA1535 (Cornet et al., 1992) at concentrations up to 50,000 ppm isobutene and no induction of micronuclei in human lymphocytes exposed to isobutene in vitro (Jorritsma et al., 1995). Both studies, however, found positive results for each endpoint (gene mutation in S. typhimurium and chromosome damage in lymphocytes) when the primary metabolite of isobutene, 2-methyl-1,2-epoxypropane, was tested in the absence of metabolic activation enzymes. Cornet et al. (1992) reported that no bacterial toxicity was noted in any of the three tester strains used to determine isobutene mutagenicity, but toxicity was noted in each strain at 75,000 ppm, the highest concentration of 2-methyl-1,2-epoxypropane tested. Further investigations by this same laboratory of the mutagenic activity of 2-methyl-1,2-epoxypropane in S. typhimurium strains TA100 and TA1535 also showed significant increases in mutations at concentrations as low as 250 ppm without S9 (Castelain et al., 1993). Mutagenic activity with S9 required approximately a fourfold increase in the concentration of 2-methyl-1,2-epoxypropane. In addition, an earlier report of a mutagenicity test with 2-methyl-1,2-epoxypropane showed a doubling of the mutation rate in Klebsiella pneumoniae exposed to 5 or 10 mmol of 2-methyl-1,2-epoxypropane/L (Voogd et al., 1981).

STUDY RATIONALE

Isobutene was nominated by the National Cancer Institute for study based on the potential for human exposure to the chemical due to its large production volume, the lack of test data, and structural relationship to the known animal carcinogens isoprene and 1,3-butadiene. Inhalation was chosen as the route of exposure because human exposure occurs primarily via this route.

MATERIALS AND METHODS

PROCUREMENT AND CHARACTERIZATION OF ISOBUTENE

Isobutene was manufactured by Exxon, Inc. (Baytown, TX), supplied by Specialty Gas Concepts (La Porte, TX), and shipped through Norco (Kennewick, WA) in two lots (SGC051091ECA and SGC020594ECA). Lot SGC051091ECA was used during the 14-week and 2-year studies, and lot SGC020594ECA was used during the 2-year studies. Identity, purity, and stability analyses were conducted by the study laboratory, Battelle Pacific Northwest Laboratories (Richland, WA). Reports on analyses performed in support of the isobutene studies are on file at the National Institute of Environmental Health Sciences.

The chemical, a colorless vapor at room temperature, was identified as isobutene by infrared and nuclear magnetic resonance spectroscopy. The purity of each lot was determined by gas chromatography relative to a reference standard with a declared purity of 99.9% purchased from Matheson Gas Products (East Rutherford, NJ). Major peak comparisons by two systems indicated a relative purity of 100.0% by one system and 100.6% by the second system for lot SGC051091ECA relative to the reference standard. For lot SGC020594ECA, gas chromatographic peak comparison indicated a relative purity of greater than 98.4% by each system. The overall purity of lot SGC051091ECA was determined to be greater than 99%, and the overall purity of lot SGC020594ECA was greater than 98%.

Additional analyses of each lot were performed with gas chromatography/mass spectrometry to identify and quantify the impurities indicated by the manufacturer or by gas chromatography. The mass spectrum pattern of the major peak was consistent with isobutene. The following impurities were detected for lot SGC051091ECA: propane/propene, 42 ppm; isobutane, 140 ppm; 1,3-butadiene, 6 ppm; *trans*-2-butene, 213 ppm; and *cis*-2-butene, 286 ppm. Butane and n-butene coeluted with the major peak and were not quantified. Lot SGC020594ECA contained

an estimated 11 ppm propane/propene, 339 ppm isobutane, 15 ppm trans-2-butene, 11 ppm cis-2butene, and no 1,3-butadiene. Samples from each cylinder of each lot of isobutene were analyzed for 1,3-butadiene before the cylinder was used for exposure by gas chromatography/mass spectrometry with the same gas chromatography system. All cylinders used in the 14-week studies contained less than 50 ppm 1,3-butadiene, well within the set limit of 100 ppm; the maximum concentration detected in cylinders used in the 2-year studies was 15 ppm. Cylinders used in the 14-week studies were also screened individually for other impurities; results indicated less than 1% impurities by peak area, with no impurity present greater than 0.1%.

In a 4-day pilot study, the stability of isobutene was monitored in grab-bag samples taken from the distribution manifold at the beginning and the end of 6-hour generation periods until approximately 94% of the cylinder was exhausted. The results from samples taken over 8 test generation days showed no significant enhancement of any volatile impurities, and no additional impurities were detected with relative areas of 0.1% or greater relative to isobutene. Based on these results, approximately 90% of the contents of each cylinder were used during the 14-week and 2-year studies.

During the studies, the bulk chemical was stored in its original shipping cylinders at approximately 22° C. Stability was monitored throughout the studies by the study laboratory with gas chromatography. No degradation of the bulk chemical was detected.

VAPOR GENERATION AND EXPOSURE SYSTEM

Isobutene was distributed under regulated pressure. The cylinder in use and a backup cylinder were connected in parallel to the exposure system. Warm circulating-water blankets surrounding the cylinders provided additional heat to replace the heat lost due to isobutene vaporization. The gas passed through a filter via a main on/off pneumatic valve and then was distributed by a manifold to five (14-week studies) or six (2-year studies) pairs of metering valves with corresponding flow meters. Isobutene was delivered to each exposure chamber through these flow meters via three-way solenoid valves located at the chamber end of the vapor delivery line. Isobutene vapor was diluted with conditioned air as it was injected into the chamber inlet duct. The study laboratory designed the inhalation exposure chamber (Harford Systems Division, Aberdeen, MD) so that uniform vapor concentrations could be maintained throughout the chamber with the catch pans in place.

VAPOR CONCENTRATION MONITORING

Chamber concentrations of isobutene were monitored by an on-line gas chromatograph. Samples were drawn from each chamber approximately every 20 minutes during exposures by a computercontrolled, 12-port, stream select valve. The on-line gas chromatograph was calibrated by direct analysis of volumetrically prepared gas bag standards during the 14-week studies and by using validated, commercially prepared standards during the 2-year studies. An on-line standard of isobutene in nitrogen was used to monitor instrument drift. Vapor concentration uniformity in the exposure chambers without animals present was measured using the on-line gas chromatograph before each of the studies began. Chamber concentration uniformity was maintained throughout the studies. Summaries of the chamber concentrations for the 14-week and 2-year studies are presented in Tables J1 and J2.

CHAMBER ATMOSPHERE CHARACTERIZATION

The times for the exposure concentration to build up to 90% of the final exposure concentration (T_{90}) and to decay to 10% of the exposure concentration (T_{10}) were measured with and without animals present in the chambers. In the 14-week and 2-year studies, with and without animals in the chambers, T_{90} values ranged from 8 to 15 minutes, and T_{10} values ranged from 6 to 12 minutes. The T_{90} value selected for all studies was 12 minutes.

Studies of isobutene degradation and monitoring for impurities were conducted throughout the studies by gas chromatography. No significant degradation of isobutene or enhancement of impurities was observed during the studies.

14-WEEK STUDIES

The 14-week studies were conducted to evaluate the cumulative toxic effects of repeated exposure to isobutene and to determine the appropriate exposure concentrations to be used in the 2-year studies.

Male and female F344/N rats and B6C3F₁ mice were obtained from Taconic Farms (Germantown, NY). On receipt, the rats and mice were 5 weeks old. Animals were quarantined for 11 to 13 days and were 6 weeks old on the first day of the studies. Before initiation of the studies, five male and five female rats and mice were randomly selected for parasite evaluation and gross observation for evidence of disease. At the end of the studies, serologic analyses were performed on five male and five female sentinel rats and control mice using the protocols of the NTP Sentinel Animal Program.

Groups of 10 male and 10 female rats and mice were exposed to isobutene by inhalation at concentrations of 0, 500, 1,000, 2,000, 4,000, or 8,000 ppm for 6 hours plus T₉₀ (12 minutes) per day, 5 days per week, for 14 weeks; 8,000 ppm was chosen as the highest exposure concentration that could be generated safely. It is less than 50% of the lower explosion limit of isobutene (approximately 18,000 ppm; Patty's, 1994). Groups of 10 male and 10 female special study rats were exposed to the same concentrations for 23 days. Feed was available ad libitum except during exposure periods. Water was available ad libitum. Rats and mice were housed individually. Clinical findings were recorded weekly for rats and mice. The animals were weighed initially, weekly, and at the end of the studies. Details of the study design and animal maintenance are summarized in Table 1.

Clinical pathology studies were performed on 10 male and 10 female special study rats per group on days 3 and 23 and on all core study rats at study termination. At all time points, rats were anesthetized with CO_2 and blood was drawn from the retroorbital sinus. Blood for hematology determinations was placed in tubes containing potassium EDTA as the anticoagulant. Blood for clinical chemistry analyses was placed in tubes without anticoagulant, allowed to clot at room temperature, and centrifuged, and the serum was separated. The hematology and clinical chemistry endpoints evaluated are listed in Table 1.

Hematology determinations, including erythrocyte, leukocyte, and platelet counts, hemoglobin concentration, hematocrit, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration, were performed with an Ortho ELT-8/ds 9000 hematology analyzer (Ortho Diagnostic Systems, Westwood, MA). Manual microhematocrit determinations were made using a Damon/IEC microcapillary centrifuge and reader (International Equipment Company, Needham Heights, MA). Leukocyte differential and nucleated erythrocyte counts and morphologic evaluation of blood cells were determined by light microscopic examination of blood films stained with a modified Wright's stain using a Wescor 7100 Aerospray slide stainer (Wescor, Logan, Smears made from preparations of equal UT). volumes of new methylene blue and whole blood and incubated for at least 20 minutes at room temperature were examined microscopically, using the Miller disc method, for the quantitative determination of reticulocytes. Clinical chemistry endpoints were determined on a Cobas Fara chemistry analyzer (Roche Diagnostic Systems, Inc., Montclair, NJ) and an Abbott VP bichromatic chemistry instrument (Abbott Laboratories, Irving, TX) using reagents and methods obtained from the manufacturers.

At the end of the 14-week studies, samples were collected for sperm motility and vaginal cytology evaluations on core study rats and mice exposed to 0, 2,000, 4,000, or 8,000 ppm. The parameters evaluated are listed in Table 1. Methods used were those described in the NTP's sperm morphology and vaginal cytology evaluations protocol (NTP, 1987). For 12 consecutive days prior to scheduled terminal sacrifice, the vaginal vaults of the females were moistened with saline, if necessary, and samples of vaginal fluid and cells were stained. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, and metestrus). Male animals were evaluated for sperm count and motility. The left testis and left epididymis were isolated and weighed. The tail of the epididymis (cauda epididymis) was then removed from the epididymal body (corpus epididymis) and

weighed. Test yolk (rats) or modified Tyrode's buffer (mice) was applied to slides and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers. Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced, and the tissue was incubated in the saline solution and then heat fixed at 65° C. Sperm density was then determined microscopically with the aid of a hemacytometer. То quantify spermatogenesis, the testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in phosphate-buffered saline containing 10% dimethyl sulfoxide. Homogenization-resistant spermatid nuclei were counted with a hemacytometer.

A necropsy was performed on all animals. The heart, liver, lung, right kidney, right testis, and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6 μ m, and stained with hematoxylin and eosin. A complete histopathologic examination was performed on chamber control and 8,000 ppm rats and mice, and the nose was examined to the no-effect level in rats. Table 1 lists the tissues and organs routinely examined.

2-YEAR STUDIES Study Design

Groups of 50 male and 50 female rats and mice were exposed to isobutene by inhalation at concentrations of 0, 500, 2,000, or 8,000 ppm 6 hours plus T_{90} (12 minutes) per day, 5 days per week, for 105 weeks.

Source and Specification of Animals

Male and female F344/N rats and B6C3F₁ mice were obtained from Taconic Farms (Germantown, NY) for use in the 2-year studies. Rats and mice were quarantined for 14 days before the beginning of the studies. Five male and five female rats and mice were randomly selected for parasite evaluation and gross observation of disease. Rats and mice were approximately 6 weeks old at the beginning of the studies. The health of the animals was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix L).

Animal Maintenance

Rats and mice were housed individually. Feed was available *ad libitum* except during exposure and urine collection periods. Water was available *ad libitum*. Cage batteries were rotated weekly. Further details of animal maintenance are given in Table 1. Information on feed composition and contaminants is provided in Appendix K.

Clinical Examinations and Pathology

All animals were observed twice daily, 7 days per week. Clinical findings were recorded initially, at weeks 5, 6, and 9 (mice), every 4 weeks from week 4 through week 91 (rats) or from week 13 through week 92 (mice), and every 2 weeks until the end of the study. Body weights were recorded initially, weekly through week 12 (rats) or week 13 (mice), every 4 weeks from week 15 (rats) or week 16 (mice) through week 91 (rats) or week 92 (mice), and every 2 weeks until the end of the study.

Five male and five female rats and mice from the control groups and 10 male and 10 female rats and mice from each exposed group were evaluated at 6, 12, and 18 months for determination of 2-hydroxyisobutyric acid (HIBA) in urine. Rats and mice were housed individually in metabolism cages for 16 hours after exposure while urine samples were collected over ice, after which samples were weighed and stored at -20° C in glass vials until analysis. All urine samples were analyzed for HIBA and creatinine and were prepared for analysis by combining a weighed aliquot of urine with sulfuric acid/sodium sulfate solution containing an internal standard This mixture was aspirated (chloroacetic acid). through a C₁₈-bonded solid-phase extraction tube and then extracted with ethyl acetate. Diazomethane was added to the ethyl acetate extract to derivatize HIBA and chloroacetic acid to their respective methyl esters. Samples were analyzed using an HP-5890 Series II gas chromatograph equipped with an HP-7673 autosampler and an HP-5971 mass selective detector (Hewlett-Packard Company, Wilmington, DE). Separation of analytes was achieved using a deactivated, fused silica capillary column (J&W Scientific DB-1701) with on-column injection and a helium carrier gas at 3 psi constant pressure. Detection and quantitation limits were calculated using analysis results from spiked urine standards. The parameters measured are listed in Table 1.

A complete necropsy and microscopic examination were performed on all rats and mice. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6 μ m, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (i.e., adrenal gland, kidney, ovary), samples from each organ were examined. Tissues examined microscopically are listed in Table 1.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, the slide and tissue counts were verified, and the histotechnique was evaluated. For the 2-year rat studies, a quality assessment pathologist evaluated slides from all tumors and all potential target organs which included the nose and lung of males and females; the heart, liver, spleen, and thyroid gland of males; the ovaries of females; and all neoplasms in all organs. For the 2-year mouse studies, a quality assessment pathologist evaluated slides from all tumors and all potential target organs which included the nose of males and females, the thyroid gland of females, and all neoplasms in all organs. In addition, the epididymis was reviewed when the diagnosis of sperm granuloma occurred.

The quality assessment report and the reviewed slides were submitted to the NTP Pathology Working Group (PWG) chairperson, who reviewed the selected tissues and addressed any inconsistencies in the diagnoses made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologist, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Final diagnoses for reviewed lesions represent a consensus between the laboratory pathologist, reviewing pathologist(s), and the PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman *et al.* (1985). For subsequent analyses of the pathology data, the decision of whether to evaluate the diagnosed lesions for each tissue type separately or combined was generally based on the guidelines of McConnell *et al.* (1986).

TABLE 1 Experimental Design and Materials and Methods in the Inhalation Studies of Isobutene

14-Week Studies	2-Year Studies			
Study Laboratory Battelle Pacific Northwest Laboratories (Richland, WA)	Battelle Pacific Northwest Laboratories (Richland, WA)			
Strain and Species Rats: F344/N Mice: B6C3F ₁	Rats: F344/N Mice: B6C3F ₁			
Animal Source Taconic Farms (Germantown, NY)	Taconic Farms (Germantown, NY)			
Time Held Before Studies Rats: 11 days (males) or 12 days (females) Mice: 12 days (males) or 13 days (females)	14 days			
Average Age When Studies Began 6 weeks	6 weeks			
Date of First Exposure Rats: 20 January 1992 (males) 21 January 1992 (females) Mice: 21 January 1992 (males) 22 January 1992 (females)	Rats: 11 March 1993 Mice: 4 March 1993			
Duration of Exposure 6 hours plus T_{90} (12 minutes) per day, 5 days per week, for 14 weeks	6 hours plus $T_{\scriptscriptstyle 90}$ (12 minutes) per day, 5 days per week, for 105 weeks			
Date of Last Exposure Rats: 20 April 1992 (males) 21 April 1992 (females) Mice: 22 April 1992 (males) 23 April 1992 (females)	Rats: 10 March 1995 Mice: 3 March 1995			
Necropsy Dates Rats: 21 April 1992 (males) 22 April 1992 (females) Mice: 23 April 1992 (males) 24 April 1992 (females)	Rats: 13-15 March 1995 Mice: 6-9 March 1995			
Average Age at Necropsy 20 weeks	Rats: 111 weeks Mice: 111-112 weeks			
Size of Study Groups 10 males and 10 females	50 males and 50 females			
Method of Distribution Animals were distributed randomly into groups of approximately equal initial mean body weights.	Same as 14-week studies			
Animals per Cage 1	1			
Method of Animal Identification Tail tattoo	Tail tattoo			

TABLE 1 Experimental Design and Materials and Methods in the Inhalation Studies of Isobutene

14-Week Studies	2-Year Studies			
Diet NIH-07 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available <i>ad libitum</i> except during exposure periods, changed weekly	NIH-07 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available <i>ad libitum</i> except during exposure and urine collection periods, changed weekly			
Water Softened tap water (Richland municipal supply) via automatic watering system (Edstrom Industries, Waterford, WI), available ad libitum	Same as 14-week studies			
Cages Stainless steel wire bottom (Hazleton Systems, Inc., Aberdeen, MD), changed weekly	Same as 14-week studies			
Chamber Air Supply Filters Charcoal filter Single HEPA (Northland Filter Systems International, Mechanicville, NY), checked twice per year Purafil® (Environmental Systems, Lynnwood, MA)	Charcoal filter Single HEPA (Flanders Filters, Inc., San Rafael, CA), checked twice per year Purafil® (Environmental Systems, Lynnwood, MA)			
Chambers Stainless steel (Lab Products, Inc., Harford Systems Division, Aberdeen, MD), changed weekly	Same as 14-week studies			
Chamber Environment Temperature: 23.7°-24.4° C Relative humidity: 53%-58% Room fluorescent light: 12 hours/day Chamber air changes: 15/hour	Temperature: 23.9°-24.2° C Relative humidity: 53%-58% Room fluorescent light: 12 hours/day Chamber air changes: 15/hour			
Exposure Concentrations), 500, 1,000, 2,000, 4,000, or 8,000 ppm	0, 500, 2,000, or 8,000 ppm			
Type and Frequency of Observation Observed twice daily; animals were weighed initially, weekly, and at the end of the studies; clinical findings were recorded weekly.	Observed twice daily; clinical findings were recorded initially, at weeks 5, 6, and 9 (mice), every 4 weeks from week 4 through week 91 (rats) or from week 13 through week 92 (mice), and every 2 weeks until the end of the studies; animals were weighed initially weekly through week 12 (rats) or week 13 (mice), every 4 weeks from week 15 (rats) or week 16 (mice) through week 91 (rats) or week 92 (mice) and every 2 weeks until the end of the studies.			
Method of Sacrifice 70% CO ₂	Same as 14-week studies			
Necropsy Necropsy was performed on all animals. Organs weighed were the heart, liver, lung, right kidney, right testis, and thymus.	Necropsy was performed on all animals.			

TABLE 1

Experimental Design and Materials and Methods in the Inhalation Studies of Isobutene

14-Week Studies	2-Year Studies
Clinical Pathology Blood was collected from the retroorbital plexus of 10 male and 10 female special study rats at day 3 and day 23 and of core study rats at terminal sacrifice for hematology and clinical chemistry analyses. Hematology: hematocrit (automated and manual); hemoglobin concentration; erythrocyte, reticulocyte, nucleated erythrocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; leukocyte count and differentials Clinical chemistry: urea nitrogen, creatinine, serum glucose, total protein, albumin, globulin, A/G ratio, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, bile acids	None
Histopathology Complete histopathology was performed on all core study chamber control and 8,000 ppm rats and mice. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone with marrow, brain, clitoral gland, esophagus, gallbladder (mice), heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, mediastinal), mammary gland (with adjacent skin), nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testes	Complete histopathology was performed on all rats and mice. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone with marrow, brain, clitoral gland, esophagus, gallbladder (mice), heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, mediastinal), mammary gland (with adjacent skin), nose, ovary, pancreatic islets, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testes (with epididymis and seminal vesicle), thymus,

Sperm Motility and Vaginal Cytology

male and female rats was examined.

At the end of the studies, sperm samples were collected from all male animals in the 0, 2,000, 4,000, and 8,000 ppm exposure groups for sperm motility evaluations. The following parameters were evaluated: spermatid heads per testis, spermatid count, and epididymal spermatozoal concentration and motility. The left cauda epididymis, epididymis, and testis were weighed. Vaginal samples were collected for up to 12 consecutive days prior to the end of the studies from all females exposed to 0, 2,000, 4,000, and 8,000 ppm for vaginal cytology evaluations. The following parameters were evaluated: estrous cycle length and relative frequency of estrous stages.

(with epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus. In addition, the nose of all

2-Hydroxyisobutyric Acid — Biomarker of Exposure None

thyroid gland, trachea, urinary bladder, and uterus.

None

Five male and five female rats and mice from the chamber control groups and 10 male and 10 female rats and mice from each exposed group were evaluated at 6, 12, and 18 months for determination of HIBA in urine. Rats and mice were housed individually in metabolism cages for 16 hours after exposure while urine samples were collected over ice. Parameters evaluated included urinary excretion, creatinine, and HIBA.

STATISTICAL METHODS

Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals found dead of other than natural causes were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

Calculation of Incidence

The incidences of neoplasms or nonneoplastic lesions are presented in Tables A1, A5, B1, B4, C1, C4, D1, and D4 as the number of animals bearing such lesions at a specific anatomic site and the number of animals with that site examined microscopically. For calculation of statistical significance, the incidences of most neoplasms (Tables A3, B3, C3, and D3) and all nonneoplastic lesions are given as the numbers of animals affected at each site examined microscopically. However, when macroscopic examination was required to detect neoplasms in certain tissues (e.g., harderian gland, intestine, mammary gland, and skin) before microscopic evaluation, or when neoplasms had multiple potential sites of occurrence (e.g., leukemia or lymphoma), the denominators consist of the number of animals on which a necropsy was performed. Tables A3, B3, C3, and D3 also give the survival-adjusted neoplasm rate for each group and each site-specific neoplasm. This survivaladjusted rate (based on the Poly-3 method described below) accounts for differential mortality by assigning a reduced risk of neoplasm, proportional to the third power of the fraction of time on study, to animals that do not reach terminal sacrifice.

Analysis of Neoplasm and Nonneoplastic Lesion Incidences

The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. This test is a survival-adjusted quantal-response procedure that modifies the Cochran-Armitage linear trend test to take survival differences into account. More specifically, this method modifies the denominator in the quantal estimate of lesion incidence to approximate more closely the total number of animal years at risk. For analysis of a given site, each animal is assigned a risk weight. This value is one if the animal had a lesion at that site or if it survived until terminal sacrifice; if the animal died prior to terminal sacrifice and did not have a lesion at that site, its risk weight is the fraction of the entire study time that it survived, raised to the kth power.

This method yields a lesion prevalence rate that depends only upon the choice of a shape parameter for a Weibull hazard function describing cumulative lesion incidence over time (Bailer and Portier, 1988). Unless otherwise specified, a value of k=3 was used in the analysis of site-specific lesions. This value was recommended by Bailer and Portier (1988) following an evaluation of neoplasm onset time distributions for a variety of site-specific neoplasms in control F344 rats and B6C3F₁ mice (Portier et al., 1986). Bailer and Portier (1988) showed that the Poly-3 test gave valid results if the true value of k was anywhere in the range from 1 to 5. A further advantage of the Poly-3 method is that it does not require lesion lethality assumptions. Variation introduced by the use of risk weights, which reflect differential mortality, was accommodated by adjusting the variance of the Poly-3 statistic as recommended by Bieler and Williams (1993).

Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall exposure-related trend. Continuity-corrected tests were used in the analysis of lesion incidence, and reported P values are one sided. Values of P greater than 0.5 are presented as 1-P with the letter N added to indicate a lower incidence or negative trend in neoplasm occurrence relative to the control group (e.g., P = 0.99 is presented as P = 0.01N).

Analysis of Continuous Variables

Two approaches were employed to assess the significance of pairwise comparisons between exposed and control groups in the analysis of continuous variables. Organ and body weight data, which have approximately normal distributions, were analyzed with the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Hematology, clinical chemistry, urinalysis, spermatid, and epididymal spermatozoal data, which have typically skewed distributions, were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Williams' or Shirley's test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunnett's or Dunn's test). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey (1951) were examined by NTP personnel, and implausible values were eliminated from the analysis. Average severity values were analyzed for significance with the Mann-Whitney U test (Hollander and Wolfe, 1973). Because vaginal cytology data are proportions (the proportion of the observation period that an animal was in a given estrous stage), an arcsine transformation was used to bring the data into closer conformance with a normality assumption. Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across exposure concentrations.

Historical Control Data

Although the concurrent control group is always the first and most appropriate control group used for evaluation, historical control data can be helpful in the overall assessment of neoplasm incidence in certain instances. Consequently, neoplasm incidences from the NTP historical control database, which is updated yearly, are included in the NTP reports for neoplasms appearing to show compound-related effects.

QUALITY ASSURANCE METHODS

The 14-week and 2-year studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the 2-year studies were submitted to the NTP Archives, these studies were audited retrospectively by an independent quality assurance contractor. Separate audits covered completeness and accuracy of the pathology data, pathology specimens, final pathology tables, and a draft of this NTP Technical Report. Audit procedures and findings are presented in the reports and are on file at NIEHS. The audit findings were reviewed and assessed by NTP staff, so all comments had been resolved or were otherwise addressed during the preparation of this Technical Report.

GENETIC TOXICOLOGY

The genetic toxicity of isobutene was assessed by testing the ability of the chemical to induce mutations in various strains of *Salmonella typhimurium* and increases in the frequency of micronucleated erythrocytes in peripheral blood of mice. The protocols for these studies and the results are given in Appendix E.

The genetic toxicity studies of isobutene are part of a larger effort by the NTP to develop a database that would permit the evaluation of carcinogenicity in experimental animals from the molecular structure and the effects of the chemical in short-term *in vitro* and *in vivo* genetic toxicity tests. These genetic toxicity tests were originally developed to study mechanisms of chemical-induced DNA damage and to predict carcinogenicity in animals, based on the electrophilicity theory of chemical mutagenesis and the somatic mutation theory of cancer (Miller and Miller, 1977; Straus, 1981; Crawford, 1985).

There is a strong correlation between a chemical's potential electrophilicity (structural alert to DNA reactivity), mutagenicity in Salmonella, and carcino-The combination of genicity in rodents. electrophilicity and Salmonella mutagenicity is highly correlated with the induction of carcinogenicity in rats and mice and/or at multiple tissue sites (Ashby and Tennant, 1991). Other in vitro genetic toxicity tests correlate less well with rodent carcinogenicity (Tennant et al., 1987; Zeiger et al., 1990), although these other tests can provide information on the types of DNA and chromosome effects that can be induced by the chemical being investigated. Data from NTP studies show that a positive response in Salmonella is the most predictive in vitro test for rodent carcinogenicity (89% of the Salmonella mutagens are rodent carcinogens), and that there is no complementarity among the in vitro genetic toxicity tests. That is, no battery of tests that included the Salmonella test improved the predictivity of the Salmonella test alone.

The predictivity for carcinogenicity of a positive response in bone marrow chromosome aberration or micronucleus tests appears to be less than the *Salmonella* test (Shelby *et al.*, 1993; Shelby and Witt, 1995). Positive responses in long-term

peripheral blood micronucleus tests have not been formally evaluated for their predictivity for rodent carcinogenicity. But, because of the theoretical and observed associations between induced genetic damage and adverse effects in somatic and germ cells, the deter-mination of *in vivo* genetic effects is important to the overall understanding of the risks associated with exposure to a particular chemical.

RESULTS

RATS 14-WEEK STUDY

All male and female rats survived to the end of the study (Table 2). The final mean body weights and body weight gains of all exposed groups of males and females were similar to those of the chamber control groups. There were no clinical findings or effects on

hematologic or clinical chemistry indices attributed to isobutene exposure (Table F1). There were no biologically significant effects on male or female reproductive endpoints as a result of exposure to isobutene (Tables H1 and H2).

TABLE 2 Survival and Body Weights of Rats in the 14-Week Inhalation Study of Isobutene

			Final Weight		
Concentration (ppm)	ı Survival ^a	Initial	<u>Mean Body Weight^b (</u> Final	Change	Relative to Controls (%)
Male					
0	10/10	139 ± 5	354 ± 7	215 ± 8	
500	10/10	138 ± 5	361 ± 6	223 ± 7	102
1,000	10/10	140 ± 6	359 ± 7	$219~\pm~8$	101
2,000	10/10	141 ± 4	357 ± 6	216 ± 6	101
4,000	10/10	142 ± 7	359 ± 7	217 ± 7	101
8,000	10/10	145 ± 7	356 ± 6	211 ± 9	101
Female					
0	10/10	117 ± 3	205 ± 4	88 ± 4	
500	10/10	115 ± 3	200 ± 2	85 ± 3	98
1,000	10/10	119 ± 2	212 ± 4	93 ± 5	103
2,000	10/10	116 ± 2	211 ± 4	95 ± 4	103
4,000	10/10	116 ± 2	205 ± 4	88 ± 4	100
8,000	10/10	120 ± 3	213 ± 5	92 ± 4	104

^a Number of animals surviving at 14 weeks/number initially in group

^b Weights and weight changes are given as mean ± standard error. Differences from the chamber control group were not significant by Williams' or Dunnett's test.

The absolute right kidney weights of 4,000 and 8,000 ppm males and the relative right kidney weights of all exposed groups of males were greater than those of the chamber controls; however, the differences were no greater than 10% and 8%, respectively (Table G1). The absolute liver weights of females exposed to 1,000 ppm and above and the relative liver

weights of all exposed groups of females were greater (up to 20%) than those of the chamber controls; however, the increases in absolute and relative liver weights did not occur in a concentration-related manner. There were no histopathologic effects supporting increased kidney or liver weights as a result of isobutene exposure. No exposure-related gross lesions were observed in male or female rats at necropsy. Microscopically, minimal hypertrophy of goblet cells lining the naso-pharyngeal duct in the most caudal nose section was observed in some rats in each exposed group of males and females (males: chamber control, 0/10; 500 ppm, 4/10; 1,000 ppm, 7/10; 2,000 ppm, 9/10; 4,000 ppm, 8/10; 8,000 ppm, 9/10; females: 0/10, 4/10, 8/10, 8/10, 7/10, 10/10).

Exposure Concentration Selection Rationale: Based on the lack of significant exposure-related toxicologic effects, 8,000 ppm was selected as the highest exposure concentration in the 2-year study. A higher concentration could not be used because of the danger of explosion. The 2-year study exposure concentrations of 0, 500, 2,000, and 8,000 ppm were based on published metabolic elimination rates for Sprague-Dawley rats and B6C3F₁ mice (Csanády *et al.*, 1991). These rates indicated that 500 ppm would be within the linear range for metabolic elimination, 2,000 ppm would be out of the linear range.

2-YEAR STUDY

Survival

Estimates of 2-year survival probabilities for male and female rats are shown in Table 3 and in the Kaplan-Meier survival curves (Figure 2). Survival of exposed males and females was similar to that of the chamber controls.

Body Weights and Clinical Findings

Mean body weights of exposed male and female rats were generally similar to those of the chamber controls throughout the study (Figure 3 and Tables 4 and 5). There were no clinical findings attributed to isobutene exposure.

TABLE 3

Cha	mber Control	500 ppm	2,000 ppm	8,000 ppm
Лаle				
nimals initially in study	50	50	50	50
Ioribund	39	40	37	41
Jatural deaths	4	5	7	1
animals surviving to study termination	7	5	6	8
ercent probability of survival at end of study ^a	14	10	12	16
Iean survival (days) ^b	630	610	612	649
urvival analysis ^c	P=0.282N	P=0.346	P=0.450	P=0.718N
emale				
nimals initially in study	50	50	50	50
Accidental death ^d	0	1	0	0
Ioribund	21	25	15	23
atural deaths	6	5	2	5
nimals surviving to study termination	23	19	33	22
ercent probability of survival at end of study	46	39	66	44
Iean survival (days)	667	635	696	658
urvival analysis	P = 0.926	P = 0.469	P=0.069N	P = 0.909

^a Kaplan-Meier determinations

^b Mean of all deaths (uncensored, censored, and terminal sacrifice)

^c The result of the life table trend test (Tarone, 1975) is in the chamber control column, and the results of the life table pairwise comparisons (Cox, 1972) with the chamber controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by **N**.

^d Censored from survival analyses




FIGURE 2 Kaplan-Meier Survival Curves for Male and Female Rats Exposed to Isobutene by Inhalation for 2 Years




FIGURE 3 Growth Curves for Male and Female Rats Exposed to Isobutene by Inhalation for 2 Years

 TABLE 4

 Mean Body Weights and Survival of Male Rats in the 2-Year Inhalation Study of Isobutene

Weeks	Chamber Control		500 ppm				2,000 ppm			8,000 ppm		
on	Av. Wt.			Wt. (% of	No. of		Wt. (% of			Wt. (% of		
Study	(g)	Survivors			controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	147	50	148	101	50	147	100	50	146	99	50	
2	192	50	194	101	50	193	100	50	193	100	50	
3	220	50	223	101	50	223	101	50	221	101	50	
4	244	50	247	101	50	248	101	50	245	100	50	
5	265	50	269	101	50	269	102	50	266	100	50	
6	282	50	285	101	50	287	102	50	283	100	50	
7	300	50	300	100	50	303	101	50	300	100	50	
8	314	50	315	100	50	317	101	50	311	99	50	
9	326	50	327	100	50	328	101	50	322	99	50	
10	339	50	339	100	50	340	100	50	335	99	50	
11	350	50	350	100	50	352	100	50	345	99	50	
12	359	50	359	100	50	361	101	50	351	98	50	
15	383	50	383	100	50	383	100	50	376	98	50	
19	409	50	413	101	50	413	101	50	406	99	50	
23	433	50	433	100	50	438	101	50	428	99	50	
27	452	50	450	100	50	453	100	50	446	99	50	
31	465	50	462	99	50	465	100	50	457	98	50	
35	472	50	470	100	50	475	101	50	469	99	50	
39	483	50	489	101	49	487	101	50	483	100	50	
43	493	50	496	101	49	498	101	50	492	100	50	
47	501	50	506	101	49	504	101	50	501	100	50	
51	511	50	511	100	49	514	101	49	509	100	50	
55	520	49	515	99	49	520	100	49	512	99	50	
59	524	49	523	100	48	525	100	49	516	99	50	
63	524	49	525	100	48	526	100	49	519	99	50	
67	525	48	529	101	47	528	101	48	520	99	50	
71	531	45	526	99	45	523	98	47	525	99	49	
75 70	528	44	523	99	42	540	102	40	519	98	48	
79	526	40	533	101	37	523	99	39	522	99	44	
83	526	36 33	526 523	100	34 29	517	98 99	32 27	523	100 98	42 38	
87 91	522 498	33 28	523 512	100	29 23	516 520	99 104	27	514 502	98 101	38 33	
		28 24	512	103				20	498		33 29	
93 05	500	24 22		100	21	500	100			100		
95 97	500 472	22 20	468 455	94 96	19 14	519 519	104 110	16 15	484 475	97 101	26 20	
97 99	472 479	20 14	455 452	96 94	14 10	503	105	15	475 452	94	20 14	
99 101	479 456	14	452 459	94 101	10	503 498	105	13	452 452	94 99	14 9	
101	456 468	8	459 450	96	5	498 508	109	10 6	452 446	99 95	9 9	
105	400	o	430	90	5	308	109	0	440	95	9	
Mean fo												
1-13	278		280	101		281	101		277	100		
14-52	460		461	100		463	101		457	99		
53-103	506		501	99		518	102		499	99		

 TABLE 5

 Mean Body Weights and Survival of Female Rats in the 2-Year Inhalation Study of Isobutene

Weeks	Chambe	er Control		500 ppm			2,000 ppn	1		8,000 ppn	1
on Study	Av. Wt. (g)		Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of	
1	111	50	110	100	50	111	100	50	109	98	50
2	134	50	132	98	50	135	100	50	131	98	49
3	144	50	143	99	49	146	101	50	143	99	49
4	154	50	152	99	49	155	101	50	152	99	49
5	162	50	162	100	49	164	102	50	161	100	49
6	167	50	167	100	49	170	101	50	166	99	49
7	172	50	173	101	49	175	102	50	170	99	49
8	178	50	177	100	49	179	100	50	175	99	49
9	183	50	183	100	49	186	102	50	181	99	49
10	189	50	188	99	49	190	101	50	185	98	49
11	193	50	191	99	49	194	101	50	190	98	49
12	194	50	192	99	49	194	100	50	189	97	49
15	203	50	202	100	49	202	100	50 50	198 208	98	49
19 23	210	50 50	213 225	101	49 40	213 224	102 102	50 50	208 218	99 99	49 49
23 27	220 231	50 50	225	102 102	49 49	224	102	50 50	218	99 98	49 49
31	231	50 50	234 241	102	49 49	232	101	50 50	220	98 97	49 49
35	238	50 50	250	101	49	238	99	50 50	240	97 96	49
39	257	50 50	259	101	48	240	101	50 50	251	98	49
43	265	50	270	101	48	268	101	50 50	261	98	49
43	279	50	284	102	48	282	101	50 50	274	98	49
51	295	50	298	102	48	296	100	50	288	98	49
55	306	50	307	100	48	305	100	50	296	97	49
59	313	49	316	101	48	315	100	50	308	98	48
63	320	48	325	102	47	325	102	49	316	99	48
67	324	47	327	101	45	328	101	49	318	98	48
71	334	45	339	102	43	337	101	49	329	99	47
75	337	44	342	101	42	343	102	48	337	100	44
79	340	43	347	102	39	347	102	47	340	100	43
83	352	40	353	100	37	360	102	45	347	99	42
87	353	39	355	101	35	361	102	44	350	99	39
91	356	38	358	101	31	362	102	42	346	97	37
93	356	35	355	100	31	362	102	41	340	96	36
95	361	34	357	99	30	367	102	40	343	95	33
97	355	33	358	101	29	367	103	40	355	100	29
99	353	31	358	101	27	372	105	37	358	101	28
101	352	29	361	102	25	370	105	35	360	102	26
103	350	27	355	101	20	369	105	34	361	103	25
Mean fo	r weeks										
1-13	165		164	99		167	101		163	99	
14-52	245		248	101		246	100		240	98	
53-103	341		345	101		349	102		338	99	

2-Hydroxyisobutyric Acid — Biomarker of Exposure

2-Hydroxyisobutyric acid (HIBA), the major urinary metabolite of isobutene, was measured in the urine of male and female rats as an indicator of isobutene exposure at 6, 12, and 18 months (Table I1). The amount of HIBA excreted increased with increasing exposure concentration (Figures 4 and 5). However, when HIBA concentration was normalized to isobutene exposure concentration, the relative amount of HIBA excreted decreased as exposure concentrations increased (Figures 6 and 7). This was true at all three collection intervals for males and females. Exposure to isobutene had no effect on the quantity of urine or the amount of creatinine excreted.






FIGURE 4







Mean (± Standard Deviation) 2-Hydroxyisobutyric Acid Concentration Normalized to Creatinine for Female Rats in the 2-Year Inhalation Study of Isobutene





FIGURE 6

Mean (± Standard Deviation) 2-Hydroxyisobutyric Excretion Normalized to Creatinine and Exposure Concentration for Male Rats in the 2-Year Inhalation Study of Isobutene





Mean (± Standard Deviation) 2-Hydroxyisobutyric Excretion Normalized to Creatinine and Exposure Concentration for Female Rats in the 2-Year Inhalation Study of Isobutene

Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the thyroid gland, nose, and heart and of mononuclear cell leukemia. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix A for male rats and Appendix B for female rats.

Thyroid Gland: The incidence of follicular cell carcinoma in male rats exposed to 8,000 ppm was greater than that in the chamber control group and exceeded the historical control range (Tables 6, A3, and A4). The histomorphology of the carcinomas that were observed in chamber control and exposed rats was similar to the morphologic spectrum typical of spontaneously developing follicular cell carcinomas. Histologically, all were unilateral, well-delineated, medium-sized to large (0.3 to 1.3 cm) nodular masses that partially or completely replaced the affected lobe (Plates 1 through 6). There was clear focal to extensive invasion of the capsule and, in some cases, the immediately adjacent tissue (Plates 3 through 5). The carcinomas consisted of follicular, papillary, or solid patterns or variable combinations of these patterns and were surrounded by a prominent scirrhous reaction. Carcinomas with predominantly follicular or papillary patterns had relatively uniform cells and often multiple prominent, cystic, colloid-filled follicles and spaces (Plate 7). The neoplastic cells in carcinomas having solid areas or that were predominantly solid were more anaplastic than the cells in follicular or papillary patterns and were characterized by moderate variation in cellular size and shape (pleomorphism) and low to high numbers of mitotic figures (Plates 8 and 9). One carcinoma had neoplastic cell emboli within the vasculature and had metastasized to the lungs (Plates 10 and 11). Concurrent increases in the incidences of follicular cell adenoma and hyperplasia did not occur in male rats (Tables 6, A1, and A5), nor were the incidences of proliferative lesions of the thyroid gland increased in female rats (follicular cell hyperplasia: chamber control, 0/50; 500 ppm, 2/50; 2,000 ppm, 0/49; 8,000 ppm, 0/49; follicular cell carcinoma: 1/50, 0/50, 0/49, 0/49; Tables B1 and B4).

Nose: Although the incidences of hyaline degeneration of the olfactory epithelium in males and females were only slightly increased in exposed rats (males: 43/49, 45/49, 46/50, 49/49; females: 44/50, 47/50, 48/50, 47/49: Tables A5 and B4), the severities of hyaline degeneration increased with increasing exposure concentration (males: 1.3, 1.4, 2.2, 2.6; females: 1.5, 2.4, 2.8, 2.8). Hyaline degeneration was characterized by accumulation of variably sized, brightly eosinophilic globules in the cytoplasm of sustentacular cells in the ethmoid turbinate olfactory epithelium. In inhalation studies, hyaline degeneration is a commonly observed change in the epithelium of the nasal cavity, the incidence and severity of which may increase with increasing exposure concentration. The accumulation of these protein globules is considered a nonspecific adaptive response to prolonged inhalation of irritant material and has no adverse effect on affected animals.

Heart: The incidences of atrial thrombosis in males occurred with a positive trend. The incidence of this lesion in 8,000 ppm males was significantly greater than that in the chamber control group (0/50, 1/50, 3/50, 6/50; Table A5). Histologically, thrombi occurred in the left atrium and were somewhat varied in size and character with no common unifying morphologic features. Atrial thrombosis is a common spontaneous lesion observed at a low incidence in chronic rat studies, and an incidence of zero in the controls is unusual. The marginal increase observed in this study was not considered to be related to isobutene exposure.

Mononuclear Cell Leukemia: The incidences of mononuclear cell leukemia in male rats occurred with a positive trend (21/50, 21/50, 20/50, 31/50; Table A3). This marginal increase most likely represents a spurious occurrence. The incidence in the 8,000 ppm group was not significant, was well within the historical control range [520/905 (57.5% \pm 9.4%), range, 34%-70%], and is not considered to be related to isobutene exposure. In addition, the incidences of mononuclear cell leukemia in exposed female rats were similar to that in the chamber controls (18/50, 16/50, 22/50, 17/50; Table B3).

TABLE 6

Incidences of Follicular Cell Neoplasms and Nonneoplastic Lesions of the Thyroid Gland in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Number Examined Microscopically Hyperplasia ^a	48 0	48 2 (3.0) ^b	48 0	50 1 (4.0)
Carcinoma ^c Overall rate ^d Adjusted rate ^e Terminal rate ^f First incidence (days) Poly-3 test ^g	1/48 (2%) 3.0% 0/7 (0%) 661 P=0.004	0/48 (0%) 0.0% 0/5 (0%) h P= 0.519N	0/48 (0%) 0.0% 0/6 (0%) — P=0.521N	5/50 (10%) 13.5% 0/8 (0%) 618 P= 0.125

^a Number of animals with lesion

^b Average severity grade of lesions in affected animals: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked

^c Historical incidence for 2-year inhalation studies with chamber control groups (mean ± standard deviation): adenoma: 7/892 (0.8% ± 1.2%), range 0%-4%; carcinoma: 9/892 (1.0% ± 1.2%), range 0%-4%; adenoma or carcinoma: 16/892 (1.8% ± 1.7%), range 0%-6%

^d Number of animals with neoplasm per number of animals with thyroid gland examined microscopically

^e Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^f Observed incidence at terminal kill

^g Beneath the chamber control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to the pairwise comparisons between the chamber controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A lower incidence in an exposure group is indicated by **N**.

^h Not applicable; no neoplasms in animal group

MICE 14-WEEK STUDY

All male and female mice survived to the end of the study (Table 7). The final mean body weights and body weight gains of all exposed groups of males and females were similar to those of the chamber controls.

There were no clinical findings or biologically significant effects on male or female reproductive endpoints attributed to isobutene exposure (Tables H3 and H4).

 TABLE 7

 Survival and Body Weights of Mice in the 14-Week Inhalation Study of Isobutene

			Mean Body Weight ^b (g)				
Concentration (ppm)	Survival ^a	Initial	Final	Change	Relative to Controls (%)		
Male							
0	10/10	$25.0~\pm~0.4$	35.9 ± 1.2	10.9 ± 1.0			
500	10/10	$24.8~\pm~0.3$	36.9 ± 0.8	$12.1~\pm~0.6$	103		
1,000	10/10	$25.2~\pm~0.4$	38.5 ± 0.8	13.3 ± 0.5	107		
2,000	10/10	$25.0~{\pm}~0.3$	35.9 ± 0.9	$10.9~\pm~0.8$	100		
4,000	10/10	$25.2~\pm~0.4$	36.1 ± 0.6	$10.9~\pm~0.5$	101		
8,000	10/10	25.0 ± 0.3	35.7 ± 0.9	$10.8~\pm~0.7$	99		
Female							
0	10/10	$19.8~\pm~0.2$	30.6 ± 0.6	$10.8~\pm~0.5$			
500	10/10	$20.0~\pm~0.3$	30.6 ± 0.7	$10.7~\pm~0.7$	100		
1,000	10/10	$20.1~\pm~0.3$	32.7 ± 1.1	$12.6~\pm~0.9$	107		
2,000	10/10	$20.1~\pm~0.2$	31.9 ± 0.9	$11.8~\pm~0.8$	104		
4,000	10/10	$20.2~\pm~0.3$	31.5 ± 1.0	11.3 ± 0.9	103		
8,000	10/10	20.1 ± 0.1	30.8 ± 0.6	10.7 ± 0.6	101		

^a Number of animals surviving at 14 weeks/number initially in group

^b Weights and weight changes are given as mean ± standard error. Differences from the chamber control group were not significant by Williams' or Dunnett's test.

The absolute and relative right kidney weights of 8,000 ppm males were greater (approximately 11%) than those of the chamber controls (Table G2). The absolute and relative right kidney weights of all groups of exposed females were greater (up to 18%) than those of the chamber controls, but, in general, were not exposure concentration related. There were no lesions detected grossly at necropsy or microscopically that supported these increases.

Exposure Concentration Selection Rationale: Based on the lack of significant exposure-related toxicologic

effects, 8,000 ppm was selected as the highest exposure concentration in the 2-year study. A higher concentration of isobutene could not be used because of the danger of explosion. The 2-year study exposure concentrations of 0, 500, 2,000, and 8,000 ppm were based on published metabolic elimination rates for Sprague-Dawley rats and B6C3F₁ mice (Csanády *et al.*, 1991). These rates indicated that 500 ppm would be within the linear range for metabolic elimination, 2,000 ppm would be out of the linear range.

2-YEAR STUDY

Survival

Estimates of 2-year survival probabilities for male and female mice are shown in Table 8 and in the Kaplan-Meier survival curves (Figure 8). Survival of exposed males and females was similar to that of the chamber controls.

Body Weights and Clinical Findings

Mean body weights of exposed male mice and 500 ppm females were generally similar to those of the chamber controls throughout the study; however, the mean body weights of 2,000 and 8,000 ppm females were slightly less than those of the chamber controls from about week 52 to week 92 (Tables 9 and 10 and Figure 9). There were no clinical findings attributed to isobutene exposure.

TABLE 8

Survival of Mice in the 2-Yea	r Inhalation Study of Isobutene
-------------------------------	---------------------------------

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Male				
Animals initially in study	50	50	50	50
Moribund	16	9	20	13
Natural deaths	6	9	3	9
Animals surviving to study termination	28	32	27	28
Percent probability of survival at end of stu	ıdy ^a 56	64	54	56
Mean survival (days) ^b	676	692	663	656
Survival analysis ^C	P=0.642	P=0.488N	P=0.835	P=0.977
Female				
Animals initially in study	50	50	50	50
Moribund	13	16	6	13
Natural deaths	5	3	5	4
Animals surviving to study termination	32	31	39	33
Percent probability of survival at end of stu	ıdy 64	62	78	66
Mean survival (days)	681	695	708	710
Survival analysis	P=0.802N	P=1.000	P=0.182N	P=0.820N

^a Kaplan-Meier determinations ^b Mean of all deaths (unconsorr

^b Mean of all deaths (uncensored, censored, and terminal sacrifice)

^c The result of the life table trend test (Tarone, 1975) is in the chamber control column, and the results of the life table pairwise comparisons (Cox, 1972) with the chamber controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by **N**.




FIGURE 8 Kaplan-Meier Survival Curves for Male and Female Mice Exposed to Isobutene by Inhalation for 2 Years

 TABLE 9

 Mean Body Weights and Survival of Male Mice in the 2-Year Inhalation Study of Isobutene

Weeks	Chambe	er Control		500 ppm			2,000 ppn	1		8,000 ppn	1
on	Av. Wt.	No. of		Wt. (% of			Wt. (% of			Wt. (% of	
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	25.6	50	25.9	101	50	25.6	100	50	25.5	100	50
2	27.5	50	27.6	100	50	27.4	100	50	27.4	100	50
3	28.4	50	28.5	100	50	28.3	100	50	28.2	99	50
4	29.3	50	29.3	100	50	29.1	99	50	29.2	100	50
5	30.2	50	30.1	100	50	29.9	99	50	29.9	99	50
6	30.8	50	30.6	99	50	30.2	98	50	30.4	99	50
7	31.3	50	31.1	99	50	30.7	98	50	31.0	99	50
8	31.7	50	31.5	99	50	31.4	99	50	31.5	99	50
9	32.7	50	32.6	100	50	32.7	100	50	32.6	100	50
10	33.2	50	33.1	100	50	33.1	100	50	33.2	100	50
11	34.0	50	34.0	100	50	33.9	100	50	33.8	99	50
12	34.6	50	34.8	101	50	34.6	100	50	34.6	100	50
13	35.4	50	35.3	100	50	35.2	99	50	35.2	99	50
16	36.3	50	37.4	103	50	36.8	101	50	37.6	104	50
20	38.7	50	38.8	100	50	38.9	101	50	39.9	103	50
24	41.5	50	41.8	101	50	41.5	100	50	43.2	104	50
28	43.7	50	44.5	102	50	42.8	98	50	45.3	104	50
32	44.8	50	45.4	101	50	44.2	99	50	46.3	103	50
36	46.4	50	47.1	102	50	46.2	100	50	48.2	104	50
40	47.0	50	47.5	101	50	46.2	98	50	48.0	102	49
44	47.7	50	48.7	102	50	47.4	99	50	49.6	104	49
48	49.1	50	49.8	101	50	48.7	99	50	50.6	103	48
52	48.9	50	50.0	102	50	48.7	100	50	50.6	104	47
56	49.7	50	50.6	102	50	49.0	99	50	50.9	102	46
60	50.5	48	51.4	102	49	50.2	99	48	51.3	102	46
64	51.0	47	52.0	102	49	50.6	99	47	51.1	100	46
68	50.1	47	51.0	102	49	49.8	99	47	50.6	101	45
72	50.8	46	51.1	101	49	50.4	99	46	50.8	100	45
76	50.3	46	51.6	103	47	50.9	101	42	51.1	102	42
80	50.2	45	51.6	103	46	50.8	101	42	52.0	104	40
84	50.7	43	51.5	102	45	51.0	101	40	52.8	104	39
88	50.5	39	51.5	102	42	50.5	100	38	51.9	103	38
92	49.9	38	50.0	100	42	50.2	101	35	51.5	103	36
94	49.4	38	50.6	102	39	50.6	102	33	52.0	105	35
96	49.9	35	49.8	100	39	49.8	100	32	50.9	102	35
98	49.7	35	49.8	100	37	49.4	99	32	51.1	103	33
100	49.4	34	49.6	100	37	49.0	99	30	50.0	101	31
102	49.8	31	48.8	98	36	48.3	97	29	49.8	100	29
104	49.8	29	49.2	99	32	47.5	95	28	49.5	99	29
Mean fo	r weeks										
1-13	31.1		31.1	100		30.9	99		31.0	100	
14-52	44.4		45.1	102		44.1	99		45.9	103	
53-104	50.1		50.6	101		49.9	100		51.1	102	

 TABLE 10

 Mean Body Weights and Survival of Female Mice in the 2-Year Inhalation Study of Isobutene

Weeks	Chambo	er Control		500 ppm			2,000 ppn	1		8,000 ppn	n
on	Av. Wt.	No. of		Wt. (% of			Wt. (% of			Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	20.0	50	19.8	99	50	20.0	100	50	19.8	99	50
2	21.6	50	21.3	99	50	21.6	100	50	21.9	101	50
3	23.0	50	22.6	98	50	22.8	99	50	22.9	100	50
4	23.3	50	23.3	100	50	23.3	100	50	23.6	101	50
5	24.2	50	24.0	99	50	24.4	101	50	24.2	100	50
6	25.0	50	24.9	100	50	25.1	100	50	24.8	99	50
7	25.6	50	25.4	99	50	25.3	99	50	25.2	98	50
8	26.0	50	25.5	98	50	25.5	98	50	25.5	98	50
9	26.8	50	26.3	98	50	26.5	99	50	26.5	99	50
10	27.1	50	27.0	100	50	27.7	102	50	27.4	101	50
11	28.2	50	27.8	99	50	27.6	98	50	28.0	99	50
12	29.2	50	28.6	98	50	28.3	97	50	29.3	100	50
13	29.5	50	28.9	98	50	28.7	97	50	29.2	99	50
16	30.9	50	31.5	102	50	30.8	100	50	31.3	101	50
20	34.9	50	34.3	98	50	33.8	97	50	34.7	99	50
24	36.9	50	37.5	102	50	37.1	101	50	37.9	103	50
28	39.9	50	40.6	102	50	39.8	100	50	39.4	99	50
32	41.2	50	42.1	102	50	40.9	99	50	40.5	98	50
36	43.9	49	44.5	101	50	41.9	95	50	43.0	98	50
40	44.9	49	45.1	100	50	42.3	94	50	43.1	96	50
44	46.3	49	47.7	103	50	44.7	97	50	45.6	99	50
48	48.3	48	49.3	102	50	46.2	96	50	45.7	95	50
52	48.8	48	49.7	102	50	46.0	94	50	45.2	93	50
56	50.4	47	51.7	103	50	47.3	94	50	47.1	94	50
60	52.8	47	53.7	102	50	50.1	95	50	49.4	94	50
64	54.9	47	55.2	101	50	52.2	95	50	51.7	94	50
68	56.2	46	55.0	98	50	52.8	94	50	52.0	93	50
72	57.3	46	56.3	98	49	54.5	95	49	53.0	93	50
76	57.9	46	57.2	99	48	55.1	95	48	53.5	92	50
80	57.9	45	56.2	97	48	55.5	96	47	54.7	95	49
84	58.1	44	56.9	98	46	56.6	97	47	55.4	95	48
88	57.6	42	54.9	95	45	54.6	95	46	53.3	93	46
92	55.9	41	54.2	97	42	54.3	97	43	52.7	94	45
94	55.6	40	55.5	100	38	54.3	98	43	53.0	95	44
96	54.1	39	55.4	102	36	53.8	99	43	52.3	97	43
98	53.8	37	54.6	102	36	53.5	99	42	52.4	97	42
100	53.6	36	53.6	100	35	52.5	98	40	51.0	95	41
102	52.5	36	54.5	104	33	51.3	98	40	50.3	96	39
104	52.0	34	53.2	102	33	50.8	98	39	51.1	98	34
Mean fo	r weeks										
1-13	25.3		25.0	99		25.1	99		25.3	100	
14-52	41.6		42.2	101		40.4	97		40.6	98	
53-104	55.0		54.9	100		53.1	97		52.1	95	
53-104	55.0		54.9	100		53.1	97		52.1	95	






FIGURE 9 Growth Curves for Male and Female Mice Exposed to Isobutene by Inhalation for 2 Years


2-Hydroxyisobutyric Acid — Biomarker of Exposure

HIBA was measured in the urine of male and female mice as an indicator of isobutene exposure at 6, 12, and 18 months (Table I2). The amount of HIBA excreted increased with increasing exposure concentration (Figures 10 and 11). However, when HIBA concentration was normalized to isobutene exposure concentration, the relative amount of HIBA excreted decreased as exposure concentrations increased (Figures 12 and 13). This was true at all three collection intervals for males and females. Exposure to isobutene had no effect on the quantity of urine or the amount of creatinine excreted.











Mean (± Standard Deviation) 2-Hydroxyisobutyric Acid Concentration Normalized to Creatinine for Female Mice in the 2-Year Inhalation Study of Isobutene





FIGURE 12

Mean (± Standard Deviation) 2-Hydroxyisobutyric Excretion Normalized to Creatinine and Exposure Concentration for Male Mice in the 2-Year Inhalation Study of Isobutene





Mean (± Standard Deviation) 2-Hydroxyisobutyric Excretion Normalized to Creatinine and Exposure Concentration for Female Mice in the 2-Year Inhalation Study of Isobutene

Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of nonneoplastic lesions of the nose. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, and statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group are presented in Appendix C for male mice and Appendix D for female mice.

Nose: The incidences of hyaline degeneration of the respiratory epithelium in all groups of exposed males

and females were significantly greater than those in the chamber control groups and occurred with positive trends (Tables 11, C4, and D4). The incidences of hyaline degeneration of the olfactory epithelium in males occurred with a positive trend. The incidences of this lesion in 2,000 and 8,000 ppm males were significantly greater than that in the chamber controls. The incidences of hyaline degeneration of the olfactory epithelium in females also occurred with a positive trend; however, the incidences were not statistically different from that in the chamber controls.

 TABLE 11

 Incidences of Nonneoplastic Lesions of the Nose in Mice in the 2-Year Inhalation Study of Isobutene

	Chambe	r Control	500 ppm	2,000 ppm	8,000 ppm
Male					
Number Examined Microscopically Respiratory Epithelium, Degeneration Hyaline Olfactory Epithelium, Degeneration Hyaline	a 50 6 6	(1.0) ^b (1.0)	49 19** (1.2) 7 (1.1)	50 29** (1.5) 16** (1.6)	48 39** (1.8) 17** (1.4)
Female					
Number Examined Microscopically Respiratory Epithelium, Degeneration Hyaline Olfactory Epithelium, Degeneration Hyaline	47 21 17	(1.8) (1.5)	50 39** (1.5) 19 (1.2)	49 41** (1.6) 24 (1.1)	50 48** (2.3) 27 (1.2)

** Significantly different (P≤0.01) from the chamber control group by the Poly-3 test

^a Number of animals with lesion

^b Average severity grade of lesions in affected animals: 1= minimal, 2= mild, 3= moderate, 4= marked

GENETIC TOXICOLOGY

Isobutene (0.001 to 0.027 mol/desiccator) was not mutagenic in *Salmonella typhimurium* strain TA97, TA98, TA100, or TA1535, with or without induced rat or hamster liver S9 enzymes (Table E1). *In vivo*, no increase in the frequency of micronucleated

normochromatic erythrocytes was seen in peripheral blood samples from male and female mice administered isobutene via inhalation for 14 weeks (Table E2).





PLATE 1

Follicular cell carcinoma (C) of the thyroid gland from a control male rat in the 2-year inhalation study of isobutene. The carcinoma has a follicular/papillary pattern and has completely replaced an entire lobe of the thyroid gland. T indicates the trachea. H&E; $10 \times$





Follicular cell carcinoma (C) of the thyroid gland from a male rat exposed to 8,000 ppm isobutene by inhalation for 2 years. The carcinoma has a follicular/papillary pattern and has completely replaced an entire lobe of the the thyroid gland. T indicates the trachea. H&E; $10 \times$



PLATE 3

Follicular cell carcinoma (C) of the thyroid gland from a male rat exposed to 8,000 ppm isobutene by inhalation for 2 years. The carcinoma has a solid pattern and has completely replaced an entire lobe of the thyroid gland. The contralateral lobe of the thyroid is normal (arrows). T indicates the trachea. H&E; $10 \times$





PLATE 4

Follicular cell carcinoma of the thyroid gland from a male rat exposed to 8,000 ppm isobutene by inhalation for 2 years. Note the mixed follicular/papillary pattern, the unilateral replacement of an entire lobe by the carcinoma, and locally extensive invasion of the adjacent peritracheal tissue (arrowheads). The contralateral lobe of the thyroid is normal (arrows). T indicates the trachea. H&E; $6 \times$






PLATE 5

Follicular cell carcinoma of the thyroid gland from a male rat exposed to 8,000 ppm isobutene by inhalation for 2 years. Note the primarily solid pattern, the unilateral replacement of an entire lobe by the carcinoma, and invasion of the adjacent peritracheal tissue (arrowheads). The contralateral lobe of the thyroid is normal (arrows). T indicates the trachea. H&E; $6 \times$

PLATE 6

Follicular cell carcinoma of the thyroid gland from a male rat exposed to 8,000 ppm isobutene by inhalation for 2 years. Note the primarily solid pattern and partial replacement of the lobe by the carcinoma. The contralateral lobe of the thyroid is normal. T indicates the trachea. H&E; $12 \times$




PLATE 7

Higher magnification of Plate 4. The neoplastic cells lining follicles (arrows) are uniformly cuboidal to low columnar. H&E; $175 \times$




PLATE 8

Higher magnification of Plate 5 illustrating the solid pattern. The neoplastic cells are densely packed and there is moderate variation in cellular size and shape (pleomorphism). Note the high number of mitotic figures (arrows). H&E; $175 \times$




PLATE 9

Higher magnification of Plate 3 illustrating the solid pattern. Note invasion (arrows) of the surrounding scirrhous capsule (arrowheads). H&E; $175 \times$



PLATE 10

Embolus of neoplastic cells (arrows) within the vasculature adjacent ot the follicular cell carcinoma illustrated in Plate 5. H&E; 230 \times




PLATE 11

Lung from the rat with the thyroid follicular cell carcinoma illustrated in Plate 5. Note a focus of metastatic neoplastic cells (arrows) adjacent to a terminal bronchiole (TB). Alveoli are indicated by asterisks. H&E; $230 \times$

DISCUSSION AND CONCLUSIONS

Isobutene was evaluated for toxicity and carcinogenicity in 14-week and 2-year inhalation studies in male and female F344/N rats and $B6C3F_1$ mice. The highest concentration (8,000 ppm) that could be generated safely was used in all studies. This concentration is somewhat less than 50% of the lower explosion limit of isobutene (*Patty's*, 1994).

In the 14-week studies, there were no exposurerelated deaths, body weight changes, clinical findings, effects on hematologic or clinical chemistry indices (rats), or biologically significant effects on male or female reproductive endpoints. No exposure-related increases in micronucleated erythrocytes were seen in mice. Kidney weights of male rats and male and female mice exposed to 8,000 ppm were greater than those of the chamber controls. For male rats and mice, these increases were approximately 10% or less, while the increases in female rats and mice were greater (about 20%). There were no histopathologic effects in the kidneys of exposed rats or mice. Liver weights of all exposed groups of female rats were also greater than those of the chamber controls; however, the increases did not occur in a concentration-related fashion, nor were there histopathologic effects in the liver. There were no exposure-related gross lesions in rats; however, a minimal hypertrophy of goblet cells lining the nasopharyngeal duct in the most caudal section of the nasal cavity was observed in all groups of exposed male and female rats. In mice, no lesions were detected grossly at necropsy or microscopically.

In the 2-year rat study, neither survival rates nor body weight gains were significantly affected by isobutene exposure. There were no exposure-related clinical findings. Isobutene exposure caused an increased incidence of thyroid gland follicular cell carcinoma in the 8,000 ppm male group compared to the chamber controls. The morphology of the carcinomas in this group was similar to the morphologic spectrum typical of spontaneously developing follicular cell carcinomas. There were no concurrent increases in the incidences of thyroid gland follicular cell hyperplasia or adenoma in male rats, nor were there increased incidences of proliferative lesions of the thyroid gland in exposed female rats compared to the chamber controls. The historical control range for follicular cell carcinoma in male rats in inhalation studies is 0% to 4%, and the highest historical control incidence of this neoplasm by any route for male rats is 3/50 (6%) (in a dosed feed study). The five carcinomas in the 8,000 ppm male group were considered treatment related because of the significant increase over historical control rates for inhalation studies as well as all other routes of administration.

Isobutene, like the structurally related compounds propylene, ethylene, 1,3-butadiene, and isoprene, is metabolized to an epoxide, 2-methyl-1,2-epoxypropane (1,1-dimethyloxirane). Although isobutene is not mutagenic in Salmonella typhimurium itself, the isobutene epoxide is mutagenic, but only at high concentrations. It was also clastogenic to human lymphocytes in vitro (Jorritsma et al., 1995). The epoxides of other olefins are mutagenic, and many are considered to be responsible for the carcinogenicity of the parent compound. For example, propylene was not carcinogenic in rats or mice (NTP, 1985a), whereas propylene oxide caused increased incidences of papillary adenoma of the nasal turbinates in male and female B6C3F₁ mice (NTP 1985b). 1,3-Butadiene (Owen et al., 1987; NTP, 1993) and isoprene (Melnick et al., 1994; NTP, 1998) were multisite carcinogens in rats and mice. Of importance is the fact that 1,3-butadiene caused thyroid gland follicular cell neoplasms in female rats following a 2-year exposure to concentrations up to 8,000 ppm. However, whether the isobutene epoxide 2-methyl-1,2-epoxypropane was responsible for the thyroid gland follicular cell carcinomas in male rats exposed to 8,000 ppm is not known, because the isobutene epoxide (at conditions of saturation) is detected in the exhaled air of rats at about 1% of that observed for 1,3-butadiene epoxide (1,2-epoxy-3-butene) or 7% of that observed for ethene oxide (Csanády et al., 1991).

Exposure of rats to isobutene caused an increase, although marginal, in the incidences of hyaline degeneration of the olfactory epithelium of the nose in males and females; more importantly, the severities of this lesion (mild to moderate) were increased in exposed males and females in a concentration-related fashion. No nasal neoplasms were observed in exposed male or female rats.

During the 2-year mouse study, neither survival rates nor body weight gains of males were significantly affected by isobutene exposure. Although survival rates for female mice were not affected by exposure, female mice exposed to 2,000 or 8,000 ppm weighed slightly less than the chamber controls in the second year of the study. There were no treatment-related clinical findings in mice. The only lesions associated with exposure in mice were nonneoplastic nasal lesions in all exposed groups of males and females. Nasal lesions included hyaline degeneration of the respiratory and olfactory epithelium; the lesions were minimal to mild in severity and the incidences increased with increasing exposure concentration. Although they were not observed in the 14-week mouse study, these lesions are fairly common in longterm inhalation studies. No nasal neoplasms were observed in male or female mice.

Exposure to isobutene for 6, 12, or 18 months had no effect on urine output or the concentration of urinary creatinine in male or female rats or mice. During the course of the study, there was no consistent time-related trend relative to the duration of exposure and the amount of 2-hydroxyisobutyric acid (HIBA) excreted per exposure concentration. Although the amount of HIBA/ μ g creatinine did increase with increasing exposure concentration at each of the three collection time points, when normalized to exposure

concentration (ng HIBA/µg creatinine per ppm isobutene), it decreased with increasing exposure concentration. The fact that the urinary excretion of HIBA was not directly proportional to exposure concentration indicates nonlinear toxicokinetics. This was true for male and female rats and mice. This finding was consistent with the findings of Csanády et al. (1991), who determined that isobutene metabolism was directly proportional to its concentration at concentrations of 500 ppm and less. Their assumptions were based on isobutene elimination from a closed inhalation exposure system. These data were used to set exposure concentrations for the 2-year rat and mouse isobutene studies in lieu of significant exposure-related toxicological effects following 14-week exposure to 8,000 ppm. Based on the 2-year results and the studies of Csanády et al. (1991) and Henderson et al. (1993), concentrations of isobutene greater than 500 ppm should result in kinetic events that are saturated.

CONCLUSIONS

Under the conditions of these 2-year inhalation studies, there was *some evidence of carcinogenic activity*^{*} of isobutene in male F344/N rats based on an increased incidence of follicular cell carcinoma of the thyroid gland. There was *no evidence of carcinogenic activity* of isobutene in female F344/N rats or male or female B6C3F₁ mice exposed to 500, 2,000, or 8,000 ppm.

Exposure to isobutene by inhalation for 2 years resulted in increased incidences and/or severities of nasal lesions including hyaline degeneration of the olfactory epithelium in male and female rats and mice and hyaline degeneration of the respiratory epithelium in male and female mice.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 8. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 10.

REFERENCES

The Aldrich Library of FT-IR Spectra (1985). 1st ed. (C.J. Pouchert, Ed.), Vol. 3, p. 28B. Aldrich Chemical Company, Inc., Milwaukee, WI.

Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. *Mutat. Res.* **257**, 229-306.

Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. *Biometrics* **44**, 417-431.

Bieler, G.S., and Williams, R.L. (1993). Ratio of estimates, the delta method, and quantal response tests for increased carcinogenicity. *Biometrics* **49**, 793-801.

Bogaards, J.J.P., Venekamp, J.C., and van Bladeren, P.J. (1996). The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. *Chem. Biol. Interact.* **102**, 169-182.

Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.

Castelain, Ph., Criado, B., Cornet, M., Laib, R., Rogiers, V., and Kirsch-Volders, M. (1993). Comparative mutagenicity of structurally related aliphatic epoxides in a modified Salmonella/ microsome assay. *Mutagenesis* **8**, 387-393.

Code of Federal Regulations (CFR) 21, Part 58.

Cornet, M., Sonck, W., Callaerts, A., Csanády, G., Vercruysse, A., Laib, R.J., and Rogiers, V. (1991). In vitro biotransformation of 2-methylpropene (isobutene): Epoxide formation in mice liver. *Arch. Toxicol.* **65**, 263-267.

Cornet, M., Castelain, Ph., Vercruysse, A., Laib, R., Kirsch-Volders, M., and Rogiers, V. (1992). Mutagenicity of 2-methylpropene (isobutene) and its epoxide in a modified Salmonella assay for volatile compounds. *Mutat. Res.* **271**, 213-221.

Cornet, M., Callaerts, A., Vercruysse, A., and Rogiers, V. (1995a). In vitro biotransformation of 2-methylpropene (isobutene) in rat lung tissue in comparison with liver tissue. *Arch. Toxicol.* **70**, 64-67.

Cornet, M., Callaerts, A., Jorritsma, U., Bolt, H., Vercruysse, A., and Rogiers, V. (1995b). Speciesdependent differences in biotransformation pathways of 2-methylpropene (isobutene). *Chem. Res. Toxicol.* **8**, 987-992.

Cox, D.R. (1972). Regression models and life-tables. *J. R. Stat. Soc.* **B34**, 187-220.

Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In *Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens* (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Princeton, NJ.

Csanády, G.A., Freise, D., Denk, B., Filser, J.G., Cornet, M., Rogiers, V., and Laib, R.J. (1991). Investigation of species differences in isobutene (2-methylpropene) metabolism between mice and rats. *Arch. Toxicol.* **65**, 100-105. Csanády, G.A., Guengerich, F.P., and Bond, J.A. (1992). Comparison of the biotransformation of 1,3-butadiene and its metabolites, butadiene mono-epoxide, by hepatic and pulmonary tissues from humans, rats, and mice. *Carcinogenesis* **13**, 1143-1153.

Del Monte, M., Citti, L., and Gervasi, P.G. (1985). Isoprene metabolism by liver microsomal monooxygenases. *Xenobiotica* **15**, 591-597.

Dixon, W.J., and Massey, F.J., Jr. (1951). Introduction to Statistical Analysis, 1st ed., pp. 145-147. McGraw-Hill Book Company, New York.

Dunn, O.J. (1964). Multiple comparisons using rank sums. *Technometrics* **6**, 241-252.

Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1096-1121.

Frank, H., Hintze, T., Bimboes, D., and Remmer, H. (1980). Monitoring lipid peroxidation by breath analysis: Endogenous hydrocarbons and their metabolic elimination. *Toxicol. Appl. Pharmacol.* **56**, 337-344.

Gervasi, P.G., and Longo, V. (1990). Metabolism and mutagenicity of isoprene. *Environ. Health Perspect.* **86**, 85-87.

Hawley's Condensed Chemical Dictionary (1993). 12th ed. (R.J. Lewis, Sr., Ed.), p. 652. Van Nostrand Reinhold, New York.

Hazardous Substances Data Bank (HSDB) (1997). Maintained, reviewed, and updated on the National Library of Medicine's Toxicology Data Network (TOXNET). Available through the MEDLARS system.

Henderson, R.F., Sabourin, P.J., Bechtold, W.E., Steinberg, B., and Chang, I.-Y. (1993). Disposition of inhaled isobutene in F344/N rats. *Toxicol. Appl. Pharmacol.* **123**, 50-61.

Hollander, M., and Wolfe, D.A. (1973). *Nonparametric Statistical Methods*, pp. 120-123. John Wiley and Sons, New York.

Jonckheere, A.R. (1954). A distribution-free *k*-sample test against ordered alternatives. *Biometrika* **41**, 133-145.

Jorritsma, U., Cornet, M., Van Hummelen, P., Bolt, H.M., Vercruysse, A., Kirsch-Volders, M., and Rogiers, V. (1995). Comparative mutagenicity of 2-methylpropene (isobutene), its epoxide 2-methyl-1,2-epoxypropane and propylene oxide in the *in vitro* micronucleus test using human lymphocytes. *Mutagenesis* **10**, 101-104.

Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **53**, 457-481.

Longo, V., Citti, L., and Gervasi, P.G. (1985). Hepatic microsomal metabolism of isoprene in various rodents. *Toxicol. Lett.* **29**, 33-37.

McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* **76**, 283-289.

MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The *in vivo* erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. *Fundam. Appl. Toxicol.* **14**, 513-522.

Malvoisin, E., and Roberfroid, M. (1982). Hepatic microsomal metabolism of 1,3-butadiene. *Xenobiotica* **12**, 137-144.

Malvoisin. E.. Lhoest. G., Poncelet. F.. Roberfroid. М., and Mercier. M. (1979).Identification and quantitation of 1,2-epoxybutene-3 as the primary metabolite of 1,3-butadiene. J. Chromatogr. 178, 419-425.

Margolin, B.H., Risko, K.J., Frome, E.L., and Tice, R.R. (1990). A general purpose statistical analysis program for micronucleus assay data. Appendix 2: Micronucleus data management and analysis version 1.4a. Integrated Laboratory Systems, Research Triangle Park, NC.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

Material Safety Data Sheet (1988). Isobutylene. Sheet No. 674. Genium Publishing Corporation, Schenectady, NY.

Melnick, R.L., Sills, R.C., Roycroft, J.H., Chou, B.J., Ragan, H.A., and Miller, R.A. (1994). Isoprene, an endogenous hydrocarbon and industrial chemical, induces multiple organ neoplasia in rodents after 26 weeks of inhalation exposure. *Cancer Res.* **54**, 5333-5339.

The Merck Index (1989). 11th ed. (S. Budavari, Ed.), p. 810. Merck and Company, Rahway, NJ.

Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In *Origins of Human Cancer* (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Morrison, D.F. (1976). *Multivariate Statistical Methods*, 2nd ed., pp. 170-179. McGraw-Hill Book Company, New York.

National Cancer Institute (NCI) (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Technical Report Series No. 1. NIH Publication No. 76-801. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

National Institute for Occupational Safety and Health (NIOSH) (1990). National Occupational Exposure Survey (1981-1983), unpublished provisional data as of July 1, 1990. NIOSH, Cincinnati, OH.

National Institutes of Health (NIH) (1978). Open Formula Rat and Mouse Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, NIH, Bethesda, MD.

National Library of Medicine (1997). MEDLINE, CANCERLIT, TOXLINE. Toxicology Data Bank databases maintained by the National Library of Medicine. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.

National Toxicology Program (NTP) (1985a). Toxicology and Carcinogenesis Studies of Propylene (CAS No. 115-07-1) in F344/N Rats and B6C3F₁ Mice (Inhalation Studies). Technical Report Series No. 272. NIH Publication No. 86-2528. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1985b). Toxicology and Carcinogenesis Studies of Propylene Oxide (CAS No. 75-56-9) in F344/N Rats and B6C3F₁ Mice (Inhalation Studies). Technical Report Series No. 267. NIH Publication No. 85-2527. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1987). National Toxicology Program (NTP). Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice, 10/31/82 version (updated April 1987). Research Triangle Park, NC.

National Toxicology Program (NTP) (1993). Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS No. 106-99-0) in $B6C3F_1$ Mice (Inhalation Studies). Technical Report Series No. 434. NIH Publication No. 93-3165. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC. National Toxicology Program (NTP) (1995). Toxicity Studies of Isoprene (CAS No. 78-79-5) Administered by Inhalation to F344/N Rats and $B6C3F_1$ Mice. Toxicity Report Series No. 31. NIH Publication No. 95-3354. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1998). Toxicology and Carcinogenesis Studies of Isoprene (CAS No. 78-79-5) in F344/N Rats (Inhalation Studies). Technical Report Series No. 486. NIH Publication No. 99-3976. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC. (In press)

Owen, P.E., Glaister, J.R., Gaunt, I.F., and Pullinger, D.H. (1987). Inhalation toxicity studies with 1,3-butadiene. 3. Two year toxicity/ carcinogenicity study in rats. *Am. Ind. Hyg. Assoc. J.* **48**, 407-413.

Patty's Industrial Hygiene and Toxicology (1994). 4th ed. (G.D. Clayton and F.E. Clayton, Eds.), Vol. 2B, pp. 1242-1243, 1247-1248. John Wiley and Sons, Inc., New York.

Peter, H., Wiegand, H.J., Bolt, H.M., Greim, H., Walter, G., Berg, M., and Filser, J.G. (1987). Pharmacokinetics of isoprene in mice and rats. *Toxicol. Lett.* **36**, 9-14.

Peter, H., Wiegand, H.-J., Filser, J.G., Bolt, H.M., and Laib, R.J. (1990). Inhalation pharmacokinetics of isoprene in rats and mice. *Environ. Health Perspect.* **86**, 89-92.

Piegorsch, W.W., and Bailer, A.J. (1997). *Statistics for Environmental Biology and Toxicology*, Section 6.3.2. Chapman and Hall, London.

Placke, M.E., Griffis, L., Bird, M., Bus, J., Persing, R.L., and Cox, L.A., Jr. (1996). Chronic inhalation oncogenicity study of isoprene in $B6C3F_1$ mice. *Toxicology* **110**, 253-262. Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. *Fundam. Appl. Toxicol.* **12**, 731-737.

Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. *Cancer Res.* **46**, 4372-4378.

Sax's Dangerous Properties of Industrial Materials (1992). 8th ed. (R.J. Lewis, Sr., Ed.), p. 2015. Van Nostrand Reinhold, New York.

Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. *Environ. Mol. Mutagen.* **25**, 302-313.

Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. *Environ. Mol. Mutagen.* **21**, 160-179.

Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* **33**, 386-389.

Staab, R.J., and Sarginson, N.J. (1984). Lack of genetic toxicity of isobutylene gas. *Mutat. Res.* **130**, 259-260.

Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. *JNCI* **67**, 233-241.

Tarone, R.E. (1975). Tests for trend in life table analyis. *Biometrika* **62**, 679-682.

Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from *in vitro* genetic toxicity assays. *Science* **236**, 933-941. Voogd, C.E., van der Stel, J.J., and Jacobs, J.J.J.A.A. (1981). The mutagenic action of aliphatic epoxides. *Mutat. Res.* **89**, 269-282.

Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* **27**, 103-117.

Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. *Biometrics* **28**, 519-531.

Wistuba, D., Weigand, K., and Peter, H. (1994). Stereoselectivity of in vitro isoprene metabolism. *Chem. Res. Toxicol.* **7**, 336-343.

Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. *Environ. Mol. Mutagen.* **16** (Suppl. 18), 1-14.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE 2-YEAR INHALATION STUDY OF ISOBUTENE

Summary of the Incidence of Neoplasms in Male Rats	
in the 2-Year Inhalation Study of Isobutene	60
Individual Animal Tumor Pathology of Male Rats	
in the 2-Year Inhalation Study of Isobutene	64
Statistical Analysis of Primary Neoplasms in Male Rats	
in the 2-Year Inhalation Study of Isobutene	84
Historical Incidence of Thyroid Gland Follicular Cell Neoplasms	
in Chamber Control Male F344/N Rats	88
Summary of the Incidence of Nonneoplastic Lesions in Male Rats	
in the 2-Year Inhalation Study of Isobutene	89
	Individual Animal Tumor Pathology of Male Ratsin the 2-Year Inhalation Study of IsobuteneStatistical Analysis of Primary Neoplasms in Male Ratsin the 2-Year Inhalation Study of IsobuteneHistorical Incidence of Thyroid Gland Follicular Cell Neoplasmsin Chamber Control Male F344/N RatsSummary of the Incidence of Nonneoplastic Lesions in Male Rats

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	39	40	37	41
Natural deaths Survivors	4	5	7	1
Terminal sacrifice	7	5	6	8
Animals examined microscopically	50	50	50	50
Alimentary System				
ntestine large, colon	(49)	(48)	(48)	(49)
ntestine large, rectum	(47)	(49)	(49)	(49)
Polyp adenomatous	1 (2%)			
ntestine large, cecum	(48)	(47)	(49)	(49)
ntestine small, jejunum	(47)	(46)	(47)	(49)
Carcinoma	1 (2%)		1 (2%)	
Hemangiosarcoma ntestine small, ileum	(47)	(46)	1 (2%) (47)	(49)
Leiomyosarcoma	(47)	(40)	(47)	(49)
iver	(50)	(50)	(50)	(50)
Histiocytic sarcoma	1 (2%)	()	2 (4%)	
Osteosarcoma, metastatic, bone	1 (2%)			
lesentery	(15)	(10)	(8)	(11)
Liposarcoma		1 (10%)	(I)	
Pral mucosa			(1)	
Pharyngeal, squamous cell papilloma ancreas	(50)	(50)	1 (100%) (50)	(50)
Adenoma	2 (4%)	1 (2%)	(50)	(30)
alivary glands	(50)	(50)	(50)	(50)
tomach, forestomach	(50)	(50)	(50)	(50)
tomach, glandular	(50)	(49)	(50)	(50)
ongue	(1)			(1)
Hemangiosarcoma				1 (100%)
Cardiovascular System				
Ieart	(50)	(50)	(50)	(50)
Endocrine System	(7.0)		(70)	(70)
Adrenal cortex	(50)	(49)	(50)	(50)
Adenoma Osteosarcoma, metastatic, bone	1 (2%) 1 (2%)			1 (2%)
drenal medulla	(50)	(49)	(50)	(50)
Pheochromocytoma malignant	(00)	1 (2%)	1 (2%)	2 (4%)
Pheochromocytoma benign	13 (26%)	7 (14%)	8 (16%)	11 (22%)
Bilateral, pheochromocytoma malignant				1 (2%)
Bilateral, pheochromocytoma benign	10 (20%)	11 (22%)	8 (16%)	12 (24%)
slets, pancreatic	(50)	(49)	(50)	(50)
Adenoma	4 (8%)	0 (404)	1 (2%)	4 (8%) 4 (8%)
Carcinoma	4 (8%) (50)	2 (4%)	1 (2%)	4 (8%) (40)
'ituitary gland Pars distalis, adenoma	(50) 43 (86%)	(49) 40 (82%)	(50) 40 (80%)	(49) 41 (84%)

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Endocrine System (continued) Thyroid gland C-cell, adenoma C-cell, carcinoma	(48) 5 (10%)	(48) 4 (8%)	(48) 5 (10%)	(50) 7 (14%)
Follicular cell, carcinoma	1 (2%)		2 (4%)	1 (2%) 5 (10%)
General Body System None				
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Preputial gland	(50)	(50)	(49)	(50)
Adenoma	4 (8%)	2 (4%)	2 (4%)	1 (2%)
Carcinoma	1 (2%)	2 (4%)	2 (4%)	3 (6%)
Bilateral, carcinoma	(50)	1 (2%)	(50)	(50)
Prostate	(50)	(49)	(50)	(50)
Adenoma Seminal vesicle	(50)	(47)	(50)	1 (2%) (50)
Festes	(50)	(47)	(50)	(50)
Bilateral, interstitial cell, adenoma	13 (26%)	14 (28%)	17 (34%)	14 (28%)
Interstitial cell, adenoma	10 (20%)	14 (28%)	12 (24%)	11 (22%)
Hematopoietic System				
Bone marrow	(50)	(48)	(50)	(50)
Histiocytic sarcoma	(30)	(40)	2 (4%)	(50)
Lymph node	(4)	(11)	(10)	(10)
Histiocytic sarcoma	1 (25%)	(11)	1 (10%)	(10)
Iliac, osteosarcoma, metastatic, bone	1 (25%)			
Pancreatic, histiocytic sarcoma	· ·		1 (10%)	
Lymph node, bronchial	(30)	(41)	(35)	(45)
Histiocytic sarcoma	1 (3%)		2 (6%)	
Lymph node, mandibular	(47)	(47)	(49)	(49)
Lymph node, mesenteric	(50)	(50)	(49)	(50)
Lymph node, mediastinal	(46)	(42)	(44)	(45)
Carcinoma, metastatic, thyroid gland			1 (2%)	1 (2%)
Histiocytic sarcoma Spleen	(50)	(49)	(50)	(50)
Histiocytic sarcoma	(30)	(43)	(50)	(30)
Thymus	(40)	(42)	(38)	(42)
Integumentary System				
Mammary gland	(41)	(41)	(40)	(44)
Carcinoma	(11)	1 (2%)	(10)	(11)
Carcinoma, multiple	1 (2%)	I (W/0)		
Fibroadenoma	1 (2%)		1 (3%)	1 (2%)

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Integumentary System (continued)				
Skin	(50)	(50)	(50)	(50)
Basal cell adenoma				2 (4%)
Basal cell carcinoma		2 (4%)		
Keratoacanthoma	3 (6%)	4 (8%)	2 (4%)	4 (8%)
Squamous cell papilloma		1 (2%)	2 (4%)	1 (2%)
Sebaceous gland, adenoma		2 (4%)	1 (2%)	
Subcutaneous tissue, fibroma	1 (2%)		2 (4%)	
Subcutaneous tissue, histiocytic sarcoma			1 (2%)	
Subcutaneous tissue, lipoma	1 (2%)			
Subcutaneous tissue, rhabdomyosarcoma				1 (2%)
Subcutaneous tissue, sarcoma	1 (2%)			
Subcutaneous tissue, schwannoma benign	1 (2%)			
Subcutaneous tissue, schwannoma maligna	nt	1 (2%)		
Subcutaneous tissue, pinna, melanoma mal	ignant	1 (2%)		
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	1 (2%)	1 (2%)	(~~)	(00)
Skeletal muscle	(1)	1 (270)	(1)	(1)
Histiocytic sarcoma	(1)		1 (100%)	(1)
			_ (,	
Nervous System				
Brain	(50)	(50)	(50)	(50)
Astrocytoma malignant	1 (2%)			
Histiocytic sarcoma			1 (2%)	
Oligodendroglioma malignant	1 (2%)			
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	2 (4%)	2 (4%)	2 (4%)	(50)
Alveolar/bronchiolar carcinoma	2 (470)	2 (4%)	1 (2%)	1 (2%)
Carcinoma, metastatic, thyroid gland		2 (470)	1 (270)	1 (2%)
Histiocytic sarcoma	1 (2%)		2 (4%)	1 (278)
Osteosarcoma, metastatic, bone	1 (2%)		2 (470)	
Mediastinum, alveolar/bronchiolar carcino				
metastatic, lung	ma,	1 (2%)		
Nose	(49)	(49)	(50)	(49)
tust	(15)	(17)	(50)	(13)
Special Senses System				
Eye	(3)		(4)	
Zymbal's gland		(2)	(1)	
Carcinoma		2 (100%)	1 (100%)	
		· · · · · /	×,	
Urinary System				
Xidney	(50)	(50)	(50)	(50)
			1 (2%)	
Histiocytic sarcoma	1 (00/)			1 (2%)
Stromal nephroma	1 (2%)			. ,
Stromal nephroma Renal tubule, adenoma	1 (2%) 2 (4%)	1 (2%)		2 (4%)
Stromal nephroma		1 (2%) (49)	2 (4%) (50)	. ,

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Histiocytic sarcoma	1 (2%)		2 (4%)	
Leukemia mononuclear	21 (42%)	21 (42%)	20 (40%)	31 (62%)
Mesothelioma malignant	3 (6%)	2 (4%)		
Neoplasm Summary Total animals with primary neoplasms ^c	50	48	49	50
Total animals with primary neoplasms ^c Total primary neoplasms	155	143	138	165
Total animals with primary neoplasms ^c Total primary neoplasms Total animals with benign neoplasms	155 48	143 46	138 49	165 49
Total animals with primary neoplasms ^c Total primary neoplasms Total animals with benign neoplasms Total benign neoplasms	155 48 117	143 46 103	138 49 104	165 49 113
Total animals with primary neoplasms ^c Total primary neoplasms Total animals with benign neoplasms Total benign neoplasms Total animals with malignant neoplasms	155 48 117 31	143 46 103 33	138 49 104 28	165 49 113 40
Total animals with primary neoplasms ^c Total primary neoplasms Total animals with benign neoplasms Total benign neoplasms	155 48 117	143 46 103	138 49 104	165 49 113

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а

b

с

TABLE A2

	3	4	4	4	4	5	5	5	5	5	5	5	5	5	5	5 5	56	6	6	3	6	6	6	6	6
Number of Days on Study	7	6	7	7	9	1	3	3	4	4	5	6		7	8	8 9	9 1	1	2	2	2	3	3	3	
	9	7	6	7	5	6			0	4							0 4							9	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 () () () (0	0	0	0	0
Carcass ID Number	0 9	0 7	2 4		4 0								2 3										1 7		
limentary System		-		-	-						-		-	-							-	-	_	-	
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷ -	÷ -	L _	L .	∟ .	+	+	+	+	+
ntestine large, colon	+	+	+	+	+	+	+	+	+	Ă		•	+	+	+ .	+ -	+ -		L .	F .	+	+	+	+	+
ntestine large, rectum	+	+	+	+	+	+	+	+	+	A		Í		+			+ -			• ⊢ ·	+	+	+	+	+
Polyp adenomatous	-	т	т	т	т	т	т	т	т	Л	т	1	т	т	т	T	T -		K	F	T	т	т	т	-
Intestine large, cecum		-		-	-	-	-	-	-	А	+	+	А	+	н.	L .	L .		• ⊢ -	L .		-	-	-	т
Intestine small, duodenum	т 	+	+	+	+	+	+	+	+	A					+	+ ·	+ -				+	+	+	+	+
ntestine small, jejunum	+	Å	+	+	+	+	+	+		A				+		+ -	+ -				+	+	+	+	+
Carcinoma	т	Л	T	т	ſ	ſ	1	1-	r.	11	C.	-	11								1	1.	X	r	1
Intestine small, ileum	-	Δ	+	+	+	+	+	+	+	Δ	+	+	А	+	+	+ -	+ -	⊢ -	F -	+ -	+	+	+	+	+
Liver	т 	л +	+	+	+	+	+	+	+	- 1 +	+	+	+	+			+ -				+	+	+	+	+
Histiocytic sarcoma	т	т	T	т	ſ	ſ	1	1-	r.	1-	C.	-	1-								1	1.	1.	r	1
Osteosarcoma, metastatic, bone																									
Aesentery				+		+	+											_	L			-		-	т
ancreas		-		т 	-	+ +	т _	-	-	_	-	-	т.	-	н.	L .	L .			L .		т _	-	т _	т
Adenoma		'				'			'					'									'		1
alivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷ -	÷ -	L _	L .	∟ .	+	+	+	+	+
tomach, forestomach	т 	+ +	- -	т 	+ +	+ +	т _	т _	+ +	т _	+ +	т _	+ +	+ +	т 	т -	т - 1			г L .	-	т _	- -	т _	т
tomach, glandular	т 1	- -	- -	т ,	т	- -	т ,	т	- -	- -	т	- -	- -	т	т :	 -	т -			г [.]	т	т	-	- -	т
'ongue	т	т	Ŧ	т	т	т	т	Ŧ	т	Ŧ	т	Ŧ	т	т	T	Τ -	Τ -				т	Ŧ	Ŧ	Ŧ	Ŧ
Tooth												+											+		
												1													
C ardiovascular System Blood vessel																								+	
leart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+ -	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	⊢ -	+	+	+	+	+	+
Adenoma																									
Osteosarcoma, metastatic, bone																									
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	⊦ -	+	+	+	+	+	+
Pheochromocytoma benign							Х						+ X	Х		2	X X	ĸ				Х			
Bilateral, pheochromocytoma benign																									
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	⊦ -	+	+	+	+	+	+
Adenoma																									
Carcinoma				Х																					
Parathyroid gland	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	⊢ -	+	+	+	М	+	+
ituitary gland													+												
Pars distalis, adenoma													X												
Thyroid gland	+	А											А												
C-cell, adenoma									X																
Follicular cell, carcinoma																									

None

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: Chamber Control

	6	6	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7	1	7	7	7	7	1	1	7	
Number of Days on Study	4	5	6	6	7	7	8	8	8	8	9	9	0				1	2	3	3	3	3	3	3	3	
	8	0	1	6	0	8	1	3	3	4	1	2	5	6	6	9	9	0	3	3	3	3	3	3	3	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	4	1	4	1	2	3	3	2	4	3	1	4	4	2	3	1	3	1	0	1	1	1	2	2	3	Tissues/
	9	3	8	4	9	0	4	5	5	5	6	6	4	1	7	8	9	9	3	0	1	2	7	8	6	Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ι	+	+	+	+	47
Polyp adenomatous																										1
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Carcinoma																										1
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma													Х													1
Osteosarcoma, metastatic, bone																						Х				1
Mesentery			+								+					+				+	+	+	+		+	15
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma											X								X							2
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Tongue		-										-				+			-							1
Γοοth																										2
Cardiovascular System																										
Blood vessel																	+									2
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
				-											-							-			-	
Endocrine System Adrenal cortex																										50
Adenoma	Ŧ	Ŧ	т	т	т	т	X	т	т	т	т	Ŧ	т	т	т	Ŧ	т	Ŧ	Ŧ	Ŧ	т	т	Ŧ	т	Ŧ	1
Osteosarcoma, metastatic, bone							Λ															Х				1
Adrenal medulla																						<u>л</u>		+		50
Pheochromocytoma benign	+	+	X	+	+	+	+	+	+ X	+	+	+ X	+	т Х	÷	+	+	+ X	+	+	X	+	+	+	+	13
Bilateral, pheochromocytoma benign	Х		л			Х			Л		Х	л	Х	Λ			Х	Л		х	л	v	v	Х	v	10
slets, pancreatic	<u>л</u>														+						+			л +		50
Adenoma	+	+	+	+ X	+	+	+	+	+	+	Ŧ	+ X	Ŧ	+ X	т	Ŧ	т	+	+	Ŧ	Ŧ	+	+ X	+	т	50 4
Carcinoma	Х			л								Λ		Λ			Х				Х		л			4
Parathyroid gland	<u>л</u>	+	+					+			+	+	+	+	+			+	+	+	л +		+		+	4 49
	+	+		+	+	+	+		+	+						++						+				49 50
Pituitary gland Pars distalis, adenoma	+ X	\mathbf{v}^+	+ V	+ V	$^+$	$^+$ v		+ V			$^+$				+ X					+	$^+$ v		$^+$	+ X		50 43
	<u>л</u>	^	л +			л +	<u>л</u>		л +												л +		л +		л +	43 48
Fhyroid gland C-cell, adenoma	+	+	+	+	+ X	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+ X	+	+ X	+	+	+	48 5
			v		Λ								л							л		л				
Follicular cell, carcinoma			Х																							1

TABLE A2

~					٣	٣	~	~	~	۲	٣	r	~	۲	۲	~	0	6	6	0	0	~	~	0
		4	4	4	5	5		5	5						5			6	6	6	6	6	6	6
																	1	1	2					4 5
	_			0		-																		
0																								
0	0		0	4	3		4			1	0							2	4	2	0	1		0
9	7	4	8	0	1	2	1	7	4	5	2	3	8	2	2	3	0	6	3	0	5	7	6	1
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	Х													Х										
											Х													
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Х						Х		Х										Х						
																	Х			Х			Х	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+																						+	
									۰.			۰ <i>۰</i>	۰.											
N	I N	i +	Μ	M	+	+	Μ	Μ	Μ	+	M	Μ	Μ	+	+	+	+	+	M	Μ	M	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+			
+	+	+	+	+	+		+				+					+	+	+	+	+	+			
+	+	+	Μ	Μ	+	+	Μ	+	+	+	+	+	М	+	+	+	+	+	+	+	+	Μ	Μ	+
N	ſN	ſN	ſМ	+	М	+	м	+	м	+	м	+	+	+	+	+	+	+	+	М	+	+	+	+
14.	- 14					·	.,,	•		'		•	•	•	•	•				.,,				
+			_	_	-	-	-	-	-	-	-	-	т.	т.	_	т	_	-	-	т.	-	-		1
т	7	7	Ŧ	Г	Г	ſ	C.	r.	1-	r	ſ	r.	1.		'	1	C.	F		r	r	F	Г	'
																			Λ					
																								Х
																							v	л
																							л	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
											+													
+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
X																								
																			X					
	-	-																					-	
+		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
т 				- -	+	+	+	+	+	+	- -	- +	+	+	+	+	+	+	+	+	- -	+	+	+
+	т	т	T	-1-	7*	τ'	т'	T,	т,	т'	т.	т	г		x	г	т'	7*	-1-	т.	т.	Τ.	-1-	1
															<i>.</i> 1									
						_	_	-	_	L	J	Δ	т	-	-	ч	L			ر		J		т
	0 9 + + + X + X + M + + + M + + + + + + + + +	7 6 9 7 0 0 9 7 + + + + + X + + + + X + + X X + + + + +	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7 6 7 7 9 9 7 6 7 7 5 0 0 0 0 0 0 9 7 4 8 0 + + + + + + + + + + + + + + + X - - - - M M + + + + + + + + + + M M + H + + + + + + + + M M M M + + + + + + + + + + + + + + + + M M M M + + + + + + + + + +	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7 6 7 7 9 1 3 3 4 4 2 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7 6 7 7 9 1 3 3 4 4 5 6 7 7 8 8 9 1 1 2 9 7 6 7 5 6 9 9 0 4 2 0 4 6 0	7 6 7 7 9 1 3 3 4 4 5 6 7 7 8 8 9 1 1 2 2 9 7 6 7 5 6 9 9 0 4 2 0 4 6 0	7 6 7 7 9 1 3 3 4 4 5 6 7 7 8 8 9 1 1 2 2 3 0	7 6 7 7 9 1 3 3 4 4 5 6 7 7 8 8 9 1 1 2 2 3 3 9 7 6 7 5 6 9 9 0 4 2 0	7 6 7 7 9 1 3 3 4 4 5 6 7 7 8 8 9 1 1 2 2 3 3 3 9 7 6 7 7 8 8 9 1 1 2 2 3 3 3 4 4 5 2 3 2 4 3 5 2 4 3 5 2 4 3 5 2 4 3 5 2 4 3 5 2 4 4 4 4 4 5 2 3 8 2 2 3 0 6 3 0 5 7 6 9 7 4 8 0 1 2 1 7 4 5 2 3 8 2 2 3 0 6 3 0 5 7 6 4 4 4 4 4 4 4 4 </td

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: Chamber Control

av																										
Number of Days on Study	6 4 8	6 5 0	6 6 1	6 6 6	6 7 0	6 7 8	6 8 1	6 8 3	6 8 3	6 8 4	6 9 1	6 9 2	0	7 0 6	7 0 6	7 1 9	7 1 9	7 2 0	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	3	7 3 3	
Carcass ID Number	0 4 9	0 1 3	0 4 8	0 1 4	0 2 9	0 3 0	0 3 4	0 2 5	0 4 5	0 3 5	0 1 6	0 4 6	4	2	3	1	3	0 1 9	0	0 1 0	0 1 1	0 1 2	0 2 7	0 2 8	3	Total Tissues/ Tumors
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
Preputial gland Adenoma	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	50 4
Carcinoma					Λ																Λ					1
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma			Х		х	х	х		Х	Х	х	Х	Х			Х		Х	Х	Х	Х	х			Х	13 10
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node													+									+				4
Histiocytic sarcoma													Х									•••				1
Iliac, osteosarcoma, metastatic, bone		,	١,		14										N۶	۸,4	,					Х	14		N /	1
Lymph node, bronchial Histiocytic sarcoma	+	+	IVI	+	Μ	+	+	+	+	+	+	+	+ X	+	М	IVI	+	+	+	+	+	IVI	IVI	+	IVI	30 1
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+		+	М	+	+	+	М	+	+	+	+	+	+	47
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Lymph node, mediastinal	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	М	+	46
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thymus	+	+	М	М	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	40
Integumentary System																										
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	41
Carcinoma, multiple							Х																			1
Fibroadenoma																Х										1
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Keratoacanthoma Subcutaneous tissue, fibroma	х			Х																			Х			3 1
Subcutaneous tissue, lipoma	л																									1
Subcutaneous tissue, sarcoma																										1
Subcutaneous tissue, schwannoma benign										Х																1
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Osteosarcoma																						Х				1
Skeletal muscle																										1
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Astrocytoma malignant																										1
Oligodendroglioma malignant																										1
Respiratory System																										
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ v	+	+	+	+	+	+	+	+	+	50
																Х										2
Alveolar/bronchiolar adenoma													X													1
Alveolar/bronchiolar adenoma Histiocytic sarcoma													Х									x				1
	+	+	+	+	+	+	+	+	+	+	+	+	X +	+	+	+	+	+	+	+	+	X +	+	+	+	1 1 49

68

TABLE A2

Individual Animal Tumor Patho	logy of Male	R	ats	s in	th	e 2	Ye	ar	In	ha	lati	ion	St	udy	y o	f I	soł	out	en	e:	Cl	ıar	nb	er	Control
	3	4	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6
Number of Days on Study	7	6	7	7	9	1	3	3	4	4	5	6	7	7	8	8	9	1	1	2	2	3	3	3	4
	9	7	6	7	5	6	9	9	0	4	2	0	4	6	0	0	0	4	6	1	8	3	6	9	5
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcass ID Number	0	0	2	0	4	3	3	4	4	0	1	0	2	3	2	4	3	5	2	4	2	0	1	0	0
	9	7	4	8	0	1	2	1	7	4	5	2	3	8	2	2	3	0	6	3	0	5	7	6	1
Special Senses System Eye																								+	
Urinary System																									
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stromal nephroma								Х																	
Renal tubule, adenoma Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
•																									
Systemic Lesions																									
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma Leukemia mononuclear		Х							Х								х	v	v		х				
Mesothelioma malignant		л							л	х							Λ	Λ	л		л				х

Individual Animal Lumor Patio	logy of Mai	e.	Кð	us	ш	ui	e 2	- 1 (ear		Шă	uat	101	13	luc	IY (. 10	120	DU	ten	e:	U	llä	шр	er	U	ntroi
Number of Days on Study	6 4 8	:	6 5 0	6 6 1	6 6 6	6 7 0	6 7 8	6 8 1	6 8 3	6 8 3	6 8 4	6 9 1	6 9 2	7 0 5	7 0 6	7 0 6	7 1 9	7 1 9	7 2 0	7 3 3							
Carcass ID Number	0 4 9		0 1 3	0 4 8	0 1 4	0 2 9	0 3 0	0 3 4	0 2 5	0 4 5	0 3 5	0 1 6	0 4 6	0 4 4	0 2 1	0 3 7	0 1 8	0 3 9	0 1 9	0 0 3	0 1 0	0 1 1	0 1 2	0 2 7	0 2 8	0 3 6	Total Tissues/ Tumors
Special Senses System Eye												+						+									3
Urinary System Kidney Stromal nephroma Renal tubule, adenoma	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+ X	+	+	+	+	+	+	+	+	50 1 2
Urinary bladder	4	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Systemic Lesions Multiple organs Histiocytic sarcoma	+	_	+	+	+	+	+	+	+	+	+	+	+	+ X		+	+	+	+	+	+	+	+	+	+	+	50 1
Leukemia mononuclear Mesothelioma malignant	У	ζ	Х	X			X X	Х	Х				Х	X				Х		Х	Х		Х	Х	X	Х	

TABLE A2

	•	0	4	4	4	٣	۲	۲	۲	٣	۲	F	۲	۲	۲	٢	٣	F	۲	e	C	c	C	C	C	
Number of Dove on State		3		4	4	5												5	5	6	6	6	6	6	6	
Number of Days on Study	4 4		6 0	6 9	8 2	0 7	1 4	2 3		2 6								8 3	9 2	0 4	0 7	1 4	2 4	2 5	2 6	
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		2	2	2	2	2	2	2	2	
Carcass ID Number	4 3	2 6			3 3	4 8			1 0				0 5					3 6	2 2		2 9	2 0		4 1		
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	A	. +	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	A	. +	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	A	. +	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	A	. +	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Mesentery																				+					+	
Liposarcoma																										
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tooth	+											+														
Cardiovascular System																										
Blood vessel																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System																										
Adrenal cortex	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal medulla	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma malignant																										
Pheochromocytoma benign												Х														
Bilateral, pheochromocytoma benign									Х																	
Islets, pancreatic	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Carcinoma																										
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pituitary gland	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pars distalis, adenoma			Х		Х	Х	Х		Х		Х	Х	Х	Х		Х	Х	Х	Х	Х	Х	Х	Х	Х		
Thyroid gland	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	
C-cell, adenoma																		Х								
General Body System None	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																		X								
Carcinoma									Х																	
Bilateral, carcinoma																										
Prostate	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Seminal vesicle	+	A	. +	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Bilateral, interstitial cell, adenoma								Х							Х									Х	Х	
Interstitial cell, adenoma			Х						Х			Х				Х			x	Х	x					

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 500 ppm

	, or ma											-		-J							• I	-			
Number of Days on Study		2 3		6 (4 4 1 2			6 6 4	6 6 4	6 7 0		7	7	66 88 44	8	6 9 2	6 9 2	7 0 2	7 0 6	7 1 6	7 3 3	7 3 3	7 3 3	7 3 3	3	
Carcass ID Number	2 1 7	L 1	1 3		2 2) 1 4 2	0	2 0 1	2 3 0	2 1 5			1	22 23 41	3	2 0 7	2 4 4	2 3 4	2 4 0	2 4 9	2 0 8	2 2 8	2 3 7	2 4 5		Total Tissues/ Tumors
Alimentary System																									
Esophagus	-	+ -	+ -	+ -	+ +	· +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	-	+ -	+ -	+ -	+ +	· +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum	-	+ -	+ /	4 -	+ +	• +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Intestine large, cecum	-	+ -	+ -	+ -	+ +	• +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	47
Intestine small, duodenum	-	+ -	+ /	4 -	+ +	· +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	-	+ -	+ /	Δ.	+ +	. +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	46
Intestine small, ileum	-	+ -	+ /	Δ.	+ +	. +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	46
Liver	_	+ -	+ -	+ -	 + +	· +	+	+	+	+	+	+	· ·	- +	+	+	+	+	+	+	+	+	+	+	50
Mesentery					 + +		'		'				+ +	-	1.	+		+	'		+	+	'		10
Liposarcoma					. т											'		X				'			10
Pancreas		F	Ŧ	+	L ./		<u></u>	÷	+	+	+	+	÷ .		-	<u>т</u>	+	+	_L	_ــ	<u>ـــ</u>	<i>.</i> ⊥	<u>ــ</u>	+	50
Adenoma	-				. +	т	т	T	T	Τ.	Τ'	т	+ + >		т	т	-	T	F	T	Ŧ	-	т	-17	50 1
Salivary glands									,					` ,											50
Stomach, forestomach	-		т - ,	т - ,	- + 	• +	+	+	+	+	+	+		- +	+	+	+	+	+	+	+	+	+	+	50 50
	-		 -	т - ,	- + 	• +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular Teath	-		+ -	+ -	+ +	• +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Tooth								+																	3
Cardiovascular System																									
Blood vessel													+								+				2
Heart	-	+ -	+ -	+ -	+ +	• +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Endocrine System Adrenal cortex Adrenal medulla Pheochromocytoma malignant Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic	-	+ -		+ - + - X 2 + -	Х		+ + X +	+ + X X +	+ + X +	+ + X +	++		+ + + + X	- +	+ + X +	Х	+ + X +	+++	+ + X +	++++	+ + X +	+ + X +	+ + X +		49 49 1 7 11 49
Carcinoma	-		+ -	+ -	+ +	• +	X	+	+	+	+	+	+ +	- +	X		+	+	+	+	+	+	+	+	49 2
																									50
Parathyroid gland Pituitary gland	-	г - L	т - L	т	+ + + +			+ +			+ +		+ + + +		++		+++	+ +	++	++	+	++	++	+ +	50 49
Pars distalis, adenoma	-		т У 1	+ - X 2									+ 1 ХУ							+	+		+ X		49 40
Thyroid gland	1		• •			· +					л +					л +			л +			л +		л +	40 48
C-cell, adenoma	-	r	T" [+ + X	X		+	Ŧ	т	т	Ŧ	+ + }		+	+	+	+	+	+	+	+	+	Ŧ	40
General Body System None																									
Genital System								_				_						_							
Epididymis	-	+ -	+ -	+ -	+ +	· +	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	-	+ -	+ -	+ -	+ +	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Adenoma																				X					2
Carcinoma															Х										2
Bilateral, carcinoma																		Х							1
Prostate	-	+ -	+ -	+ -	+ +	. +	+	+	+	+	+	+	+ -	- +	+	+	+	+	+	+	+	+	+	+	49
Seminal vesicle	_	 L -	+ .	Å -	. T L _	ـــــ	+	+	, +	+	+	+	 		+	+	+	+	+	+	+	+	+	+	43
Testes	-	 -		- . -	. + L -	т 	т 	-T J	-r -		т' _	т -	г 1 	+ _ ,	- -	т 	+	-r J		- -	т	-T	+	+	47 50
Bilateral, interstitial cell, adenoma	-	r	T -	т	τ' + ν	X	+	+	Ŧ	Ŧ	т	+ X	+ V	- +	+	+		+ X	\mathbf{v}^+	\mathbf{v}^+	+	+		X X	50 14
Interstitial cell, adenoma	•		x	x	Δ	Л			Х	x		Λ	Λ		v	Х	л	л	л	л			л	Λ	14
incistitiai celi, aucifullia	1	* 4	· • •	×.					~	11					Λ	Λ									14

TABLE A2

Individual Animal Tumor Pathology of N	ale	, K	ats		u	c 4	-10	tal'	111	uid.	เสเ	IOII	. 31	uu	y U		3VI.	ul	CIII	.	JU	٩v	Υľ			
	2	3	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	
Number of Days on Study	4	8	6	6	8	0	1	2	2	2	2	3	4	5	6	7	8	8	9	0	0	1	2	2	2	
	4	9	0	9	2	7	4	3	6	6	7	7	7	2			3	3	2	4	7	4	4	5	6	
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
Carcass ID Number	4	2	4	3	3	4	5	2	1	1	4	2	0	2	0	0	1	3	2	2	2	2	0	4	3	
	3	6												3										1	9	
Hematopoietic System																										
Bone marrow	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node							+			+		+		+	+											
Lymph node, bronchial	Μ	Μ	[+	Ν	I M	Μ	+	+	М	М	М	+	М	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mandibular	+	Α	+	+	+	+	+	+	М	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mediastinal	+	Α	Μ	+	+	+	+	+	+	+	М	+	М	+	+	+	+	М	М	+	+	+	+	+	+	
Spleen	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thymus	Μ	А	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Integumentary System																										
Mammary gland	М	Ν	[+	Ν	I M	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	
Carcinoma	141	141	- r	14	. 191	1.41	'	'	'			'								'		X	'		141	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	
Basal cell carcinoma		1-			1		'	'	'			'								'	X	1	'			
Keratoacanthoma														Х												
Squamous cell papilloma														21												
Sebaceous gland, adenoma																										
Subcutaneous tissue, schwannoma malignant				Х																						
Subcutaneous tissue, schwalinolia marghant Subcutaneous tissue, pinna, melanoma malignant				~																						
Musculoskeletal System																										
Bone	1	-	-	-	<u>т</u>	-	-	-	-	-	т	-	-	-	+	+	-	-	-	-		-	-	-	-	
Osteosarcoma	т	т	т	-	T	т	т	т	т	т	т	т	т	т	т	т	+ X	т	т	т	т	т	т	т	Т	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System		٨																								
Larynx	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma																Х										
Alveolar/bronchiolar carcinoma																										
Mediastinum, alveolar/bronchiolar carcinoma,																										
metastatic, lung																										
Nose					+		+			+	+	+					+			+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System																										
Zymbal's gland																					+					
Carcinoma																					Х					
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Renal tubule, adenoma																										
Urinary bladder	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions																										
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions Multiple organs Leukemia mononuclear	+	+	+	+	+	+	$^+_{\rm X}$	+ X	+	$^+_{\rm X}$	+	+ X	+	+ X	+ X	+ X	+	+	+	+ X	+	+	+ X	+	+ X	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 500 ppm

															5				-			- I	1			
Number of Days on Study	6 2 7	6 3 2	6 4 1	6 4 2	6 6 0	6 6 2			6 7 0	6 7 1	6 7 1	6 7 8	6 8 4	6 8 4	8	6 9 2		7 0 2	0	7 1 6	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	
Carcass ID Number	2 1 7	2 1 9	2 3 2	2 0 4	2 1 2	2 0 6		3	1	2 1 3		2 1 6		2 3 1		2 0 7		2 3 4				2 2 8	2 3 7	2 4 5		Total Tissues/ Tumors
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Thymus	+ + + + + +	+ + + + + + + + + + + + + + + + + + +	A + + A + A	+ + + + + + +	+ + + + + + + M	+ + + + + + +	+ + + M + +	+ + + + + + +	+ + + + + + M	+ + + + + + +	+ + + + + + +	+ + + + + + + + +	+ + + + + + + + +	+ + + + + + + + +	+ + + + + + + + +	+ + + + + + +	+ + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + M	+ + + + + + + M	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + +	+ + + + + + +	+ + + + + + + + +	+ + + + + + + + +	48 11 41 47 50 42 49 42
Integumentary System Mammary gland Carcinoma Skin Basal cell carcinoma Keratoacanthoma Squamous cell papilloma Sebaceous gland, adenoma Subcutaneous tissue, schwannoma malignant Subcutaneous tissue, pinna, melanoma malignant	+	M +	+	+	+	+	+ + X	+ + X	+	+	+	M +	+ + X	+	+ + X X X	+	+	+	+	M +	+	+ + X	+ + X	+	++	41 1 50 2 4 1 2 1
Musculoskeletal System Bone Osteosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Mediastinum, alveolar/bronchiolar carcinoma, metastatic, lung Nose Trachea	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + + +	+ + + +	+ + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+ + + + +	+ + + +	+ + + +	+ + X + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + X X + +	++++++	+ + + + +	++++++	+ + + +	+ + X +	+ + + +	+ + + +	+ + + + + + + + + + + + + + + + + + + +	49 50 2 2 1 49 50
Special Senses System Zymbal's gland Carcinoma			+ X																							2 2
Urinary System Kidney Renal tubule, adenoma Urinary bladder	+	++	++	+	++	+	+	+	+	+	++	++	++	+ X +	+	+	++	+	+	+	++	++	++	++	+	50 1 49
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+	+ X	+ X	+	+ X		+	+	+	+	+	+	+	+	+	+	+ X	+ X	+	+ X	+ X	+ X	+	+ X	+ X	50 21 2

TABLE A2

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene:	2,000 ppm
---	-----------

	or mu					-									, •					•••	~,		· P.	P	-
	3	4	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6
Number of Days on Study	5 2	5 3	8 0	9 6	9 7	0 0		1 6	2 0		5 1	5 2	5 5			6 8	7 4	7 9	8 0	8 3	8 5	9 0		1 4	
		-	-			-																			
Carcass ID Number	4		4				4							4					4			4		4	
Carcass ID Number	2 3	4 6	3 8	3 7	0 1	2 6		1 1	2 1		1 6	3 3	4 1	0 7		5 0		1 2	2 5		0 4	1 8	3 0	0 5	
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma																									
Hemangiosarcoma																									
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma				Х																					
Mesentery													+												
Oral mucosa					+																				
Pharyngeal, squamous cell papilloma					Х																				
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tooth	+																								
Cardiovascular System																									
Blood vessel			+																						
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant		Х																							
Pheochromocytoma benign				Х										Х											
Bilateral, pheochromocytoma benign																			Х		Х				
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma																									
Carcinoma																									
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+	+	+	+	+	+	+
Pars distalis, adenoma			Х				Х							Х											
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+
C-cell, adenoma										1 7															
C-cell, carcinoma										Х															
General Body System None																									
Genital System																									
Epididymis Promotial alard	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+
Adenoma										1 7											• •				
Carcinoma										Х											Х				
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Testes Bilatonal interativial call adaptation	+	+	+	+	+	+	+	+	+ V	+ V	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Bilateral, interstitial cell, adenoma				v		v			Х	Х				v		v	v					v		v	
Interstitial cell, adenoma				Х		Х								Х		Х	Х					Х		Х	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

Individual Animal Lumor Pathology	UI IVIAI	c I	rati	» III	un	C 4.	-16	ar	1111	ıdlö	auv	ш З	uu	iy t	,, ,	301	Jui	CII	с.	۵,۱	υυι	'P	րո	L	
Number of Days on Study	6 1 4	2	2 2	2	6 2 8	6 5 0	5	5	5	6 (7 7 1 8	78	0	7 0 1	7 0 5	7 0 6	7 0 6	7 1 4	7 1 4	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	3	
Carcass ID Number	4 3 4	0) 4	3	4 4 0	4 0 6	2	2		4 4 1 1 7 3		4	1	4 2 4	4 1 0	1	4 1 4	4	2	4 2 7	4 3 1	4 3 9	4 4 3	4	Total Tissues/ Tumors
Alimentary System																									
Esophagus	-		+ +	• +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	A	\ -	+ +	• +	+	+	+	+	+	+ -	+ +	+	+	А	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	А	+	+	+	+	+	+	+	+	+	+	49
Intestine large, cecum	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	А	+	+	+	+	+	+	+	+	+	+	49
Intestine small, duodenum	+		÷ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	A	1 -1	+ +	+	+	+	+	+	A	+ -	+ +		+	А	+	+	+	+	+	+	+	+	+	+	47
Carcinoma											Х														1
Hemangiosarcoma																								Х	1
Intestine small, ileum	A	1 -	≻ +	+	+	+	+	+	A	+ -	+ +	+	+	А	+	+	+	+	+	+	+	+	+	+	47
Liver	+		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																					Х				2
Mesentery										+ -	+	+				+				+		+		+	8
Oral mucosa																									1
Pharyngeal, squamous cell papilloma																									1
Pancreas	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular Tooth	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Blood vessel Heart Endocrine System Adrenal cortex Adrenal medulla Pheochromocytoma malignant Pheochromocytoma benign	- - -		- + - + + +	+ · + · +	++++	+ + + X	+++++	+ + +	+ + + X	+ -	+ + + + + +	+ +	+++++	+++++	++++	+ + + X	+++++	+ + + X	+ + + X	+++++	++++	+ + + X	+++++	+++++	2 50 50 50 1 8
Bilateral, pheochromocytoma benign		Σ	ζ									Х	Х		Х						Х			Х	8
Islets, pancreatic	4			+	+	+	+	+	+	+ -	+ +					+	+	+	+	+	+	+	+	+	50
Adenoma			_															Х							1
Carcinoma		У																						_	1
Parathyroid gland	+		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+		Μ	49
Pituitary gland	-	- +			+	+	+	+		+ -	+ +		+	+	+	+	+	+	+	+	+	+	+	+	50
Pars distalis, adenoma		()			Х						ХХ									Х					40
Thyroid gland	+		+ +	• +	+	+	+	+	A		+ +	+				+	+		+		+	+	+	+	48
C-cell, adenoma C-cell, carcinoma										2	X		Х		Х			Х		Х				х	5 2
General Body System None																									
Genital System																									
Epididymis	+		+ +	• +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	4		+ +	• +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma				Х				Х																	2
Carcinoma																									2
Prostate	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	4		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Testes	-		+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	2		X X					х	X	X	ХХ	X	Х	х		Х	Х	Х	Х	Х	Х	х	Х	х	17 12

Number of Days on Study 5 5 8 9 0 1 1 2 5 5 5 6 6 7 7 4 Z 3 0 6 7 0 2 6 8 4<		3	4	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6
Carcass ID Number 4	Number of Days on Study																									
3 6 8 7 1 6 6 3 1 7 2 0 8 2 5 8 4 8 0 5 2 Hemacopicitic System Bone marrow Histocytic sarcoma Lymph node +		4	4	4	4	4			4	4	4	4	4	4	4	4	4	4	4	4			4	4	4	4
Bone marrow + + + + + + + + + + + + + + + + + + +	Carcass ID Number	2 3					2 6	0 9																		
Histocyclic sarcoma X Lymph node + <																										
Lymph node + + + + + + + + + + + + + + + + + + +		+	+	• +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histocytic sarcoma Lymph node, bronchial M + M + M + M M M + + M M M M + + + M + M + + + M +					Х																					
Pancraite, histocytic sarcoma Lymph node, monchial M + M + M + M M M M + + + M M M M + + + M +							+				+		+													
$ \begin{array}{c} \text{Lymph node, bronchial} \\ \text{Histicoytic sarcoma} \\ \text{Lymph node, mandibular} \\ \text{Lymph node, mandibular} \\ \text{Lymph node, mandibular} \\ \text{Histicoytic sarcoma} \\ \text{Lymph node, mesenteric} \\ \text{Histicoytic sarcoma} \\$																										
Histocytic sarcoma Lymph node, messettericX Lymph node, messettericX 		Μ	[+	N - N	1 +	Μ	+	М	М	М	+	+	Μ	М	Μ	М	+	+	+	Μ	+	+	+	Μ	+	+
$\begin{array}{c} \text{Lymph node, mesenticic} & + + + + + + + + + + + + + + + + + + $	Histiocytic sarcoma																									
Lymph node, mediastinal M M + + + + + + + + + + + + + + + + + + +		+									+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma X Spleen + + + + + + + + + + + + + + + + + + +		+																			+	+	+	+	+	+
Spleen + + + + + + + + + + + + + + + + + +		Μ	ιN	1 +			+	+	Μ	+	+	+	+	+	+	+	M	M	+	+	+	+	M	+	+	+
Histiccytic sarcoma X Thymus + M M M +							_ــ	+	+	-	_L	ъ	<u>ــ</u> ـ	_L	_ــ	-	<u>ــ</u>	-	÷	ъ	ـ ـ	_ـ	<u>ـــ</u>	<i>т</i>	_ــ	+
Thymus + M M M + <td></td> <td>+</td> <td>+</td> <td>- +</td> <td></td> <td></td> <td>+</td> <td>Ŧ</td> <td>Ŧ</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>Ŧ</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>Τ'</td>		+	+	- +			+	Ŧ	Ŧ	+	+	+	+	+	+	+	Ŧ	+	+	+	+	+	+	+	+	Τ'
Mammary gland + M + + M + <	5	+	N	1 N			+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	М
Mammary gland + M + + M + <	Integumentary System																									
Skin +	Mammary gland	+	Ν	1 +	+	+	Μ	+	+	+	М	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+
Squamous cell papilloma Subcutaneous tissue, fibroma Subcutaneous tissue, histiocytic sarcoma + + + + + + + + + + + + + + + + + + +	Skin	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Sebaceous gland, adenoma Subcutaneous tissue, fibroma Subcutaneous tissue, histiocytic sarcoma + + + + + + + + + + + + + + + + + + +																		Х								
Subcutaneous tissue, fibroma Subcutaneous tissue, histiocytic sarcoma Musculoskeletal System Bone Skeletal muscle Histiocytic sarcoma Nervous System Brain Histiocytic sarcoma ** + </td <td>Squamous cell papilloma</td> <td></td>	Squamous cell papilloma																									
Subcutaneous tissue, histiocytic sarcoma Musculoskeletal System Bone Skeletal muscle Histiocytic sarcoma Nervous System Brain Histiocytic sarcoma Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Histiocytic sarcoma X Special Senses System Eye																										
Bone skletal muscle Histocytic sarcoma + + + + + + + + + + + + + + + + + + +	Subcutaneous tissue, histiocytic sarcoma																									
Bone states in the series of t	Musculoskeletal System																									
Histiocytic sarcoma Nervous System Brain Histiocytic sarcoma * + <td< td=""><td></td><td>+</td><td>+</td><td>• +</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></td<>		+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System Brain +																										
Brain + + + + + + + + + + + + + + + + + + +	Histiocytic sarcoma																									
Histocytic sarcoma X Respiratory System + + + + + + + + + + + + + + + + + + +	Ū																									
Larynx + + + + + + + + + + + + + + + + + + +		+	+	• +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Larynx + + + + + + + + + + + + + + + + + + +	Respiratory System																									
Lung + + + + + + + + + + + + + + + + + + +		+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar carcinoma Histiocytic sarcoma X Nose + + + + + + + + + + + + + + + + + + +	Lung	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma X Nose + + + + + + + + + + + + + + + + + + +																								Х		
Nose + + + + + + + + + + + + + + + + + + +																										
Trachea + + + + + + + + + + + + + + + + + + +	0									,				,		,		,								
Eye +		+	++	· + · +	· + · +	++	++	+ +	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	+ +
Eye +	Spacial Sansas System																									
																										+
	Zymbal's gland																									

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

														5											
Number of Days on Study	6 1 4	6 2 0	6 2 7	6 2 8	6 2 8	6 5 0	6 5 2	6 5 4	6 5 4	7	7	8	7 (0 (0 (0 (7 0 6	7 0 6	7 1 4	7 1 4	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	3	
Carcass ID Number	4 3 4	4 0 3	4	4 3 5	4 4 0	4 0 6	2	2		1	1	2	4	4 4 1 2 9 4	1	4 1 5	4 1 4	4 4 2	4 2 0	4 2 7	4 3 1	4 3 9	4 4 3	4	Total Tissues/ Tumors
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																					Х				2
Lymph node		+	+			+		+													+	+	+		10
Histiocytic sarcoma																					Х				1
Pancreatic, histiocytic sarcoma															<i>.</i>						Х				1
Lymph node, bronchial	+	+	+	+	+	+	+	+	+	+	+	Μ	+ -	+ N	1 +	+	+	+	+	+		+	M	+	35
Histiocytic sarcoma																м					X				2
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	M	+	+	+	++	+ M	++	++	+ +	49 49
Lymph node, mesenteric Lymph node, mediastinal	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	IVI	++	+	+	49 44
Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	44
Spleen			-	-	-	-	т.	т	-	т.	т	-	т.			-	-	-	-	-	-	-	-	-	50
Histiocytic sarcoma		'			'				'			'							'			'			1
Thymus	Ν	1+	Μ	[+]	+	М	М	+	+	+	+	М	+ -	+ +	+	+	+	М	+	+	+	+	+	+	38
9																									
Integumentary System																									
Mammary gland	+	Μ	1 +	Μ	Μ	+	+	+	+	+	+	+	+ -	+ +	+	+	Μ	+	+	+	+	Μ	Ι	+	40
Fibroadenoma																			Х						1
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Keratoacanthoma																				Х					2
Squamous cell papilloma									Х											Х					2
Sebaceous gland, adenoma													Х												1
Subcutaneous tissue, fibroma											Х					Х									2
Subcutaneous tissue, histiocytic sarcoma																					Х				1
Musculoskeletal System																									
Bone			-	-	-	-	т.	т	-	т.	т	-	т.			-	-	-	-	-	-	-	-	-	50
Skeletal muscle	-	т	т	т	т	Т	т	т	т	т	т	т	Τ -	т т	т	т	т	т	т	т	+	т	т	т	1
Histiocytic sarcoma																					x				1
Tilstocytic sarconia																					71				1
Nervous System																									
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1
Respiratory System																									50
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma												Х				17									2
Alveolar/bronchiolar carcinoma																Х					17				1
Histiocytic sarcoma																					Х				2
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																									
Eye						+												+			+				4
						r												+			r				4
Zymbal's gland Carcinoma																		X							1

78

TABLE A2

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

Number of Days on Study	5	3 · 5 ·	4 5 3	4 8 0	4 9 6	4 9 7	5 0 0	5 1 2	5 1 6	5 2 0	5 2 0	5 5 1	5 5 2	5 5 5	5 5 8	5 6 5	5 6 8	5 7 4	5 7 9	5 8 0	5 8 3	5 8 5	5 9 0	6 0 7	6 1 4	6 1 4	
Carcass ID Number	-	2	-	4 3 8	4 3 7	4 0 1	4 2 6	4 0 9	4 1 1	4 2 1	4 3 6	4 1 6	4 3 3	4 4 1	4 0 7	4 0 2	4 5 0	4 0 8	4 1 2	4 2 5	4 4 8	4 0 4	4 1 8	4 3 0	4 0 5	4 3 2	
Urinary System Kidney Histiocytic sarcoma	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Renal tubule, carcinoma Urinary bladder	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear	-	+	+	+	+ X	+ X	+ X	+		+ X	+	+	+ X	+	+	+	+ X	+	+	+ X	+	+	+	+ X		+ X	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

Number of Days on Study	6 1 4	2	6 (2 : 0 ⁻	6 2 7	6 2 8	6 2 8	6 5 0	6 5 2	6 5 4	6 5 4	6 7 1	6 7 8	6 8 0	7 0 0	7 0 1	7 0 5	7 0 6	7 0 6	7 1 4	7 1 4	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	
Carcass ID Number	4 3 4	(4 4 0 4 3 4	4 4 4	4 3 5	4 4 0	4 0 6	4 2 8	4 2 2	4 4 9	4 1 7	4 1 3	4 2 9	4 4 5	4 1 9	4 2 4	4 1 0	4 1 5	4 1 4	4 4 2	4 2 0	4 2 7	4 3 1	4 3 9	4 4 3	4 4 7	Total Tissues/ Tumors
Urinary System Kidney Histiocytic sarcoma	+		+ ·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	50 1
Renal tubule, carcinoma Urinary bladder	+		+ •	+	+	+	+	+	+	+	+	+	+	+	X +	+	+	+	+	+	X +	+	+	+	+	+	2 50
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear	+ X		+ - X 2	+ X	+ X	+	+ X	+	+ X	+ X	+	+	+ X	+	+ X	+	+	+	+	+ X	+	+	+ X		+ X	+	50 2 20

Individual Animal Tumor Pathology	of Mal	e R	ats	in in	th	e 2	-Ye	ear	· In	ha	lat	ion	ı St	tud	ly (of]	so	bu	ten	e:	8,	00	0 p	pn	1
							5																		
Number of Days on Study	9 0	0 5	2 5	3 4		4 0	6 0		8 3				0 8						3 6					5 8	6 4
	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6
Carcass ID Number	3	4					2																	3	-
	9	5	1	3	4	7	6	7	8	9	8	6	8	1	9	2	5	8	9	6	1	6	4	2	2
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	+	+	+	+	+	+		A						+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+	+	+	+		A				+		+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	+	+	+	+	+	A	+			+		+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	+	+	+	+	+	+		A	+			+		+	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Leiomyosarcoma										,															
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Mesentery										+			+					+						+	+
Pancreas Solivery glands	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+
Tongue Hemangiosarcoma																								+ X	
Tooth																								л	
Cardiovascular System																									
Blood vessel																									
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma				Ċ	Ċ		·		X			·	·			·		Ċ	·		·	Ċ	Ċ		
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant		-								-				-		-	X				-				
Pheochromocytoma benign			Х				Х						Х				X					Х			
Bilateral, pheochromocytoma malignant																									
Bilateral, pheochromocytoma benign																		Х		Х					
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+	+	+
Adenoma		'					'			'						x				x					x
Carcinoma				Х												••									
Parathyroid gland	+	+	+		+	+	+	+	М	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+
Pituitary gland	+	+	+				+																		
Pars distalis, adenoma	x						x						x										x		
Thyroid gland							+																		
C-cell, adenoma					x				•							•	•		x		x		•		
C-cell, carcinoma												Х													
Follicular cell, carcinoma																Х							Х		
General Body System																									
None																									
Genital System																									
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma																									
Auenoma						Х																			
Carcinoma																									
Carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

TABLE A2 Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 8.000 ppm

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene: 8,000 ppm 6 6 6 6 6 6 6 6 6 6 6 6 7 7 77 7 7 7 7 7 7 7 7 7 Number of Days on Study 6 66 6 7 7 8 8 8 8 9 9 0 0 0 0 2 3 3 3 3 3 3 3 3 4 6 7 0 8 8 8 8 9 0 2 0 1 1 2 0 3 3 3 3 3 3 3 3 4 6 6 6 6 Total **Carcass ID Number** 3 1 1 1 2 0 1 2 2 3 4 5 1 3 4 4 0 0 2 2 2 3 3 4 0 Tissues/ 0 5 0 1 9 4 3 0 4 6 7 0 2 7 1 3 7 8 2 3 5 3 4 0 Tumors 5 **Alimentary System** Esophagus 50 Intestine large, colon 49 Intestine large, rectum 49 + Intestine large, cecum 49 Intestine small, duodenum 49 Intestine small, jejunum 49 Intestine small, ileum 49 Leiomyosarcoma Х 1 Liver 50 Mesentery 11 50 Pancreas + Salivary glands 50 + + + + 50 Stomach, forestomach + + + + Stomach, glandular 50 Tongue 1 Hemangiosarcoma 1 Tooth 1 + **Cardiovascular System** 2 Blood vessel Heart 50 + + + + + + + ++ + + + + + + **Endocrine System** 50 Adrenal cortex Adenoma 1 Adrenal medulla 50 + + Pheochromocytoma malignant Х 2 Pheochromocytoma benign Х Х ХХ Х 11 Х Bilateral, pheochromocytoma malignant Х 1 Bilateral, pheochromocytoma benign 12 Х ХХ Х XX Х Х Х Х Islets, pancreatic 50 + Adenoma 4 Carcinoma Х Х Х 4 Parathyroid gland 47 + M + + ++ + + + Pituitary gland + M + + + + + 49 Х Pars distalis, adenoma Х ХХХХ Х ХХХ 41 Х Х Х Х Х Х Х ХХ Thyroid gland + + + + + + 50 ххх C-cell, adenoma 7 C-cell, carcinoma 1 Х ХХ Follicular cell, carcinoma 5 **General Body System** None **Genital System** Epididymis 50 Preputial gland 50 + Adenoma Х 1 Carcinoma Х 3 50 Prostate + + Adenoma Х 1 Seminal vesicle 50 + + + + ++ + + + + + + ++ + + + ++ +

Individual Animal Tumor Pathology o					•	•	_ `								.j `					••	•,		· [*]	r		
Jumber of Days on Study	4 9 0	5 0 5	2	5 3 4	3	4	5 6 0	7	8	0	0	0	0	1	1	1	3	3		4	6 4 8		6 5 0	6 5 8	6	
Carcass ID Number	6 3 9	6 4 5		0	1	2	6 2 6	1		1	4	4	2	3	6 0 9	4	3	3	4	1		0	4		0	
Genital System (continued) estes Bilateral, interstitial cell, adenoma	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+ X		+ X	+	+	+		+ X		+ X		
Interstitial cell, adenoma									Х							Х				Х					X	
Hematopoietic System Bone marrow _ymph node _ymph node, bronchial _ymph node, mandibular _ymph node, mesenteric _ymph node, mediastinal Carcinoma, metastatic, thyroid gland Spleen	+ M + + +	+ + + + + + +	+ + + + + + +	+ + +	+ + +	+ + +		+ + +	+ + M	M + +	+ +	+ + M	+ + +	+ +	+ +	+ +	+ +	+ +	+ + + + + +	+ +	+ +	+ + + + + +	+ + + + X +			
Thymus	+	M	M				+ M											+	+	+	+		+ M			
Integumentary System Mammary gland Fibroadenoma Skin Basal cell adenoma Keratoacanthoma Squamous cell papilloma Subcutaneous tissue, rhabdomyosarcoma	+	+	+	+	+	+			+		+	+	+	+	+	+	+	+	+	+	M +		+		Х	
Musculoskeletal System Bone skeletal muscle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
N ervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System Larynx Lung Alveolar/bronchiolar carcinoma	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	
Carcinoma, metastatic, thyroid gland Nose Frachea	+ +						+ +																			
Special Senses System None																										
J rinary System Lidney Stromal nephroma Renal tubule, adenoma Jrinary bladder	+	+	+++	+	+	+	+++	+++	+	+	+	+++	+	+ X +	+	+	+	+	+	+	+	+ X +	+	+	+	
Systemic Lesions Multiple organs Leukemia mononuclear	+	+ X	+ X	+ X	+	+ X	+	+	+	+	+ X	+	+	+ X	+		+	+ X	+	+ X	+ X	+	+	+	+ X	

 TABLE A2

 Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene:
 8,000 ppm

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Isobutene:	8,000 ppm

				~	~	~	~	~			~			~	~	~	~	~	~	~	~	~	~	~	~	~	
Number of Days on Study	6 6 4	(3	6	6	6 7 0	6 7 8	6 8 8	6 8 8	8	6 8 9	6 9 0	6 9 2	7 0 0	7 0 1	7 0 1	7 0 2	7 2 0	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	
Carcass ID Number	6 0 5	:	3	1	1	6 1 1	6 2 9	6 0 4	6 1 3	2	6 2 4	6 3 6	6 4 7	6 5 0	6 1 2	6 3 7	6 4 1	6 4 3	6 0 7	6 0 8	6 2 2	6 2 3	6 2 5	6 3 3	6 3 4	6 4 0	Total Tissues/ Tumors
Genital System (continued) Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+		+ X	+ X	+	+ X	+	+	+ X	+ X	+	+	+ X	+ X	+ X	+	+	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+	+	50 14 11
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Carcinoma, metastatic, thyroid gland Spleen Thymus	+ + + + + N		+ + + M M	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + +	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + M + +	+ + + M + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + M	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	50 10 45 49 50 45 1 50 42
Integumentary System Mammary gland Fibroadenoma Skin Basal cell adenoma Keratoacanthoma Squamous cell papilloma Subcutaneous tissue, rhabdomyosarcoma	+		+	+	+	+	+	+	+	+ + X	+	+ + X	+	+ + X X	+	+	+ + X	M +	+ +	+ + X	M +	+	+	+ + X	M + X	+	44 1 50 2 4 1 1
Musculoskeletal System Bone Skeletal muscle	+		÷	+	+	+	+	+	+	+	+	+	+	++++	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Nervous System ^{Brain}	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Alveolar/bronchiolar carcinoma Carcinoma, metastatic, thyroid gland Nose Trachea	+ + +		+++++++++++++++++++++++++++++++++++++++	+++++	++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + +	++++++	++++++	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + +	+++++	+++++	+++++	+ + X + +	49 50 1 1 49 50
Special Senses System	+	-	r	T	7	-r	-	7	7	T	T	T	T	т	т	Ŧ	T	Ŧ	T	T	F	Ŧ	T	+	т	T	50
Urinary System Kidney Stromal nephroma Renal tubule, adenoma Urinary bladder	+		+ +	+ +	+	+++	+++	+	++	+++	+++	+	+	+++	+++	+	+++	+	+++	+ X +	+	+	+	+++	+++	+	50 1 2 50
Systemic Lesions Multiple organs Leukemia mononuclear	+		÷	+ X	+ X	+ X	+ X	+	+ X	+	+ X	+ X	+ X	+	+ X	+ X	+ X	+	+ X	+	+ X	+ X	+ X	+ X		+ X	50 31

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Adrenal Medulla: Benign Pheochromocytoma				
Dverall rate ^a	23/50 (46%)	18/49 (37%)	16/50 (32%)	23/50 (46%)
Adjusted rate ^b	60.0%	52.1%	46.2%	56.9%
Ferminal rate ^C	6/7 (86%)	4/5 (80%)	4/6 (67%)	6/8 (75%)
First incidence (days)	539	526	496	525
Poly-3 test ^d	P=0.497	P=0.309N	P=0.146N	P=0.476N
drenal Medulla: Malignant Pheochromocytom	าล			
Dverall rate	0/50 (0%)	1/49 (2%)	1/50 (2%)	3/50 (6%)
djusted rate	0.0%	3.2%	3.2%	8.3%
erminal rate	0/7 (0%)	0/5 (0%)	0/6 (0%)	1/8 (13%)
irst incidence (days)	e	664	453	631
oly-3 test	P=0.085	P = 0.485	P = 0.489	P = 0.132
drenal Medulla: Benign or Malignant Pheoch	romocytoma			
Overall rate	23/50 (46%)	18/49 (37%)	17/50 (34%)	24/50 (48%)
Adjusted rate	60.0%	52.1%	48.0%	59.1%
'erminal rate	6/7 (86%)	4/5 (80%)	4/6 (67%)	6/8 (75%)
irst incidence (days)	539	526	453	525
oly-3 test	P = 0.399	P = 0.309N	P = 0.187N	P = 0.564N
.ung: Alveolar/bronchiolar Adenoma or Carci	noma			
Dverall rate	2/50 (4%)	4/50 (8%)	3/50 (6%)	1/50 (2%)
djusted rate	2/30 (4%) 5.9%	4/50 (8%)	3/30 (0%) 9.5%	2.8%
erminal rate	0/7 (0%)	1/5 (20%)	9.578 0/6 (0%)	1/8 (13%)
irst incidence (days)	580	579	607	733 (T)
oly-3 test	P = 0.196N	P = 0.301	P = 0.466	P = 0.482N
01y-5 test	1 - 0.1301	1 - 0.301	1 - 0.400	1 - 0.4021
Pancreatic Islets: Adenoma Overall rate	4/50 (80/)	0/40 (00/)	1/50 (90/)	4/50 (80/)
	4/50 (8%)	0/49 (0%)	1/50 (2%)	4/50 (8%)
djusted rate	11.8%	0.0%	3.2%	10.8%
erminal rate	1/7 (14%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
irst incidence (days)	666 D 0 070	— D 0.071N	714	618 D. 0 500N
oly-3 test	P=0.276	P=0.071N	P = 0.203N	P= 0.599N
ancreatic Islets: Carcinoma				
Overall rate	4/50 (8%)	2/49 (4%)	1/50 (2%)	4/50 (8%)
djusted rate	11.6%	6.4%	3.2%	10.8%
erminal rate	1/7 (14%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
'irst incidence (days)	477	664	620	534
oly-3 test	P=0.451	P=0.383N	P = 0.206N	P=0.609N
ancreatic Islets: Adenoma or Carcinoma				
Overall rate	8/50 (16%)	2/49 (4%)	2/50 (4%)	8/50 (16%)
djusted rate	22.8%	6.4%	6.4%	21.0%
erminal rate	2/7 (29%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
irst incidence (days)	477	664	620	534
oly-3 test	P = 0.238	P = 0.060N	P = 0.058N	P = 0.540N
'ituitary Gland (Pars Distalis): Adenoma				
verall rate	43/50 (86%)	40/49 (82%)	40/50 (80%)	41/49 (84%)
Adjusted rate	93.0%	89.2%	87.1%	86.9%
'erminal rate	6/7 (86%)	3/5 (60%)	5/6 (83%)	6/8 (75%)
irst incidence (days)	476	460	453	490
	· -	P = 0.377N	P = 0.240N	P = 0.233N

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Preputial Gland: Adenoma				
Overall rate	4/50 (8%)	2/50 (4%)	2/49 (4%)	1/50 (2%)
Adjusted rate	11.4%	6.4%	6.4%	2.8%
Terminal rate	1/7 (14%)	1/5 (20%)	0/6 (0%)	0/8 (0%)
First incidence (days)	467	583	628	700
oly-3 test	P = 0.170N	P = 0.386N	P = 0.390N	P = 0.167N
·				
Preputial Gland: Carcinoma	1/50 (00/)	9/50 (00/)	0/40 (40/)	0/50 (00/)
Overall rate	1/50 (2%)	3/50 (6%)	2/49 (4%)	3/50 (6%)
djusted rate	2.9%	9.4%	6.3%	8.2%
Cerminal rate	0/7 (0%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
irst incidence (days)	560	526	520	540
oly-3 test	P = 0.431	P = 0.278	P = 0.474	P = 0.331
reputial Gland: Adenoma or Carcinoma				
Overall rate	5/50 (10%)	5/50 (10%)	4/49 (8%)	4/50 (8%)
Adjusted rate	14.1%	15.5%	12.4%	10.9%
Serminal rate	1/7 (14%)	1/5 (20%)	0/6 (0%)	0/8 (0%)
irst incidence (days)	467	526	520	540
oly-3 test	P = 0.383N	P = 0.572	P = 0.562N	P = 0.477N
kin: Keratoacanthoma				
	2/50 (00/)	4/50 (00/)	9/50 (40/)	1/50 (00/)
Overall rate	3/50 (6%)	4/50 (8%)	2/50 (4%)	4/50 (8%)
Adjusted rate	8.8%	12.5%	6.4%	11.1%
Ferminal rate	1/7 (14%)	1/5 (20%)	1/6 (17%)	2/8 (25%)
First incidence (days)	621	552	574	700
oly-3 test	P = 0.523	P = 0.463	P = 0.538N	P = 0.530
Skin: Squamous Cell Papilloma or Keratoacanthon	ıa			
Overall rate	3/50 (6%)	5/50 (10%)	3/50 (6%)	5/50 (10%)
Adjusted rate	8.8%	15.6%	9.5%	13.9%
Cerminal rate	1/7 (14%)	1/5 (20%)	1/6 (17%)	3/8 (38%)
First incidence (days)	621	552	574	700
Poly-3 test	P = 0.442	P = 0.318	P = 0.631	P=0.384
lin, Samamana Call Danillana, Kanataaaanthama	Decel Cell Adamama		·····	
Skin: Squamous Cell Papilloma, Keratoacanthoma, Dverall rate	, Basal Cell Adenoma, 3/50 (6%)	7/50 (14%)	arcinoma 3/50 (6%)	7/50 (14%)
Adjusted rate	8.8%	21.5%	9.5%	19.2%
Cerminal rate	8.8% 1/7 (14%)	2/5 (40%)	9.5% 1/6 (17%)	3/8 (38%)
First incidence (days)	. ,	. ,	, ,	· · ·
	621 D 0 975	552 D 0 128	574	688 D 0 170
oly-3 test	P=0.275	P = 0.128	P = 0.631	P=0.176
Sestes: Adenoma				
Overall rate	23/50 (46%)	28/50 (56%)	29/50 (58%)	25/50 (50%)
Adjusted rate	59.1%	70.4%	74.2%	61.1%
erminal rate	5/7 (71%)	3/5 (60%)	6/6 (100%)	6/8 (75%)
irst incidence (days)	379	460	496	583
oly-3 test	P = 0.343N	P = 0.180	P = 0.087	P = 0.522
Chyroid Gland (C-cell): Adenoma				
Dverall rate	5/48 (10%)	4/48 (8%)	5/48 (10%)	7/50 (14%)
Adjusted rate	· · ·	4/48 (8%)	. ,	, ,
	14.8%		16.5%	18.3%
Cerminal rate	2/7 (29%)	0/5 (0%)	1/6 (17%)	0/8 (0%)
First incidence (days)	540	583	678	534
Poly-3 test	P = 0.360	P = 0.549N	P = 0.563	P = 0.468

TABLE A3

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Thyroid Gland (C-cell): Adenoma or Carcinoma				
Overall rate	5/48 (10%)	4/48 (8%)	7/48 (15%)	8/50 (16%)
Adjusted rate	14.8%	12.8%	22.7%	20.7%
Terminal rate	2/7 (29%)	0/5 (0%)	2/6 (33%)	0/8 (0%)
First incidence (days)	540	583	520	534
Poly-3 test	P=0.290	P = 0.549N	P=0.310	P=0.365
Thyroid Gland (Follicular Cell): Carcinoma				
Overall rate	1/48 (2%)	0/48 (0%)	0/48 (0%)	5/50 (10%)
Adjusted rate	3.0%	0.0%	0.0%	13.5%
Terminal rate	0/7 (0%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
First incidence (days)	661	—	—	618
Poly-3 test	P=0.004	P=0.519N	P = 0.521N	P=0.125
All Organs: Malignant Mesothelioma				
Overall rate	3/50 (6%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
Adjusted rate	8.7%	6.3%	0.0%	0.0%
Terminal rate	0/7 (0%)	0/5 (0%)	0/6 (0%)	0/8 (0%)
First incidence (days)	544	547	_	_
Poly-3 test	P=0.081N	P = 0.540N	P=0.138N	P=0.110N
All Organs: Mononuclear Cell Leukemia				
Overall rate	21/50 (42%)	21/50 (42%)	20/50 (40%)	31/50 (62%)
Adjusted rate	54.9%	55.5%	52.4%	71.1%
Terminal rate	6/7 (86%)	4/5 (80%)	2/6 (33%)	7/8 (88%)
First incidence (days)	467	514	497	505
Poly-3 test	P = 0.028	P = 0.575	P = 0.504N	P = 0.075
All Organs: Benign Neoplasms				
Overall rate	48/50 (96%)	46/50 (92%)	49/50 (98%)	49/50 (98%)
Adjusted rate	98.3%	98.3%	99.8%	98.4%
Terminal rate	7/7 (100%)	5/5 (100%)	6/6 (100%)	8/8 (100%)
First incidence (days)	379	460	453	490
Poly-3 test	P=0.793N	P = 0.898	P = 0.659	P = 0.821
All Organs: Malignant Neoplasms				
Overall rate	31/50 (62%)	33/50 (66%)	28/50 (56%)	40/50 (80%)
Adjusted rate	72.1%	78.4%	68.5%	87.1%
Terminal rate	7/7 (100%)	5/5 (100%)	5/6 (83%)	7/8 (88%)
First incidence (days)	379	469	453	505
Poly-3 test	P = 0.030	P = 0.314	P = 0.445N	P = 0.040

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rate	50/50 (100%)	48/50 (96%)	49/50 (98%)	50/50 (100%)
Adjusted rate	100.0%	99.6%	99.8%	100.0%
Terminal rate	7/7 (100%)	5/5 (100%)	6/6 (100%)	8/8 (100%)
First incidence (days)	379	460	453	490
Poly-3 test	P = 1.000	P=1.000N	P = 1.000N	f

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, lung,

pancreatic islets, pituitary gland, preputial gland, testes, and thyroid gland; for other tissues, denominator is number of animals necropsied.

b Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality с

Observed incidence at terminal kill

d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

e Not applicable; no neoplasms in animal group

f Value of statistic cannot be computed.

		Incidence in Con	trols	
Study	Adenoma	Carcinoma	Adenoma or Carcinoma	
istorical Incidence at Battelle Pacif	ic Northwest Laborator	ries		
Acetonitrile	0/48	0/48	0/48	
-Chloroacetophenone	1/45	0/45	1/45	
obalt Sulfate Heptahydrate	0/49	1/49	1/49	
Epinephrine Hydrochloride	0/50	2/50	2/50	
exachlorocyclopentadiene	0/49	0/49	0/49	
butyraldehyde	0/50	0/50	0/50	
olybdenum Trioxide	1/50	0/50	1/50	
romethane	0/50	1/50	1/50	
Chlorobenzalmalononitrile (CS-2)	0/48	0/48	0/48	
one	0/49	1/49	1/49	
rafluoroethylene	1/50	0/50	1/50	
trahydrofuran	2/50	1/50	3/50	
verall Historical Incidence				
Total	7/892 (0.8%)	9/892 (1.0%)	16/892 (1.8%)	
Standard deviation	1.2%	1.2%	1.7%	
Range	0%-4%	0%-4%	0%-6%	

^a Data as of 15 October 1996

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary Animals initially in study	50	50	50	50
Early deaths	50	50	50	30
Moribund	39	40	37	41
Natural deaths	4	5	7	1
Survivors	-	-		-
Terminal sacrifice	7	5	6	8
Animals examined microscopically	50	50	50	50
Alimentary System				
Esophagus	(50)	(50)	(50)	(50)
Inflammation, suppurative	1 (2%)	1 (2%)	2 (4%)	(00)
Intestine large, colon	(49)	(48)	(48)	(49)
Diverticulum		x - /	1 (2%)	x - /
Mineralization				1 (2%)
Parasite metazoan	4 (8%)	1 (2%)	2 (4%)	2 (4%)
Intestine large, rectum	(47)	(49)	(49)	(49)
Necrosis			1 (2%)	
Parasite metazoan		2 (4%)	3 (6%)	3 (6%)
Intestine large, cecum	(48)	(47)	(49)	(49)
Inflammation, acute				1 (2%)
Necrosis			2 (4%)	1 (2%)
Parasite metazoan	3 (6%)	2 (4%)	6 (12%)	4 (8%)
intestine small, duodenum	(49)	(49)	(50)	(49)
Necrosis	2 (4%)		2 (4%)	
Liver	(50)	(50)	(50)	(50)
Angiectasis	3 (6%)	1 (2%)	14 (999)()	1 (2%)
Basophilic focus	17 (34%)	14 (28%)	14 (28%)	22 (44%)
Clear cell focus	3 (6%)	1 (2%)	3 (6%)	3 (6%)
Cyst	19 (960/)	10 (900/)	14 (989/)	2 (4%)
Degeneration, cystic	13 (26%) 14 (28%)	10 (20%) 18 (26%)	14 (28%)	16 (32%)
Degeneration, fatty Eosinophilic focus	14 (28%) 6 (12%)	18 (36%) 2 (4%)	18 (36%) 5 (10%)	14 (28%) 5 (10%)
Eosinophilic focus Hepatodiaphragmatic nodule	6 (12%) 4 (8%)	2 (4%) 2 (4%)	5 (10%) 1 (2%)	5 (10%) 2 (4%)
Inflammation, granulomatous	4 (070)	L (470)	1 (2%)	L (470)
Mineralization			1 (2%)	1 (2%)
Mixed cell focus	3 (6%)	2 (4%)	4 (8%)	I (4/0)
Necrosis	5 (0/0)	2 (4%)	4 (870) 3 (6%)	1 (2%)
Regeneration		ω (1/0)	0 (070)	2 (4%)
Thrombosis	2 (4%)			~ (1/0)
Vacuolization cytoplasmic, focal	~ (1/0)		1 (2%)	
Bile duct, hyperplasia	23 (46%)	27 (54%)	23 (46%)	29 (58%)
Centrilobular, necrosis	10 (20%)	9 (18%)	10 (20%)	15 (30%)
Mesentery	(15)	(10)	(8)	(11)
Mineralization	1 (7%)	((*)	()
Pigmentation	1 (7%)			
Artery, inflammation, chronic active	(····)	1 (10%)		1 (9%)
Artery, mineralization	1 (7%)	1 (10%)		1 (9%)
Fat, hemorrhage		1 (10%)		1 (9%)
Fat, necrosis	14 (93%)	9 (90%)	8 (100%)	8 (73%)

 a Number of animals examined microscopically at the site and the number of animals with lesion

TABLE A5 Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber	Control	50	0 ppm	2,00	0 ppm	8,00	00 ppm
Alimentary System (continued)								
Pancreas	(50)		(50)		(50)		(50)	
Atrophy	22 (44%)	17	(34%)	26	(52%)	18	(36%)
Basophilic focus	1 (2%)	1	(2%)	1	(2%)	2	(4%)
Hyperplasia	4 (8%)	3	(6%)	4	(8%)		(6%)
Artery, inflammation								(2%)
Artery, mineralization						(2%)	1	(2%)
Salivary glands	(50)		(50)		(50)		(50)	
Artery, mineralization			1	(2%)				
Stomach, forestomach	(50)		(50)		(50)		(50)	
Inflammation, chronic								(2%)
Mineralization		2%)		(2%)		(2%)		(2%)
Necrosis	17 (34%)	16	(32%)		(38%)	10	(20%)
Perforation						(2%)		
Stomach, glandular	(50)		(49)	()	(50)		(50)	()
Mineralization	,	6%)		(6%)		(10%)		(8%)
Necrosis		16%)	5	(10%)	11	(22%)		(18%)
Tongue	(1)	10000					(1)	
Necrosis		100%)						
Tooth	(2)	10000	(3)	(222)	(1)		(1)	(1000)
Developmental malformation	2 (100%)		(33%)		(1000)	1	(100%)
Inflammation, chronic active				(67%)	1	(100%)		
Necrosis			1	(33%)				
Cardiovascular System								
Blood vessel	(2)		(2)		(2)		(2)	
Aorta, mineralization		100%)		(100%)		(100%)		(100%)
Heart	(50)	10070)	(50)	(10070)	(50)	(10070)	(50)	(10070)
Cardiomyopathy		78%)		(78%)		(82%)		(82%)
Artery, mineralization		6%)		(8%)		(8%)		(10%)
Atrium, thrombosis	0 (0,0)		(2%)		(6%)		(12%)
Endoaring System								
Endocrine System	(50)		(40)		(50)		(50)	
Adrenal cortex	(50)	90/)	(49)		(50)		(50)	
Atrophy Degeneration existin	1 (2%)					4	(90/)
Degeneration, cystic	01 (490/)	0.0	(170/)	0.4	(190/)		(2%)
Hyperplasia Hypertrophy		42%)		(47%) (12%)		(48%)		(46%)
Hypertrophy Necrosis	7 (14%)		(12%)		(14%) (2%)	4	(8%)
Necrosis Vacuolization cytoplasmic				(2%) (2%)		(2%) (6%)		
Adrenal medulla	(50)			(~ /0)		(0/0)	(50)	
	(50)	2%)	(49)		(50)		(50)	
Atrophy		2%) 28%)	10	(37%)	90	(56%)	15	(30%)
Hyperplasia Bilateral hyperplasia						(56%) (4%)		
Bilateral, hyperplasia Islets, pancreatic		2%)		(2%)		(4%)		(6%)
· •	(50)		(49)	(8%)	(50)	(6%)	(50)	(6%)
Hyperplasia Parathuroid gland	(40)			(070)		(6%)		(6%)
Parathyroid gland	(49)	100/)	(50)	(990/)	(49)	(940/)	(47)	(910/)
Hyperplasia Pituitory gland		18%)		(22%)		(24%)		(21%)
Pituitary gland	(50)	90/)	(49)		(50)		(49)	
Angiectasis		2%)	-	(100/)	0	(00/)	0	(190/)
Pars distalis, hyperplasia		10%)	5	(10%)	3	(6%)	6	(12%)
Pars distalis, thrombosis		2%)	(10)		(10)		(50)	
Fhyroid gland	(48)	070/)	(48)	(750/)	(48)	(710/)	(50)	
C-cell, hyperplasia Follicular cell, hyperplasia	32 (67%)		(75%)	34	(71%)		(52%)
Kollicular coll hyporplasia			2	(4%)			1	(2%)

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber	Control	50	0 ppm	2,00	0 ppm	8,00	0 ррт
General Body System								
None								
Genital System								
Epididymis	(50)		(50)		(50)		(50)	
Granuloma sperm					1	(2%)		
Preputial gland	(50)		(50)		(49)		(50)	
Hyperplasia	2	(4%)		(2%)	2	(4%)	1	(2%)
Inflammation, acute				(2%)				
Inflammation, chronic active		(6%)		(6%)				(4%)
Prostate	(50)		(49)		(50)		(50)	<i></i>
Hyperplasia		(12%)		(12%)		(12%)		(14%)
Inflammation, chronic active		(8%)		(8%)		(8%)		(12%)
Seminal vesicle	(50)	(00)	(47)		(50)	(00)	(50)	
Inflammation, chronic active	1	(2%)		(00/)		(2%)		(00/)
Mineralization	(50)			(2%)		(2%)		(2%)
l'estes	(50)	(1.40/)	(50)		(50)	(00/)	(50)	(100/)
Atrophy	1	(14%)	0	(00/)	3	(6%)		(10%)
Necrosis		(00/)		(6%)	1	(00/)		(2%)
Artery, inflammation, chronic active	4	(8%)	Z	(4%)	1	(2%)		(6%)
Artery, mineralization	A	(8%)	4	(8%)	4	(8%)		(2%) (4%)
Interstitial cell, hyperplasia	4	(070)	4	(0%)	4	(070)	٤	(470)
Hematopoietic System								
Bone marrow	(50)		(48)		(50)		(50)	
Necrosis	(00)		(10)		(00)			(2%)
Lymph node	(4)		(11)		(10)		(10)	(270)
Hemorrhage		(25%)	(11)		(10)		(10)	
Iliac, ectasia	1	(2070)			1	(10%)		
Renal, hemorrhage			1	(9%)	-	(1070)		
Lymph node, mandibular	(47)		(47)	(0.0)	(49)		(49)	
Hemorrhage						(2%)		
Infiltration cellular, plasma cell	1	(2%)	1	(2%)			1	(2%)
Infiltration cellular, polymorphonuclear		(2%)		. ,				. ,
Lymph node, mesenteric	(50)	. ,	(50)		(49)		(50)	
Ectasia		(2%)				(2%)		
Lymph node, mediastinal	(46)		(42)		(44)		(45)	
Hemorrhage			1	(2%)				
Spleen	(50)		(49)		(50)		(50)	
Accessory spleen		(2%)			1	(2%)		(2%)
Fibrosis		(18%)		(12%)		(20%)	11	(22%)
Hematopoietic cell proliferation		(4%)		(10%)	4	(8%)		(6%)
Hemorrhage	1	(2%)	1	(2%)		((2%)
Necrosis					2	(4%)	1	(2%)
Integumentary System	(41)		(11)		(40)		(AA)	
Mammary gland Galactocele	(41)	(5%)	(41)	(17%)	(40)	(3%)	(44)	(9%)
Galactocele Hyperplasia, atypical	۷.	(J /0)			1	(370)	4	(3/0)
Inflammation, chronic	1	(2%)	1	(2%)	1	(3%)	1	(2%)
Skin	(50)	(~ /0)	(50)		(50)	(3/0)	(50)	(~ /0)
Cyst epithelial inclusion	(30)			(2%)	(30)		(30)	
	1	(2%)	1	(270)	1	(2%)	1	(2%)
Hyperkeratosis Inflammation, chronic active								(2%)
minamination, chi onic active	1	(2%)			1	(2%)	5	(10%)

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Fibrous osteodystrophy	9 (18%)	7 (14%)	9 (18%)	6 (12%)
Hyperostosis			1 (2%)	1 (2%)
Skeletal muscle	(1)		(1)	(1)
Mineralization				1 (100%)
Nervous System				
Brain	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Hemorrhage			1 (2%)	
Respiratory System				
Larynx	(50)	(49)	(50)	(49)
Necrosis	1 (2%)	1 (2%)	(/	()
Epiglottis, metaplasia, squamous	- ()	- ()		1 (2%)
Lung	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Hemorrhage	1 (2%)	1 (2%)		1 (2%)
Inflammation, granulomatous	9 (18%)	3 (6%)	1 (2%)	5 (10%)
Inflammation, suppurative	1 (2%)			1 (2%)
Metaplasia, squamous	1 (2%)			
Mineralization	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Alveolar epithelium, hyperplasia	9 (18%)	5 (10%)	7 (14%)	5 (10%)
Alveolus, infiltration cellular, histiocyte			1 (2%)	
Artery, mediastinum, mineralization	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Bronchiole, hyperplasia				1 (2%)
Mediastinum, inflammation, suppurative			1 (2%)	
Nose	(49)	(49)	(50)	(49)
Inflammation, suppurative	14 (29%)	11 (22%)	16 (32%)	9 (18%)
Thrombosis	4 (8%)	7 (14%)	10 (20%)	6 (12%)
Lateral wall, metaplasia, squamous	1 (2%)			
Olfactory epithelium, atrophy	3 (6%)	15 (699)	10 (222.1)	10 (1000)
Olfactory epithelium, degeneration, hyaline	43 (88%)	45 (92%)	46 (92%)	49 (100%)
Olfactory epithelium, metaplasia	4 (8%)			
Respiratory epithelium, metaplasia, squamou	. ,	(50)	(50)	(50)
Trachea	(50) (40()	(50)	(50)	(50)
Inflammation, suppurative	2 (4%)			
Special Senses System				
Eye	(3)		(4)	
Cataract	2 (67%)		3 (75%)	
Degeneration	1 (33%)		. ,	
Inflammation, chronic active			2 (50%)	
Retina, atrophy	1 (33%)		3 (75%)	

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Isobutene

	Chambe	r Control	50	0 ppm	2,00	0 ppm	8,000 ppm				
Urinary System											
Kidney	(50)		(50)		(50)		(50)				
Cyst	3	(6%)	3	(6%)			1	(2%)			
Hydronephrosis	1	(2%)									
Hyperplasia, oncocytic	1	(2%)									
Infarct			1	(2%)			1	(2%)			
Mineralization	4	(8%)	2	(4%)	3	(6%)	4	(8%)			
Nephropathy	50	(100%)	48	(96%)	50	(100%)	50	(100%)			
Papilla, necrosis					1	(2%)					
Pelvis, inflammation, acute	1	(2%)	1	(2%)	2	(4%)	1	(2%)			
Renal tubule, hyperplasia	2	(4%)	4	(8%)	3	(6%)	4	(8%)			
Transitional epithelium, hyperplasia	1	(2%)					2	(4%)			
Urinary bladder	(50)		(49)		(50)		(50)				
Hemorrhage	1	(2%)			1	(2%)					
Inflammation, chronic active			1	(2%)	3	(6%)	2	(4%)			
Inflammation, suppurative	1	(2%)									
Necrosis	1	(2%)									
Transitional epithelium, hyperplasia	1	(2%)	1	(2%)	1	(2%)	3	(6%)			

APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE 2-YEAR INHALATION STUDY OF ISOBUTENE

TABLE B1	Summary of the Incidence of Neoplasms in Female Rats	
	in the 2-Year Inhalation Study of Isobutene	97
TABLE B2	Individual Animal Tumor Pathology of Female Rats	
	in the 2-Year Inhalation Study of Isobutene	100
TABLE B3	Statistical Analysis of Primary Neoplasms in Female Rats	
	in the 2-Year Inhalation Study of Isobutene	118
TABLE B4	Summary of the Incidence of Nonneoplastic Lesions in Female Rats	
	in the 2-Year Inhalation Study of Isobutene	121

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths	00	00	00	00
Accidental death		1		
Moribund	21	25	15	23
Natural deaths	6	5	2	5
Survivors				
Terminal sacrifice	23	19	33	22
Animals examined microscopically	50	50	50	50
Alimontary System				
Alimentary System Intestine large, colon	(49)	(50)	(49)	(49)
Intestine large, rectum	(43)	(47)	(43)	(49)
Polyp adenomatous	1 (2%)	(11)	(1)	(10)
Intestine large, cecum	(48)	(49)	(48)	(49)
Intestine small, duodenum	(49)	(50)	(48)	(48)
Intestine small, jejunum	(47)	(47)	(48)	(47)
Leiomyosarcoma			1 (2%)	
ntestine small, ileum	(46)	(47)	(48)	(47)
Liver	(50)	(50)	(50)	(49)
Carcinoma, metastatic, thyroid gland		1 (2%)		
Hepatocellular carcinoma				1 (2%)
Aesentery	(8)	(10)	(12)	(7)
Oral mucosa				(1)
Pharyngeal, squamous cell papilloma				1 (100%)
Pancreas	(50)	(50)	(49)	(49)
Salivary glands	(50)	(50)	(50)	(50)
Stomach, glandular	(50)	(50)	(50)	(49)
Cardiovascular System				
Heart	(50)	(50)	(49)	(50)
Endocrine System				
Adrenal cortex	(50)	(50)	(49)	(49)
Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Adrenal medulla	(50)	(50)	(49)	(49)
Pheochromocytoma complex	1 (2%)	· ·	· /	. /
Pheochromocytoma benign	3 (6%)	3 (6%)	9 (18%)	4 (8%)
Bilateral, pheochromocytoma benign			1 (2%)	
slets, pancreatic	(50)	(50)	(49)	(49)
Adenoma	1 (2%)			
Pituitary gland	(50)	(49)	(50)	(49)
Pars distalis, adenoma	39 (78%)	33 (67%)	37 (74%)	36 (73%)
Fhyroid gland	(50)	(50)	(49)	(49)
C-cell, adenoma	7 (14%)	6 (12%)	3 (6%)	5 (10%)
C-cell, carcinoma	2 (4%)	3 (6%)	6 (12%)	2 (4%)
Follicular cell, carcinoma	1 (2%)			

General Body System

None

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Genital System				
Clitoral gland	(50)	(49)	(47)	(48)
Adenoma	3 (6%)	3 (6%)	6 (13%)	()
Carcinoma			5 (11%)	1 (2%)
Bilateral, carcinoma	1 (2%)			
Ovary	(50)	(50)	(50)	(50)
Granulosa cell tumor malignant				1 (2%)
Uterus	(50)	(50)	(50)	(50)
Polyp stromal	7 (14%)	9 (18%)	7 (14%)	4 (8%)
Polyp stromal, multiple	1 (2%)		1 (2%)	1 (2%)
Vagina	(1)	(1)		(1)
Polyp	1 (100%)			
Hematopoietic System				
Bone marrow	(50)	(50)	(49)	(49)
Lymph node	(6)	(30)	(3)	(43)
Deep cervical, carcinoma, metastatic,	(*)	(*)	(0)	(~)
thyroid gland				1 (50%)
Renal, sarcoma	1 (17%)			- (00/0)
Lymph node, bronchial	(36)	(31)	(36)	(27)
Lymph node, mandibular	(44)	(46)	(47)	(47)
Lymph node, mesenteric	(50)	(50)	(49)	(49)
Lymph node, mediastinal	(42)	(45)	(39)	(45)
Plasma cell tumor malignant	1 (2%)	× -7	x/	× -7
Spleen	(50)	(50)	(49)	(50)
Hemangiosarcoma	x/	<u> </u>		1 (2%)
Thymus	(48)	(47)	(45)	(41)
5	. ,			
Integumentary System	(50)	(50)	(70)	(70)
Mammary gland	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (00/)
Carcinoma	2 (4%)	2 (4%)	4 (8%)	4 (8%)
Fibroadenoma	16 (32%)	14 (28%)	24 (48%)	22 (44%)
Fibroadenoma, multiple	6 (12%)	5 (10%)	6 (12%)	5 (10%)
Skin	(50)	(50)	(50)	(50)
Keratoacanthoma	1 (2%)		1 (2%)	
Squamous cell papilloma	1 (00/)		1 (2%)	
Subcutaneous tissue, fibroma	1 (2%)	1 (00/)	1 (2%)	
Subcutaneous tissue, fibrosarcoma		1 (2%)		
Subcutaneous tissue, fibrous histiocytoma	1 (00/)			
malignant Sub-stanting based in the second	1 (2%)			
Subcutaneous tissue, hemangioma	1 (2%)		1 (00/)	
Subcutaneous tissue, melanoma malignant	1 (00/)	0 (40/)	1 (2%)	
Subcutaneous tissue, sarcoma	1 (2%)	2 (4%)		
Subcutaneous tissue, schwannoma malignan		1 (2%)		
Subcutaneous tissue, pinna, melanoma malig	gnant 1 (2%)			
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	1 (2%)	< /	N/	×/
Usieusai cuilla				

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene

J			5	
	Chamber Control	500 ррт	2,000 ppm	8,000 ppm
Nervous System Brain	(50)	(50)	(50)	(50)
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Adenoma Alveolar/bronchiolar adenoma	2 (4%)	1 (2%)		
Carcinoma, metastatic, mammary gland	1 (2%)			
Carcinoma, metastatic, thyroid gland			2 (4%)	1 (2%)
Fibrosarcoma, metastatic, skin Plasma cell tumor malignant, metastatic,		1 (2%)		
lymph node, mediastinal	1 (2%)			
Mediastinum, plasma cell tumor malignant	,			
metastatic, lymph node, mediastinal	1 (2%)	(50)	(50)	(10)
Nose	(50)	(50)	(50)	(49)
Special Senses System				
Zymbal's gland			(1)	
Carcinoma			1 (100%)	
Urinary System				
Kidney	(50)	(50)	(49)	(49)
Lipoma Stromal nephroma		1 (2%)		1 (2%)
Renal tubule, carcinoma	1 (2%)	1 (870)		
Urinary bladder	(50)	(49)	(49)	(49)
Transitional epithelium, papilloma			1 (2%)	
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Leukemia mononuclear	18 (36%)	16 (32%)	22 (44%)	17 (34%)
Neoplasm Summary Total animals with primary neoplasms ^c	50	48	49	48
Total primary neoplasms	125	48	49 140	48
Total animals with benign neoplasms	42	45	48	46
Total benign neoplasms	92	76	100	80
Total animals with malignant neoplasms	30	24	30	25
Total malignant neoplasms Total animals with metastatic neoplasms	33 2	26 2	40 2	27 1
Total metastatic neoplasms	23	2	2	2
•				

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а

b

с

TABLE B2

Number of Days on Study 9 2 4 8 8 9 2 5 5 7 8 0 4 4 6 6 0 0 1 1 2 2 Carcass ID Number 4 2 1 </th <th></th> <th>3</th> <th>4</th> <th>4</th> <th>4</th> <th>4</th> <th>4</th> <th>5</th> <th>5</th> <th>5</th> <th>5</th> <th>5</th> <th>6</th> <th>6</th> <th>6</th> <th>6</th> <th>6</th> <th>6</th> <th>6</th> <th>6</th> <th>7</th> <th>7</th> <th>7</th> <th>7</th> <th>7</th> <th>7</th> <th></th>		3	4	4	4	4	4	5	5	5	5	5	6	6	6	6	6	6	6	6	7	7	7	7	7	7	
0 1 0 8 8 6 9 2 2 8 3 4 8 1 5 5 4 5 0 0 Carcass ID Number 1	Number of Davs on Study		-	-	8	8	q	2		5	-	8	0			-	-	6	7	å	0	0	1	1	2	2	
Carcass ID Number 4 2 1 1 2 1	under of Days on Study						-																	5			
3 2 2 0 4 1 7 6 5 5 5 7 7 8 6 9 9 4 2 Lineating Large, colon + </td <td></td> <td>1</td> <td></td>		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Sophage + </td <td>Carcass ID Number</td> <td>-</td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td>1 7</td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Carcass ID Number	-			-		-	1 7				-										-					
Sophags + </td <td>Alimentary System</td> <td></td>	Alimentary System																										
intestine large, colon + + + + + + + + + + + + + + + + + + +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
intestine large, rectum + <td></td> <td>+</td> <td> +</td> <td>+</td> <td>А</td> <td>+</td> <td></td>		+	 +	+	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	
intesting large, cecum + + + + + + + + + + + + + + + + + + +	ntestine large, rectum	+	 +	+	+	+		+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	Α	+	+	
intestine small, duodenum + + + + + + + + + + + + + + + + + + +															٨									٨			
intestine small, jejnum + A + A + + + + + <td></td> <td>+</td> <td> +</td> <td>+</td> <td>A</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>A</td> <td>+</td> <td></td> <td></td>		+	 +	+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	A	+		
intesting small, iteum + A + + + + + + + + + + + + + + + + + +		+	 Τ Λ	т	т	- -	- -	- -	т	- -	т ,	т	- -	- -	Λ	т	-			- -	- -	т ,	т ,	A A	- -	т 1	
Liver + + + + + + + + + + + + + + + + + + +		+	Α. Λ	+	+	+	+	+	+	+	+	+	+	+	A	+	+		+	+	+	+ ^	+	A	+	+	
Meson(try y + + + + + + + + + + + + + + + + + + +		+	- \ ⊥	+	+	+	+	+	+	+	+	+	+	+	A	+	+		+	+	+	A	+	A	+	+	
Pancreas´		+	 T	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	
Salivary glands + + + + + + + + + + + + + + + + + + +					,			+			+			,					,					+			
Stomach, forestomach, glandular + + + + + + + + + + + + + + + + + + +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Heart + + + + + + + + + + + + + + + + + + +		+	 + +	+	+	++	+	+	++	++	++	+	+	++	+	+	+	++	++	++	++	++	++	++	+	+ +	
Heart + + + + + + + + + + + + + + + + + + +	Cardiovascular System																										
Adrenal cortex +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Addenoma Adrenoma Adrenoma Adrenoma medulla Pheochromocytoma complex Pheochromocytoma benign islets, pancreatic Adrenoma Parathyroid gland + + + + + + + + + + + + + + + + + + +																											
Adrenal medulla +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma complex Pheochromocytoma benign Silets, pancreatic Adenoma Parathyroid gland + + + + + + + + + + + + + + + + + + +	Adenoma																										
Pheochromocytoma benign islets, pancreatic +	Adrenal medulla	+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign Islets, pancreatic +	Pheochromocytoma complex																										
islets, pancreatic +																											
Adenoma Parathyroid gland + + + + + + + + + + + + + + + + + + +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland +																											
Pituitary gland $+ + + + + + + + + + + + + + + + + + +$		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pars distalis, adenoma X <td></td> <td>+</td> <td> +</td> <td>+</td> <td></td>		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thyroid gland + + + + + + + + + + + + + + + + + + +							Х	Х					Х	Х	Х			Х									
C-cell, adenoma C-cell, carcinoma Follicular cell, carcinoma X General Body System Sevent None X General Body System X Cilitoral gland + + + + + + + + + + + + + + + + + + +		+	 +	+	+	+			+	+						+	+										
C-cell, carcinoma X Follicular cell, carcinoma X General Body System X None X Genital System X Clitoral gland + + + + + + + + + + + + + + + + + + +													·											·			
Follicular cell, carcinoma General Body System None Genital System Clitoral gland + + + + + + + + + + + + + + + + + + +																										х	
None Genital System Clitoral gland + + + + + + + + + + + + + + + + + + +																											
None Genital System Clitoral gland + + + + + + + + + + + + + + + + + + +	General Body System																										
Clitoral gland + + + + + + + + + + + + + + + + + + +	None																										
Adenoma Bilateral, carcinoma X Dvary + + + + + + + + + + + + + + + + + + +			 																								
Adenoma Bilateral, carcinoma X Dvary + + + + + + + + + + + + + + + + + + +	Clitoral gland	+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Ovary + + + + + + + + + + + + + + + + + + +																											
Dvary + + + + + + + + + + + + + + + + + + +	Bilateral, carcinoma																	Х									
Uterus + + + + + + + + + + + + + + + + + + +		+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	
Polyp stromal X X X X Polyp stromal, multiple //agina +	0	+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Polyp stromal, multiple Vagina +								Х		Х	Х			Х		Х										Х	
Vagina +								-		-	-			-		-											
	. .																								+		
	Polyp																								x		

A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

77 7 7 7 7 7 7 7 7 7 7 7 7 77 777 7 7 7 7 7 7 Number of Days on Study 3 3 3 3 3 3 3 3 3 2 6 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 Total **Carcass ID Number** Tissues/ 2 1 2 3 9 3 4 8 0 1 3 5 7 0 3 4 5 6 9 0 1 4 8 9 Tumors 1 **Alimentary System** Esophagus 50 Intestine large, colon 49 Intestine large, rectum 47 Polyp adenomatous 1 Intestine large, cecum 48 Intestine small, duodenum 49 Intestine small, jejunum 47 + Intestine small, ileum 46 50 Liver Mesentery 8 50 Pancreas + Salivary glands 50 + + + + + + + ++ + Stomach, forestomach 50 + + + + + + + +Stomach, glandular 50 + + + + + ++ +++ + + ++ **Cardiovascular System** Heart 50 + $^{+}$ + +++ **Endocrine System** Adrenal cortex 50 Adenoma 1 Adrenal medulla 50 Pheochromocytoma complex 1 Pheochromocytoma benign Х 3 Islets, pancreatic 50 + + + + Adenoma Х 1 48 Parathyroid gland Μ + + ++ + Μ + + + + Pituitary gland 50 + + + + + + + + + + + + + + + + + + $^{+}$ 39 Pars distalis, adenoma X ХХХ Thyroid gland + X 50 + X + + + + X + + + + + + + X + + + + + +++ X ++++ X X C-cell, adenoma 7 C-cell, carcinoma Х 2 Follicular cell, carcinoma Х 1 **General Body System** None **Genital System** Clitoral gland 50 $^{+}$ Х 3 Adenoma Bilateral, carcinoma 1 Ovary 50 Uterus 50 + + Polyp stromal 7 Х Polyp stromal, multiple 1 Vagina 1 Polyp 1

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: Chamber Control

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Number of Days on Study	3 9	4 2	4 4	4 8	4 8	4 9	5 2	5 5	5 5	5 7	5 8	6 0	6 4	6 4	6 4	6 6	6 6	6 7	6 9	7 0	7 0	7 1	7 1	7 2	7 2
Carcases ID Number 4 2 1		0	1	0	8	8	6	9	2	2	3	1	8	2	2	8	3	4	8	1	5	5	4	5	0	0
3 2 2 0 4 1 7 6 5 5 5 7 8 8 0 7 7 8 6 9 6 9 4 2 Hematopoletic System Bone marrow Lymph node, madibular Lymph node, mediastinal + <t< td=""><td></td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></t<>		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Bone marrow $+ + + + + + + + + + + + + + + + + + +$	Carcass ID Number				-		1 1		-	-		1 5	-												-	-
Lymph node + + + + + + + + + + + + + + + + + + +																										
$\overline{\mathbf{R}}$ real, sarcoma \mathbf{X} Lymph node, monchialMMMHH <td></td> <td>+</td>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
$ \begin{array}{llllllllllllllllllllllllllllllllllll$										Ŧ	Ŧ		т				т								Ŧ	
$\begin{array}{c} \text{Lymph node, mesenteric} \\ \text{Lymph node, mediastinal} \\ \text{Lymph node, mediastinal} \\ \text{Thymph node, mediastinal} \\ T$		Μ	Μ		Μ	М	+	М	Μ	М	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
$\begin{array}{llllllllllllllllllllllllllllllllllll$		+	+	Μ	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Plasma cell tumor malignantXSpleen+ + + + + + + + + + + + + + + + + + +		+	+								+			+	+	+	+	+	+	+	+	+	+	+	+	
Spleen + + + + + + + + + + + + + + + + + + +				+	+	+	M	+	+	+	M	+	+	+	+	+	+	+	+	+	M	+	+	+	+	IVI
Thymus + </td <td></td> <td>л +</td> <td>+</td>		л +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Mammary gland + <		+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М
$\begin{array}{cccccccccccccccccccccccccccccccccccc$																										
Carcinoma X		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
XXXXXXXXXXSkin+ + + + + + + + + + + + + + + + + + +						x																				
Skin + + + + + + + + + + + + + + + + + + +						••									Х			Х	Х	Х	Х	Х				
Keratoacanthoma Subcutaneous tissue, fibroma isticocytoma malignant Subcutaneous tissue, hemangioma Subcutaneous tissue, hemangioma Subcutaneous tissue, pinna, melanoma malignantXMusculoskeletal System Bone Osteosarcoma SarcomaMervous System BrainBrain++<												Х														Х
Subcutaneous tissue, fibroma X Subcutaneous tissue, searcoma Subcutaneous tissue, pinna, melanoma malignant Musculoskeletal System Bone + <t< td=""><td></td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></t<>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Subcutaneous tissue, fibrous histiocytoma malignant Subcutaneous tissue, hemangioma Subcutaneous tissue, pinna, melanoma malignantXMusculoskeletal System Bone Osteosarcoma Sarcoma++ <td></td>																										
Subcutaneous tissue, hemangioma Subcutaneous tissue, sarcoma Subcutaneous tissue, pinna, melanoma malignant Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +		nt			x																					
Subcutaneous tissue, sarcoma Subcutaneous tissue, pinna, melanoma malignant Musculoskeletal System Bone +																										
Musculoskeletal System Bone Osteosarcoma Sarcoma Nervous System Brain + + + + + + + + + + + + + + + + + + +																										
Bone + + + + + + + + + + + + + + + + + + +	Subcutaneous tissue, pinna, melanoma malignant																									
Osteosarcoma Sarcoma Nervous System Brain Brain + + + + + + + + + + + + + + + + + + +	Musculoskeletal System																									
Sarcoma Nervous System Brain + <td></td> <td>+</td>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System Brain + + + + + + + + + + + + + + + + + + +																										
Brain + + + + + + + + + + + + + + + + + + +																										
Respiratory System Larynx + + + + + + + + + + + + + + + + + + +										,							,									
Larynx+ + + + + + + + + + + + + + + + + + +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lung+ + + + + + + + + + + + + + + + + + +	T									,																
Alveolar/bronchiolar adenoma X Carcinoma, metastatic, mammary gland X Plasma cell tumor malignant, metastatic, X lymph node, mediastinal X Mediastinum, plasma cell tumor malignant, metastatic, lymph node, mediastinal X X Nose + + + + + + + + + + + + + + + + + + +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma, metastatic, mammary gland X Plasma cell tumor malignant, metastatic, X lymph node, mediastinal X Mediastinum, plasma cell tumor malignant, metastatic, lymph node, mediastinal X X Nose + + + + + + + + + + + + + + + + + + +		+	+	+	+	Ŧ	т	т	т	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	7
Plasma cell tumor malignant, metastatic, Iymph node, mediastinal X Mediastinum, plasma cell tumor malignant, metastatic, lymph node, mediastinal X Nose + + + + + + + + + + + + + + + + + + +						Х																				
Mediastinum, plasma cell tumor malignant, metastatic, lymph node, mediastinal X Nose + + + + + + + + + + + + + + + + + + +	Plasma cell tumor malignant, metastatic,																									
metastatic, lymph node, mediastinal X Nose + + + + + + + + + + + + + + + + + + +		Х																								
Nose + + + + + + + + + + + + + + + + + + +	Mediastinum, plasma cell tumor malignant,	v																								
			<u>т</u>	-	_ــ	<u>т</u>	+	+	+	÷	<u>ـ</u> ــ	÷	<u>ــ</u>	_ــ	<u>ـ</u> ــ	<u>ــ</u> ـ	÷	<u>ـ</u> ـ	_ــ	-	-	<i>т</i>	<i>т</i>	<u>т</u>	-	+
1172CI102 + + + + + + + + + + + + + + + + + + +	Trachea	+	++	++	++	+	+ +	+ +	+ +	+	++	++	++	++	++	+	++	++	++	++	++	++	++	++	++	+
	Eye			+					+		+					+										
Special Senses System	±,,~			T					- E																	

Number of Days on Study	2	2	'	'	'	'	'	'	'	'	'	'	'		'	'			'	'		'	'		'	
vumber of Days on Study			- 3	3	3	3	2	3	3	3	3	2	3	3	3	3	3	2	3	3	3	3	2	3	3	
	$\tilde{2}$	6	3	3	3	3	3	3 4		4		3 4	4					4			5	5	5	5		
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total
Samaara ID Number						-			1																	Total
Carcass ID Number	3	3	0	0	0	0	1	1	1	2	2	2	2	2	3	3	3	3		3	4	4	4	4		Tissues/
	1	2	I	2	3	9	3	4	8	0	I	3	5	7	0	3	4	5	6	9	0	1	4	8	9	Tumors
Iematopoietic System																										
Sone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
.ymph node																										6
Renal, sarcoma																										1
ymph node, bronchial	+	Μ	+	Μ	+	+	+	+	+	М	+	+	+	+	+	+	М	+	М	+	+	+	+	+	+	36
ymph node, mandibular	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	М	М	+	+	+	+	+	+	+	Μ	+	44
ymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ymph node, mediastinal	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	Μ	+	+	Μ	+	42
Plasma cell tumor malignant																										1
pleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
hymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
ntegumentary System																										
Aammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma	T	т	т	X	T	т	Г	r	r.	1	1	1-	Г [.]	ſ	1-	1		1.	1	-	ſ	r.	r	ſ	17	1
Carcinoma				л																					Х	2
Fibroadenoma			Х				Х			Х		Х			v	Х	v				v	Х			X	
			л			v	л			л		л			л	л	л	v			л	л			л	16
Fibroadenoma, multiple kin				X		X					X							X								6 50
	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Keratoacanthoma								X									17									1
Subcutaneous tissue, fibroma																	Х									1
Subcutaneous tissue, fibrous histiocytoma malignar	nt											•••														1
Subcutaneous tissue, hemangioma												Х														1
Subcutaneous tissue, sarcoma							Х																			1
Subcutaneous tissue, pinna, melanoma malignant																					Х					1
Ausculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Osteosarcoma			Х																							1
Sarcoma																				Х						1
Jervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																						_	_	_		
arynx							ر	L	-	ч	ч	ч	-	_	ч	-	-	-	-	-	_	J	_			50
ung	+	+	+	+	+	+	+	+	- -	т ,	т ,	- -	+ -	- -	т ,	- -	- -	- -	- -	- -	- -	т ,	+	+	- -	50 50
	+	+	+	+ X	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2
Alveolar/bronchiolar adenoma				л								л														
Carcinoma, metastatic, mammary gland																										1
Plasma cell tumor malignant, metastatic,																										
lymph node, mediastinal																										1
Mediastinum, plasma cell tumor malignant,																										
metastatic, lymph node, mediastinal																										1
lose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Trachea																	-									50

TABLE B2

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: Chamber Control

Number of Days on Study	3 4 4 4 5 5 5 5 6 6 6 6 6 7
Carcass ID Number	1 1
Urinary System Kidney Renal tubule, carcinoma Urinary bladder	+ + + + + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: Chamber Control

Number of Days on Study	7 2 2		2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 4	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5												
Carcass ID Number	1 3 1		1 3 2	1 0 1	1 0 2	1 0 3	1 0 9	1 1 3	1 1 4	1 1 8	1 2 0	1 2 1	1 2 3	1 2 5	1 2 7	1 3 0	1 3 3	1 3 4	1 3 5	1 3 6	1 3 9	1 4 0	1 4 1	1 4 4	1 4 8	1 4 9	Total Tissues/ Tumors
Urinary System Kidney Renal tubule, carcinoma Urinary bladder	+	-	+	+	++	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	++	++		+	50 1 50
Systemic Lesions Multiple organs Leukemia mononuclear	+ >	-	+ X	+ X	+	+	+	+	+ X	+ X	+ X	+ X	+	+	+ X	+	+	+	+	+	+	+	+	+	+ X	+	50 18

	^	~		,					٣	٣	٣	٣	٣	٣	0	0	0	0	0	0	0	0	C	0	7	
		2	4				4	4	5	5		5	5		6			6	6	6	6	6	6	6		
Number of Days on Study	1		2		5	7	9	9	3	3	4	6	7	8	0	0	2	3	3	6	6	8	8	9	0	
	3	6	0	0	5	9	4	6	4	4	Ø	5	3	0	3	8	1	0	5	2	4	8	8	۵	1	
	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	0	4	4	1	4	4	1	0	2	3	0	1	3	2	1	1	4	3	4	0	2	1	2	2	3	
	5	2	5	1	8	6	8	1	6	6	2	6	3	9	7	3	0	5	1	9	3	9	2	1	7	
A K-m and a mar S-mat and																										
Alimentary System Esophagus																										
Intestine large, colon	+ +	т 4		· +	+	+ +	+ +	+	+	+ +	+	+ +	+ +	+	+ +	+	+	+ +	+ +	+	+	+	+	+	+	
Intestine large, rectum	+	-	- +	. +	+	+	+	+	+	+	+	Ť	+	+	+	Ĺ	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	-+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	À	+	+	+	+	+	+	+	
Intestine small, duodenum	+	-+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	À	+	+	À	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	A	+	+	A	+	+	+	+	+	+	+	
Liver	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Carcinoma, metastatic, thyroid gland																								Х		
Mesentery				+																+			+			
Pancreas	+	+	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tongue																										
Cardiovascular System																										
Heart	+	4	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
incurt										'	<u> </u>	1		'		1		'		1		'	'		1	
Endocrine System																										
Adrenal cortex	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Adrenal medulla	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign																										
Islets, pancreatic	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+	+	- N	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ		
Pituitary gland	+	+	- +	+			+		+	+		+	+	+	+	+	+			+	+		+	+		
Pars distalis, adenoma							Х				Х				Х			Х				Х			Х	
Thyroid gland	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
C-cell, adenoma																										
C-cell, carcinoma															Х			Х						Х		
General Body System																										
None																										
Genital System																										_
Clitoral gland										5	J		J	5	L										т	
Adenoma	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Ovary				ر .	-	т.	_	_	-		-	-	-		-	-	_ _	_	<u>ـــ</u>	-	<i>т</i>	ᆂ	_ _	-	+	
Uterus	+	۲ ب	+ 	+ 	+ +	+ +	- -	-T -	- -		 	 	 		+	 	-T -	-T -	- -	- +	- +	т +		+	+	
Polyp stromal	т	-1	X		Τ'	X	т	г	г	Г	Г	F	X	Г	r	F	г	г	Г	X	т	т	т	X	•	
Vagina			+			Λ							~							Λ				Λ		
Hematopoietic System																										
Bone marrow	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node												+														
Lymph node, bronchial				1 N	1 M	[+	+	+	+	Μ	Μ	+	+	+	Μ	Μ	Μ	+	Μ	+	Μ	+	Μ	М	+	
Lymph node, mandibular	Μ	[]	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mediastinal	+	+	- +	+	+	Μ	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	
Spleen	+	+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thymus	+	-			-	+	+	+	+	+	+	+	+	M	+	+	Μ	+	+	+					+	

TABLE B2 Individual A ... л т. alati C+ J ∖f Te ohut 500 r 41 9 v . 1. п р

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: 500 ppm

		—																							
Number of Days on Study	7 0	7 1	7	77 1	7	7 2	7 3	7 3	7 3				77 33		7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	
	8	4	6	8	9	2	3	3	3	3	4	4 4	4 4	4	4	4	4	4	4	4	5	5	5	5	
	3	3	3	3	3	3	3	3	3	3	3	3 3	33	3	3	3	3	3	3	3	3	3	3	3	Total
Carcass ID Number	0						0	0	1				22		2	3	3	3	3	4	4	4	4		Tissues/
	4						6	7				5 (1		9	3		7	9		Tumors
Alimontowy System																									
Alimentary System Esophagus	+	- +		⊢ →	- +	+	+	+	+	+	+	+ -	+ +	. +	+	+	+	+	+	+	+	+	+	+	50
ntestine large, colon	+	- +		· ·	- +	+	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+	50
ntestine large, rectum	+	• +		+ +	- +	+	+	+	+	I	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	47
ntestine large, cecum	+	• +	+	+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	49
ntestine small, duodenum	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
ntestine small, jejunum	+	• +	+	+ +	- A	. +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	47
ntestine small, ileum	+	• +	+	+ +	- A	. +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma, metastatic, thyroid gland																									1
Mesentery		+	-	+	- +	+		+			+							+							10
Pancreas	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
tomach, glandular	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+	50
Congue													+												1
Cardiovascular System																									
Ieart	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	• +	+	+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma												Х													1
Adrenal medulla	+	• +	+	+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign						Х											Х							Х	3
slets, pancreatic	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	• +		+ +	- +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	• +	+		- +	+	+	+	+			+ -	+ +	+	+	+	+	+	+	+	+	+	Μ	+	49
Pars distalis, adenoma		Х	()	X	X	X	Х	Х	Х	Х	Х		Х	2	Х	Х	Х	Х	Х		Х			Х	33
Thyroid gland	+	• +	+	+ +	- +	+		+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	50
C-cell, adenoma							Х	Х			Х				Х		Х		Х						6
C-cell, carcinoma																									3
G eneral Body System None																									
Genital System																									
Clitoral gland				L .1		<u> </u>	-	÷	+	+	T	+	+ . [,]		-	_	+	+	+		-	-	-	+	49
Adenoma	+	+	-		+	т	Ŧ	× X	77	т.	T		- +	т	т	Y	x	-	-	-	-	Ŧ	Ŧ	7	49
Dvary	-	ı		L .1		+	+	л +	+	+	+	+ -	+ -	+	+	X +	X +	+	+	+	+	+	+	+	50
Jterus				, т 		+	+	+	+	+	+	· ·	 + +	- + +	+	+	+	+	+	+	+	+	+	+	50 50
Polyp stromal	-		-	. т	r	1.	'		'	X			. т	1.		'	1	X	'	X	x	'	'	'	9
/agina																									1
Iematopoietic System																									
Sone marrow								J	ц	-	1	L	_ ·				_	_			J			Т	50
.ymph node	+	+		- +	- +	+	+	+	Ŧ	Ŧ	т		- +	+	+	+	+	Ŧ	Ŧ	+	+	+	+	Ŧ	50 3
.ymph node, bronchial		- N	1 -					J	+	м		+	м +		[]		L	_		J	+			ч	31
Jymph node, mandibular	+	- IV	·1 1			+	+	+	++	M			+ N		ι + 	+	++	+ +	+	+	+	+	+	⊤ +	46
	+	- +	_	- + 	- +	+	+	+	++		+		+ IV + +		+	+	++	+ -	+ _	+	+	+	+	т ⊥	40 50
vmnh node mesenteric	+	+	-		+	т	т	-F	-1-	т.	Τ.	C 7	- +		т	Τ	-r	-	-	-	T	Ŧ	Τ	-1-	
Lymph node, mesenteric		. J		L .)	_ N	[⊥]	1		+	+	+	+	+ N	/ ⊥		_L_	+	+	+	+		_L_	_L_	+	/15
Lymph node, mesenteric Lymph node, mediastinal Spleen	+	- + 		⊦ + ⊦ -≭	- N	1 +	+	+	+ +	+ +	+ +	+ -	+ N + +	1 + · +	+	+	++	+	+	+	+	+	+	+ +	45 50

	0	2	4	4	4	4	4	4	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	7	
Number of Days on Study	1 3	1 6	2 0	4 0	5 5	7 9				3 4		6 5			0 3			3 0	3 5		6 4	8 8	8 8	9 2		
	3	3	3	3	3	3	3	3	3	3			3	3			3	3	3	3	3	3	3	3	3	
Carcass ID Number	0 5	4 2	4 5	1 1	4 8	4 6							3 3		1 7	1 3	4 0	3 5	4 1		2 3	1 9	2 2	2 1		
Integumentary System																										
Mammary gland Adenoma Carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibroadenoma Fibroadenoma, multiple				Х				X	Х				Х			X		х		X			Х		Х	
Skin Subcutaneous tissue, fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Subcutaneous tissue, sarcoma Subcutaneous tissue, schwannoma malignant		Х									Х															
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System																										
Larynx Lung Adenoma	+	+	+	+	+ +	+	+ +	+	+	+ +	+ +	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+ +	
Fibrosarcoma, metastatic, skin Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System Ear																				+						
Eye				+									+		+											
Urinary System																										
Kidney Stromal nephroma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	
Urinary bladder															-	+	+	+	+	-	+		M			

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: 500 ppm

																·								-		
Number of Days on Study	7 0 8	7 1 4	7 1 6	7 1 8	7 1 9	7 2 2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 5	7 3 5	7 3 5	7 3 5	
Carcass ID Number	3 0 4	3 3 8	3 2 7	3	3 0 8	3 0 3	3 0 6	3 0 7	3 1 0	3 1 2	3 1 4	3 1 5	3 2 0	3 2 4	3 2 5	3 2 8	3 3 0	3 3 1	3 3 4	3 3 9	3 4 3	3 4 4	3 4 7	3 4 9		Total Tissues/ Tumors
Integumentary System Mammary gland Adenoma Carcinoma Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, sarcoma Subcutaneous tissue, schwannoma malignant	+ X + X	+	+	++	+ X +	+	+ X +	+ X +	+ X + X	+ X +	+	+	+ X +	+ X +	+	+	+ X +	+	+	+	+ X +	+ X +	+	+ X X +	+	50 1 2 14 5 50 1 2 1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Adenoma Fibrosarcoma, metastatic, skin Nose Trachea	+ + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++	++++++	++++++	++++++	+ + X + +	++++++	+ + + +	++++++	+ + + +	++++++	+++++++	++++++	+++++++	+ + +	+ + X + +	++++++	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++	+ + +	50 50 1 1 50 50
Special Senses System Ear Eye							+																			1 4
Urinary System Kidney Stromal nephroma Urinary bladder	+	+	+	++++	++	++	++	++	+	+	+	+	+	++	+	+	+	++	++	+	++	++	++	++	+	50 1 49
Systemic Lesions Multiple organs Leukemia mononuclear	+	+	+	+	+	+ X	+ X	+ X	+	+	+	+ X	+ X	+	+	+ X	+	+	+	+	+ X	+	+ X	+	+	50 16

	3				55			6	6	6	6		•	•	7			7	7	7	7	7	7	7		
Number of Days on Study	9 9		2 3					2 6	4 4	5 1	8 0	8 4	8 6	0 1	0 5	0 6	2 0	3 3	3 3	3 3	3 3	3 3	3 4	3 4	3 4	
Concose ID Number	5				5 5			5	5	5	5	5	5	5		5		5	5	5	5	5	5	5		
Carcass ID Number	3 7	(44 73			2 6	3 8	4 6	3 6	3 5	4 2	0 2	2 4	0 7	4 4	0 1	0 4	0 5	0 6	0 8		1 0		
Alimentary System																										
Esophagus	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+		+ -	+ ·	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+		+ -	+ •	+ +	- +	- A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+		+ -	+ •	+ +	- +	- A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+		+ -	+ •	+ +	- +	- N	1 +	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Leiomyosarcoma																										
Intestine small, ileum	+		+ -	+ •	+ +	- +	- A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Liver	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Mesentery		-	+		-+	- +	- +			+		+		+	^			+								
Pancreas Solivora glonda	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+		+ -	+ ·	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular Footh	+		+ -	+ •	+ +	- +	- +	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System																										
Heart	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	
Endocrine System																										
Adrenal cortex	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Adrenal medulla	+		+ -	+ •	+ +	- +	- +	+		+	+	+		+	А	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign								Х		Х			Х								Х	Х				
Bilateral, pheochromocytoma benign																										
slets, pancreatic	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Pituitary gland	+		+ -	+ •	+ +	- +					+						+	+	+		+	+		+		
Pars distalis, adenoma	Х		X	X	Σ	ζ	Х		Х	Х		Х	Х	Х	Х	Х			Х	Х	Х		Х	Х	Х	
Thyroid gland	+		+ -				- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
C-cell, adenoma					X	Х	K																	Х		
C-cell, carcinoma			2	X										Х												
General Body System None																										
Genital System																										
Clitoral gland	+		+ -	+]	М +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma							Х						Х								Х					
Carcinoma																	Х		Х							
Ovary	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Uterus	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Polyp stromal								Х												Х		Х	Х	Х		
Polyp stromal, multiple																		Х								
Hematopoietic System																										
Bone marrow	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	
Lymph node			-	+				+		_																
Lymph node, bronchial	+		+ -	+ •	+ N	Λ +	- +	+	+	Μ			М			+		М		М	+	+	+	+	+	
Lymph node, mandibular	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+		+ -	+ •	+ +	- +	- +	+	+	+	+	+	+		Μ			+	+	+	+	+	+	+	+	
	Μ	1 -	+ -	+ 1	M +	- +	- +	+	+	+	Μ		+	+		+	+	+	+	+	+	+	+	Μ	+	
	+	• •	+ -	+ ·	+ +	- +	- +	+	+	+	+	+			А		+	+	+	+	+	+	+	+	+	
Lymph node, mediastinal Spleen Thymus	M + +		+ - + - + -	+] + · + ·	M + + + + +	- + - + - +	- + - + - +	+ + +	+ + +	+ + +		+	+	+	А	+	+	+	+	+ + +	+ + M	+ + +	+ + +	M + +	+	

	7	7	- 7	- 7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	- 7	7	7	
Number of Days on Study	3	3	3		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
· ·	4	4	4	4	4	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	Total
Carcass ID Number	1	1	1	1	1	1	1	1	2	2	2	2	2	2	3	3	3	3	3	3	4	4	4	4	4	Tissues/
	2	3	4	5	6	7	8	9	0	2	5	7	8	9		1	2	3	4	9	0	1	5		9	Tumors
Here and a week for the second and																										
Alimentary System Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	. +	Ť	+	+	+	Ť	+	+	+	+	Ť	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, cecum	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Leiomyosarcoma			'		•	x	ŕ						, i				÷			, i	•			•		10
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Mesentery			+	. '	ŕ	·	·	•	+	+	·	•	·	·	•	•	•	•	•	+	•	1		'	•	12
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	- -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	, +	+	+	+	+	+	50
Footh	т	1-	ſ		'	'	'					'	'				'			'	'		'	'		1
Cardiovascular System																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Find a cuitra a Structure																										
Endocrine System																										10
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma						Х																				1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pheochromocytoma benign						Х								Х		Х								v	Х	9
Bilateral, pheochromocytoma benign																								Х		1
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pituitary gland	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Pars distalis, adenoma	Х	X		X			Х		Х			Х					Х							Х		37
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
C-cell, adenoma C-cell, carcinoma		v					v			v				v												3 6
C-cell, carcillonia		Х					Х			Х				Х												0
G eneral Body System None																										
Genital System																										
Clitoral gland	+	+	+	+	-	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	+	т.	м	+	÷	47
Adenoma	+	T	+		+ X	T	T	-1-	+ X	141	-	F	-	-	7	+	-	-1-	-1-	-	-	т	141	T	Т	47
Carcinoma				л	Λ		Х		~		Х							Х								5
Ovary		-	J		-	+		+	+	+	л +	+	+	+	+	+	+		+	+	_L_	т.	ᆂ	<i>т</i>	÷	50
Jterus	+	- -	+ _	т 	- -	-T -L	+	+	 +	 	-r +	-r -	+	+	+	-r +	+	+	+	 	-r -L	+	т 	т 	+	50 50
Polyp stromal	+	Ŧ	т	т	-	-1-		+ X	т'	г	Τ'	Τ.	τ'	т.	г	т.	τ'	г,	т.	т.	7*	+ X	-	-	Τ'	30 7
Polyp stromal, multiple								Λ														Λ				1
Iematopoietic System Bone marrow	-	+	L	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
_ymph node	т	7	-1	Τ.	т	г	ſ	1-	+	1	r.	F	ſ	ſ	1-	-	ſ	1-	-	ſ	Г	т	т	т	Г	45
Lymph node, bronchial			,		.1		_	м	+ M	м		+	+	м	+	м	м	м	м	м	5				J	36
Lymph node, mandibular	+	- -	+ _	т 	- -	-T -L	-r +	1VI	1VI	1VI	+	+	+	M		+		M	+	+	-r -L	-T -L	т 	т 	+	30 47
Jymph node, mesenteric	+	- -	+ _	т 	- -	-T -L	-r +	+	 +	 	-r +	+	+	+	+	+	+	+	+	 	-r -L	-T -L	т 	т 	+	47
Lymph node, mediastinal	+	+	- N	· + 1	+	+	т	+ M		++	+ M		+ M				-	++	+ M	+	+	+	+	+	+	49 39
Spleen	+	+	10	1 +	+	+	141	111		т		+		Ŧ	Ŧ	+	+	Ŧ	141	Ŧ	+	+	+	+	+	39 49
				!	_	-	_L_		+	_	+	<u> </u>	+	_L_	_L	<u> </u>	_L_	_L_	<u> </u>	-		_			-	

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

	3	5	5	5	5	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	9 9	2 2	3 4	5 2	6 0				4 4		8 0	8 4		0 1				3 3	3 3	3 3	3 3	3 3	3 4	3 4	3 4	
	5	5	5	5	5		5		5	5		5	5	5	5	5	5	5	5	5	5	5	5	5	5	
Carcass ID Number	3 7	0 3	5 0		4 3				3 8		3 6			0 2					0 4		0 6			1 0		
Integumentary System																										
Mammary gland Adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	
Carcinoma														Х										••		
Fibroadenoma					Х		Х				Х	Х	Х		Х	Х		Х		• •	• •		• •		Х	
Fibroadenoma, multiple Skin															+	+	+	+	+		X +	+	X			
Keratoacanthoma	+	т	т	т	Ŧ	Ŧ	+	Ŧ	+	+ X	-	-	-	т	т	-	т	т	т	т	Ŧ	Ŧ	т	т	Ŧ	
Squamous cell papilloma																						Х				
Subcutaneous tissue, fibroma Subcutaneous tissue, melanoma malignant				х																						
Ũ				Λ																						
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System																										
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Carcinoma, metastatic, thyroid gland Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System																										
Eye											+											+				
Zymbal's gland Carcinoma											+ X															
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	
Transitional epithelium, papilloma																										
Systemic Lesions																										
Multiple organs	+	+							+				+							+		+		+	+	

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene: 2,000 ppm 7 7 7 7 7 7 7 7 7 7 7 7777 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 4 5 5 5 5 5 5 5 5 Total **Carcass ID Number** 1 1 1 1 1 1 1 2 2 2 2 2 2 3 3 3 3 3 4 4 4 4 1 4 Tissues/ 2 3 4 5 6 7 8 9 0 2 5 7 8 9 0 1 2 3 4 9 0 1 5 8 9 Tumors **Integumentary System** Mammary gland 50 + + + + + + + + + + + + + + + + + + + Adenoma 1 X X x x x $\begin{smallmatrix} X \\ X & X & X & X \end{smallmatrix}$ Carcinoma 4 ХХХ ХХ 24 Fibroadenoma ХХ Fibroadenoma, multiple Х ХХ 6 Skin 50 + + + + + + Keratoacanthoma 1 Squamous cell papilloma 1 Х Subcutaneous tissue, fibroma 1 Subcutaneous tissue, melanoma malignant 1 **Musculoskeletal System** Bone 50 +**Nervous System** Brain 50 + + + + + + **Respiratory System** Larynx 50 + + + ++ + 50 Lung + + + + + Carcinoma, metastatic, thyroid gland 2 Х Х 50 Nose + Trachea 50 + **Special Senses System** Eye + 6 + + + Zymbal's gland 1 Carcinoma 1 **Urinary System** Kidney 49 + + + + + ++ + + Urinary bladder 49 + + + + + + + + + + Transitional epithelium, papilloma Х 1 Systemic Lesions 50 Multiple organs + Leukemia mononuclear Х Х Х ХХХ 22 Х Х Х

Number of Days on Study	0 0	4 0	-	•	5 1	5 1	4	5			9		34	5		6	6 6	6 6	6 7	6 7	6 8	6 9	7 0	7 0
	5	7	9	0	1	2	7	9	0	2	7	8 (0 2	2 0	7	3	4	8	1	4	1	2	2	6
	7	7	7	7	7	7	7	7	7	7	7	7 3	77	7	7	7	7	7	7	7	7	7	7	7
Carcass ID Number	3	2	3	1	4	3	1	3	2	4	0	0	1 2	2 0	4	1	0	2	3	1	3	3	2	0
	9	4	5	9	4	3	1	0	5	3	8	5 3	3 8	3	8	0	1	3	8	4	6	7	2	2
Alimentary System																								
Esophagus	+	-+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	+ +	- +	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	- +	- +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	- +	- +	- +	+	+	+	+	+	+	+	+ •	+ +	+ +	• +	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	- +	- +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	• +	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	A	۰ +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	• +	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	A	۰ +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	• +	+	+	А	+	+	+	+	+	+
Intestine small, ileum	+	A	\ +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	Α	+	+	+	+	+	+
Liver	+	+	- +	- +	A	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Hepatocellular carcinoma																								
Mesentery								+				-	+		+		+						+	
Oral mucosa												+												
Pharyngeal, squamous cell papilloma												Х												
Pancreas	+	+	- +	+ +	A	+	+	+	+	+			+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	- +	+ +	+	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	- +	+ +	+	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	+	- +	+ +	A	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Tongue																								
Condiousseulon System																								
Cardiovascular System Heart																								
	-	7		· •	т	т	т	т	т	+	+	+ •	+ +	+ +	• +	+	т	т	т	т	т	Ŧ	т	Ŧ
Endocrine System																								
Adrenal cortex	+	+	- +	- +	A	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+
Adenoma																					Х			
Adrenal medulla	+	+	- +	+ +	A	+	+	+	+	+	+	+ •	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+
Pheochromocytoma benign														Х										Х
Islets, pancreatic	+	+	- +	+	A	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+
Parathyroid gland	+	+	- +		1 A				+			+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+
Pituitary gland	+	+	- +	+ +	A	+	+	+	+	+	+	+ ·	+ +	+ +							+	+	+	+
Pars distalis, adenoma				Х							Х			Х	Х	X	Х	Х	Х		Х	Х	Х	
Thyroid gland	+	+	- +	+ +	A	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+
C-cell, adenoma																Х				Х				
C-cell, carcinoma																								
General Body System																								
None																								
Genital System																								
Clitoral gland	+	-+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	+ +	- +	+	+	+	+	+	+	+	+	+
Carcinoma																								
Ovary	+	+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	+ +	- +	+	+	+	+	+	+	+	+	+
Granulosa cell tumor malignant		'				•												•	•	•				
Uterus	+	+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	+ +	- +	+	+	+	+	+	+	+	+	+
Polyp stromal		Ż	сx	Ċ		•												•	•	•				
Polyp stromal, multiple		-	-						Х															

7 7 7 7 7 7 7 7 7 7 7 7 77 77 777 7 7 7 7 7 7 Number of Days on Study 2 2 2 3 0 7 Total **Carcass ID Number** 2 4 0 0 0 0 1 1 1 1 1 2 2 2 2 3 3 3 4 4 4 4 4 4 5 Tissues/ 6 2 7 4 6 9 2 5 6 7 8 0 1 7 9 1 2 4 0 5 6 7 9 0 Tumors 1 **Alimentary System** Esophagus 50 Intestine large, colon 49 Intestine large, rectum 48 I + + + + 49 Intestine large, cecum + + + + + Intestine small, duodenum 48 Intestine small, jejunum 47 + Intestine small, ileum 47 + + + + + + + + ++ Liver 49 + + + Hepatocellular carcinoma Х 1 Mesentery 7 Oral mucosa 1 Pharyngeal, squamous cell papilloma 1 Pancreas 49 50 Salivary glands + + ++Stomach, forestomach 50 49 Stomach, glandular + Tongue 1 + **Cardiovascular System** 50 Heart + + + + + ++ + + + ++ + + + + + ++++ + + + + **Endocrine System** 49 Adrenal cortex + Adenoma 1 Adrenal medulla 49 + Pheochromocytoma benign Х Х 4 Islets, pancreatic 49 + + + + + + + + ++ + Parathyroid gland 48 + + + + + + + + + + + + + + + + + + Pituitary gland + + + + + + + + + + + + + + + + + 49 + + + + + + + Pars distalis, adenoma X X X X X X X X X X XXXXX 36 Х Х Х Х ХХ Х Х ХХ Thyroid gland + + + + 49 + + + + + + + + C-cell, adenoma Х Х Х 5 C-cell, carcinoma Х Х 2 **General Body System** None **Genital System** Clitoral gland 48 ΜМ Carcinoma Х 1 Ovary 50 Granulosa cell tumor malignant Х 1 Uterus 50 + + + + + Polyp stromal Х Х 4 Polyp stromal, multiple 1 Vagina 1

116

Individual Animal Tumor Pathology	y of Female Rats in the 2-Year Inhalation Study of Isobutene: 8,000 ppm
Number of Days on Study	0 4 4 5 5 5 5 5 5 5 6 7 7 0 0 1 1 4 5 8 9 9 2 3 4 5 5 6 6 6 6 7 7 8 9 0 0 5 7 9 0 1 2 7 9 0 2 7 8 0 2 0 7 3 4 8 1 4 1 2 2 6
Carcass ID Number	7 7
Hematopoietic System Bone marrow Lymph node Deep cervical, carcinoma, metastatic, thyroid gland	+ + + + A + + + + + + + + + + + + + + +
Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Hemangiosarcoma	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Thymus Integumentary System Mammary gland Carcinoma Fibroadenoma Fibroadenoma, multiple	+ + + + + + + + + + + + + + + + + + +
Skin Musculoskeletal System Bone Skeletal muscle	+ + + + + + + + + + + + + + + + + + +
Nervous System Brain	+ + + + + + + + + + + + + + + + + + + +
Respiratory System Larynx Lung Carcinoma, metastatic, thyroid gland Nose Trachea	$\begin{array}{c} + \ + \ + \ + \ + \ + \ + \ + \ + \ + $
Special Senses System Eye Lacrimal gland	+ +
Urinary System Kidney Lipoma Urinary bladder	+ + + + A + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +

 TABLE B2

 Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Isobutene:
 8,000 ppm

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	1	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
5 5	0	(0	9	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	5	5	5	5	5	5	
	7	,	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	Total
Carcass ID Number	. 9			0	0	0	0	1	1	1	1	1	9	2	2	2	3	3	3	4	4	1	4	1	4	5	Tissues/
Carcass ID Number	2 C						0	1	1 7	0	7	0	۵ ۵									4	-	4			
	6	2	2	7	4	6	9	2	5	6	7	8	0	1	1	9	I	Z	4	0	1	5	6	7	9	0	Tumors
Hematopoietic System																											
Bone marrow	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Lymph node																									+		2
Deep cervical, carcinoma, metastatic,																											
thyroid gland																									Х		1
Lymph node, bronchial	N	л		NЛ	м			м	м					М	м					м	м	м		м			27
	101																				111	111	+	111	111		
Lymph node, mandibular	+				Μ		+	+	+	+	+	+	+	Μ		+	+	+	+	+	+	+	+	+	+	+	47
Lymph node, mesenteric	+				+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Lymph node, mediastinal	+	- 1	М	+	Μ	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	45
Spleen	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma								Х																			1
Thymus	M	1	+	+	+	Μ	+	+	+	+	+	+	+	+	+	М	Μ	+	+	+	+	+	+	+	+	+	41
Integumentary System		_																									
Mammary gland	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma	+	-	r	т.	+ X	T	-	T	-r	F	-	Ŧ	Ŧ	-	T	T	-	T	77	\mathbf{v}	-	-	-	F	T	-r	
		,	v	v	Λ	17	17	v	v	v			v	37						Х			v	v	37	v	4
Fibroadenoma		4	X	Х		Х	Х	Х	Х	Х	•••		Х	Х					•••	•••			Х	Х	Х	Х	22
Fibroadenoma, multiple											Х						Х	Х		Х							5
Skin	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Musculoskeletal System																											
Bone	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Skeletal muscle															+												1
		—													-												_
Nervous System																											
Brain	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																											
Larynx	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lung	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma, metastatic, thyroid gland			-			•							•		·			·		•	•				x	•	1
Nose																									~	+	49
	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Frachea	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																											
Eye												+						+									4
Lacrimal gland																											1
-		—																									-
																											10
	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Kidney																				Х							1
Urinary System Kidney Lipoma																											
Kidney Lipoma	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Xidney Lipoma Urinary bladder	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Kidney	+	 —	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 50

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Adrenal Medulla: Benign Pheochromocytoma				
Overall rate ^a	3/50 (6%)	3/50 (6%)	10/49 (20%)	4/49 (8%)
Adjusted rate ^b	7.5%	8.2%	22.7%	10.2%
Ferminal rate ^C	3/23 (13%)	2/19 (11%)	7/33 (21%)	2/22 (9%)
First incidence (days)	733 (T)	722	626	650
oly-3 test ^d	P=0.589	P = 0.625	P=0.050	P=0.493
Adrenal Medulla: Benign or Complex Pheochro	mocytoma			
Dverall rate	4/50 (8%)	3/50 (6%)	10/49 (20%)	4/49 (8%)
djusted rate	10.0%	8.2%	22.7%	10.2%
erminal rate	4/23 (17%)	2/19 (11%)	7/33 (21%)	2/22 (9%)
irst incidence (days)	733 (T)	722	626	650
oly-3 test	P = 0.516N	P = 0.545N	P = 0.101	P = 0.638
Clitoral Gland: Adenoma	3/50 (6%)	3/49 (6%)	6/47 (13%)	0/48 (0%)
Adjusted rate	7.5%	3/49 (0%) 8.4%	0/47 (13%) 14.2%	0.0%
erminal rate	7.5% 3/23 (13%)	8.4% 3/18 (17%)	4/31 (13%)	0.0% 0/22 (0%)
'irst incidence (days)	3/23 (13%) 733 (T)	3/18 (17%) 733 (T)	4/31 (13%) 620	0/22 (0%) e
oly-3 test	P = 0.080N	P = 0.611	P = 0.269	P = 0.129N
ory o test	1 - 0.0001	1 - 0.011	1 - 0.203	1 - 0.160IN
litoral Gland: Carcinoma				
overall rate	1/50 (2%)	0/49 (0%)	5/47 (11%)	1/48 (2%)
djusted rate	2.5%	0.0%	12.0%	2.7%
erminal rate	0/23 (0%)	0/18 (0%)	4/31 (13%)	1/22 (5%)
irst incidence (days)	664 D. 0.000N	— D 0 500N	720	733 (T)
oly-3 test	P = 0.622N	P = 0.523N	P = 0.109	P = 0.746
Clitoral Gland: Adenoma or Carcinoma				
Overall rate	4/50 (8%)	3/49 (6%)	11/47 (23%)	1/48 (2%)
djusted rate	10.0%	8.4%	26.1%	2.7%
erminal rate	3/23 (13%)	3/18 (17%)	8/31 (26%)	1/22 (5%)
'irst incidence (days)	664	733 (T)	620	733 (T)
oly-3 test	P = 0.115N	P=0.564N	P=0.051	P=0.199N
Iammary Gland: Fibroadenoma				
Overall rate	22/50 (44%)	19/50 (38%)	30/50 (60%)	27/50 (54%)
adjusted rate	52.9%	46.6%	65.6%	62.9%
erminal rate	14/23 (61%)	8/19 (42%)	23/33 (70%)	16/22 (73%)
irst incidence (days)	581	440	560	511
oly-3 test	P = 0.144	P=0.357N	P = 0.152	P = 0.230
fammary Gland: Fibroadenoma or Adenoma				
overall rate	22/50 (44%)	20/50 (40%)	31/50 (62%)	27/50 (54%)
djusted rate	52.9%	49.1%	67.8%	62.9%
erminal rate	14/23 (61%)	9/19 (47%)	24/33 (73%)	16/22 (73%)
irst incidence (days)	581	440	560	511
ply-3 test	P = 0.178	P = 0.446N	P = 0.104	P = 0.230
fammary Gland: Carcinoma				
Derall rate	2/50 (4%)	2/50 (4%)	4/50 (8%)	4/50 (8%)
djusted rate	4.9%	5.5%	9.1%	10.0%
erminal rate	1/23 (4%)	2/19 (11%)	3/33 (9%)	2/22 (9%)
'irst incidence (days)	488	733 (T)	701	597
Poly-3 test	P = 0.284	P = 0.658	P = 0.377	P = 0.331

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Mammary Gland: Adenoma or Carcinoma				
Overall rate	3/50 (6%)	3/50 (6%)	5/50 (10%)	4/50 (8%)
Adjusted rate	7.4%	8.2%	11.3%	10.0%
erminal rate	2/23 (9%)	3/19 (16%)	4/33 (12%)	2/22 (9%)
'irst incidence (days)	488	733 (T)	701	597
ol-3 test	P = 0.478	P = 0.616	P = 0.403	P=0.494
Aammary Gland: Fibroadenoma, Adenoma, or (Carcinoma			
Overall rate	23/50 (46%)	21/50 (42%)	32/50 (64%)	30/50 (60%)
djusted rate	54.4%	51.5%	69.8%	68.5%
erminal rate	14/23 (61%)	10/19 (53%)	24/33 (73%)	17/22 (77%)
irst incidence (days)	488	440	560	511
oly-3 test	P = 0.081	P = 0.481N	P = 0.092	P= 0.117
ituitary Gland (Pars Distalis): Adenoma				
verall rate	39/50 (78%)	33/49 (67%)	37/50 (74%)	36/49 (73%)
djusted rate	87.8%	77.1%	76.5%	83.7%
Ferminal rate	21/23 (91%)	13/18 (72%)	25/33 (76%)	21/22 (95%)
irst incidence (days)	496	455	399	469
oly-3 test	P = 0.492	P = 0.126N	P = 0.111N	P = 0.391N
kin (Subcutaneous Tissue): Fibrous Histiocytoma	Fibrosarcoma or Sa			
verall rate	2/50 (4%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
djusted rate	4.9%	8.0%	0.0%	0.0%
erminal rate	1/23 (4%)	1/19 (5%)	0/33 (0%)	0/22 (0%)
irst incidence (days)	488	548	0/33 (0/0)	0/22 (0/0)
oly-3 test	P = 0.117N	P = 0.462	P=0.219N	P=0.244N
Skin (Subcutaneous Tissue): Fibroma, Fibrous Hi	stigartama Fibrasaraa	ma an Canaama		
Overall rate	3/50 (6%)	3/50 (6%)	1/50 (2%)	0/50 (0%)
djusted rate	7.4%	8.0%	2.3%	0.0%
erminal rate	2/23 (9%)	1/19 (5%)	1/33 (3%)	0/22 (0%)
First incidence (days)	488	548	733 (T)	0/22 (0/8)
oly-3 test	P = 0.079N	P = 0.625	P = 0.276N	P = 0.123N
hyroid Gland (C-cell): Adenoma verall rate	7/50 (149/)	6/50 (199/)	2/40 (60/)	5/40 (109/)
	7/50 (14%) 17.6%	6/50 (12%)	3/49 (6%)	5/49 (10%)
djusted rate 'erminal rate	17.6% 7/23 (30%)	16.4% 6/19 (32%)	6.8% 1/33 (3%)	12.7%
	, ,		· · ·	3/22 (14%)
irst incidence (days)	733 (T) D 0 416N	733 (T) D 0 565N	552 D 0 117N	663 D 0 284N
oly-3 test	P=0.416N	P=0.565N	P=0.117N	P = 0.384 N
hyroid Gland (C-cell): Carcinoma				
overall rate	2/50 (4%)	3/50 (6%)	6/49 (12%)	2/49 (4%)
djusted rate	5.0%	8.0%	13.7%	5.1%
erminal rate	0/23 (0%)	0/19 (0%)	4/33 (12%)	1/22 (5%)
irst incidence (days)	720	603	534	729
oly-3 test	P = 0.444N	P = 0.473	P = 0.164	P = 0.686
Thyroid Gland (C-cell): Adenoma or Carcinoma				
Overall rate	9/50 (18%)	9/50 (18%)	9/49 (18%)	7/49 (14%)
djusted rate	22.5%	23.9%	20.1%	17.7%
erminal rate	7/23 (30%)	6/19 (32%)	5/33 (15%)	4/22 (18%)
irst incidence (days)	720	603	534	663
Poly-3 test	P = 0.326N	P = 0.550	P = 0.495N	P = 0.400N

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ррт	2,000 ppm	8,000 ppm
Uterus: Stromal Polyp				
Overall rate	8/50 (16%)	9/50 (18%)	8/50 (16%)	5/50 (10%)
Adjusted rate	18.9%	23.0%	18.0%	12.1%
Terminal rate	1/23 (4%)	4/19 (21%)	7/33 (21%)	2/22 (9%)
First incidence (days)	529	420	626	407
Poly-3 test	P = 0.169N	P = 0.429	P = 0.567 N	P=0.287N
All Organs: Mononuclear Cell Leukemia				
Overall rate	18/50 (36%)	16/50 (32%)	22/50 (44%)	17/50 (34%)
Adjusted rate	41.6%	39.9%	46.8%	37.3%
Terminal rate	7/23 (30%)	7/19 (37%)	13/33 (39%)	3/22 (14%)
First incidence (days)	421	420	534	407
Poly-3 test	P = 0.349N	P = 0.525N	P=0.386	P = 0.421N
All Organs: Benign Neoplasms				
Overall rate	42/50 (84%)	45/50 (90%)	48/50 (96%)	46/50 (92%)
Adjusted rate	92.7%	94.8%	96.1%	95.7%
Terminal rate	22/23 (96%)	17/19 (90%)	32/33 (97%)	21/22 (96%)
First incidence (days)	496	420	399	407
Poly-3 test	P = 0.444	P = 0.507	P=0.375	P=0.417
All Organs: Malignant Neoplasms				
Overall rate	30/50 (60%)	24/50 (48%)	30/50 (60%)	25/50 (50%)
Adjusted rate	63.6%	56.1%	63.6%	54.3%
Terminal rate	12/23 (52%)	9/19 (47%)	20/33 (61%)	9/22 (41%)
First incidence (days)	390	216	534	407
Poly-3 test	P=0.257N	P=0.303N	P = 0.585	P=0.237N
All Organs: Benign or Malignant Neoplasms				
Overall rate	50/50 (100%)	48/50 (96%)	49/50 (98%)	48/50 (96%)
Adjusted rate	100.0%	98.0%	98.0%	98.0%
Terminal rate	23/23 (100%)	18/19 (95%)	32/33 (97%)	21/22 (96%)
First incidence (days)	390	216	399	407
Poly-3 test	P = 0.521N	P=0.496N	P = 0.500N	P = 0.496N

(T)Terminal sacrifice

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, clitoral gland, pituitary gland, thyroid gland, and uterus; for other tissues, denominator is number of animals necropsied.

^b Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

^e Not applicable; no neoplasms in animal group

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Accidental death		1		
Moribund	21	25	15	23
Natural deaths	6	5	2	5
Survivors				
Terminal sacrifice	23	19	33	22
nimals examined microscopically	50	50	50	50
Alimentary System				
Sophagus	(50)	(50)	(50)	(50)
Inflammation, suppurative	· ·	· ·	1 (2%)	× -/
itestine large, colon	(49)	(50)	(49)	(49)
Inflammation, acute		1 (2%)		
Parasite metazoan	5 (10%)		1 (2%)	1 (2%)
ntestine large, rectum	(47)	(47)	(47)	(48)
Parasite metazoan	8 (17%)	5 (11%)	5 (11%)	3 (6%)
testine large, cecum	(48)	(49)	(48)	(49)
Inflammation, acute	1 (2%)	1 (2%)	1 (00())	0 (00/)
Parasite metazoan	5 (10%)	2 (4%)	4 (8%)	3 (6%)
testine small, jejunum	(47)	(47)	(48)	(47)
Inflammation, acute Necrosis		1 (2%)	1 (2%)	
testine small, ileum	(46)	(47)	(48)	(47)
Inflammation, acute	(40)	1 (2%)	(40)	(47)
Parasite metazoan		1 (270)		1 (2%)
iver	(50)	(50)	(50)	(49)
Angiectasis	1 (2%)	3 (6%)	4 (8%)	3 (6%)
Basophilic focus	36 (72%)	36 (72%)	43 (86%)	36 (73%)
Clear cell focus	6 (12%)	9 (18%)	12 (24%)	5 (10%)
Cytomegaly				1 (2%)
Degeneration, cystic			2 (4%)	
Degeneration, fatty	12 (24%)	10 (20%)	12 (24%)	12 (24%)
Eosinophilic focus	6 (12%)	6 (12%)	5 (10%)	9 (18%)
Hematopoietic cell proliferation		a (1.10()	1 (2%)	0 (00/)
Hepatodiaphragmatic nodule	4 (8%)	7 (14%)	5 (10%)	3 (6%)
Inflammation, granulomatous Mitotic alteration	1 (2%)	1 (2%)		
Mixed cell focus	7 (14%)	1 (2%) 11 (22%)	9 (18%)	8 (16%)
Nixed cell locus	2 (4%)	11 (22/0)	9 (18%) 2 (4%)	0 (10/0)
Regeneration	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Thrombosis	1 (2%) 1 (2%)	I (w/0)	~ (T/U)	3 (070)
Bile duct, hyperplasia	9 (18%)	5 (10%)	7 (14%)	10 (20%)
Centrilobular, necrosis	4 (8%)	4 (8%)	5 (10%)	9 (18%)
Aesentery	(8)	(10)	(12)	(7)
Thrombosis	~ /	· ·	1 (8%)	. /
Artery, inflammation, chronic active			· · /	2 (29%)
Fat, hemorrhage	1 (13%)			. ,
Fat, necrosis	8 (100%)	10 (100%)	12 (100%)	6 (86%)

 a Number of animals examined microscopically at the site and the number of animals with lesion

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm				
Alimentary System (continued)								
Pancreas	(50)	(50)	(49)	(49)				
Atrophy	9 (18%)	11 (22%)	17 (35%)	10 (20%)				
Basophilic focus	1 (2%)	4 (8%)	3 (6%)	2 (4%)				
Hyperplasia	1 (270)	1 (2%)	1 (2%)	2 (470)				
Metaplasia, hepatocyte	1 (2%)	1 (276)	1 (278)					
Salivary glands	(50)	(50)	(50)	(50)				
	(50)	(50)	(50)					
Atrophy Stomach, forestomach	(50)		(50)	1 (2%)				
	(50)	(50) (50)	(30)	(50)				
Hyperplasia, basal cell	1 (90/)	1 (2%)						
Inflammation, acute	1 (2%)							
Mineralization	$\frac{1}{7}$ (2%)	7 (140/)	0 (100/)	E (100/)				
Necrosis	7 (14%)	7 (14%)	6 (12%)	5 (10%)				
Stomach, glandular	(50)	(50)	(50)	(49)				
Mineralization	C (20)	0 (10)	1 (2%)	1 (00/)				
Necrosis	3 (6%)	2 (4%)	1 (2%)	1 (2%)				
Fongue		(1)		(1)				
Hyperplasia, squamous				1 (100%)				
Footh			(1)					
Necrosis			1 (100%)					
Cardiomyopathy Atrium, thrombosis	30 (60%)	29 (58%)	37 (76%) 1 (2%)	31 (62%)				
Endocrine System								
Adrenal cortex	(50)	(50)	(49)	(49)				
Atrophy		1 (2%)		1 (2%)				
Degeneration, cystic	2 (4%)	2 (4%)	4 (8%)	2 (4%)				
Hyperplasia	15 (30%)	16 (32%)	24 (49%)	21 (43%)				
Hypertrophy	11 (22%)	8 (16%)	9 (18%)	9 (18%)				
Necrosis	2 (4%)		3 (6%)	1 (2%)				
Thrombosis		1 (2%)						
Vacuolization cytoplasmic	(1-1)	()	()	1 (2%)				
Adrenal medulla	(50)	(50)	(49)	(49)				
	10 (20%)	5 (10%)	6 (12%)	10 (20%)				
Hyperplasia		(50)	(49)	(49)				
Hyperplasia Íslets, pancreatic	(50)		()					
Hyperplasia slets, pancreatic Hyperplasia	(50)	1 (2%)	()					
Hyperplasia slets, pancreatic Hyperplasia Pituitary gland			(50)	(49)				
Hyperplasia slets, pancreatic Hyperplasia Pituitary gland Angiectasis	(50)	1 (2%) (49)						
Hyperplasia slets, pancreatic Hyperplasia Pituitary gland Angiectasis Pars distalis, angiectasis	(50)	1 (2%)	(50)	1 (2%)				
Hyperplasia Islets, pancreatic Hyperplasia Pituitary gland Angiectasis Pars distalis, angiectasis Pars distalis, cyst	(50) (50)	1 (2%) (49) 1 (2%)	(50) 1 (2%)	1 (2%) 1 (2%)				
Hyperplasia slets, pancreatic Hyperplasia Pituitary gland Angiectasis Pars distalis, angiectasis Pars distalis, cyst Pars distalis, hyperplasia	(50)	1 (2%) (49)	(50)	1 (2%)				
Hyperplasia Islets, pancreatic Hyperplasia Pituitary gland Angiectasis Pars distalis, angiectasis Pars distalis, cyst Pars distalis, hyperplasia Thyroid gland	(50) (50)	1 (2%) (49) 1 (2%)	(50) 1 (2%)	1 (2%) 1 (2%)				
Hyperplasia Islets, pancreatic Hyperplasia Pituitary gland Angiectasis Pars distalis, angiectasis Pars distalis, cyst Pars distalis, hyperplasia	(50) (50) 7 (14%)	1 (2%) (49) 1 (2%) 7 (14%)	(50) 1 (2%) 11 (22%)	1 (2%) 1 (2%) 5 (10%)				

General Body System

None

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm			
Genital System							
Clitoral gland	(50)	(49)	(47)	(48)			
Hyperplasia	1 (2%)		5 (11%)	1 (2%)			
Inflammation, chronic active			1 (2%)				
Ovary	(50)	(50)	(50)	(50)			
Cyst	9 (18%)	4 (8%)	4 (8%)	2 (4%)			
Inflammation, granulomatous		()	1 (2%)	(
Uterus	(50)	(50)	(50)	(50)			
Fibrosis			1 (2%)	1 (00())			
Inflammation, chronic active				1 (2%)			
Necrosis Coming hypertrephy		1 (90/)		1 (2%)			
Cervix, hypertrophy	(1)	1 (2%) (1)		(1)			
Vagina Inflammation, suppurative	(1)	(1)		(1) 1 (100%)			
initalinitation, supputative				1 (10076)			
Hematopoietic System							
Bone marrow	(50)	(50)	(49)	(49)			
Atrophy	1 (2%)	1 (2%)	x - 7	2 (4%)			
Hyperplasia, histiocytic				1 (2%)			
Hyperplasia, reticulum cell			1 (2%)	× /			
Lymph node	(6)	(3)	(3)	(2)			
Pancreatic, ectasia		1 (33%)					
Lymph node, mandibular	(44)	(46)	(47)	(47)			
Infiltration cellular, plasma cell		1 (2%)					
Infiltration cellular, polymorphonuclear				1 (2%)			
Lymph node, mesenteric	(50)	(50)	(49)	(49)			
Infiltration cellular, plasma cell	(7.0)	(70)	1 (2%)	(70)			
Spleen	(50)	(50)	(49)	(50)			
Accessory spleen		1 (2%)	0 (100/)	0 (10))			
Fibrosis	F (100/)	3 (6%)	6 (12%) 2 (00()	2 (4%)			
Hematopoietic cell proliferation	5 (10%) 1 (29%)	2 (4%)	3 (6%)	2 (4%)			
Hemorrhage	1 (2%)			2 (4%)			
Inflammation, granulomatous	1 (90/)			1 (2%)			
Necrosis	1 (2%)						
Integumentary System							
Mammary gland	(50)	(50)	(50)	(50)			
Galactocele	2 (4%)	2 (4%)	1 (2%)	2 (4%)			
Hyperplasia, atypical				1 (2%)			
Inflammation, acute			1 (2%)				
Inflammation, chronic	1 (2%)						
Skin	(50)	(50)	(50)	(50)			
Cyst epithelial inclusion		1 (2%)					
Hyperkeratosis	1 (2%)						
Inflammation, acute			1 (2%)				
Inflammation, chronic active	1 (2%)		1 (2%)	2 (4%)			

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Musculoskeletal System Bone Hyperostosis Skeletal muscle Artery, inflammation, chronic	(50) 9 (18%)	(50) 7 (14%)	(50) 11 (22%)	(50) 15 (30%) (1) 1 (100%)
Nervous System Brain Hemorrhage Artery, inflammation, chronic	(50) 1 (2%)	(50)	(50)	(50) 1 (2%)
Respiratory System Larynx Epiglottis, metaplasia, squamous Lung	(50) (50)	(50) (50)	(50) (50)	(50) 2 (4%) (50)
Inflammation, granulomatous Inflammation, suppurative Alveolar epithelium, hyperplasia Alveolus, infiltration cellular, histiocyte	(30) 7 (14%) 9 (18%)	5 (10%) 5 (10%) 1 (2%) 9 (18%) 1 (2%)	(30) 9 (18%) 7 (14%)	(30) 11 (22%) 6 (12%)
Bronchiole, hyperplasia Nose Inflammation, suppurative Thrombosis Lateral wall, metaplasia, squamous	(50) 7 (14%) 2 (4%)	(50) 2 (4%) 3 (6%)	1 (2%) (50) 8 (16%) 2 (4%)	(49) 8 (16%) 3 (6%) 3 (6%)
Olfactory epithelium, degeneration, hyaline Respiratory epithelium, metaplasia, squamou	44 (88%) Is	47 (94%) 1 (2%)	48 (96%)	3 (0%) 47 (96%)
Special Senses System Eye	(4)	(4)	(6)	(4)
Cataract Retina, atrophy	(4) 4 (100%) 3 (75%)	(4) 3 (75%) 3 (75%)	6 (100%) 6 (100%)	(4) 4 (100%) 4 (100%)
Urinary System	(50)	(70)	(10)	(10)
Kidney Infarct Nephropathy	(50) 1 (2%) 46 (92%)	(50) 46 (92%)	(49) 46 (94%)	(49) 2 (4%) 46 (94%)
Renal tubule, hyperplasia Urinary bladder Hemorrhage	(50)	1 (2%) (49)	(49)	(49) 1 (2%)

APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE 2-YEAR INHALATION STUDY OF ISOBUTENE

TABLE C1	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Inhalation Study of Isobutene	127
TABLE C2	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Inhalation Study of Isobutene	130
TABLE C3	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Inhalation Study of Isobutene	146
TABLE C4	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Inhalation Study of Isobutene	149

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	16	9	20	13
Natural deaths	6	9	3	9
Survivors				
Terminal sacrifice	28	32	27	28
Animals examined microscopically	50	50	50	50
Alimentary System				
Gallbladder	(46)	(40)	(45)	(34)
Intestine large, cecum	(47)	(45)	(49)	(42)
Leiomyoma				1 (2%)
Intestine small, duodenum	(46)	(45)	(48)	(42)
Histiocytic sarcoma	1 (2%)	()	(()
Intestine small, jejunum	(45)	(43)	(48)	(43)
Carcinoma	(10)	1 (2%)	(10)	1 (2%)
Intestine small, ileum	(46)	(43)	(48)	(42)
Liver	(50) 1 (2%)	(50)	(50) 2 (4%)	(49) 2 (4%)
Hemangiosarcoma Hepatoblastoma	1 (2%)		2 (4%) 1 (2%)	L (470)
Hepatocellular carcinoma	12 (24%)	12 (24%)	10 (20%)	7 (14%)
Hepatocellular carcinoma, multiple	1 (2%)	12 (24)0) 1 (2%)	4 (8%)	7 (14%)
Hepatocellular adenoma	15 (30%)	20 (40%)	13 (26%)	10 (20%)
Hepatocellular adenoma, multiple	5 (10%)	4 (8%)	5 (10%)	7 (14%)
Histiocytic sarcoma	,	()	1 (2%)	(/
Pancreas	(50)	(48)	(50)	(47)
Salivary glands	(50)	(49)	(50)	(50)
Stomach, forestomach	(50)	(49)	(50)	(48)
Squamous cell papilloma	1 (2%)			
Tooth	(7)	(14)	(9)	(16)
Odontoma	1 (14%)	3 (21%)	2 (22%)	2 (13%)
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma				1 (2%)
Pheochromocytoma malignant, metastatic	,	1 (90/)		
adrenal medulla		1 (2%)		
Endocrine System				<i></i>
Adrenal cortex	(49)	(49)	(50)	(49)
Adenoma	1 (2%)	1 (2%)	1 (2%)	0 (00/)
Capsule, adenoma	1 (2%)	2 (4%)	(50)	3 (6%)
Adrenal medulla Rhaachromacutama malignant	(49)	(49) 1 (2%)	(50)	(49)
Pheochromocytoma malignant Pheochromocytoma benign		1 (2%) 1 (2%)	1 (2%)	2 (4%)
Islets, pancreatic	(50)	(48)	(50)	(48)
Adenoma	(00)	1 (2%)	(00)	(01)
Pituitary gland	(50)	(48)	(49)	(48)
Pars intermedia, adenoma	(00)	(10)	()	1 (2%)
Thyroid gland	(50)	(50)	(50)	(49)
Follicular cell, adenoma			1 (2%)	

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
General Body System None				
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Prostate	(48)	(46)	(47)	(48)
Seminal vesicle	(49)	(47)	(50)	(47)
Testes Interstitial cell, adenoma	(50)	(50)	(50) 1 (2%)	(50) 1 (2%)
Hematopoietic System				
Bone marrow	(50)	(49)	(50)	(49)
Histiocytic sarcoma		(0)	1 (2%)	(1)
Lymph node Ronal histiocytic sarcoma	(4) 1 (25%)	(3)	(7)	(1)
Renal, histiocytic sarcoma Lymph node, bronchial	1 (25%) (30)	(33)	(32)	(32)
Pheochromocytoma malignant, metastatic,	(00)	(00)	(02)	(02)
adrenal medulla		1 (3%)		
Lymph node, mandibular	(34)	(29)	(33)	(35)
Lymph node, mesenteric	(48)	(49)	(48)	(49)
Histiocytic sarcoma	1 (2%)	(29)	(26)	(21)
Lymph node, mediastinal Histiocytic sarcoma	(37)	(38)	(36) 1 (3%)	(31)
Pheochromocytoma malignant, metastatic,			1 (570)	
adrenal medulla		1 (3%)		
Spleen	(50)	(49)	(50)	(48)
Hemangiosarcoma	(22/)	1 (2%)	1 (22())	1 (2%)
Histiocytic sarcoma	1 (2%)	(49)	1 (2%)	1 (2%)
Thymus	(41)	(42)	(38)	(41)
Integumentary System	(10)	(50)	(50)	(50)
Skin	(49)	(50)	(50) 1 (2%)	(50)
Subcutaneous tissue, hemangioma Subcutaneous tissue, sarcoma			1 (2%)	1 (2%)
Subcutaneous ussue, sarcoma			1 (270)	1 (270)
Musculoskeletal System None				
Nervous System None				
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	9 (18%)	5 (10%)	5 (10%)	3 (6%)
Alveolar/bronchiolar adenoma, multiple	3 (6%)	2 (4%)	()	- ()
Alveolar/bronchiolar carcinoma	6 (12%)	5 (10%)	4 (8%)	3 (6%)
Alveolar/bronchiolar carcinoma, multiple	A (001)	1 (2%)	0 (10)	3 (6%)
Hepatocellular carcinoma, metastatic, liver	4 (8%)	4 (8%)	2 (4%)	3 (6%)
Histiocytic sarcoma Pheochromocytoma malignant, metastatic,			1 (2%)	
adrenal medulla		1 (2%)		

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Special Senses System				
Harderian gland	(4)	(4)	(4)	(4)
Adenoma	2 (50%)	3 (75%)	4 (100%)	2 (50%)
Carcinoma	1 (25%)			2 (50%)
Bilateral, adenoma	1 (25%)			
Urinary System				
Kidney	(50)	(49)	(50)	(50)
Hepatocellular carcinoma, metastatic, live	er	1 (2%)	. ,	
Histiocytic sarcoma			1 (2%)	
Pheochromocytoma malignant, metastatic	,			
adrenal medulla		1 (2%)		
Renal tubule, adenoma	1 (2%)		2 (4%)	
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Histiocytic sarcoma	1 (2%)	(00)	1 (2%)	1 (2%)
Lymphoma malignant	4 (8%)	2 (4%)	5 (10%)	5 (10%)
Neoplasm Summary				
Fotal animals with primary neoplasms ^c	41	41	36	38
Total primary neoplasms	66	66	64	66
Total animals with benign neoplasms	30	32	27	23
Total benign neoplasms	40	42	36	32
Fotal animals with malignant neoplasms	21	19	23	23
Total malignant neoplasms	26	24	28	34
Total animals with metastatic neoplasms	4	5	2	3
Total metastatic neoplasms	4	10	2	3

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а

b

с

	0	0	4		۲	٣	۲	۲	۲	e	e	e	C	e	C	e	e	e	7	~	7	7	7	1	7
Number of Days on Study	3	3 9	4 2	4 8	5 2	5 6						6 1	6 5	6 5				6 9	/ 0	7 0	1	7 2	7 3	7 3	7 3
Number of Days on Study	8 7	9 9	2 6		2 7	ю 0						1							8	9	1 5	2 3	3 3	3 3	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcass ID Number	4	5	1		2	0							2						3		1		0	0	
	0	0	4	3	6	2	2	7					8		5						6		1	4	5
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	+	+	А	+					+			+		+	+	+			Α		+	+	+	+	+
Intestine large, colon	+	+	+	+					+			+	+		+	+			A	+	+	+	+	+	+
Intestine large, rectum	+	+	+	+				A				+	+	+	+	+		+	A	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+		A										+			A	+	+	+	+	+	+
Intestine small, duodenum	+	+	Α	+	+	Α	+	A	+	+	+	+		+	+	+	+	+	A	+	+	+	+	+	+
Histiocytic sarcoma													Х												
Intestine small, jejunum	+	+		+															A	+	+	+	+	+	+
Intestine small, ileum	+	+	Α	+	+	А									+				Α		+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+
Hemangiosarcoma		17		v		v	v	v					v		Х	v	v			17		17			
Hepatocellular carcinoma		Х		Х		Х	Х	Х		v			Х			Х	Х			Х		Х			
Hepatocellular carcinoma, multiple										Х					v		v	v		v					v
Hepatocellular adenoma									v						Х		Х	х		Х					Х
Hepatocellular adenoma, multiple									Х					Х											
Mesentery											+		+								+				
Pancreas Saltaren alemak	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Squamous cell papilloma								٨																	
Stomach, glandular Tooth	+	+	+	+	+	+	+	A		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Odontoma					X^+				+										+				+		
Cardiovascular System Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
		-	-	-	-	-		-		-		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma																									
Capsule, adenoma																									
Adrenal medulla	+	+	+	+	+	+	+		A			+	+	+	+	+	+	+	+	+	+	+	+	+	+
Islets, pancreatic	+	+	+	+	+	+			+					+				+	+	+	+	+	+	+	+
Parathyroid gland	+	+	+	+	+	+							+						Μ	+	+	+	+	+	+
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
General Body System None																									
Genital System																									
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Prostate	+	+	+	+	+	+	+	Å	+	+	+	+	+	+	+	+	+	+	+	, +	+	+	+	+	+
Seminal vesicle	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Testes				:		÷			÷				•	•		·	·		÷	1	'	1			

+: Tissue examined microscopically A: Autolysis precludes examination

X: Lesion present Blank: Not examined

M: Missing tissue I: Insufficient tissue

Individual Animal Tumor Patholog	y ui mai	e IV.	nu	сш	l III	e 4	-16	ar		Шă	llat	101	13	luu	iy t		130	Du	len	e.	U	uai	шv		CU	111 01
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
j	3		3		3	3		3	3	3	3	3	4	4	4	4	4	4	4	4	4		4	4		
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	0		0		1	1		1	2	2	2	2	2	2	2	3	3	3	3		4	4	4	4	4	Tissues/
Carcass ID Number	6		8		1	3			0	2 1	2		ء 5	2 7	2 9	0	5 6	3 7	3 9	4 1	4 2	4	4 5	4 6		Tumors
	0	1	0	0	1	3	0	9	0	1	۵	4	5	1	9	U	0	1	9	1	۵	3	9	0	9	TUINOIS
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, cecum	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, duodenum	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Histiocytic sarcoma																										1
Intestine small, jejunum	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, ileum	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Liver	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Hepatocellular carcinoma																Х			Х							12
Hepatocellular carcinoma, multiple																										1
Hepatocellular adenoma				х	Х						Х	х			Х		Х	х	Х	х					Х	15
Hepatocellular adenoma, multiple		Х			••						••	••			••		••	••	••	••	Х		Х		••	5
Mesentery								+													••		••			4
Pancreas	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	-	· +	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+		+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma	'	'				'						'				'	'		'	'			X			1
Stomach, glandular	L		_	. <u>т</u>	-	-		-	-	-	т.	-	-		т	-	-	-	-	-	+	+	+	+	-	49
Tooth	7		-	т	т	+	т	т	т	т	+	т	т	т	T	т	т	т	т	т	т	т	т	т	т	43 7
Odontoma						т	Ŧ				т															1
Guomonia																										1
Cardiovascular System																										
Heart	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma						Х																				1
Capsule, adenoma														Х												1
Adrenal medulla	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Islets, pancreatic	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	• +	+	+	+	+	+	+	+	+	+	+	+	I	+	+	+	M	+	+	+	+	+	+	+	41
Pituitary gland	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Contract De des Constants																										
General Body System None																										
Genital System																										
Epididymis	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Prostate	+	· +	+	+	+	+	+	+	+	+	+	I	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Seminal vesicle	+	· +	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Testes	، ب	، بد .	_	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
1 05105	т								'			'			1	'				'						50

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control

TABLE C2

individual Animal Tumor Pathology of	Iale Mice in the 2-Year Inhalation Study of Isobuto	ene: Unamper Control
	3 3 4 4 5 5 5 5 5 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7
Number of Days on Study	8 9 2 8 2 6 8 8 9 0 1 1 5 5 6 8 9 9	0 0 1 2 3 3 3
- · ·	7 9 6 3 7 0 0 9 2 8 0 1 3 3 4 1 5 5	8 9 5 3 3 3 3
	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0
Carcass ID Number	4 5 1 0 2 0 3 4 4 3 0 3 2 3 1 1 1 4	3 2 1 3 0 0 0
		8 3 6 5 1 4 5
Hematopoietic System		
Bone marrow	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Lymph node	+ +	
Renal, histiocytic sarcoma	Х	
Lymph node, bronchial	M M M + + + M + + M + M M + M M + M	+ + + + + + M
Lymph node, mandibular	+ + + + M + + M + + + + M M M + M M	
Lymph node, mesenteric	+ + + + + A + + + + + + + + + + + + + +	+ + M + + + +
Histiocytic sarcoma	Х	
Lymph node, mediastinal	+ + + M + M + + + M + + + + + + + + + +	M + + + + + M
Spleen	+ + + + + + + + + + + + + + + + + + +	+ + + + + + +
Histiocytic sarcoma	Х	
Thymus	+ + + + + + M + + + + + M + M + M + M +	+ M + + + + +
Integumentary System		
Mammary gland	М М М М М М М М М М М М М М М М М	ММММММ
Skin	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Musculoskeletal System		
Bone	+ + + + + + + + + + + + + + + + + + +	+ + + + + + +
Nervous System		
Brain	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Respiratory System		
Larynx	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Lung	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Alveolar/bronchiolar adenoma	Х	X X
Alveolar/bronchiolar adenoma, multiple		X X
Alveolar/bronchiolar carcinoma	X X	Х
Hepatocellular carcinoma, metastatic, liver	X X X	Х
Nose	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Trachea	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Special Senses System		
Eye	+	
Harderian gland	+ v	+ V
Adenoma	Х	Х
Carcinoma Bilateral. adenoma		
Dilateral, autilonia		
Urinary System		
Kidney	+ + + + + + + + + + + + + + + + + + +	+ + + + + + +
Renal tubule, adenoma		
Urinary bladder	+ + + + + + + + + + + + + + + + + + +	+ + + + + + +
Systemic Lesions		
Multiple organs	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
Histiocytic sarcoma	Х	
Lymphoma malignant	Х	

7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 77 777 7 77 7 7 7 Number of Days on Study 3 Total **Carcass ID Number** 0 0 0 1 1 1 1 1 2 2 2 2 2 2 2 3 3 3 3 4 4 4 4 4 4 Tissues/ 7 8 0 1 3 8 9 0 1 2 4 5 7 9 0 6 7 9 1 2 3 5 6 9 Tumors 6 **Hematopoietic System** Bone marrow 50 + + + + + + + + + + + + + + Lymph node 4 Renal, histiocytic sarcoma 1 Lymph node, bronchial 30 M M + M M + + + + M M + + + M + + M + + M + + + + Lymph node, mandibular + M + + + M + 34 + + + + + + + + + M M +Μ M M ++ + Lymph node, mesenteric + + + + + + + + + + + + + 48 + + + + + + + + + + + + Histiocytic sarcoma 1 Lymph node, mediastinal M M + M + M + M M + + ++ M + 37 + + + + + + + Spleen + + + + + ++ + + + + + + 50 Histiocytic sarcoma 1 Thymus 41 **Integumentary System** Mammary gland Skin 49 Musculoskeletal System 50 Bone + + + + + + + + ++ + + $^{+}$ $^{+}$ + + + + + +**Nervous System** Brain 50 + **Respiratory System** Larynx 50 Lung 50 + + + Alveolar/bronchiolar adenoma ХХХ 9 Alveolar/bronchiolar adenoma, multiple 3 Х Alveolar/bronchiolar carcinoma Х Х Х 6 Hepatocellular carcinoma, metastatic, liver 4 Nose 50 + + + + + + + + + + + + + ++ + + + + + + + + + + Trachea 50 +Special Senses System 2 Eye + Harderian gland 4 + + 2 Adenoma Carcinoma Х 1 Bilateral, adenoma Х 1 **Urinary System** 50 Kidney +Renal tubule, adenoma Х 1 Urinary bladder 49 + + + + Systemic Lesions Multiple organs 50 + + + + + + + + + + + + + + Histiocytic sarcoma 1 Lymphoma malignant Х Х 4

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control

TABLE C2

Individual Animal Tumor Pathology of														_	•										
	4	5	5	5	5	5	5	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	0	1	2	4	6	8	9	0	3	4	5	6	6	9	0	1	1	1	3	3	3	3	3	3	3
	5	2	2	6	2	3	6	1	9	9	2	7	7	8	9	1	5	6	3	3	3	3	3	3	3
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Carcass ID Number	2 0	23			2 3			2 4	2	ړ 4	2	2 0	2 3	2 3			ړ 1	2 3	2 0		2 0	2 0	2 0		1
	8				9		3																	7	
Alimentary System																									
Esophagus Gallbladder	- Δ	· +	· + . Δ	T T	+	+			+				+ +				+	+	+	+	+ M	+ M	+	+	+
Intestine large, colon	Ā					+			+				+					+	+	+	+	111		+ +	+
Intestine large, rectum			- A			+									+			+	+	+	Ī	+	- -	- -	+
Intestine large, rectum					+													+	+	- -	1	- -	- -	- -	+
Intestine small, duodenum					+													+	+	+	+	+	+	+	+
Intestine small, jejunum					+														+	+	+	+	+	+	+
Carcinoma	А	. +	· A	A	+	+	А	A	X	+	+	А	+	А	+	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum	٨		٨	۸	+		٨	٨		,	,	٨	,	٨				,	,						
,																		+	++	+	+	+	+	+	+
Liver Henatocallular carcinoma					+			+	+	+	+	+ X	+	+	+	+	+ X	+	+	+	+	+ X		+	+
Hepatocellular carcinoma	Х		X	X		Х	Х					Å				v	л					Х			
Hepatocellular carcinoma, multiple			v	v			v	v			v			v		Х				v		v	v		v
Hepatocellular adenoma			Х	Х			Х	Å	v		Х			Х						Х		Х	Х		Х
Hepatocellular adenoma, multiple									Х																
Mesentery																									
Pancreas	A	. +	• +	+	+	+	+	+	+	+	+		+					+	+	+	+	+	+	+	+
Salivary glands	+	• +	• +	+	+	+	+	+	+	+	+			Α				+	+	+	+	+	+	+	+
Stomach, forestomach	A	· +	• +	+	+	+	+	+	+	+	+	+						+	+	+	+	+	+	+	+
Stomach, glandular	A	. +	• +	+	+	+	А	+	+			+	+	A	+	+	+	+	+	+	+	+	+	+	+
Tooth											+													+	
Odontoma										л	Х														
Cardiovascular System																									
Heart	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant, metastatic,																									
adrenal medulla																									
Endocrine System																									
Adrenal cortex														٨											
Adrenal cortex Adenoma	+	• +	• +	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+
Capsule, adenoma Adrenal medulla							,		,	,	,		,	٨				,	,						
	+	• +	• +	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant																									
Pheochromocytoma benign																									
Islets, pancreatic	A	. +	• +	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+
Adenoma Devedence id alexa d					r					۰.															
Parathyroid gland	+	+	• IV	IM	+	+	+	M	+	M			+		+	+	+	+	+	+	+	+	+	+	+
Pituitary gland	A	. +	• +	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+
Thyroid gland	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
G eneral Body System None																									
Genital System																									
Epididymis	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	• +	+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+
Prostate	А	. +	· A	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	Ι	+	+	+	+	+	+	+
Seminal vesicle	А	. +	· A	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+
Testes	+																								

Individual Animal Tumor Pathology o	t Male			, 111	<u> </u>	e 4	- 10			ina	uat	101	1 3	uu	iy u		130	Ju		с.	50		hhi			
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	3	3	3	3	3	3	3	3	4	4	4	4	4	4		4	4	4	4	4	4	4	4		4	
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	Total
Carcass ID Number	2 1	1	2 1	2 1	2 1	2 1	2 1	2	2	2	2	2	2	2	23	23	23	23	23	2 4	2 4	2 4	2 4	2 4	5	Tissues/
	1	2	4	5		8	9			2					0		4				3		6	9		Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	40
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Carcinoma																										1
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma	Х												Х								Х					12
Hepatocellular carcinoma, multiple																										1
Hepatocellular adenoma	X		Х	Х	Х	Х									Х	Х				Х		Х		Х		20
Hepatocellular adenoma, multiple		Х							Х																Х	4
Mesentery	+															+										2
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Tooth Odontoma		+ X	+		+				+	+	+		+	+	+		+								+	14 3
Odomonia		л																								3
Cardiovascular System																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant, metastatic,						• •																				
adrenal medulla						Х																				1
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma		Х																								1
Capsule, adenoma			Х																				Х			2
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pheochromocytoma malignant						Х						• •														1
Pheochromocytoma benign												Х														1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Adenoma			X																							1
Parathyroid gland	+	Μ	+	+	+	+	Μ	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	42
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
G eneral Body System None																										
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47

4										atio			-										
4	5		5							6				7	7 7	' 7	1	1	7	7	7	7	
0	1	2			8	9			4 5		6	9	0		1 1	. 3				3	3	3	3
5	2	2	6	2	3	6	1	9	9 2	27	7	8	9	1	56	3	3 3	3 3	3	3	3	3	3
2	2	2	2	2	2	2	2	2	2 2	2 2	2	2	2	2	2 2	2			>	2	2	2	2
0			0	0		Ū	~	0		, 1		-							, 	, ·	•	<u> </u>	0
+	+	• +	- +	+	+	+	+	+	+ -	+ +	+	А	+	+	+ -	+ +		⊦ -	+	+	+	+	+
	_		_		_			+								_	_						
N	1 +	• +	- N	1 N	l +	Μ	+	+	M -	+ +	+	Μ	Μ	+	М -	⊢ N	Λ-	+ -	ł	+	+	+	+
	r.		ر ب	۸r.		Ъ Л	M	١đ		.	1.4	1.1										٦ſ	
																		⊢ -	+	+ ·	+	M	+
+	+																			+ •	+ M	+ \/	+
+	+	- +	- +	- IV	ι +	IVI	+	+	+ ľ	VI IV	ı +	IVI	+	+	IVI -				t	+ .	IVI	IVI	+
	J				-	-	+	+	+	L .	-	Δ	+	+	+	L .!	L	L	F	Ŧ	+	+	+
+	+	+	+	Ŧ	т	T	Τ'	т		. +	Ŧ	п	7						17	с	г	т'	
+	+	. N	/ →	. +	+	м	+	+	+ -	+ +	+	А	+				÷ -	⊢ -	+	M	+	+	+
т	г	1	• T	r		141				. г													
Ν	1 N	1 N	4 N	1 M	I M	Μ	М	М	MN	ΜN	1 M	Μ	М	М	MI	ΛN	Λl	A 1	M	M	М	М	М
+	+	• +	• +	+	+	+	+	+	+ -	+ +	+	+	+	+	+ -	+ +	+ -	+ -	ł	+	+	+	+
+	+	• +	• +	- +	+	+	+	+	+ -	- +	+	+	+	+	-				F	+	+	+	+
+	+	• +	- +	+ +	+	+	+	+	+ -	+ +	+	+	+	+	+ -	+ +	+ -	+ -	+	+	+	+	+
				,								٨					1						
+	+	- +	- +	· +	+	+	+	+	+ -	- + - '	+		+	+	т - ⊥			 L	г L	т . -	+	+	т -
+	+	+	+	+	+	+	+	т	Τ -	r +	+		+	т			r -	r •	17	r '	т	Ŧ	7
												л											
																		,	x				
																		4	*				
			х	<u>r</u>		х																	
			2	-		21																	
+	+	• +	- +	+ +	+	+	+	+	+ -	+ +	+	А	+	+	+ -	+ -+		+ -	+	+	+	+	+
+	+	• +	- +	+	+	+	+	+	+ -	+ +	+	А	+	+	+ -	+ +		+ -	ŀ	+	+	+	+
																			F				
																			+ X				
																		4					
+	+	· +	- +	· +	+	+	+	+	+ -	+ +	+	Α	+	+	+ -			+ -	+	+	+	+	+
+	+	- +	- +	• +	+	+ X	+	+	+ -	+ +	+	A	+	+	+ -				ł	+	+	+	+
+	+	- +	- +	- +	+		+	+	+ -	+ +	+	Α	+	+	+ -				ł	+	+	+	+
+	+	- +	- +	- +	+		+	+	+ -	+ +	+	A	+	+	+ -				÷	+	+	+	+
+ A	+	- +	- +	- + - +	+	X	+	+	+ -	+ +	+			+	+ -		+ -	+ -	+	+	+	+	+
+ A	+	- +	- +	· +	++	X		+	+ -	+ +					+ -	+ -	+ -	+ -	+	+ -	+	+	+
+ A	+	- + - +	- +	- + - +	+++	X		+	+ -	+ +					+ -	+ 4	+ -	F -	+	+ -	+	+ +	+ +
-	0 8 + M + + + + +	0 3 8 7 + + M + + + + + + +	0 3 4 8 7 1 + + + + M + + + + + + + + + + N	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 3 4 0 3 4 1 4 2 4 2 0 3 3 1 +	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 2 1 3 +	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 1 3 0 8 7 1 9 9 8 3 2 9 4 3 4 3 1 7 7 7 7 8 1 + + + + + + + + + + + + + + + + + + +	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 1 3 0 0 0 8 7 1 9 9 8 3 2 9 4 3 4 3 1 7 7 7 8 1 2 + + + + + + + + + + + + + + A + + + + +	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 1 3 0 0 0 8 7 1 9 9 8 3 2 9 4 3 4 3 1 7 7 7 8 1 2 3 + + + + + + + + + + + + + + + A + + + +	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 1 7 7 7 8 1 2 3 3 + + + + + + + + + + + + + + + + + + +	0 3 4 0 3 4 1 4 2 4 2 0 3 3 4 1 7 7 7 8 1 2 3 5 + + + + + + + + + + + + + + + + + + +	0 3 4 0 3 4 2 1 3 0 0 0 0 0 8 7 1 9 9 8 3 2 9 4 3 4 3 1 7 7 7 8 1 2 3 5 6 + <td>0 3 4 0 3 4 1 3 2 9 4 3 4 1 7 7 7 8 1 2 3 5 6 7 +</td>	0 3 4 0 3 4 1 3 2 9 4 3 4 1 7 7 7 8 1 2 3 5 6 7 +

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Isobutene: 500 ppm

		-				-							-		J -		-			-					
Number of Days on Study	7 3 3	3	3 3	3	3 3		7 3 3	7 3 3	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	3	3	7 7 3 3 4 4		3	7 3 4	7 3 4	7 3 4		3	7 3 4	
Carcass ID Number	2 1 1	2 1 2	1	. 1	1	1	2 1 9	2 2 0		2 2 2	2 2 4			2	3	2 2 3 3 2 4	3 3	3	2 4 0	2 4 3			4	2 5 0	Total Tissues/ Tumors
Hematopoietic System																									
Bone marrow	+		+ +	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	49
Lymph node Lymph node, bronchial	+		+ +		+ M/+	. +	+	м	+	+	м	+	+	м	+	MN	ví⊣	- +	+	+	+	+	N	ГМ	3 33
Pheochromocytoma malignant, metastatic,							·		·	·		·	·												00
adrenal medulla						Х																		1	
Lymph node, mandibular	+	- 1	vî ⊣	⊦ I		4 +			+	+	+	+	+	+	+	MN			[+]	+	N	I M	1 M		29
Lymph node, mesenteric Lymph node, mediastinal	+	- + . N	⊢ ⊣ √⊺ ⊒	ר - ני		· + · +		+	++	++	++	+ +	+ +	++	++	+ -	+ + + +		+ N	+ 1 +	++	+	+	++	49 38
Pheochromocytoma malignant, metastatic,		1	*1	. 1	*1 1		141					'	'	'		'			1.			'			00
adrenal medulla						Х																			1
Spleen	+		+ +	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	49
Hemangiosarcoma Thymus				- 1	M +	. +											+ +		N	r M	ſ,	M	f ,		1 42
Thymus	т				VI T	· •	Ŧ	т	т	т	т	Ŧ	Ŧ	т	т				10.	1 10	1 -	10.	1 -	т	42
Integumentary System																									
Mammary gland	Ν																							I M	
Skin	+		+ +	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	50
Musculoskeletal System Bone	+		⊦ -	+ -	+ +	· +	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	49
Nervous System																									
Brain	+	+	+ +	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	50
D																									
Respiratory System Larynx				L _			_	-	-	-	-	-	-	-	-	<u> </u>			<u>ــ</u>		1			т.	49
Lung	+			, 	· ·	• +	+	+	+	+	+	+	+	+	+	+ -		- +	+	+	+	· +	+	+	50
Alveolar/bronchiolar adenoma			K							Х									Х						5
Alveolar/bronchiolar adenoma, multiple												Х						Х							2
Alveolar/bronchiolar carcinoma	v	,			Х	X	Х													Х					5
Alveolar/bronchiolar carcinoma, multiple Hepatocellular carcinoma, metastatic, liver	Х												Х							Х					1 4
Pheochromocytoma malignant, metastatic,													21							21					1
adrenal medulla						Х																			1
Nose	+		+ +	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	49
Trachea	+				+ +	• +	+	+	+	+	+	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	49
Special Senses System																									
Harderian gland										+								- +							4
Adenoma										Х							Σ	ζ							3
Urinary System																									
Kidney	+	+	+ +	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	49
Hepatocellular carcinoma, metastatic, liver																									1
Pheochromocytoma malignant, metastatic,						.,																			
adrenal medulla Urinary bladder	+		⊢ ⊣	⊢ -	+ +	X	+	+	+	+	+	+	+	+	+	+ -	+ -		+	+	+	. +	+	1+	47
•	-				. т	1.	'			'									1	17	1	1-			-11
Systemic Lesions																									
Multiple organs	+		+ +	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	50
Lymphoma malignant									Х																2

Individual Animal Tumor Patholog	y of Ma	le	IVI.	ice	in	th	e 2	2-Y	eai	r Iı	nha	lat	ioı	n S	tud	ly e	of 1	lso	bu	ten	e:	2,	00	0 p	pn	1
		3	3	4	4	4	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	7	7	7	7	7
Number of Days on Study		8	8	2	8	9	1	1	2	5	5	8	8	2	3	3	3	4	5	8	8	0	1	2	3	3
		7	9	8	0	9	2	2	7	5	9	3	4	8	1	6	9	5	3	1	6	8	3	9	3	3
		4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
Carcass ID Number		2		3	1	2	1	2	0	0	0	1	0	1	2	3	3	4	4	2	4	2	5	4	0	0
		1	1	1	0	7	8	9	1	4	7	1	5	9	6	7	8	0	7	3	9	5	0	5	2	3
Alimentary System																										
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder		+	+	+	А	+	+	М	+	+	+	Μ	А	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon		+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum		+	+	+	+	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum		+	+	+	A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum		+	+	+	A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum		+	+	+	A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver		+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X
Hemangiosarcoma Hepatoblastoma											л															л
Hepatocellular carcinoma			Х									x	Х					x	Х				Х			
Hepatocellular carcinoma, multiple			7 1				x	х		Х		л	л					Λ	л				л			
Hepatocellular adenoma							Λ	~		Λ			Х				х	Х		Х		Х			Х	
Hepatocellular adenoma, multiple															Х			- 1				11			21	
Histiocytic sarcoma																						Х				
Mesentery		+													+							-			+	
Pancreas		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular		+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tooth					+																+					
Odontoma																										
Cardiovascular System																										
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																										
Adrenal cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma				,																						
Adrenal medulla Phoochromocytoma honign		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma benign Islets, pancreatic				,																						
Parathyroid gland		++	+	+	+ M	+ M	+	+ M	+	+	+ M	+	+	+	+	+	+	+	+ M	+	+	+	+ M	+	+	- -
Pituitary gland		+	+	-r +	1V1 +		- +	1VI +	+	- -		-T -	- - -		 		- - -	+	1VI +	- -	M			- -	- -	r +
Thyroid gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	, +
Follicular cell, adenoma		•	•	'						'				'		x										
General Body System																										
None																										
Genital System						+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Genital System Epididymis		+	+	+	+																					
Genital System Epididymis Penis		+	+	+	+					+						+										
Genital System Epididymis Penis Preputial gland		+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Genital System Epididymis Penis Preputial gland Prostate		+ + +	+ + +	++++	++++	+ M	+ +	+ I	+ +	+ + +	+ +	+ +	+ +	+ +	+ +	++++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +
Genital System Epididymis Penis Preputial gland		++++++	++++++	+ + + +	++++.	+ M +	+ + +	+ I +	+ + +	+ + + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +

Individual Animal Tumor Pathology	y of Male	; IVI	lce	: 111	the	: 4-	1 64	U. I.	Шă	uat	101	I St	uuy	UI	130	Du	ten	с.	۵,	UUU	' P	Рш	L	
Number of Days on Study	7 3 3	7 3 3	7 3 3				7 7 3 3 3 3	3	7 3 3	7 3 3	7 3 3	3	77 33 44	3 3	7 3 4	3								
Carcass ID Number	4 0 6	4 0 8	4 0 9	1	1	1	4 4 1 1 5 6	1	4 2 0	4 2 2	4 2 4	2	4 4 3 3 0 2	3 3	3	4 3 5	4 3 6	4 3 9	4 4 2	4 4 3	4 4 4	4 4 6	4	Total Tissues/ Tumors
Alimentary System																								
Esophagus	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Gallbladder	I	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	45
Intestine large, colon	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50 40
Intestine large, cecum Intestine small, duodenum	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	49 48
Intestine small, jejunum	+	+	+	+	+	+ ·	+ + 	- +	+	+	+	+	+ -	+ + 	+	+	+	+	+	+	+	+	+	48
Intestine small, Jejunum		+	+	+	+	+ ·	 	- +	+	+	+	+				+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+ .	+ +	- +	+	+	+	+	+ -	· ·	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma		·			·					Ċ	·	·			·	Ċ	Ċ	·	Ċ		·	·		2
Hepatoblastoma																							Х	1
Hepatocellular carcinoma			Х								Х		Х										Х	10
Hepatocellular carcinoma, multiple																Х								4
Hepatocellular adenoma	Х	X	Х									Х		Х		Х					Х			13
Hepatocellular adenoma, multiple						1	ХУ	ζ		Х					Х									5
Histiocytic sarcoma																								1
Mesentery																	+							4
Pancreas	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Stomach, glandular Tooth	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	49 9
Odontoma			+ X	+ X	+	+				+	+	+												9 2
Cardiovascular System																								
Heart	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Endocrine System																								
Adrenal cortex	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Adenoma		•	•							•					•	•	•		•		x			1
Adrenal medulla	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+		+	+	50
Pheochromocytoma benign																				Х				1
Islets, pancreatic	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	Μ	Μ	+	+	+	+	+	+	42
Pituitary gland	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	49
Thyroid gland	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma		_	_																					1
General Body System None																								
Genital System																								
Epididymis	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Penis																								2
Preputial gland	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Prostate	+	+	+	+	+	+ ·	+ N	Λ +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	47
Seminal vesicle	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Testes	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	50
Interstitial cell, adenoma						Х																		1

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

TABLE C2

Individual Animal Tumor Pathology of	Male	e I		ce	ш	u	e 2	- Y	eai	r In	ha	ilat	ioi	1 5	tud	ly (Df 1	lso	bu	ten	e:	Z,	,00	v p	pr	n	
	3	3	3	4	4	4	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	7	7	7	7	7	
Number of Days on Study	8	8		2	8	9	1	1	2	5	5	8	8	2	3	3	3	4	5	8	8	0	1	2	3	3	
0	7	ę			0	9	2	2	7	5	9	3	4		1	6	9	5	3	1	6	8	3		3		
	4	4	1.	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
Carcass ID Number	2							2		0		1		1	2			4	4		4	2	5	4	0		
										4														5			
Hematopoietic System																											
Bone marrow	+		± .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma										'			'									x					
Lymph node						+								+	+	+		+		+	+						
Lymph node, bronchial	+	1	M	М	+		+	М	+	+	М	М	+	+	+	+	+	+	+	+		Μ	M	M	N	[+	
Lymph node, mandibular	+									M				+	+	+		+		+							
Lymph node, mesenteric	+									+						+		+								+	
Histiocytic sarcoma									•	•		•	•	, i			, i	•	•			x		•			
Lymph node, mediastinal	+		+	+	+	+	М	+	+	+	М	+	+	М	+	М	М	+	+	М	+			+	Ν	[+	
Histiocytic sarcoma									•	•		•	•					•	•			x		•			
Spleen	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	
Histiocytic sarcoma				•	Ċ			'			'			·	•	·	·					x					
Thymus	Μ	1 -	+ 1	М	+	+	+	+	+	М	М	+	+	+	М	+	+	+	М	+	М			[+	+	М	
Internmentary System																											
Integumentary System	N /	יז	۰. T	۸ <i>۲</i>	۸,	٦đ	N /	۸4	۸.4	м	۸4	١ſ	۸.4	۸.4	٦đ	١ .4	۸4	N /	۸.4	٦.4	۸,4		г ъ 4			Г М Г	
Mammary gland																										IM	
Skin	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Subcutaneous tissue, hemangioma								v																			
Subcutaneous tissue, sarcoma								Х																			
Musculoskeletal System																											
Bone	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																											
Brain	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System																											
Larynx	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lung	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma												Х															
Alveolar/bronchiolar carcinoma										_		_															
Hepatocellular carcinoma, metastatic, liver										Х		Х															
Histiocytic sarcoma																						Х					
Nose	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System																											
Harderian gland															+				+				+				
Adenoma															x				x				x				
																							_				
Urinary System																											
Kidney	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	
Histiocytic sarcoma																						Х					
Renal tubule, adenoma																											
Urinary bladder	+	-	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemia Losiona																											
Systemic Lesions																											
	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions Multiple organs Histiocytic sarcoma	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	

 Individual Animal Tumor Pathology of Male
 Wice in
 the
 2-Year
 Individual Since in
 Study
 G
 Study
 Bit in in

 Number of Days on Study
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7
 7

5 5	3	3	3	3	3	3	3	3	3	3	3	3	3 4	4	4	4	4	4	4	4	4	4	4	4	
Carcass ID Number	4 0 6	4 0 8	0	4 1 2			1	1	1	2	2	2	4 4 2 3 8 (4 3 4	4 3 5	4 3 6	4 3 9	4 4 2	4 4 3	4 4 4	4 4 6	4	Total Tissues/ Tumors
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1
Lymph node		N	г м	Г М			м	м		м			M	+ +		м						м			7 32
Lymph node, bronchial Lymph node, mandibular	+					++								+ + + +				++	+	+	+ M	1VI +	+ M		32 33
Lymph node, mesenteric	+	+		+	+								+ -			+	+	+	+	+	+		M		48
Histiocytic sarcoma																							101		10
Lymph node, mediastinal	Μ	1 +	+	+	М	+	+	+	+	+	М	Μ	М-	⊦ N	1 +	+	+	+	+	+	М	+	+	+	36
Histiocytic sarcoma																									1
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+ 1	- N	+	+	Μ	М	+	+	+	+	+	+	38
Integumentary System																									
Mammary gland	Μ	I M	ΙM	M	М	М	М	М	М	М	М	Μ	MI	M N	1 M	M	Μ	М	М	М	М	М	М	М	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Subcutaneous tissue, hemangioma																						Х			1
Subcutaneous tissue, sarcoma																									1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Nervous System																									
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																									
Larynx		-	-	1	-	-	-	т	-	-	-	+	<u> </u>		-	-	-	-	-	-	-	-	-	-	50
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+ -	 + +	+	+	+	+	+	+	+	+	+	+	50 50
Alveolar/bronchiolar adenoma	x	. '	'		'		'		'		x	'	'		'	'		'	'	'		x	'	x	5
Alveolar/bronchiolar carcinoma		X									••					Х	Х					••	Х	••	4
Hepatocellular carcinoma, metastatic, liver																									2
Histiocytic sarcoma																									1
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																									
Harderian gland												+													4
Adenoma												Х													4
Urinary System																									
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1
Renal tubule, adenoma																						Х			2
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	49
Systemic Lesions																									
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1
Lymphoma malignant																									

Individual Animal Tumor Pathology	of Mal	e N	110	e in	th	le z	-Y	ear	In	hala	atio	on S	Stu	dy	of 1	lso	bu	ten	e:	8,	000) p	pn	1
	2	3	3	3	4	4	5	5	5	55	6	6	6	6	6	6	6	6	6	7	7	7	7	7
Number of Days on Study	5 1			8 6	5 7	9 9	0 8			46 72			3 3	3 9	6 7	7 0	8 2	8 9	9 5	0 6	2 7	3 3	3 3	3 3
	6	6	6	6	6	6	6	6	6	66	6	6	6	6	6	6	6	6	6	6	6	6	6	6
Carcass ID Number	4 4			3 9	1 0	0	5	2 3	1	31	1		1	4	0	3	1	1 4			0 2	0 1		
Alimentary System																								
Esophagus	+	. +	· +	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	+	A	A	Α	+	+						+							+	А	+	+	+	+
Intestine large, colon	+		A					+		+ +			+		+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+		A					+		+ +	- +	- +	+	+	+	+	+	А	+	+	+	+	+	+
Intestine large, cecum	A		A					+		+ +	- +	- +	+			А					+	+	+	+
Leiomyoma																								
Intestine small, duodenum	Д	A	A	А	+	+	А	+	+	+ +	- +	+ +	+	+	+	А	А	А	+	+	+	+	+	+
Intestine small, jejunum								+		+ +			+								+	+	+	+
Carcinoma	1	•		•											•				•			, i	•	
Intestine small, ileum	Д	A	A	+	+	+	А	+	+	+ +	- +	- +	+	+	+	А	А	А	+	А	+	+	+	+
Liver	+			+		+	+			+ +			+	+		+			+		+		+	+
Hemangiosarcoma	,			•											•				•			, i	x	
Hepatocellular carcinoma		Х	C	Х		Х				ху	ζ													
Hepatocellular carcinoma, multiple		1	-				Х		X	- '	`х	ζ			х	Х								
Hepatocellular adenoma		Х	<u>r</u>				••		••		•	-	Х		••	••				Х				
Hepatocellular adenoma, multiple		1	-																	••	х	x		
Mesentery																					~ 1	+		
Pancreas	-		. Δ	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	А	+	+	+	+	+	+
Salivary glands	+	· -+	· +	+	+	+	+			+ +			+		+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	т 4		A	+	+	+	+			+ +	- +		+		+	+	+	Ă	+	+	+	, +	+	+
Stomach, glandular	т 4			+	+	+		+		+ +			+		+	Ă			+	+	+	+	+	+
Tooth	Т	т	11	- T.		'	1				т	- F			'	+		+	'			'		+
Odontoma																1		'						
Cardiovascular System Heart																								
	+	- +	• +	÷	+	+	+	+	+	+ +	- +	- +	+	÷	+	+	+	+	+	+	+	+	+ X	+
Hemangiosarcoma																							л	
Endocrine System Adrenal cortex							,								,	,	,	٨						
	+	• +	• +	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	A	+	+	+	+	+	+
Capsule, adenoma							,								,	,		٨						
Adrenal medulla	+	• +	• +	+	+	+	+	+	+	+ +	- +	+ +	+ X	+	+	+	+	А	+	+	+	+	+	+ v
Pheochromocytoma benign			٨																					X
Islets, pancreatic	+	. – л	• A	+				14		+ +	- +	+ +	+	+					+	+	+	+	+	+
Parathyroid gland	N	u +	· +	+	M			M		+ +	- +	+ +	+	+		М			+	+	+	+	+	+
Pituitary gland	+	• +	· I	+	+	+	1	+	+	+ +	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Pars intermedia, adenoma																								
Thyroid gland	+	• +	• +	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	А	+	+	+	+	+	+	+
General Body System None																								
Genital System																								
Epididymis	+	+	+	+	+	+	+	+	+	+ +	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	+	+	+	+	+	+	+	+	+ +	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Prostate	A	. +	+	+	+	+	+	+	+	+ +	- +	+ +	+	+	М	+	+	+	+	+	+	+	+	+
Seminal vesicle	+	+	A	+	+	+	+	+	+	+ +	- +	+ +	+	+	+	+	А	А	+	+	+	+	+	+
Testes	+	· +	· +	+	+	+	+	+	+	+ +	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Interstitial cell, adenoma																								

individual Animal Tumor Pathology		C 10			-									5				-							
Number of Days on Study	7 3 3		7 3 3	7 3 3	7 3 3	3	77 33 33	3	7 3 3	7 3 3	7 3 4	3	3	3	3		7 (3 (4 4				3	7 3 4	7 3 4	3	
Carcass ID Number	6 0 8	0	6 1 1	6 1 7	1	2	6 6 2 2 1 2	2	2	6 2 6	6 2 7	2	6 2 9	3	3	3	6 (3 : 4 :	3 4	1	4	4	6 4 7	6 4 8	6 4 9	Total Tissues/ Tumors
Alimentary System																									
Esophagus	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+ •	+ •	+	+	+	+	+	+	50
Gallbladder	+	· N	í M	+	+	М	+ -	+ +	+	+	+	+	+	+	+	+	+ •	+ -	+	+ .	M	+	+	+	34
Intestine large, colon	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+ •	+ -	+	+	+	+	+	+	48
Intestine large, rectum	+	· +	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+ ·	+ •	+ -	⊦ ·	+ •	+	+	1	+	46
Intestine large, cecum	+	+	+	+	+	+	+ -	- +	• +	+	+	+	+	+	+	+ ·	+ •	+ -	+	+	+	+	$^+$ v	+	42
Leiomyoma Intestine small, duodenum																							X +	+	1 42
Intestine small, jejunum	+	· +	+	+	+	+	+ -	- +	· +	+	+	+	+	+	+	+ ·	+ ·	+ ·	F .	+	+	+	+	+	42
Carcinoma	т	т	т	т	т	т	- x	ζ Τ	Т	т	т	т	т	Т	Т	т .	T 1		F	T	Т	т	т	т	1
Intestine small, ileum	+	. +	+	+	+	+	+ -		+	+	+	+	+	+	+	+ -	+ -	+ -	+	+	+	+	+	+	42
Liver	+	· +	+	+	+	+	+ -	+ +	· +	+	+	+	+	+	+	+ •	+ .	+ .	⊢ ·	+	+	+	+	+	49
Hemangiosarcoma		X																							2
Hepatocellular carcinoma							y	ζ															Х		7
Hepatocellular carcinoma, multiple			Х										Х												7
Hepatocellular adenoma		Х			Х		Х								Х				X			Х		Х	10
Hepatocellular adenoma, multiple	Х	Ľ.					2	X	[Х					2	X							7
Mesentery				+																					2
Pancreas	+	• +	+	+	+	+	+ -	+ +	+	+	+	Ι	+	+	+	+	+ •	+ -	+	+	+	+	+	+	47
Salivary glands	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+ •	+ •	+ -	+ •	+ 1	+	+	+	+	50
Stomach, forestomach	+	• +	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+ ·	+ •	⊢ -	⊢ ·	+	+	+	+	+	48
Stomach, glandular Tooth	+	• +	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+ •	+ -	+ ·	+ •	+	+	+	+	46 16
Odontoma		+		+			+ - X	F	+		+						+ · X		F '	+	+				2
Cardiovascular System																									
Heart	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+ ·	+ •	+ -	+	+	+	+	+	+	50
Hemangiosarcoma																									1
Endocrine System																									
Adrenal cortex	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+ •	+ -	+	+	+	+	+	+	49
Capsule, adenoma					Х					Х		Х													3
Adrenal medulla	+	• +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+ •	+ -	+	+	+	+	+	+	49
Pheochromocytoma benign																									2
Islets, pancreatic	+	+	+	+	+	+	+ -	+ +	+	+	+		+	+		+ ·	+ •	+ - .√r	+ •	+ • •	+	+	+	+	48
Parathyroid gland Bituiteau gland	+	• +	+	+	+	+	+ -	+ +		M		M								M	+	+	+	М	37
Pituitary gland	+	+	+	+	+	+	+ -		+	+	+	+	+	+	+	+	+ •	+ -	+	+	+	+	+	+	48
Pars intermedia, adenoma Thyroid gland		,			,			ζ.																+	1 49
	+	• +	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+ ·	+ •	г [.]	+ ·	+	+	+	+	т	43
General Body System None																									
Genital System																									
Epididymis	+	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+ -	+ -	+ -	+	+	+	+	+	+	50
Preputial gland	+	· +	+	+	+	+	+ -	+ +	· +	+	+	+	+	+	+	+ •	+ •	+ -	+ ·	+	+	+	+	+	50
Prostate	+	· +	+	+	+	+	+ -		· +	+	+	+	+	+	+	+ •	+ -	+ -	+	+	+	+	+	+	48
Seminal vesicle	+	· +	+	+	+	+	+ -	· +	+	+	+	+	+	+	+	+	+ •	+ -	+	+	+	+	+	+	47
	+	- +	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+ -	+ -	+ -	+ -	+	+	+	+	+	50
Testes Interstitial cell, adenoma																									00

TABLE C2

Individual Animal Tumor Pathology of	f Male Mice in the 2-Year Inhalation Study of Isobutene: 8,000 ppm	
	2 3 3 3 4 4 5 5 5 5 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7	
Number of Days on Study	5 3 4 8 5 9 0 1 4 4 6 0 3 3 3 6 7 8 8 9 0 2 3 3 3	
	1 0 1 6 7 9 8 2 7 7 2 8 1 3 9 7 0 2 9 5 6 7 3 3 3	
	$6 \hspace{0.1in} 6 0.1in$	
Carcass ID Number	4 3 0 3 1 0 5 2 1 3 1 1 4 1 4 0 3 1 1 4 3 0 0 0 0 4 8 3 9 0 4 0 3 2 6 6 5 5 3 0 5 7 9 4 3 2 2 1 6 7	
Hematopoietic System		
Bone marrow	+ + + + + + + + + + + + + + + + + + +	
Lymph node	+	
Lymph node, bronchial	M + M M M M M M + M + + + + + M + M M M + + + +	
Lymph node, mandibular	+ M M + + + M + M M + + + + + + M M + + + + M + +	
Lymph node, mesenteric	+ + + + + + + + + + + + + + + + + + +	
Lymph node, mediastinal	+ M + + M + + M + M + + + + + M + + M M M M + M +	
Spleen	+ + A + + + + + + + + + + + + + + + + +	
Hemangiosarcoma	X	
Histiocytic sarcoma	X	
Гhymus	+ + + M + + + M + M + M + + + + M + A + + M + + +	
Integumentary System		
Mammary gland	M M M M M M M M M M M M M M M M M M M	
Skin	+ + + + + + + + + + + + + + + + + + +	
Subcutaneous tissue, sarcoma	Х	
Musculoskeletal System		
Bone	+ + + + + + + + + + + + + + + + + + +	
Nervous System		
Brain	+ + + + + + + + + + + + + + + + + + + +	
Peripheral nerve	+	
Respiratory System		
Larynx	+ + + + + + + + + + + + + + + + A A + + + + + +	
Lung	+ + + + + + + + + + + + + + + + + + + +	
Alveolar/bronchiolar adenoma		
Alveolar/bronchiolar carcinoma	Х	
Alveolar/bronchiolar carcinoma, multiple		
Hepatocellular carcinoma, metastatic, liver	X X X	
Nose	+ + A + + + + + + + + + + + + + + A +	
Гrachea	+ + + + + + + + + + + + + + + + + + +	
Special Senses System		
Eye		
Harderian gland	+	
Adenoma	Х	
Carcinoma		
Urinary System		
Kidney	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Urinary bladder	A + A + + + + + + + + + + + + + + A A + + + + + +	
Systemic Lesions		
Multiple organs	+ + + + + + + + + + + + + + + + + + + +	
Histiocytic sarcoma	Х	
Lymphoma malignant	X X X	

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Isobutene: 8,000 ppm

80													-									-		
Number of Days on Study	7 3	7 3	7 3	7 3	7 3	7 3	77 33	7 33	7 3	7 3	7 3	•	77 33		7 3									
	3	3	3	3	3	3	3 3	3	3	3	4	4	4 4	4	4	4	4	4	4	4	4	4	4	
	6	6	6	6	6	6	66	6	6	6	6	6	66	6	6	6	6	6	6	6	6	6	6	Total
Carcass ID Number	0	0	1	1	1	2	22	2	2	2	2	2	2 3	3	3	3	3	4	4	4	4	4	4	Tissues/
	8	9	1	7	8	0	1 2	2 4	5	6	7	8	9 0) 1	3	4	5	1	2	6	7	8	9	Tumors
Hematopoietic System																								
Bone marrow	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	49
Lymph node																								1
Lymph node, bronchial	+	+	+	+	Μ		+ +	+ +	+	+	+	+	+ +	+ +		Μ		+	+	+	М	Μ	М	32
Lymph node, mandibular	+	+	+			+ 1				+	М				1 +					+	+		+	35
Lymph node, mesenteric	+	+	+				+ +			+			+ +				+			+	+	+		49
Lymph node, mediastinal	M	. +				M			+	+	+		M +			+		+	+	M	+		M	31 48
Spleen Hemangiosarcoma	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	40
Histiocytic sarcoma																								1
Thymus	+	+	+	+	+	Μ	+ +	+ +	+	+	+	М	+ +	+ +	+	+	+	+	+	+	+	+	+	41
•		—												-							—			
Integumentary System	14		N.4	N 4	1.4			<i>г</i> х.			14	۸.4	۱. ۱. ۱.	<i>.</i> ۲	r . ,		1.4	۸4	۸4	۸4	۸4		۸.4	1
Mammary gland Skin	M	M											MN						M	M	M			1 50
Subcutaneous tissue, sarcoma	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50 1
																					—			1
Musculoskeletal System																								
Bone	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50
Nervous System																								
Brain	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50
Peripheral nerve																								1
Respiratory System																								
Larynx	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	48
Lung	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma						Х													Х		Х			3
Alveolar/bronchiolar carcinoma				Х														Х						3
Alveolar/bronchiolar carcinoma, multiple								Х			Х											Х		3
Hepatocellular carcinoma, metastatic, liver																								3
Nose Trachea	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	48 49
iiathta	+	+	+	+	т	Τ.		- +	+	+	т	т		- +	+	+	+	+	+	Ŧ	Ŧ	+	т	43
Special Senses System																								~
Eye																+							+	2
Harderian gland							ž															+	+	4 2
Adenoma Carcinoma							2															x	Х	2 2
																						л	<u> </u>	2
Urinary System																								
Kidney	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50
Urinary bladder	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	46
Systemic Lesions																								
Multiple organs	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	50
																								1
Histiocytic sarcoma Lymphoma malignant																								-

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Adrenal Cortex: Adenoma				
Overall rate ^a	2/49 (4%)	3/49 (6%)	1/50 (2%)	3/49 (6%)
Adjusted rate ^b	4.9%	7.0%	2.5%	7.8%
Ferminal rate ^C	2/28 (7%)	3/32 (9%)	1/27 (4%)	3/28 (11%)
First incidence (days)	733 (T)	733 (T)	733 (T)	733 (T)
oly-3 test ^d	P=0.432	P = 0.520	P = 0.511N	P=0.474
Iarderian Gland: Adenoma				
Dverall rate	3/50 (6%)	3/50 (6%)	4/50 (8%)	2/50 (4%)
djusted rate	7.2%	6.9%	10.0%	5.1%
erminal rate	2/28 (7%)	3/32 (9%)	1/27 (4%)	2/28 (7%)
irst incidence (days)	610	733 (T)	631	733 (T)
oly-3 test	P = 0.434N	P = 0.643N	P = 0.480	P = 0.527N
larderian Gland: Adenoma or Carcinoma				
Dverall rate	4/50 (8%)	3/50 (6%)	4/50 (8%)	4/50 (8%)
Adjusted rate	9.6%	6.9%	10.0%	10.2%
Ferminal rate	3/28 (11%)	3/32 (9%)	1/27 (4%)	4/28 (14%)
irst incidence (days)	610	733 (T)	631	733 (T)
oly-3 test	P = 0.477	P=0.477N	P = 0.624	P = 0.612
Liver: Hepatocellular Adenoma				
Overall rate	20/50 (40%)	24/50 (48%)	18/50 (36%)	17/49 (35%)
djusted rate	46.9%	51.8%	43.6%	42.6%
'erminal rate	14/28 (50%)	17/32 (53%)	12/27 (44%)	13/28 (46%)
irst incidence (days)	592	522	584	330
oly-3 test	P = 0.299N	P = 0.400	P = 0.468N	P = 0.432N
Liver: Hepatocellular Carcinoma				
Dverall rate	13/50 (26%)	13/50 (26%)	14/50 (28%)	14/49 (29%)
Adjusted rate	28.6%	27.4%	31.9%	31.7%
'erminal rate	2/28 (7%)	4/32 (13%)	5/27 (19%)	4/28 (14%)
irst incidence (days)	399	405	389	330
oly-3 test	P = 0.401	P = 0.541N	P = 0.453	P = 0.464
.iver: Hepatocellular Adenoma or Carcinoma				
Overall rate	30/50 (60%)	32/50 (64%)	28/50 (56%)	29/49 (59%)
Adjusted rate	64.2%	65.7%	62.4%	64.9%
'erminal rate	15/28 (54%)	19/32 (59%)	15/27 (56%)	16/28 (57%)
First incidence (days)	399	405	389	330
oly-3 test	P = 0.549	P = 0.528	P = 0.516N	P = 0.563
.iver: Hepatocellular Carcinoma or Hepatoblastom	а			
Overall rate	13/50 (26%)	13/50 (26%)	14/50 (28%)	14/49 (29%)
Adjusted rate	28.6%	27.4%	31.9%	31.7%
'erminal rate	2/28 (7%)	4/32 (13%)	5/27 (19%)	4/28 (14%)
irst incidence (days)	399	405	389	330
oly-3 test	P = 0.401	P = 0.541N	P = 0.453	P = 0.464
.iver: Hepatocellular Adenoma, Hepatocellular Ca	rcinoma. or Henatohl	astoma		
verall rate	30/50 (60%)	32/50 (64%)	28/50 (56%)	29/49 (59%)
djusted rate	64.2%	65.7%	62.4%	64.9%
'erminal rate	15/28 (54%)	19/32 (59%)	15/27 (56%)	16/28 (57%)
First incidence (days)	399	405	389	330
Poly-3 test	P = 0.549	P = 0.528	P = 0.516N	P = 0.563
015 0 1051	1 = 0.010	1 - 0.020	1 - 0.01011	1 - 0.000

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Lung: Alveolar/bronchiolar Adenoma				
Overall rate	12/50 (24%)	7/50 (14%)	5/50 (10%)	3/50 (6%)
Adjusted rate	28.7%	16.1%	12.5%	7.6%
Cerminal rate	9/28 (32%)	6/32 (19%)	4/27 (15%)	3/28 (11%)
irst incidence (days)	592	698	583	733 (T)
oly-3 test	P = 0.031N	P = 0.125N	P = 0.060N	P = 0.013N
ung: Alveolar/bronchiolar Carcinoma				
Overall rate	6/50 (12%)	6/50 (12%)	4/50 (8%)	6/50 (12%)
djusted rate	14.2%	13.8%	10.1%	15.3%
erminal rate	4/28 (14%)	6/32 (19%)	4/27 (15%)	6/28 (21%)
irst incidence (days)	580	733 (T)	733 (T)	733 (T)
oly-3 test	P = 0.490	P = 0.601N	P = 0.411N	P = 0.571
.ung: Alveolar/bronchiolar Adenoma or Carcinor Overall rate	na 17/50 (34%)	13/50 (26%)	9/50 (18%)	9/50 (18%)
djusted rate	39.7%	29.8%	22.5%	22.9%
erminal rate	12/28 (43%)	12/32 (38%)	8/27 (30%)	9/28 (32%)
First incidence (days)	580	698	583	9/28 (32/8) 733 (T)
oly-3 test	P = 0.119N	P = 0.227N	P = 0.070N	P = 0.077N
	1 011011	1 0122111	1 0101011	1 0101111
ooth: Odontoma	1/50 (00/)	0/50 (00/)	0/50 (40/)	0/50 (40/)
verall rate	1/50 (2%)	3/50 (6%)	2/50 (4%)	2/50 (4%)
djusted rate	2.4%	6.8%	5.1%	5.1%
erminal rate	0/28 (0%)	1/32 (3%)	2/27 (7%)	2/28 (7%)
'irst incidence (days)	527	649	733 (T)	733 (T)
oly-3 test	P = 0.575	P = 0.323	P = 0.479	P = 0.478
All Organs: Hemangioma or Hemangiosarcoma				
Overall rate	1/50 (2%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
Adjusted rate	2.4%	2.3%	7.5%	5.1%
erminal rate	0/28 (0%)	0/32 (0%)	2/27 (7%)	2/28 (7%)
irst incidence (days)	664	715	559	733 (T)
oly-3 test	P = 0.405	P=0.750N	P=0.291	P= 0.481
ll Organs: Malignant Lymphoma				
Overall rate	4/50 (8%)	2/50 (4%)	5/50 (10%)	5/50 (10%)
Adjusted rate	9.6%	4.6%	12.3%	12.6%
'erminal rate	2/28 (7%)	2/32 (6%)	1/27 (4%)	3/28 (11%)
'irst incidence (days)	611	733 (T)	631	667
oly-3 test	P = 0.266	P = 0.318N	P = 0.481	P = 0.469
All Organs: Benign Neoplasms	30/50 (60%)	32/50 (64%)	27/50 (54%)	23/50 (46%)
djusted rate	68.5% 91/99 (750()	68.6%	63.6%	56.5%
erminal rate	21/28 (75%)	24/32 (75%)	17/27 (63%)	19/28 (68%)
irst incidence (days)	527	522	583	330
oly-3 test	P = 0.115N	P=0.591	P=0.394N	P=0.167N
ll Organs: Malignant Neoplasms				00 /M0 / 105 11
Overall rate	21/50 (42%)	19/50 (38%)	23/50 (46%)	23/50 (46%)
djusted rate	45.0%	39.7%	50.8%	50.9%
erminal rate	7/28 (25%)	9/32 (28%)	9/27 (33%)	12/28 (43%)
First incidence (days)	399	405	389	330
oly-3 test	P = 0.237	P = 0.376N	P = 0.363	P = 0.362

148

TABLE C3	
Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Is	obutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
All Organs: Benign or Malignant Neoplasms Overall rate Adjusted rate Terminal rate	41/50 (82%) 85.0% 22/28 (79%) 399	41/50 (82%) 83.6% 27/32 (84%) 405	36/50 (72%) 78.4% 20/27 (74%) 389	38/50 (76%) 83.1% 24/28 (86%) 330
First incidence (days) Poly-3 test	P = 0.530N	P = 0.537N	P = 0.281N	P = 0.516N

(T)Terminal sacrifice

~ -

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, liver, and lung; for other tissues, denominator is number of animals necropsied.

Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Isobutene^a

	Chambe	r Control	50	0 ppm	2,00	0 ppm	8,00	00 ppm
Disposition Summary								
Animals initially in study	5	0		50		50		50
Early deaths								
Moribund		6		9		20		13
Natural deaths		6		9		3		9
Survivors	_	_						
Terminal sacrifice	2	8		32		27		28
Animals examined microscopically	5	0		50		50		50
Alimentary System								
Liver	(50)		(50)		(50)		(49)	
Basophilic focus	. ,	(14%)		(16%)		(12%)	• • •	(10%)
Clear cell focus		(18%)		(8%)		(12%)		(20%)
Cyst		(2%)		(2%)		. ,		/
Degeneration, fatty	2	(4%)	1	(2%)	2	(4%)	5	(10%)
Eosinophilic focus		(10%)		(8%)		(22%)	7	(14%)
Mixed cell focus			2	(4%)	1	(2%)		
Necrosis	1	(2%)	5	(10%)	2	(4%)	1	(2%)
Vacuolization cytoplasmic, focal	1	(2%)	1	(2%)			1	(2%)
Centrilobular, necrosis	2	(4%)						
Mesentery	(4)		(2)		(4)		(2)	
Fat, inflammation, chronic active		(25%)						
Fat, necrosis		(75%)		(100%)		(100%)		(100%)
Pancreas	(50)		(48)		(50)		(47)	
Atrophy	1	(2%)		/··				
Basophilic focus	/ ·			(2%)	/ -			
Stomach, forestomach	(50)	(40/)	(49)		(50)	(00/)	(48)	(00/)
Hyperplasia	2	(4%)				(2%)		(2%)
Inflammation, acute	(40)		(17)			(2%)		(2%)
Stomach, glandular	(49)	(2%)	(47)		(49)		(46)	
Inflammation, acute Necrosis	1	(~ ⁷ 0)	9	(4%)	1	(2%)		
Footh	(7)		(14)	(1/0)	(9)	(~ /0)	(16)	
Malformation		(86%)		(86%)		(78%)		(88%)
	0	(00 /0)	12	(00 /0)		(10/0)	14	(00/0)
Cardiovascular System								
Heart	(50)		(50)		(50)		(50)	
Cardiomyopathy	21	(42%)	18	(36%)	16	(32%)	19	(38%)
Inflammation, chronic		(2%)						
Thrombosis	1	(2%)			1	(2%)		

^a Number of animals examined microscopically at the site and the number of animals with lesion

TABLE C4 Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Endocrine System				
Adrenal cortex	(49)	(49)	(50)	(49)
Hyperplasia	14 (29%)	10 (20%)	15 (30%)	16 (33%)
Hypertrophy	32 (65%)	24 (49%)	24 (48%)	29 (59%)
Adrenal medulla	(49)	(49)	(50)	(49)
Hyperplasia			1 (2%)	1 (2%)
slets, pancreatic	(50)	(48)	(50)	(48)
Hyperplasia	1 (2%)		1 (2%)	1 (2%)
ituitary gland	(50)	(48)	(49)	(48)
Pars distalis, hyperplasia	1 (2%)	4 (8%)	3 (6%)	4 (8%)
Thyroid gland	(50)	(50)	(50)	(49)
Follicular cell, hyperplasia	5 (10%)	6 (12%)	3 (6%)	3 (6%)
General Body System None				
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Granuloma sperm	(/	1 (2%)	1 (2%)	5 (10%)
enis		- ((2)	- (10/0)
Inflammation, acute			1 (50%)	
reputial gland	(50)	(48)	(50)	(50)
Cyst	()	</td <td>2 (4%)</td> <td>1 (2%)</td>	2 (4%)	1 (2%)
Inflammation, chronic active		2 (4%)	()	3 (6%)
rostate	(48)	(46)	(47)	(48)
Inflammation, chronic active		2 (4%)	4 (9%)	4 (8%)
eminal vesicle	(49)	(47)	(50)	(47)
Necrosis			1 (2%)	
estes	(50)	(50)	(50)	(50)
Atrophy	· ·	, ,	1 (2%)	1 (2%)
Mineralization		1 (2%)	· ·	· · ·
Iematopoietic System				
Sone marrow	(50)	(49)	(50)	(49)
Congestion	()	1 (2%)	()	(/
Hemorrhage		(1 (2%)
ymph node	(4)	(3)	(7)	(1)
Iliac, infiltration cellular, plasma cell		1 (33%)	2 (29%)	1 (100%)
Iliac, infiltration cellular,				()
polymorphonuclear			1 (14%)	
Lumbar, infiltration cellular, plasma cell		1 (33%)	· · /	
Pancreatic, infiltration cellular, plasma		. /		
cell	1 (25%)			
ymph node, mesenteric	(48)	(49)	(48)	(49)
Angiectasis	1 (2%)		1 (2%)	
Infiltration cellular, plasma cell		1 (2%)		
pleen	(50)	(49)	(50)	(48)
Hematopoietic cell proliferation	4 (8%)	3 (6%)	5 (10%)	4 (8%)
Infiltration cellular, histiocyte		1 (2%)		1 (2%)

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Isobutene

	Chambe	r Control	50	0 ppm	2,00	0 ppm	8,00	00 ppm
Integumentary System	(10)		1.00					
Skin Cyst	(49)	(2%)	(50)		(50)		(50)	
Prepuce, inflammation, chronic active Subcutaneous tissue, edema		(14%)	6	(12%)	13	(26%)		(18%) (2%)
fusculoskeletal System Ione								
Vervous System								
Peripheral nerve Sciatic, degeneration							(1) 1	(100%)
espiratory System								
Lung	(50)		(50)		(50)	(00/)	(50)	
Hemorrhage Thrombosis	1	(2%)	1	(2%)	3	(6%)		
Alveolar epithelium, hyperplasia		(10%)		(12%)	4	(8%)	3	(6%)
lose	(50)	. ,	(49)		(50)		(48)	()
Inflammation, suppurative		(2%)	2	(4%)	2	(4%)		(00)
Polyp, inflammatory Nasolacrimal duct, polyp, inflammatory	1	(2%)						(2%) (2%)
Olfactory epithelium, atrophy	1	(2%)	1	(2%)	1	(2%)		(2 %)
Olfactory epithelium, degeneration, hyaline	6	(12%)	7	(14%)		(32%)		(35%)
Respiratory epithelium, degeneration, hyalin	e 6	(12%)	19	(39%)	29	(58%)	39	(81%)
Special Senses System								
Eye Cataract	(2)						(2)	(50%)
Cornea, inflammation, chronic active	1	(50%)					1	(3078)
Iarderian gland	(4)	, ,	(4)		(4)		(4)	
Hyperplasia			1	(25%)				
J rinary System Kidney	(50)		(49)		(50)		(50)	
Cyst		(2%)	(43)		(30)			(2%)
Infarct	1	(2%)		(4%)	4	(8%)	1	()
Inflammation, chronic active				(2%)				(10)
Metaplasia, osseous Minoralization		(2%)	1	(2%)			2	(4%)
Mineralization Nephropathy		(2%) (72%)		(2%)	38	(76%)	40	(80%)
Capsule, inflammation, chronic	00	(00	(-0/0)		(2%)	10	(00/0)
Papilla, inflammation, suppurative		(6%)		(6%)	6	(12%)		(10%)
Pelvis, dilatation		(6%)	2	(4%)		(8%)	4	(8%)
Renal tubule, hyperplasia Irinary bladder	1 (49)	(2%)	(47)		(49)	(2%)	(46)	
Calculus, gross observation	(1)		(17)			(2%)	(01)	
Inflammation, chronic active	4	(8%)	3	(6%)		(14%)	6	(13%)

APPENDIX D SUMMARY OF LESIONS IN FEMALE MICE IN THE 2-YEAR INHALATION STUDY OF ISOBUTENE

TABLE D1	Summary of the Incidence of Neoplasms in Female Mice	
	in the 2-Year Inhalation Study of Isobutene	154
TABLE D2	Individual Animal Tumor Pathology of Female Mice	
	in the 2-Year Inhalation Study of Isobutene	158
TABLE D3	Statistical Analysis of Primary Neoplasms in Female Mice	
	in the 2-Year Inhalation Study of Isobutene	180
TABLE D4	Summary of the Incidence of Nonneoplastic Lesions in Female Mice	
	in the 2-Year Inhalation Study of Isobutene	184

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths Moribund	13	16	6	13
Natural deaths	5	3	5	4
Survivors	Ũ	0	0	-
Terminal sacrifice	32	31	39	33
Animals examined microscopically	50	50	50	50
Alimentary System				
Intestine large, colon	(46)	(48)	(49)	(50)
Intestine large, cecum	(46)	(47)	(47)	(48)
Intestine small, jejunum	(46)	(47)	(46)	(47)
Carcinoma		1 (2%)		
Intestine small, ileum	(46)	(48)	(46)	(47)
Liver	(47)	(50)	(50)	(50)
Hepatoblastoma		1 (2%)		
Hepatoblastoma, multiple		1 (2%)		
Hepatocellular carcinoma	4 (9%)	8 (16%)	6 (12%)	9 (18%)
Hepatocellular carcinoma, multiple	1 (2%)		1 (2%)	2 (4%)
Hepatocellular adenoma	15 (32%)	18 (36%)	11 (22%)	13 (26%)
Hepatocellular adenoma, multiple	5 (11%)	4 (8%)	8 (16%)	7 (14%)
Hepatocholangiocarcinoma	1 (2%)	4 (00/)		
Histiocytic sarcoma	2 (4%)	4 (8%)		(10)
Mesentery	(7)	(8) 1 (13%)	(8)	(10)
Histiocytic sarcoma		1 (13%)	1 (13%)	
Lipoma Pancreas	(47)	(50)	(48)	(49)
Salivary glands	(47) (48)	(50)	(50)	(49)
Stomach, forestomach	(48)	(49)	(49)	(49)
Squamous cell carcinoma	(10)	(1)	1 (2%)	(01)
Stomach, glandular	(46)	(48)	(48)	(49)
Squamous cell carcinoma, metastatic, s		(10)	(10)	(10)
forestomach	,		1 (2%)	
Tongue				(1)
Squamous cell papilloma				1 (100%)
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Histiocytic sarcoma	()	1 (2%)	x/	·/

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ррт	2,000 ppm	8,000 ppn
Endocrine System				
Adrenal cortex	(49)	(50)	(49)	(50)
Hepatocellular carcinoma, metastatic, liver			1 (2%)	
Histiocytic sarcoma		1 (2%)		
Capsule, adenoma		2 (4%)		1 (2%)
Adrenal medulla	(48)	(49)	(49)	(49)
Pheochromocytoma benign		1 (2%)	2 (4%)	2 (4%)
Bilateral, pheochromocytoma malignant				1 (2%)
Islets, pancreatic	(47)	(49)	(48)	(49)
Adenoma	1 (2%)	1 (2%)	1 (2%)	()
Pituitary gland	(49)	(49)	(49)	(49)
Pars distalis, adenoma	8 (16%)	13 (27%)	12 (24%)	12 (24%)
Pars distalis, carcinoma	0 (1070)	10 (1170)	1 (2%)	12 (21/0)
Pars intermedia, adenoma			1 (2%)	
Thyroid gland	(48)	(50)	(49)	(50)
Follicular cell, adenoma	1 (2%)	4 (8%)	3 (6%)	1 (2%)
Follicular cell, adenoma, multiple	1 (270)	(0,0)	0 (0/0)	1 (2%)
Follicular cell, carcinoma			1 (2%)	1 (2%)
General Body System				
None Genital System				
None Genital System Ovary	(48)	(50)	(48)	(50)
None Genital System Ovary Cystadenoma		3 (6%)	(48) 1 (2%)	(50) 2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign	(48) 1 (2%)			2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign		3 (6%) 2 (4%)	1 (2%)	
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma		3 (6%)	1 (2%)	2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma	1 (2%)	3 (6%) 2 (4%) 1 (2%)	1 (2%) 1 (2%) 1 (2%)	2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma Histiocytic sarcoma		3 (6%) 2 (4%)	1 (2%) 1 (2%) 1 (2%) 1 (2%)	2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma Histiocytic sarcoma Luteoma	1 (2%) 2 (4%)	3 (6%) 2 (4%) 1 (2%)	1 (2%) 1 (2%) 1 (2%)	2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangiosarcoma Histiocytic sarcoma Luteoma Teratoma benign	1 (2%) 2 (4%) 1 (2%)	3 (6%) 2 (4%) 1 (2%)	1 (2%) 1 (2%) 1 (2%) 1 (2%)	2 (4%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangiosarcoma Histiocytic sarcoma Luteoma Teratoma benign Yolk sac carcinoma	1 (2%) 2 (4%) 1 (2%) 1 (2%)	3 (6%) 2 (4%) 1 (2%) 3 (6%)	1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	2 (4%) 1 (2%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma Histiocytic sarcoma Luteoma Teratoma benign Yolk sac carcinoma Uterus	1 (2%) 2 (4%) 1 (2%)	3 (6%) 2 (4%) 1 (2%) 3 (6%) (50)	1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	2 (4%)
Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma Histiocytic sarcoma Luteoma Teratoma benign Yolk sac carcinoma Uterus Histiocytic sarcoma	1 (2%) 2 (4%) 1 (2%) 1 (2%) (49)	3 (6%) 2 (4%) 1 (2%) 3 (6%) (50) 2 (4%)	$ \begin{array}{c} 1 (2\%) \\ 1 (2\%) \\ 1 (2\%) \\ 1 (2\%) \\ 1 (2\%) \\ 1 (2\%) \\ (50) \\ 1 (2\%) \end{array} $	2 (4%) 1 (2%)
None Genital System Ovary Cystadenoma Granulosa cell tumor benign Granulosa-theca tumor benign Hemangioma Hemangiosarcoma Histiocytic sarcoma Luteoma Teratoma benign Yolk sac carcinoma Uterus	1 (2%) 2 (4%) 1 (2%) 1 (2%)	3 (6%) 2 (4%) 1 (2%) 3 (6%) (50)	1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	2 (4%) 1 (2%)

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Hematopoietic System				
Bone marrow	(48)	(49)	(49)	(50)
Hemangiosarcoma	1 (2%)			
Histiocytic sarcoma		2 (4%)		
Lymph node	(7)	(2)	(5)	(4)
Iliac, histiocytic sarcoma	1 (14%)	1 (50%)		
Inguinal, hemangiosarcoma			1 (20%)	
Renal, histiocytic sarcoma	1 (14%)	2 (100%)	((
Lymph node, bronchial	(38)	(33)	(44)	(44)
Histiocytic sarcoma	()	1 (3%)	(()
Lymph node, mandibular	(41)	(42)	(44)	(38)
Histiocytic sarcoma	(10)	2 (5%)	(47)	(40)
Lymph node, mesenteric	(46)	(48)	(47)	(49)
Histiocytic sarcoma	2 (4%)	3 (6%)	(0.0)	(40)
Lymph node, mediastinal	(38)	(42) (50()	(36)	(42)
Histiocytic sarcoma	1 (3%) (49)	2 (5%) (50)	(50)	(50)
Spleen Hemangiosarcoma	(49)	(30)	(30)	(50)
Hepatocholangiocarcinoma, metastatic, live				1 (2/0)
Histiocytic sarcoma	1 (2%)	2 (4%)		
Thymus	(47)	(44)	(48)	(46)
Histiocytic sarcoma	1 (2%)	(11)	(40)	(40)
Integumentary System				
Mammary gland	(48)	(49)	(49)	(50)
Carcinoma	2 (4%)	()	2 (4%)	()
Skin	(49)	(50)	(49)	(50)
Subcutaneous tissue, fibrosarcoma		2 (4%)	1 (2%)	1 (2%)
Subcutaneous tissue, fibrous histiocytoma		1 (001)		
malignant		1 (2%)	1 (00/)	
Subcutaneous tissue, hemangiosarcoma	9 (40/)	1 (2%)	1 (2%)	9 (40/)
Subcutaneous tissue, sarcoma	2 (4%)	2 (4%)		2 (4%)
Musculoskeletal System None				
Nervous System Brain	(49)	(50)	(50)	(50)
Astrocytoma benign	1 (2%)			. /
Carcinoma, metastatic, pituitary gland			1 (2%)	

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Respiratory System				
Lung	(49)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	2 (4%)	2 (4%)	2 (4%)	2 (4%)
Alveolar/bronchiolar carcinoma	4 (8%)	2 (4%)	2 (4%)	1 (2%)
Alveolar/bronchiolar carcinoma, metastatic	·,			
lung		1 (2%)		
Carcinoma, metastatic, mammary gland	1 (2%)			
Hepatoblastoma, metastatic, liver		1 (2%)		
Hepatocellular carcinoma, metastatic, liver	1 (2%)	4 (8%)	2 (4%)	1 (2%)
Histiocytic sarcoma	2 (4%)	4 (8%)		
Pheochromocytoma malignant, metastatic,				
adrenal medulla				1 (2%)
Sarcoma, metastatic, skin		1 (2%)		
Nose	(47)	(50)	(49)	(50)
Pleura		(1)		
Hepatoblastoma, metastatic, liver		1 (100%)		
Special Senses System				
Harderian gland	(2)	(2)	(1)	(2)
Adenoma	1 (50%)	1 (50%)	1 (100%)	1 (50%)
Carcinoma	1 (00/0)	1 (50%)	1 (10070)	1 (50%)
Bilateral, carcinoma	1 (50%)	1 (0070)		1 (0070)
,	- (00.0)			
Urinary System	(10)	(7.0)	(10)	(7.0)
Kidney	(49)	(50)	(49)	(50)
Histiocytic sarcoma	(3 (6%)	(1-2)	(
Urinary bladder	(45)	(49)	(49)	(50)
Histiocytic sarcoma		1 (2%)		
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Histiocytic sarcoma	2 (4%)	4 (8%)	2 (4%)	(00)
Lymphoma malignant	16 (32%)	9 (18%)	17 (34%)	19 (38%)
_jp.ion.c. including	10 (02/0)		11 (01/0)	10 (0070)
Neoplasm Summary	40	45		
Total animals with primary neoplasms ^C	43	45	44	44
Total primary neoplasms	77	86	83	82
Total animals with benign neoplasms	29	35	33	32
Total benign neoplasms	39	53	46	44
Total animals with malignant neoplasms	29	29	30	31
Total malignant neoplasms	38	33	37	38
Total animals with metastatic neoplasms	3	7	4	2
Total metastatic neoplasms	3	8	5	2

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а

b

с

TABLE D2

	of Female Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Number of Days on Study	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
5 5	0 2 8 9 1 0 8 0 1 9 3 7 7 1 9 9 3 3 5 5 5 5 5 5 5
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Carcass ID Number	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	0 0 4 0 7 7 8 9 6 3 7 5 4 1 4 7 6 9 1 2 5 7 9 1 2
Alimontony System	
Alimentary System Esophagus	A + + + + + + + + + + + + + + + + + + +
Gallbladder	A + A + A + A + A + A + A + A + A + A +
Intestine large, colon	A + A + A + + + + + + + + + + + + + + +
Intestine large, rectum	A A A + A + + + + + + + + + + + + + I + + + +
Intestine large, cecum	A + A + A + + + + + + + + + + + + + + +
Intestine small, duodenum	A + A + A + + + + + + + + + + + + + + +
Intestine small, jejunum	A + A + A + + + + + + + + + + + + + + +
Intestine small, ileum	A + A + A + + + + + + + + + + + + + + +
Liver	A + A + A + A + A + A + A + A + A + A +
Hepatocellular carcinoma	X X X
Hepatocellular carcinoma, multiple	X
Hepatocellular adenoma	X X X X X X X X
Hepatocellular adenoma, multiple	х х х х х х х х х х х х х х х х х х х
Hepatocholangiocarcinoma	X
Histiocytic sarcoma	Λ
Mesentery	
Pancreas	+ + + + + + + + + + + + + + + + + + +
Salivary glands Stomach, forestomach	A + M + + + + + + + + + + + + + + + + +
Stomach, forestomach Stomach, glandular	A + A + + + + + + + + + + + + + + + + +
-	
Cardiovascular System	
Heart	+ + + + + + + + + + + + + + + + + + + +
Endocrine System	
Adrenal cortex	A + + + + + + + + + + + + + + + + + + +
Adrenal medulla	A + + + + + + + + + + + + + I + + + + +
Islets, pancreatic	$A \ A \ A \ + \ + \ + \ + \ + \ + \ + \ $
Adenoma	Х
Parathyroid gland	A + + M M + + M + + + + M + + + M M + M + M + + + +
Pituitary gland	M + + + + + + + + + + + + + + + + + + +
Pars distalis, adenoma	XX
Thyroid gland	A + A + + + + + + + + + + + + + + + + +
Follicular cell, adenoma	X
General Body System	
None	
Genital System	
Clitoral gland	A M + + + + + + + + + I + + + + + + + + +
Ovary	A + A + + + + + + + + + + + + + + + + +
Granulosa cell tumor benign	
Histiocytic sarcoma	
Teratoma benign	Х
Yolk sac carcinoma	X
	A + + + + + + + + + + + + + + + + + + +
Uterus Polyn stromal	\mathbf{v}
Uterus Polyp stromal Polyp stromal, multiple	Х

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

Individual Animal Tumor Patholog	y of Fem	aic					~~~	10	ai					·····	<u>.</u>	<u>, , , , , , , , , , , , , , , , , , , </u>	501			•					
	7	7	7	7	7	7	7	7	7	7	7	7	77	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3 3	33	3	3	3	3	3	3	3	3	3	3	3	
· ·	5	5	5	5	5	5	5	5	5	5	5	6 (66	6	6	6	6	6	6	6	6	6	6	6	
	1	1	1	1	1	1	1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number	1	1	1	1	1	2	2	2	2	2			3 3		3	3	3	4	4	4	4	4	4	5	Tissues/
	3	4	6		9	1				8		0 1		4		6		1		3			8		Tumors
	0	-1	U	0	0	1	~	0	0	0	0		~ 0	-	0	0	0	1	~	0	0	U	0	U	1 unior 5
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	49
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	• +	+	+	+	+	+	+	+	+	+	1	46
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	• +	+	+	+	+	+	+	+	+	+	+	46
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	45 46
Intestine large, cecum Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	40 46
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	40 46
Intestine small, jejunum	+	+	+	+	+	+	+ +	+ +	+ +	+ +	+ +			· +	+	+	+	+	+ +	+ +	+ +	+ +	+	++	40 46
Liver	+	- -	+	+	- -	-r +	+	+	+	+	+	- ·	+ + + +		- -	- -		+	 		-7 +	+		-7 +	40 47
Hepatocellular carcinoma	т	X		-1-	Ŧ	т	т	Ŧ	т	т	г		. т	-	7	Τ'	Ŧ	т	т	т	Ŧ	т	т	т	47
Hepatocellular carcinoma, multiple		~																							1
Hepatocellular adenoma			Х		х	Х		х	Х	х										х				Х	15
Hepatocellular adenoma, multiple					••	••		••	••	••		x	хх	C						••		Х		••	5
Hepatocholangiocarcinoma													- 1	-								••			1
Histiocytic sarcoma		Х														Х									2
Mesentery		+						+	+												+				7
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	• +	+	+	+	+	+	+	+	+	+	+	47
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	· +	+	+	+	+	+	+	+	+	+	+	48
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	48
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+	46
Cardiovascular System																									
Heart	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	. +	+	+	+	+	+	+	+	+	+	+	50
			•								-									÷	-				20
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	49
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	48
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	47
Adenoma	-																								1
Parathyroid gland	N	[+	+	+	+	+	+	+					+ N					+	+		Μ			+	35
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+ ·			+	+	+	+	+	+	+	+		+	49
Pars distalis, adenoma		X			X				X				X				X						X		8
Thyroid gland Follicular cell, adenoma	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	48 1
General Body System																									
None																									
Genital System																									
Clitoral gland	-	+	T	+	T	+	+	+	+	+	+	+ -	+ +		+	+	+	+	+	+	+	+	+	+	44
Ovary	- -	+	1 +	+	• +	+	+	+	+	+	+	+ .	. – + –	- +	+	+	+	+	- +	+	+	+	+	+	44
Granulosa cell tumor benign	Ŧ	7*		7	т	r	1-	1-	1-	1.			. т		7	т	F	ſ	X	ſ	r.	ſ	г	r	40
Histiocytic sarcoma		Х														х			~						2
Teratoma benign		~														Λ									1
Yolk sac carcinoma																									1
Uterus	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	. +	+	+	+	+	+	+	+	+	+	+	49
Polyp stromal	Ŧ	7*		7	т	r	1-	1-	1-	1.		X	. т		7	т	F	ſ	ſ	ſ	r.	ſ	г	r	43
Polyp stromal, multiple			Х																						1
JP Subman, manapie																									1

160

TABLE D2

2 3 3 4 5 5 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 2 7 4 4 8 0 1 2 3 5 6 6 8 0 0 2 2 3 3 3 3 3 3 3 0 2 8 9 1 0 8 0 1 9 3 7 7 1 9 9 3 3 5 5 5 5 5 5 5 **Carcass ID Number** 4 1 2 2 3 4 0 3 0 0 2 1 4 3 0 1 2 4 0 0 0 0 0 1 1 0 0 4 0 7 7 8 9 6 3 7 5 4 1 4 7 6 9 1 2 5 7 9 1 2 **Hematopoietic System** Bone marrow A + A + + + + + + X^+ + + Hemangiosarcoma Lymph node + Iliac, histiocytic sarcoma Renal, histiocytic sarcoma Lymph node, bronchial A + M M M + + + + + + + + + + M M + + + + M + MLymph node, mandibular A + M + + + + + + + M + + + +M + + + M + + + + Lymph node, mesenteric A + A + + + + ++ + M + + + I + + + + + + Histiocytic sarcoma Lymph node, mediastinal A M + M + ++ M + M + M + M + Histiocytic sarcoma Spleen A + + + + + + + ++ + + + + ++Hemangiosarcoma Hepatocholangiocarcinoma, metastatic, liver Histiocytic sarcoma Thymus $^{+}$ ++ + + Histiocytic sarcoma **Integumentary System** Mammary gland Carcinoma Х Х Skin Subcutaneous tissue, sarcoma Х Х Musculoskeletal System Bone + + **Nervous System** Brain Astrocytoma benign Х **Respiratory System** Larynx A + Lung A + + + $^{+}$ + + Х Х Alveolar/bronchiolar adenoma Х Х Alveolar/bronchiolar carcinoma Х Carcinoma, metastatic, mammary gland Х Х Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma Nose + + + + + Trachea A + A + + + + + + + + + ++ + + + + + + + + + + ++ + **Special Senses System** Eye Harderian gland + + Х Adenoma Bilateral, carcinoma Х

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control 7 Number of Days on Study 3 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 1 Total 1 1 **Carcass ID Number** 1 1 1 1 2 2 2 2 2 2 3 3 3 3 3 $3 \ 3 \ 4$ 4 4 4 4 4 5 Tissues/ 1 3 4 6 8 9 1 2 3 5 8 9 0 2 3 4 5 6 8 2 3 5 6 8 0 Tumors 1 **Hematopoietic System** Bone marrow 48 Hemangiosarcoma 1 Lymph node 7 Х Iliac, histiocytic sarcoma 1 Renal, histiocytic sarcoma Х 1 М Lymph node, bronchial 38 Μ Μ Μ + ++ + + +Lymph node, mandibular 41 Μ + Μ Μ + + + + + + + +Μ + Lymph node, mesenteric + 46 + + + + Histiocytic sarcoma Х Х 2 Lymph node, mediastinal 38 Μ Histiocytic sarcoma Х 1 Spleen + X 49 ++Х Hemangiosarcoma 3 Hepatocholangiocarcinoma, metastatic, liver 1 Histiocytic sarcoma X 1 47 Thymus + + Histiocytic sarcoma 1 **Integumentary System** Mammary gland 48 2 Carcinoma Skin 49 Subcutaneous tissue, sarcoma 2 Musculoskeletal System Bone 50 + + **Nervous System** Brain 49 + Astrocytoma benign 1 **Respiratory System** Larynx 49 Lung 49 + + 2 Alveolar/bronchiolar adenoma Х Alveolar/bronchiolar carcinoma 4 Carcinoma, metastatic, mammary gland 1 Hepatocellular carcinoma, metastatic, liver 1 Histiocytic sarcoma Х Х 2 Nose 47 + + + + + Trachea + 48 + + + + + + + + + + + +++ + + + + + + + + ++ **Special Senses System** Eye 1 Harderian gland 2 Adenoma 1 Bilateral, carcinoma 1

162

TABLE D2

Number of Days on Study	2 3 0	2	3 7 8	4 4 9	5 4 1	5 8 0	6 0 8	6 1 0	6 2 1	6 3 9	6 5 3	6 6 7	6 6 7	6 8 1	7 0 9	7 0 9	7 2 3	7 2 3	7 3 5	 						
Carcass ID Number	1 4 0	1 1 0	1 2 4	1 2 0	1 3 7	1 4 7	1 0 8	1 3 9	1 0 6	1 0 3	1 2 7	1 1 5	1 4 4	1 3 1	1 0 4	1 1 7	1 2 6	1 4 9	1 0 1	1 0 2	1 0 5	1 0 7	1 0 9	1 1 1	1 1 2	
Urinary System Kidney Urinary bladder		+ A		+++	+ A		+ +				-	+ +		+ +	+ +	+ +			+++		+ +	+++	+ +	+ +	++	
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	+	+	+ X	+	+	+ X	+ X	+	+	+	+ X	+	+	+	+	+	+	+	+ X	+ X	+ X	+	·	+ X	+	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: Chamber Control

Number of Days on Study		7 3 5	7 3 6																								
Carcass ID Number	1 1 5	1 1 3	1 1 4	1 1 6	1 1 8	1 1 9	1 2 1	1 2 2	1 2 3	1 2 5	1 2 8	1 2 9	1 3 0	1 3 2	1 3 3	1 3 4	1 3 5	1 3 6	1 3 8	1 4 1	1 4 2	1 4 3	1 4 5	1 4 6	1 4 8	1 5 0	Total Tissues/ Tumors
Urinary System Kidney Urinary bladder	-	+ +	+ +	+ +	+++	+++	+++	+ +	+ +	+ +	+ +	+ M	+ +	+ +	+++	+ +	+ +	+ +	+ +		+ +	+ +	+ +	+ +	+ +	+ +	49 45
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	-	+	+ X	+	+ X	+ X	+	+	+	+ X	+	+ X	+	+	+	+	+	+ X	+	+ X	+ X	+ X	+	+	+	+	50 2 16

Individual Animal Tumor Patholog	sy or rema	are	IVI	ice	m)	uie	: 4-1	i ea	u. 11	nia	lat	IUII	3(uay	y U	1 13	501)	ul	ell	5	JU	h n	hц	L	
						6	66									6		7	7	7	7	7	7		
Number of Days on Study	8	0		7			1 1		3 3		4	5	5		9	9	2	3	3	3	3	3	3	3	
	3	6	7	2	4	1	1 5	5 9	99	9	9	3	3	1	5	5	7	1	5	5	5	5	5	5	
	3	3	3	3	3	3	3 3	3 3	33	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	2	1	4	3	3	1	2 4					1	2	0		0		1	0	0	0	0	1	1	
	9	5	4	5			8 5														6	7	3	4	
Alimentary System																									
Esophagus	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	Å	+	+	+	+	+ -	+ +	 + +		Å								+	+	+	+	+	+	
Intestine large, colon	+	A	+	+	+	+	+ -		+ +								+	+	+	+	+	+	+	+	
Intestine large, rectum	+	А	+	+	+	+	+ I		+ +							+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	А	. +	+	+	+	+ -	+ +	+ +	+	Α	+	+	+	+	+	+	А	+	+	+	+	+	+	
Intestine small, duodenum	+	А	+	+	+	+	+ -	+ +	+ +	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	А	. +	+	+		+ -	+ +	+ +	+	А	+	+	+	+	+	+	А	+	+	+	+	+	+	
Carcinoma							Х																		
Intestine small, ileum	+	A	+	+	+		+ -		+ +						+	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+			+	+	+	+	+	+	+	+	+	
Hepatoblastoma															Х										
Hepatoblastoma, multiple							v	-			x ,														
Hepatocellular carcinoma			Х				Х	2	ХХ		Х		v		v	v				v	v	v		v	
Hepatocellular adenoma Hopatocellular adenoma multiple						х						Х	Х		Х	Х				X	Х	X		Х	
Hepatocellular adenoma, multiple Histiocytic sarcoma						Λ	,	x					х												
Mesentery	+						1	n.					л							+					
Histiocytic sarcoma	+																			т					
Pancreas	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+ -	 + .+	. r + +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	Å	. +	+	+	+	+ -	+ +	+ +	+	+	+				+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	A	. +	+	+	+	+ -	+ +	+ +	+		+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System																									
Heart																									
Histiocytic sarcoma	т	т	Т	т	т	т			т т	-	т	т	X	т	т	т	т	т	т	т	т	т	т	-	
Endocrine System Adrenal cortex					,													,	,	,		,	,		
	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma Capsule, adenoma																									
Adrenal medulla		۸																							
Pheochromocytoma benign	+	А	. +	+	Ŧ	Ŧ	т -	1. 1	+ +	X		+	Ŧ	т	Ŧ	Ŧ	т	+	+	+	Ŧ	+	+	т	
Islets, pancreatic	+	+	+	+	+	+	+ -	+ -	+ +			+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma	т	T	т,	r	X	1		. 1	. т	τ.	17	1.			1	1		1.	1.	1.	1.	17	1.		
Parathyroid gland	Μ	N	1 M	+		+	+ -	+ +	+ +	+	М	+	+	+	+	М	М	+	+	+	+	М	М	+	
Pituitary gland	+						+ -																		
Pars distalis, adenoma								ху								Х							Х		
Thyroid gland	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+			+	+	+	+	+	+	+	+	
Follicular cell, adenoma							_									Х									
General Body System																									
None																									
Genital System																									
Clitoral gland	M	· +	М	+	+	+	М -	+ -	+ -	+	+	+	+	+	+	+	+	+	+	+	м	+	+	+	
Ovary			+	+		+	+ -	 + -	, + + +	τ +	+	+	+	+	+	+	+	+	+	+	.vi +	+	+	+	
Cystadenoma	т		1.	X	'				. г	1.		'					X	'	'	'		'	'		
Granulosa cell tumor benign																									
Hemangioma																			Х						
Histiocytic sarcoma													Х						-						
Uterus	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+		+	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma													Х												
Polyp stromal																									

TABLE D2 Individual Animal Tu Pathol f Fo nala Mica in tha 2-Va Inhalation Study of Isobut 500

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 500 ppm

Number of Days on Study	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3					77 33		7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	
umber of Days on Study	5 5	5 5	5 5	5 5	5	5	5	5 5					66		5 6	5 6	5 6	5 6	5 6	5 6	5 6	5 6	5 6		
	3	3	3	3	3	3	3	3			3		33			3	3	3	3	3	3	3	3	3	Total
Carcass ID Number	1 6	1 7	1 9	2 0	2 1	2 2	2 3	2 4			3 1		33 34			4 0	4 1	4 2	4 3	4 6	4 7	4 8	4 9		Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	Ν	1 +	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	Μ	43
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+ •	+ •	+ +	- +	+	+	+	+	+	+	+	1	+	+ +	45 47
Intestine large, cecum Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- + 	+	+	+	+	+	+	+	+	+	+	47
Intestine small, jejunum	+ +	+		+	+	+	+ +	+ +	+	+ +	+ ·	+ ·	 			+ +	+	+	+ +	+ +	+	+ +	+	+	40
Carcinoma		'													'				'						1
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Hepatoblastoma																									1
Hepatoblastoma, multiple							Х																		1
Hepatocellular carcinoma			X																					Х	8
Hepatocellular adenoma		Х		Х	Х			Х		Х			y	Κ	Х			Х	Х					Х	18
Hepatocellular adenoma, multiple	Х						Х		Х																4
Histiocytic sarcoma													Х			Х									4
Mesentery			+						+							+		+				+	+		8
Histiocytic sarcoma																Х									1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	48
Cardiovascular System																									50
Heart Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50 1
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																Х									1
Capsule, adenoma								Х	Х																2
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Pheochromocytoma benign																									1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Adenoma																									1
Parathyroid gland	+	+	+	+	+	+	+	+		М	+	+	+ +	- +	+	Μ		+	+	+	+	+	+	+	39
Pituitary gland	+	+			+	+	+	+	+	+	+	+	+ +				+	+	+	+	+	+	+	+	49
Pars distalis, adenoma	Х			X											X				Х		Х		Х		13
Thyroid gland Follicular cell, adenoma	+ X		+	+ X		+	+	+	+		+ X	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	50 4
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			21							~ 1														1
General Body System None																									
Constant Constants																									
<b>Genital System</b> Clitoral gland		ч		т	ъ	÷	+	+	+	+	+	+	+ -			ъ	+	+	+	+	+	+	÷	+	46
Dvary	+	+ _	т 	- -	- -	т _	-r -		 	+	+	- ·	- 1 + -	т 	- -	Ť	-T -+	 	 	 	- +	- -	т _		40 50
Cystadenoma	+	Ŧ	Ŧ	Ŧ	Ŧ	т	-		X	Τ'	т	E.	с Т	т	Ŧ	т	Ŧ	T	T	-	Ŧ	Ŧ	т	7	30
Granulosa cell tumor benign		Х	-						23								Х								2
Hemangioma			-														21								1
Histiocytic sarcoma													Х			Х									3
Uterus	+	+	+	+	+	+	+	+	+	+	+			- +	+	+	+	+	+	+	+	+	+	+	50
		, i											X												2
Histiocytic sarcoma																									
Histiocytic sarcoma Polyp stromal											Х														1

Individual Animal Tumor Pathology of Fe	ema	ie	WI	ce i	in 1	the	۲-	r ea	r I	nha	alat	<b>10</b> 1	St	udy	y Oi	r Is	ob	ut	ene	e:	<b>3U</b>	л р	pn	1
	4	5	5	5	5	6		66	3 6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7
Number of Days on Study	8	0	6	7	9	1	1	1 3	3 3	3	4	5	5	9	9	9	2	3	3	3	3	3	3	3
	3	6	7	2	4	1		5 9	9 9	9	9	3	3	1	5	5	7	1	5	5	5	5	5	5
	3	3	3	3	3	3	3	3 3	33	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
Carcass ID Number	2	1	4	3	3			4 (						0							0	0	1	1
	9	5										0						2	1	5				
Hematopoietic System																								
Bone marrow	+	А	+	+	+	+	+	+ -	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma																								
Lymph node								+																
Iliac, histiocytic sarcoma								X																
Renal, histiocytic sarcoma								Х																
Lymph node, bronchial	М	+	+	+	+	+			+ 1	Л+	. +	М	М	+	+	+	м	+	+	+	+	+	+	М
Histiocytic sarcoma	1.11		'	•	•	•	•		. 1		'	1.1	.,,	•	•	·		•	•	'		•	'	
Lymph node, mandibular	м	+	м	+	+	м	+	м -	+ 1	Л -		+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma	111	F	141	1	1.	141	1		, 1	т т	-r	т	Г	1	1.		'	1.	Г.	r	C.	r.	r	
Lymph node, mesenteric		J	J	м	Т	т	-	-	L			+	J	ч	м	-	_	-	_	ر	_	-	J	т
Histiocytic sarcoma	+	+	+	111	Ŧ	т	т	v V	T	+	+	+	+	т	141	т	Ŧ	Ŧ	Ŧ	+	т	Ŧ	+	Τ'
		,	,				м	л ,	, 1	۸.	N	ſ,	м						,	,				
Lymph node, mediastinal	+	+	+	+	+	+			+ ľ	vi +	- IV	1 +	IVI	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma			,					X											,	,				
Spleen	+	+	+	+	+	+		+ - X	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma	۸./		,										<b>N</b> /	۸.4			ŊЛ			,				
Thymus	IVI	+	+	+	+	+	+	+ -	+ -	- +	- +	+	IVI	IVI	+	+	IVI	+	+	+	+	+	+	+
Integumentary System																								
Mammary gland	+	+	М	+	+	+	+	+ -	+ -	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+
Skin	+	+	+	+	+	+	+	+ -	+ -	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+
Subcutaneous tissue, fibrosarcoma																								Х
Subcutaneous tissue, fibrous, histiocytoma																								
malignant																								
Subcutaneous tissue, hemangiosarcoma																								
Subcutaneous tissue, acroma						Х			3	ζ														
									1	-														
Musculoskeletal System		,	,																,	,				
Bone	+	+	+	+	+	+	+	+ -	+ -	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System																								
Brain	+	+	+	+	+	+	+	+ -	+ -	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																								
Larynx	+	+	+	+	+	+	+	+ -	+ -	- +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+
Lung	+	+	+	+	+	+	+	+ -	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma								,																
Alveolar/bronchiolar carcinoma										Χ	C													
Alveolar/bronchiolar carcinoma, metastatic, lung										X														
Hepatoblastoma, metastatic, liver										2	-				Х									
Hepatocellular carcinoma, metastatic, liver			Х					3	X		Х													
Histiocytic sarcoma			~					х́	•		Δ		Х											
Sarcoma, metastatic, skin								4 <b>h</b>	2	7			11											
Nose		J	J	ч	Т	т	-	-		<b>.</b> .		. 1	J	ч	-	-	_	Т	_	ر	_	-	J	т
Pleura	+	+	+	Ŧ	Ŧ	т	т	-r -	T	+	+	+	+	т	++	т	Ŧ	Ŧ	Ŧ	+	т	Ŧ	+	Τ'
Hepatoblastoma, metastatic, liver															+ X									
•			,																,	,				
Trachea	+	+	+	+	+	+	+	+ -	+ -	- +	- +			+	+	+	+	+	+	+	+	+		

 TABLE D2

 Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 500 ppm

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 500 ppm

murvidual Ammai Fumor Factorogy of F	Cina	IC	141	icc	111	ur		- 1 (	cai	111		ιαι	1011		uu	J	<i>,</i> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	301	Jui	cii		00	o h	P		
Number of Days on Study	7 3 5	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	3																
Carcass ID Number	1	3 1 7	3 1 9	3 2 0	3 2 1	3 2 2	3 2 3	3 2 4	3 2 5	3 2 7	3 3 1	3 3 2	3 3 3	3 3 4	3 3 8	3 3 9	3 4 0	3 4 1	3 4 2	3 4 3	3 4 6	3 4 7	3 4 8	3 4 9	5	Total Tissues/ Tumors
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Histiocytic sarcoma													Х				Х									2
Lymph node																	+									2
Iliac, histiocytic sarcoma																										1
Renal, histiocytic sarcoma																	Х									2
Lymph node, bronchial	Μ	+	+	+	+	+	+	Μ	+	+	+	Μ	Μ	+	+	+		Μ	Μ	+	Μ	+	Μ	Μ	Μ	33
Histiocytic sarcoma																	Х									1
Lymph node, mandibular	+	+	+	+	+	+	+	+	Μ	+	+	+		+	Μ	+		+	Μ	+	+	+	+	+	+	42
Histiocytic sarcoma													Х				Х									2
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 3
Histiocytic sarcoma Lymph node, mediastinal	М		+	м	[ +					м	+				+		+		м							3 42
Histiocytic sarcoma	111	Ŧ	Ŧ	IVI	. –	т	Ŧ	т	т	111	. Τ	Ŧ	т	Ŧ	т	Ŧ	x	т	111	Ŧ	Ŧ	т	Ŧ	т	Ŧ	42
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma		·	·		·	Ċ		Ċ	·	·	Ċ	Ċ		·			x		Ċ	·	Ċ	Ċ	·	•	·	2
Thymus	+	+	+	Μ	[ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	44
International Cristens																										
Integumentary System																										40
Mammary gland Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	+	+	++	49 50
Subcutaneous tissue, fibrosarcoma	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	30 2
Subcutaneous tissue, fibrous, histiocytoma															Λ											2
malignant			Х																							1
Subcutaneous tissue, hemangiosarcoma											Х															1
Subcutaneous tissue, sarcoma																										2
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
																						—				
<b>Nervous System</b> Brain																										50
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	30
Respiratory System																										
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma										Х										<b>.</b> ,						2
Alveolar/bronchiolar carcinoma																				Х						2
Alveolar/bronchiolar carcinoma, metastatic, lung																										1
Hepatoblastoma, metastatic, liver																									v	1
Hepatocellular carcinoma, metastatic, liver													v				v								Х	4
Histiocytic sarcoma													Х				Х									4
Sarcoma, metastatic, skin		,																								1 50
Nose Pleura	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Hepatoblastoma, metastatic, liver																										1
Trachea	-	-	-	_	ч	ч	-	-	-	-	-	-	_	_	т.	-	-	-	-	_	-	-	-	_	-	50
11atilta	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ŧ	50

168

TABLE D2 Individual Animal Tu

Individual Animal Tumor Patholo	ogy of Fem	ale	M	ice	in	the	e <b>2</b> -	Ye	ear	In	hal	atio	on S	Stuo	ły (	of 1	[so]	but	ten	e:	50	)0 j	ppr	n	
	4	5	5	5	5	6	6	6	6	6	6	6	66	6	6	6	7	7	7	7	7	7	7	7	
Number of Days on Study	8	0	6	7	9	1	1	1	3	3	3	4	5 5	9	9	9	2	3	3	3	3	3	3	3	
	3	6	7	2	4	1	1	5	9	9	9	9	3 3	1	5	5	7	1	5	5	5	5	5	5	
	3	3	3	3	3	3	3	3	3	3	3	3	3 3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	2	1	4	3	3	1	2	4	0	3	3	0	1 2	0	0	0	1	1	0	0	0	0	1	1	
	9	5	4	5	6	8	8	5	2	0	7	4	06	9	3	8	1	2	1	5	6	7	3	4	
<b>Special Senses System</b> Eye Harderian gland Adenoma Carcinoma																									
Urinary System																									
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma Urinary bladder	+	+	+	+	+	+	+	X +	+	+	+	Δ	+ +	- +	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma			·		·	·		·	·	·	·	••	2			·					·		·		
Systemic Lesions																									
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma								Х					Z												
Lymphoma malignant		Х												Х					Х	Х					

individual Animal Tumor Patho	ology of Female Mice in the 2-Year Inhalation Study of Isodutene: 500 ppm
Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Carcass ID Number	3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3
<b>Special Senses System</b> Eye Harderian gland Adenoma Carcinoma	+ + + X X X
<b>Urinary System</b> Kidney Histiocytic sarcoma Urinary bladder Histiocytic sarcoma	+ + + + + + + + + + + + + + + + + + +
<b>Systemic Lesions</b> Multiple organs Histiocytic sarcoma Lymphoma malignant	++++++++++++++++++++++++++++++++++++

# Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 500 ppm

Number of Days on Study	4 7	0	5 4		6 1	2		7	6 8	9	7 0	3	3	3	3	3	3 3						3	7 3	3
	7	9	3	0	8	0	8	5	6	2	9	5	5	5	5	5	5 !	5	5	5	5	5	5	5	5
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5 5	5	5	5	5	5	5	5	5
Carcass ID Number	1 3	2 3	0 8	4 9	2 6	2 1	3 5	4 1	4 5	3 4	3 6	0 1			0 4						1 1			1 5	
Alimentary System																									
Esophagus	+	+	+	+		+			+					+		+	+ ·	+	+	+	+	+	+	+	+
Gallbladder	+			Α										+		+	+ ·	+	+	+	+	+	Μ	+	+
Intestine large, colon	+			+					+		+	+		+	+	+	+ •	+	+	+	+	+	+	+	+
Intestine large, rectum	+				Ι		+		+		+		+	+	+	+	+ •	+	+	+	+	+	+	+	+
Intestine large, cecum	+		A	A					+					+		+	+ •	+	+	+	+	+	+	+	+
Intestine small, duodenum Intestine small, jejunum	+			A A					A A							+ +	+ ·	+	+	+	+	+	+	+	+
Intestine small, jejunum Intestine small, ileum	+			A A					A A								+ •	+	+	+	+	+	+	+	+
Liver	+	+	л ⊥	A +			++		A +						++			+ +	+ +	+	-π -	τ +	++	++	
Hepatocellular carcinoma	Ŧ	F	T	-	-	+ X	-	-				Τ.	7	+ X	т	г		+ X	E.	Г		+ X	Τ.	-	г
Hepatocellular carcinoma, multiple				х		Δ											-								
Hepatocellular adenoma			Х	••				Х									Х				Х	Х			
Hepatocellular adenoma, multiple														Х				Х		Х					
Mesentery									+																+
Lipoma																									
Pancreas	+	+	Α	+	+	+	+	+	А	+	+	+	+	+	+	+	+ •	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+	+	+	+	+	+	+	+
Squamous cell carcinoma															Х										
Stomach, glandular	+	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+	+	+	+	+	+	+	+
Squamous cell carcinoma, metastatic, stomach,																									
forestomach															Х										
Tooth																									
Cardiovascular System																									
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+
Hepatocellular carcinoma, metastatic, liver																		X							
Adrenal medulla	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+	+	+	+	+	+	+	+
Pheochromocytoma benign																									
Islets, pancreatic	+	+	A	+	+	+	+	+	А	+	+	+	+	+	+	+	+ ·	+	+	+	+	+	+	+	+
Adenoma Departmentid along				۸.				۸.4	۸.4		۸4				1.4		1.1							۸.4	
Parathyroid gland Bituitary gland	+	+	A	1 <b>V1</b>	+	+	+	IVI				+	+		M	+	IVI ·	+	+	+	+	+	+	IVI	+
Pituitary gland Pars distalis, adenoma	+	+	+	+	+	+	+	+	A	+	+ X	+	+	+	+ X	$^+$ v	$\mathbf{v}^+$	+	+	+	+ X	+	+	+	+ X
Pars distalis, adenoma Pars distalis, carcinoma	х										л				Λ	л	л				л				л
Pars intermedia, adenoma	л																		Х						
Thyroid gland	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -			+	+	+	+	+	+
Follicular cell, adenoma	7	Г	17	Г	г	г	r	r	r.		1.	1.	1-		X	'		1		X		1	1.	X	
Follicular cell, carcinoma															••						Х				

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3 5	3 5	3 5	3 6		3 6																				
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	Total
Carcass ID Number	1 7	1 8	1 9	2 0	2 2	2 4	2 5	2 7	2 8	2 9	3 0	3 1	3 2	3 3		3 8	3 9	4 0	4 2	4 3	4 4	4 6	4 7	4 8	5 0	Tissues/ Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	Μ	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	Ι	+	+	+	+	+	+	+	+	+	+	+	+	+	47
intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma												Х					Х									6
Hepatocellular carcinoma, multiple																										1
Hepatocellular adenoma	Х	Х		Х													Х	Х					Х			11
Hepatocellular adenoma, multiple						Х									Х	Х					Х			Х		8
Mesentery				+				+							+		+	+			+					8
Lipoma															Х											1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach Squamous cell carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Squamous cell carcinoma, metastatic, stomach,				·																'						
forestomach Footh										+																1 1
Cardiovascular System																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Hepatocellular carcinoma, metastatic, liver																										1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pheochromocytoma benign										Х		Х														2
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	48
Adenoma																		Х								1
Parathyroid gland	+	+	+	+	Μ	Μ	+	+	М	+	+	Μ	+	+	+	+	+	+	М	+	+	+	+	+	+	37
Pituitary gland	+	+	+	+		+	+	+	+		+	+	+		+	+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma				Х	Х					Х				Х								Х	Х			12
Pars distalis, carcinoma																										1
Pars intermedia, adenoma																										1
Гhyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Follicular cell, adenoma																										3
Follicular cell, carcinoma																										1

TABLE D2

Individual Animal Tumor Pathology of	rem	ale		lice		un	e 4-	- 1 6	ear	IU	па	au	UII	30	uu	y U	1 13	SON	uu	en	e:	۵,٩	500	' P	hm	
	4	5	5	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	7	0	4	0	1	2	2	7	8	9	0	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	7	9	3	0	8	0	8	5	6	2	9	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
Carcass ID Number	1	2	0	4	2	2	3	4	4	3	3	0	0	0	0	0	0	0	0	1	1	1	1		1	
	3	3	8	9	6	1	5	1	5	4	6		2	3	4	5							4	5	6	
Genital System																										
Clitoral gland	N	[	Δ	. +	-	-	М	-	Δ	м	-	+	-	-	т	-	-	-	-	-	-	-	-	-	т.	
Ovary	+			. +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cystadenoma					'				'			'													•	
Hemangioma																						Х				
Hemangiosarcoma					Х																	21				
Histiocytic sarcoma					Λ		Х																			
Luteoma							Λ	Х																		
Uterus										,	,									,						
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	
Histiocytic sarcoma Polyp stromal																		л		х						
i oryp su oniai																				л			_			
Hematopoietic System																										
Bone marrow	+	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node									+		+											+				
Inguinal, hemangiosarcoma																										
Lymph node, bronchial	+	Ν	1 +	+	+	+	+	+	+	+	+	М	+	+	М	+	М	+	+	+	+	+	+	+	+	
Lymph node, mandibular	+	+	A	. +	+	+	+	М	+	+	+	+	+	+	+	+	+	М	М	+	+	+	+	+	+	
Lymph node, mesenteric	N	[ +	A	. +	+	Ι	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mediastinal	+	Ν	1 N	1 +	Μ	+	Μ	+	+	+	+	М	+	М	+	М	+	+	+	+	+	+	+	Μ	+	
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thymus	N	[ +	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Integumentary System																										
Mammary gland	+	+	+		+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Carcinoma									11			'	'			'			'							
Skin									А						+											
Subcutaneous tissue, fibrosarcoma	т	т	T	· •	т	Ŧ	Ŧ	т	А	X	т	+	т	+	т	+	т	т	Ŧ	Ŧ	т	т	т	т	Ŧ	
Subcutaneous tissue, hemangiosarcoma										л											Х					
Subcutaneous ussue, nemangiosarcoma																					л		—			
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Carcinoma, metastatic, pituitary gland	X																									
Respiratory System																										
			۸							,	,															
Larynx	+	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma												Х		17		<b>x</b> 7										
Alveolar/bronchiolar carcinoma														Х		Х										
Hepatocellular carcinoma, metastatic, liver																		Х								
Nose	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System																										
Harderian gland																										
													+													

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

	~	~	~	~	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	~	~	7	
Number of Days on Study	7 3	7 3	7 3	7 3	7 3	73	7 3	7 3	7 3	7 3	7 3	73	7 3	73	7 3	3	73	73	73	73	3	3	3	7 3	7 3	
	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	б	
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	Total
Carcass ID Number	1	1	1	2	2	2	2	2	2	2	3	3	3	3	3	3	3	4	4	4	4	4	4	4	5	Tissues/
	7	8	9	õ	2	4	5	7		9	0	1						0		3	4		7	8		Tumors
Conital System																										
<b>Genital System</b> Clitoral gland																										45
	+	+	+	+	+	+	+	+	+	+	+	+ T	+	+	+	+	+	+	+	+	+	+	+	+	+	45 48
Ovary Cystadenoma	+	+	+	+	+ X	+	+	+	+	+	+	1	+	+	+	+	+	+	+	+	+	+	+	+	+	40
Hemangioma					л																					1
																										1
Hemangiosarcoma Histiocytic sarcoma																										1
Histiocytic sarcoma Luteoma																										1
Luteoma Uterus					,	,			,									,	,						,	1 50
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Histiocytic sarcoma Bolym stromal																										1
Polyp stromal																										1
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Lymph node								+													+					5
Inguinal, hemangiosarcoma								Х																		1
Lymph node, bronchial	Μ	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	44
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Lymph node, mediastinal	+	+	+	+	+	+	+	+	+	+	Μ	Μ	Μ	+	+	+	+	+	+	Μ	+	Μ	+	+	М	36
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Integumentary System																										
Mammary gland					,	,			,									,	,	,					,	40
Carcinoma	+	+	+	+	+	+	+	+	+ X	+	+	+		+ X	+	+	+	+	+	+	+	+	+	+	+	49 2
					,	,												,	,						,	
Skin Subautanaans tissua, fibrasaraama	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Subcutaneous tissue, fibrosarcoma																										1
Subcutaneous tissue, hemangiosarcoma																										1
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma, metastatic, pituitary gland			·			•																				1
Dominatowy System																										
Respiratory System					,																					40
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma			Х																							2
Alveolar/bronchiolar carcinoma												v														2
Hepatocellular carcinoma, metastatic, liver												Х														2
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Special Senses System																										
Harderian gland																										1
Adenoma																										1

174

TABLE D2

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 2,000	ppm
-----------------------------------------------------------------------------------------------------	-----

																-										
Number of Days on Study	4 7 7	0	4	0	6 1 8	6 2 0	2	7	8	6 9 2	7 0 9	7 3 5														
Carcass ID Number	5 1 3	2	5 0 8	4	5 2 6	5 2 1	5 3 5	4	-	Ŭ,	5 3 6	5 0 1	5 0 2	5 0 3	5 0 4	5 0 5	5 0 6	5 0 7	5 0 9	5 1 0	5 1 1	5 1 2	5 1 4	5 1 5	5 1 6	
<b>Urinary System</b> Kidney Urinary bladder	+ +				+ +		+ +							+ +	+ +	+ +	+ +	+++	+ +	+ +	+ +	++	+++	+ +	+ +	
<b>Systemic Lesions</b> Multiple organs Histiocytic sarcoma Lymphoma malignant	+	+	+ X	+	+	+ X	+ X	+ X	+ X	+	+ X	+	+ X	+	+	+ X	+	+ X	+	+	+	+ X	+ X	+	+	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 2,000 ppm

Number of Days on Study	7 3 5	-	7 3 5	7 3 6																						
Carcass ID Number	5 1 7	5 1 8	5 1 9	5 2 0	5 2 2	5 2 4	5 2 5	5 2 7	5 2 8	5 2 9	5 3 0	5 3 1	5 3 2	5 3 3	5 3 7	5 3 8	5 3 9	5 4 0	5 4 2	5 4 3	5 4 4	5 4 6	5 4 7	5 4 8	5 5 0	Total Tissues/ Tumors
<b>Urinary System</b> Kidney Urinary bladder	+ +	+++	+ +	+++	+ +	+ +	+ +	+++	+ +	+++	+ +	49 49														
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	+	+	+	+	+ X	+ X	+ X	+ X	+	+	+	+	+	+	+	+	+	+ X	+	+	+ X	+ X	+	+ X	+	50 2 17

	5	5	5	5	6	6	6	6	6	77	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2 7	6 5	8 3	9 6	1 7	4 5			-	) 0 1 3	0 9	0 9	1 5	2 1		2 9			3 5	3 5	3 5	3 5	3 5	3 5	
	7	7	7	7	7	7	7	7	7 '	77	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	2 9	0 1	1 2	2 8	4 4	3 2		0 3 7 3	3 8 (	1 4 ) 2	3 6	4 7		1 1		0 8				0 6		1 3	1 4		
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	А	+	+	+	+	М	+ ·	+ ·	+ A	. +	+	+	+	А	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	Ι	+	+	+	+ ·	+ ·	+ +	+	+	+	+	А	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	А	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	А	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	А	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	А	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	А	+	+	+	+	+	+ ·	+ .	4 +	+	+	+	+	А	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	А	+	+	+	+	+	+ ·	+ ·	+ A	. +	+	+	+	А	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+		+ ·		+ +	+	+	+		+	+	+	+	+	+	+	+	+	+	
Hepatocellular carcinoma	Х			Х	Х	Х	Х		2	X				Х											
Hepatocellular carcinoma, multiple																									
Hepatocellular adenoma												Х				Х			Х			Х			
Hepatocellular adenoma, multiple				Х					2	X								Х							
Mesentery	+						+	+				+						+			+				
Pancreas	+	А	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+				+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+	· ·		+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+			+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	A	+	+	+	+	+	+	+	+	+	
Tongue												+													
Squamous cell papilloma												Х													
Tooth				+																					
Cardiovascular System																									
Heart	+	+	+	+	+	+	+	+ ·	+ •	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Capsule, adenoma								-																	
Adrenal medulla	+	+	+	+	+	+	+	1 .	+ ·	+ +	+	+	+	+	+			+	+	+	+	+	+	+	
Pheochromocytoma benign																	Х	v							
Bilateral, pheochromocytoma malignant																		X							
Islets, pancreatic	+	A	+	+	+	+				+ + 		+ r .	+	+			+	+	+	+	+	+	+	+	
Parathyroid gland	+	+	+	+	N	+				+ N			+						+	+	+	+	+	+	
Pituitary gland	+	+	+	+	ſVI	+				+ + v v				+	+			+	+	+	+ v	+	+	+	
Pars distalis, adenoma								X		ХХ							X				A				
Thyroid gland	+	+	+	+	+	+	+	+ ·	+ •	+ +	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	
Follicular cell, adenoma Follicular coll, adenoma, multiple																					л				
Follicular cell, adenoma, multiple Follicular cell, carcinoma																									
General Body System																									
None																									
Genital System							14											. /							
Clitoral gland	+	+	Μ	+						+ +											+	+	+	+	
Ovary	+	+	+	+	+	+	+	+ ·	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cystadenoma																									
L-raniilosa-theca tumor benign																									
Granulosa-theca tumor benign Uterus		+			+		+			+ +															

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
	7	1	7	7	1	1	7					7					7	1	7	7	1	1	1		7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	Total
Carcass ID Number	1	1	2	, 9	2	' 9	, 9	2	2	2	3	3	3	3	3	-	3	4	4	4	1	4	1	4	5	Tissues/
	7	8	2 0	2 1	2	23	ء 4				-	3 1				3 7		4 0	4		4 5	4 6	4 8	4 9		Tumors
	1	0	U	1	۵	3	4	9	0	1	0	1	3	4	3	7	9	U	1	3	3	0	0	9	U	1 uniors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	Μ	+	+	+	+	М	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma		X	-			·															·		·		X	9
Hepatocellular carcinoma, multiple				Х														Х							••	2
Hepatocellular adenoma				21	x	Х				Х				х		х		2 <b>x</b>		x	Х	x		х		13
Hepatocellular adenoma, multiple				Х	21	11			х			Х	x								11	- 1		21		13
Mesentery				+			+		~			Λ	Λ			+					+					10
Pancreas	<u>т</u>	-	-	т _	-	-	т _	т	-	-	-	-	-	т.	-	+	-	_	-	-	+	-	-	-	-	49
Salivary glands	т ,	- -	- -	- -	- -	т	т	т	- -	т	т	-	- -	т	т	- -	т	т	т	- -	т	т	- -	- -	- -	45 50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	30 49
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tongue																										1
Squamous cell papilloma Tooth																										1
10011																										1
Cardiovascular System																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Capsule, adenoma	x	'			'	'			'	'		'	'			'			'		'		'			1
Adrenal medulla	л +	+	+																							49
Pheochromocytoma benign	т	Ŧ	Ŧ	т	т	т	т	т	т	т	т	Ŧ	т	т	т	Ŧ	т	т	т	Ŧ	т	Ŧ	т	+	+ X	45
																									Λ	2 1
Bilateral, pheochromocytoma malignant																		,	,							1 49
Islets, pancreatic	+	+	+	+	+	+	+ \/	+	+	+ \/	+	+	+ \/	+	+	+	+ \/	+	+	+	+	+ \/	+	+	+	
Parathyroid gland	+	+	+	+	+	+	Μ			М			M			+	M			+	+		+		+	41
Pituitary gland	+	+	+	+	+	+	+		+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	49
Pars distalis, adenoma		Х						Х									Х			Х						12
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma																										1
Follicular cell, adenoma, multiple		Х																• -								1
Follicular cell, carcinoma																		Х								1
General Body System																										
None																										
Genital System																										
Clitoral gland	+	+	+	+	Μ		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cystadenoma			Х					Х																		2
Granulosa-theca tumor benign																				Х						1
																										50

TABLE D2

Individual Animal Tumor Pathology of	гета	ale						-10	cai	111		uuu	•	Ju	iu j				- ui			-,		<b>F</b> I	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	5	5	55	Ę	56	6	6	6	6	7	7	7	7	7 7	7 '	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	6	8	ę	) 1	4	5	7	8	0	0	0	0	1 2	2 2	2	2	3	3	3	3	3	3	3	3	
	7	5	53	6	37	5	3	2	7	1	3	9	9	5 1	1	1	9	5	5	5	5	5	5	5	5	
	7	7	' 7	1	77	7	7	7	7	7	7	7	7	7 7	7 '	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	2	C	) 1	2	2 4	3	0	0	3	1	4	3	4	1 1	1	1	0	0	0	0	0	0	1	1	1	
	9	1	2	8	3 4	2	3	7	8	0	2			6 1	1 9	9	8	2	4	5	6	9	3	4	5	
Hematopoietic System																										
Bone marrow	+		+ +		+ +	+	+	+	+	+	+	+	+	+ -	+ •	+	+	+	+	+	+	+	+	+	+	
Lymph node									+	·				+ -	+								·			
Lymph node, bronchial	+				+ +	M	r ,				м								м				+			
		_	г т 																							
Lymph node, mandibular	Μ	1 -	- +		+ +									+ -				+	+	+	+	IVI	Μ			
Lymph node, mesenteric	+	4	+ +		+ +	• +	+	+	+	+	+	+	+	+ -	+ .	A	+	+	+	+	+	+		+		
Lymph node, mediastinal	+	4	+ +		+ +	+	Μ	+	+	+	+	+	+	+ -	+ ·	+	+	+	+	+	Μ	+	+	Μ	Μ	
Spleen	+	ŕ	+ +		+ +	+	+	+	+	+	+	+	+	+ -	+ ·	+	+	+	+	+	+	+	+	+	+	
Hemangiosarcoma																					Х					
Thymus	+	÷	+ +		+ +	+	+	+	+	+	+	М	+	+ -	+ ·	+	+	+	+	+	+	+	+	+	+	
Integumentary System																										
Mammary gland			L .I	_	L .		т	-	÷	+	+	+	+	+	+	+	+	+	+	÷	_L	<i>т</i>	1	_L_	+	
Skin	+	-	. +	-	· +	- -	т	т ,	- <del>-</del> -	-r -	-T"		т 1		с . 1	F I	T I	T'		- <b>F</b>	-T -	т ,	- <del>-</del> -	т	r I	
	+	-	- +		+ +	+	+	+	+	+	+	+	+	+ -	+ ·			+	+	+	+	+	+	+	+	
Subcutaneous tissue, fibrosarcoma																	Х									
Subcutaneous tissue, sarcoma												Х												Х		
Musculoskeletal System																										
Bone	+	4	+ +		+ +	+	+	+	+	+	+	+	+	+ -	+ ·	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain																										
	+	_	+		+ +	· +	+	+	+	+	+	+	+	+ -	+ •	+	+	+	+	+	+	+	+	+	+	
Respiratory System																										
Larynx	+	Ą	⊦ +		+ +	+	+	+	+	+	+	+	+	+ -	+ •	+	+	+	+	+	+	+	+	+	+	
Lung	+	÷	⊦ +		+ +	+	+	+	+	+	+	+	+	+ -	+ •	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma										Х																
Alveolar/bronchiolar carcinoma																							Х			
Hepatocellular carcinoma, metastatic, liver	Х																						••			
Pheochromocytoma malignant, metastatic, adrenal medulla																			v							
																			Х							
Nose	+	4	+ +		+ +	+	+	+	+	+	+	+	+	+ -	+ ·	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	+ +		+ +	• +	+	+	+	+	+	+	+	+ -	+ •	+	+	+	+	+	+	+	+	+	+	
Special Senses System																										
Eye														+												
Harderian gland														+												
Adenoma																										
Carcinoma														Х												
Urinary System																										
Kidney																				,						
Urinary bladder	+	+	г + ⊢ ⊥		- + 	+	+	+	+	++	+	++	++	+ -	т : + :	+ +	+	++	++	+	+	+	+	+	+	
	т ———	_	, т		. т	Ŧ	7	Τ'	т	т	т	т	г	r -		r.	г	т	Ŧ	Ŧ	Τ'	Τ'	Ŧ	Τ'		
<b>Systemic Lesions</b> Multiple organs Lymphoma malignant	+		⊦ + X		+ +	+	+	+	+ X	+	+ X	+		+ - X 2		+		+ X	+	+ X	+	+	+	+ X	+	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Isobutene: 8,000 ppm

															-											
Number of Days on Study	7 3 5		3 3	;		3	77 33 55	7 3 5	7 3 6	7 3 6	3	3	3	3	3	3	3	3	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	3	
Carcass ID Number	7 1 7	1	2	2	2	2	77 22 34	7 2 5	7 2 6	7 2 7	7 3 0	7 3 1	3	3	3	3	3	4	7 4 1	7 4 3	7 4 5	7 4 6	7 4 8	7 4 9	5	Total Tissues/ Tumors
Hematopoietic System																										
Bone marrow Lymph node	+	+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, bronchial	+		⊢ N	A	+ -	+	+ +	+	+	+	+	+	+	+	М	+	М	+	+	+	+	+	+	+	+	4 44
Lymph node, mandibular	+	· +	+ +		м́.		· ·		+	M		+								+	+	+	M		M	38
Lymph node, mesenteric	+	. +	+ +	+	+ ·	+ •	+ +	+	+	+	+	+								+	+	+	+		+	49
Lymph node, mediastinal	+	+	+ +	F	+ ·	+	+ +	M	[ +	+	+	+	+	М	+	+	+	+		М	+	+	+	Μ	+	42
Spleen	+	+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Thymus	+	N	- N	F	+ ·	+	+ N	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	46
Integumentary System																										
Mammary gland	+	+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Skin	+	+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Subcutaneous tissue, fibrosarcoma																										1
Subcutaneous tissue, sarcoma																										2
Musculoskeletal System Bone	+	- +	+ +	F	+ -	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System																										
Brain	+	-+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Larynx	+	+	+ +	F	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lung	+	. +	+ +	+	+ •	+ •	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma							X																			2
Alveolar/bronchiolar carcinoma																										1
Hepatocellular carcinoma, metastatic, liver																										1
Pheochromocytoma malignant, metastatic,																										
adrenal medulla																										1
Nose Trachea	+	+ + +	+ + + +	F L	+ ·	+ ·	+ + + +	· +	++	++	+	+	++	++	++	+ +	+	++	+	+	+	+	++	++	++	50 50
Special Senses System						1			1				1			1	1		1	1			1	1	1	50
Eye																										1
Harderian gland															+											2
Adenoma															Х											1
Carcinoma																										1
Urinary System																										
ormary System	+	+	+ +	F	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Kidney						+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Kidney	+	+	+ +	F	Τ '																					
Kidney Urinary bladder	+	- +	+ -	-	т ·																					
Kidney Urinary bladder Systemic Lesions Multiple organs	+	· +	+ +	+	+ ·	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

Advand Medulla: Benigu or Malignant Pheochromocytoma Overall rate in the problem of the pr		Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Adjusted rate Derminal rate ( $932 (0\%)$ ) $2.3\%$ ( $333 (0\%)$ ) $4.4\%$ ( $239 (5\%)$ ) $6.7\%$ ( $239 (5\%)$ )Puby-3 test Dy-3 testP=0.116P=0.509P=0.257P=0.113Liver: Hepatocellular Adenoma 	Adrenal Medulla: Benign or Malignant Pheochron	nocytoma			
Terminal rate ⁶ 0.32 (0%) 0.31 (0%) 2.29 (3%) 3.33 (9%) $-\frac{-6}{2}$ 639 735 (T) 735 (T) 735 (T) 735 (T) 745 (T) 75 (T) 745 (T) 745 (T) 75 (T) 745 (T	Overall rate ^a	0/48 (0%)	1/49 (2%)	2/49 (4%)	3/49 (6%)
First incidence (days) $-6^{-0}$ 6.9 $-9 - 0.509$ $P - 0.257$ $P - 0.133$ Liver:       Heptocellular Adenoma       20/47 (43%)       22.050 (44%)       19.50 (38%)       20.50 (40%)         Adjusted rate       40.3%       42.2%       19.50 (38%)       20.50 (40%)       43.1%         Terminal rate       16.33 (64%)       19.20 (38%)       20.50 (40%)       16.73 (48%)       16.73 (48%)         Poly 3 test       P - 0.389N       P - 0.474       P - 0.379N       P - 0.462N         Liver:       Hepatocellular Carcinoma       750 (14%)       11.7%       15.0%       22.9%         Correll rate       5/47 (11%)       8/50 (16%)       7/50 (14%)       11.50 (22%)         Adjusted rate       5/47 (11%)       8/50 (16%)       7/50 (14%)       11.50 (22%)         Terminal rate       5/47 (11%)       8/50 (16%)       7/50 (14%)       11.50 (22%)         Terminal rate       5/47 (11%)       8/50 (16%)       7/50 (14%)       11.50 (22%)         Overall rate       5/47 (11%)       8/50 (16%)       7/50 (14%)       11.50 (22%)         Iteriminal rate       5/47 (11%)       10.7%       20.50 (44%)       9/33 (58%)         Divert       Hepatocellular Adenoma or Carcinoma	Adjusted rate ^b	0.0%	2.3%	4.4%	6.7%
Poly-3 test ^d P=0.116         P=0.059         P=0.257         P=0.133           Liver:         Hepatocellular Adenoma         20/47 (43%)         22/50 (44%)         19/50 (38%)         20/50 (40%)           Overall rate         40.3%         49.2%         40.8%         43.1%         19/50 (38%)         20/50 (40%)           Terminal rate         16/32 (50%)         17/31 (55%)         17/39 (44%)         16/33 (48%)           First incidence (days)         621         61         543         596           Poly-3 test         P=0.389N         P=0.474         P=0.379N         P=0.482N           Liver:         Hepatocellular Carcinoma         5/47 (11%)         5/50 (16%)         7/50 (14%)         11/50 (22%)           Adjusted rate         11.7%         17.7%         15.0%         22.9%         4/32 (15%)         4/33 (12%)           Poly-3 test         P=0.313         P=0.315         P=0.442         P=0.132         P=0.442         P=0.132           Liver:         Hepatocellular Adenoma or Carcinoma         25.7%         60.0%         64.4%         58.1%           Adjusted rate         23/47 (19%)         18/31 (68%)         18/39 (40%)         19/33 (68%)           Verent lrate         25.7%         60.0%	Terminal rate ^c		0/31 (0%)		3/33 (9%)
Liver:       Hepatocellular Adenoma       20/47 (43%)       22/50 (44%)       40/50 (38%)       42.1%         Overall rate       46.3%       40.2%       40.8%       43.1%         Adjusted rate       16/32 (50%)       17/31 (55%)       17/39 (44%)       16/33 (48%)         Prov all rate       16/32 (50%)       17/31 (55%)       17/39 (44%)       16/33 (48%)         poly-3 test       P=-0.389N       P=-0.474       P=-0.379N       P=-0.422N         Liver:       Hepatocellular Carcinoma		e	639	735 (T)	735 (T)
Overall rate20/47 (43%)22/50 (44%)19/50 (38%)20/50 (40%)Adjusted rate46.3%49.2%40.8%43.1%Terminal rate16/32 (50%)17/31 (55%)17/39 (44%)16/33 (48%)Poly-3 testP=0.389NP=0.474P=0.379NP=0.462NOverall rateAdjusted rate11.7%17.7%15.0%22.9%Trix incidence (days)11/50 (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (13%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.132P=0.482P=0.132P=0.132Ever: Hepatocellular Adenoma or CarcinomaOverall rateAdvact (13%)28/50 (56%)22/50 (44%)28/50 (56%)Overall rateCoveral rate16/32 (47%)28/50 (56%)22/50 (44%)19/33 (58%)Terminal rate18/32 (64%)18/31 (65%)18/31 (65%)19/33 (58%)Advacting colspan="4">Advacting	Poly-3 test ^a	P=0.116	P = 0.509	P=0.257	P=0.133
Overall rate20/47 (43%)22/50 (44%)19/50 (38%)20/50 (40%)Adjusted rate46.3%49.2%40.8%43.1%Terminal rate16/32 (50%)17/31 (55%)17/39 (44%)16/33 (48%)Pirst incidence (days)P=0.389NP=0.474P=0.379NP=0.462NOverall rate5/47 (11%)8/50 (16%)7/50 (14%)11/50 (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (15%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Pol.313P=0.315P=0.442P=0.132Uverall rate2/3/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52/7%600.9%46.4%58.1%Terminal rate18/32 (69%)18/32 (69%)19/33 (58%)Diverall rate2/3/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate2/3/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%600.9%46.4%58.1%Terminal rate11/50 (22%)Adjusted rate52.7%Overall rate4/32 (15%)13/31 (65%)13/39 (46%)19/33 (58%)Terminal rate11/7%20.9%750 (14%)12/50 (22%)Adjusted rate52.7%600.9%46.4%	Liver: Henatocellular Adenoma				
Adjusted rate46,3%49,2%40,8%43,1%Terminal rate16/32 (50%)17/31 (55%)17/39 (44%)16/33 (48%)First incidence (days)621611543596Poly-3 testP=0.389NP=0.474P=0.379NP=0.462NLiver:Hepatocellular Carcinoma5/47 (11%)8/50 (11%)5/59 (13%)4/33 (12%)Overall rate11.7%17.7%15.0%22.9%Adjusted rate11.7%10.0%5/59 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.133P=0.315P=0.442P=0.132Liver:Hepatocellular Adenoma or Carcinoma23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate23/37 (58%)18/33 (18%)18/39 (49%)19/33 (58%)18/39 (49%)Terminal rate11.7%20.390P=0.318P=0.318Overall rate24/24 (13%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%20.6%1573 (13%)5/39 (13%)4/33 (12%)First incidence (days)610567563527Poly-3 testP=0.206P=0.138P=0.348NP=0.312Liver:Hepatocellular Carcinoma or Hepatoblastoma10.750 (20%)7/50 (14%)11/50 (22%)Adjusted rate52.7%60.0%57363.9%577Poly-3 testP=0.206P=0.158P=0.442P=0.132Liver:Hepatocellular Carcinoma <td< td=""><td></td><td>20/47 (43%)</td><td>22/50 (44%)</td><td>19/50 (38%)</td><td>20/50 (40%)</td></td<>		20/47 (43%)	22/50 (44%)	19/50 (38%)	20/50 (40%)
Terminal rate First incidence (days)16/32 (69%) 62117.31 (55%) 62117.39 (44%) 56616/33 (48%) 566Poly-3 testP=0.389NP=0.474P=0.379NP=0.462NLiver: Hepatocellular CarcinomaUrerall rate5/47 (11%)8/50 (149%)7/50 (149%)11/50 (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (13%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Pol.33P=0.315P=0.442P=0.132Liver: Hepatocellular Adenoma or CarcinomaOverall rate23/47 (49%)28/50 (56%)22/50 (44%)58.1%Terminal ratePol.33P=0.315P=0.442P=0.132Liver: Hepatocellular Adenoma or CarcinomaOverall rate23/47 (49%)28/50 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Pol.389P=0.309P=0.348NP=0.377Overall rateAdjusted rateCarcinoma or HepatoblastomaOverall rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate23/47 (49%)28/50 (56%)22.50 (44%)28/50 (56%)Overall rate5/47 (11%)10/50 (20%)7/50 (1					. ,
First incidence (days) $621$ $611$ $543$ $596$ Poly3 testP=0.389NP=0.474P=0.379NP=0.462NLiver:Hepatocellular Carcinoma $5/47$ (11%) $8/50$ (16%) $7/50$ (14%) $11/50$ (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate $4/32$ (13%) $3/31$ (10%) $5/39$ (13%) $4/33$ (12%)Poly3 testP=0.133P=0.315P=0.442P=0.132Liver:Hepatocellular Adenoma or Carcinoma $28/50$ (56%)22/50 (44%)28/50 (56%)Overall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate18/32 (56%)18/31 (58%)19/33 (58%)19/33 (58%)First incidence (days)610567543527Poly3 testP=0.399P=0.309P=0.348NP=0.377Liver:Hepatocellular Carcinoma or Hepatoblastoma10/50 (20%)7/50 (14%)11/50 (22%)Qverall rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%22.9%15.0%22.9%Terminal rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%92.0%15.0%22.9%Terminal rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%92.0%15.0%22.9%Terminal rate14.7%11/50 (22%)24.7%Poly3 testP=0.206P=0.158P=0.422 <t< td=""><td>5</td><td></td><td></td><td></td><td></td></t<>	5				
Poly-3 testP= 0.389NP= 0.474P= 0.379NP= 0.462NLiver: Hepatocellular CarcinomaOverall rateAdjusted rate11.7%17.7%15.0%22.9%Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (13%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP= 0.133P= 0.315P= 0.442P= 0.132Liver: Hepatocellular Adenoma or CarcinomaUverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%18/32 (69%)18/31 (69%)18/33 (49%)19/33 (69%)First incidence (days)8103 (69%)18/31 (69%)18/32 (69%)18/32 (69%)18/32 (69%)11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%Civer: Hepatocellular Carcinoma or Hepatoblastoma00527000527Poly-3 testP= 0.206P= 0.188P= 0.13211/50 (22%)Adjusted rate11.7%28/50 (66%)46.4%58.1%First incidence (days)610567600527Poly-3 testP= 0.206P= 0.188P= 0.422P= 0.132Coverall rate23/47 (49%)28/50 (66%)46.4%58.1%First incidence (days)610567600527<				, ,	, ,
Overall rate5/47 (11%)8/50 (16%)7/50 (14%)11/50 (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (13%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.133P=0.442P=0.132Liver: Hepatocellular Adenoma or CarcinomaOverall rate23/47 (49%)28/50 (56%)22.50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (69%)19/33 (58%)First incidence (days)P=0.399P=0.309P=0.348P=0.377Diverall rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%Adjusted rate23/47 (49%)28/50 (56%)22.9%Adjusted rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate24/32 (13%)4/31 (13%)5/39 (13%)4/33 (12%)First incidence (days)P=0.266P=0.158P=0.422P=0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or Hepatoblastoma18/32 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%First incidence (days)P=0.266P=0.58P=0.432P=0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or Hepatoblastoma28/50 (56%)22/50 (44%)28/50 (56%)<		P=0.389N	P = 0.474	P=0.379N	P = 0.462N
Overall rate5/47 (11%)8/50 (16%)7/50 (14%)11/50 (22%)Adjusted rate11.7%17.7%15.0%22.9%Terminal rate4/32 (13%)3/31 (10%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.133P=0.442P=0.132Liver: Hepatocellular Adenoma or CarcinomaOverall rate23/47 (49%)28/50 (56%)22.50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (69%)19/33 (58%)First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.348NP=0.377Liver: Hepatocellular Carcinoma or Hepatoblastoma5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%Terminal rate5/42 (13%)4/31 (13%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.266P=0.158P=0.422P=0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or Hepatoblastoma28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%58.1%First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.380P=0.377Liver: Hepatocellular Adenoma, Hepatocellular C	Liver: Hepatocellular Carcinoma				
Terminal rate $4/32$ (13%) $3/31$ (10%) $5/39$ (13%) $4/33$ (12%)First incidence (days)Poly-3 testPol.33P=0.315P=0.442P=0.132 <b>Liver: Hepatocellular Adenoma or Carcinoma</b> Overall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%)Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32$ (65%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%)First incidence (days) $610$ $567$ $543$ $527$ Poly-3 testP=0.399P=0.309P=0.348NP=0.377 <b>Liver: Hepatocellular Carcinoma or HepatoblastomaU</b> $10/50$ (20%) $7/50$ (14%) $11/50$ (22%)Adjusted rate $11.7\%$ $20.9\%$ $15.0\%$ $22.9\%$ Adjusted rate $11.7\%$ $20.9\%$ $573$ 600 $527$ Poly-3 testP=0.206P=0.158P=0.132 <b>Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaU</b> $573$ 600Adjusted rate $11.7\%$ $22.9\%$ $573$ 600 $527$ Poly-3 testP=0.206P=0.158P=0.442P=0.132 <b>Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaU</b> $573$ 600 $527$ Poly-3 testP=0.399P=0.309P=0.348N $733$ (12%) <b>Liver: Hepatocellular Adenoma, Hepatocellular CarcinomaU</b> $577$ 600 $527$ Poly-3 testP=0.399 $28/50$ (56%) $18/39$ (46%) $19/33$ (58%)Firs		5/47 (11%)	8/50 (16%)	7/50 (14%)	11/50 (22%)
First incidence (days) Poly-3 test610567600527Poly-3 testP=0.133P=0.315P=0.442P=0.132Uverall rate Adjusted rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Overall rateAdjusted rate18/32 (66%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)First incidence (days)Pint incidence (days)11/50 (22%)Adjusted rate10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11/7%22.0%First incidence (days)Pint colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="	Adjusted rate	11.7%	17.7%	15.0%	22.9%
Poly-3 testP= 0.133P= 0.315P= 0.442P= 0.132Liver: Hepatocellular Adenoma or CarcinomaOverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Liver: Hepatocellular Carcinoma or Hepatoblastoma0verall rate11.7%22.0%15.0%Overall rate11.7%22.0%15.0%22.9%Adjusted rate11.7%22.0%15.0%22.9%First incidence (days)610567600527Poly-3 testP= 0.206P= 0.158P= 0.442P= 0.132Uverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)P= 0.399P= 0.309P= 0.388P= 0.377Overall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)P= 0.399P= 0.309P= 0.309P= 0.377Lung: Alveolar/bronchiolar Carcinoma9	Terminal rate	4/32 (13%)	3/31 (10%)	5/39 (13%)	4/33 (12%)
Liver: Hepatocellular Adenoma or Carcinoma Overall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%) Adjusted rate $52.7\%$ 60.0% $46.4\%$ $58.1\%$ Terminal rate $18/32$ (56%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%) First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Liver: Hepatocellular Carcinoma or Hepatoblastoma Overall rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ $15.0\%$ $22.9\%$ Terminal rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Terminal rate $4/32$ (13%) $4/31$ (13%) $5/39$ (13%) $4/33$ (12%) First incidence (days) $610$ $567$ $600$ $527$ Poly-3 test $P=0.206$ $P=0.158$ $P=0.422$ $P=0.132$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or Hepatoblastoma Overall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%) Adjusted rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%) Adjusted rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%) Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ First incidence (days) $P=0.339$ $P=0.309$ $P=0.348N$ $P=0.377$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or Hepatoblastoma Overall rate $8/32$ (56%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%) First incidence (days) $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Ling: Alveolar/bronchiolar Carcinoma Overall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%) Adjusted rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%) First incidence (days) $P=0.331N$ $P=0.311N$ $P=0.161N$ Ling: Alveolar/bronchiolar Adenoma or Carcinoma Overall rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%) First incidence (days) $P=0.31N$ $P=0.18N$ $P=0.331N$ $P=0.31N$ $P=0.31N$ $P=0.18N$	First incidence (days)		567	600	527
Overall rate $23/47 (49\%)$ $28/50 (56\%)$ $22/50 (44\%)$ $28/50 (56\%)$ Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ First incidence (days) $610$ $567$ $543$ $527$ Poly-3 testP=0.399P=0.309P=0.348NP=0.377Liver: Hepatocellular Carcinoma or HepatoblastomaOverall rate $547$ $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Adjusted rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Terminal rate $4/32$ ( $13\%$ ) $4/31$ ( $13\%$ ) $5/39$ ( $13\%$ ) $4/33$ ( $12\%$ )First incidence (days) $610$ $567$ $600$ $527$ Poly-3 testP=0.206P=0.158P=0.348N $P=0.328$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $23/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ )<	Poly-3 test	P=0.133	P=0.315	P = 0.442	P = 0.132
Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (40%)19/33 (58%)First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.348NP=0.377Liver: Hepatocellular Carcinoma or HepatoblastomaOverall rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%Adjusted rate11.7%22.0%15.0%22.9%First incidence (days)610567600527Poly-3 testP=0.206P=0.158P=0.442P=0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.348NP=0.32Coreall rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.348NP=0.377Lung: Alveolar/bronchiolar CarcinomaOverall rate1/32 (3%)1/31 (3%)2/39 (6%)1/50 (2%)Adjusted rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)	Liver: Hepatocellular Adenoma or Carcinoma				
Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.398P= 0.377Liver: Hepatocellular Carcinoma or HepatoblastomaOverall rate5/47 (11%)10/50 (20%)7/50 (14%)11/50 (22%)Adjusted rate11.7%22.0%15.0%22.9%Terminal rate4/32 (13%)4/31 (13%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP= 0.206P= 0.158P= 0.442P= 0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaUverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)19/33 (58%)19/33 (58%)Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar Carcinoma1/32 (3%)1/31 (58%)1/33 (3%)Overall rate4/49 (8%)2/50 (4%)2/50 (4%)1/50 (2%)Adjusted rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)2/39 (5%)1/33 (3%)First incidence (days)639639735 (T)735 (T)P	Overall rate	23/47 (49%)	28/50 (56%)	22/50 (44%)	28/50 (56%)
First incidence (days) $610$ $567$ $543$ $527$ Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Liver: Hepatocellular Carcinoma or HepatoblastomaOverall rate $5/47$ (11%) $10/50$ (20%) $7/50$ (14%) $11/50$ (22%)Adjusted rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Terminal rate $4/32$ (13%) $4/31$ (13%) $5/39$ (13%) $4/33$ (12%)First incidence (days) $610$ $567$ $600$ $527$ Poly-3 testP= 0.206P= 0.158P= 0.442P= 0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%)Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ $527$ Poly-3 testP= 0.399P= 0.309P= 0.309P= 0.337Liver: Hepatocellular Carcinoma $18/32$ (56%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%)First incidence (days) $610$ $567$ $543$ $527$ Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar Carcinoma $730$ $730$ $733$ (17) $733$ (17)Overall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (1	Adjusted rate				
Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Liver: Hepatocellular Carcinoma or Hepatoblastoma $J/T$ </td <td></td> <td>18/32 (56%)</td> <td></td> <td>, ,</td> <td>. ,</td>		18/32 (56%)		, ,	. ,
Liver: Hepatocellular Carcinoma or HepatoblastomaOverall rate $5/47$ (11%) $10/50$ (20%) $7/50$ (14%) $11/50$ (22%)Adjusted rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Terminal rate $4/32$ (13%) $4/31$ (13%) $5/39$ (13%) $4/33$ (12%)First incidence (days) $610$ $567$ $600$ $527$ Poly-3 test $P=0.206$ $P=0.158$ $P=0.442$ $P=0.132$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%)Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32$ (56%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%)First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Lung: Alveolar/bronchiolar CarcinomaOverall rate $9.3\%$ $4.6\%$ $2.50$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or Carcinoma $P=0.193N$ $P=0.331N$ $P=0.161N$ Lung: Alveolar/bro					
Overall rate $5/47$ (11%) $10/50$ (20%) $7/50$ (14%) $11/50$ (22%)Adjusted rate $11.7\%$ $22.0\%$ $15.0\%$ $22.9\%$ Terminal rate $4/32$ (13%) $4/31$ (13%) $5/39$ (13%) $4/33$ (12%)First incidence (days) $610$ $567$ $600$ $527$ Poly-3 test $P=0.206$ $P=0.158$ $P=0.442$ $P=0.132$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32$ ( $56\%$ ) $18/31$ ( $58\%$ ) $18/39$ ( $46\%$ ) $19/33$ ( $58\%$ )First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P=0.309$ $P=0.309$ $P=0.348N$ $P=0.377$ Lung: Alveolar/bronchiolar Carcinoma $V=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Coverall rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ ( $3\%$ ) $1/31$ ( $3\%$ ) $2/39$ ( $5\%$ ) $1/33$ ( $3\%$ )First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or Carcinoma $V=0.931N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or Carcinoma $V=0.931N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma	Poly-3 test	P = 0.399	P = 0.309	P = 0.348N	P = 0.377
Adjusted rate11.7%22.0%15.0%22.9%Terminal rate4/32 (13%)4/31 (13%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP=0.206P=0.158P=0.442P=0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rateCoverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP=0.399P=0.309P=0.348NP=0.377Lung: Alveolar/bronchiolar CarcinomaOverall rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)2/39 (5%)1/33 (3%)First incidence (days)639639639735 (T)735 (T)Poly-3 testP=0.193NP=0.331NP=0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rateAdjusted rate6/49 (12%)4/50 (8%)4/50 (8%)3/50 (6%)Adjusted rate8.8%6.5%735 (T)735 (T)Poly-3 testP=0.193NP=0.331NP=0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate6/49 (12%)4/50 (8%)4/50 (8%)3/50 (6%)Adjusted rate13.8%					
Terminal rate4/32 (13%)4/31 (13%)5/39 (13%)4/33 (12%)First incidence (days)610567600527Poly-3 testP= 0.206P= 0.158P= 0.442P= 0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar CarcinomaOverall rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)2/39 (5%)1/33 (3%)First incidence (days)639639735 (T)735 (T)Poly-3 testP= 0.193NP= 0.331NP= 0.117Dverall rateAdjusted rate9.3%4/50 (8%)3/50 (6%)First incidence (days)639639735 (T)735 (T)Poly-3 testP= 0.193NP= 0.331NP= 0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate6/49 (12%)4/50 (8%)3/50 (6%)Adjusted rate13.8%9.1%8.8%6.5%Terminal rate2/32 (6%)2/31 (6%)4/39 (10%)2/33 (6%)		. ,	· · ·		. ,
First incidence (days)610567600527Poly-3 testP= 0.206P= 0.158P= 0.442P= 0.132Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblascomeOverall rate23/47 (49%)28/50 (56%)22/50 (44%)28/50 (56%)Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar CarcinomaOverall rate4/49 (8%)2/50 (4%)2/50 (4%)1/50 (2%)Adjusted rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)2/39 (5%)1/33 (3%)First incidence (days)639639735 (T)735 (T)Poly-3 testP= 0.193NP= 0.331NP= 0.311NP= 0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate6/49 (12%)4/50 (8%)4/50 (8%)3/50 (6%)Adjusted rate13.8%9.1%8.8%6.5%Tarminal rate13.8%9.1%8.8%6.5%	5				
Poly-3 test $P = 0.206$ $P = 0.158$ $P = 0.442$ $P = 0.132$ Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47$ (49%) $28/50$ (56%) $22/50$ (44%) $28/50$ (56%)Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32$ (56%) $18/31$ (58%) $18/39$ (46%) $19/33$ (58%)First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P = 0.399$ $P = 0.309$ $P = 0.348N$ $P = 0.377$ Lung: Alveolar/bronchiolar CarcinomaOverall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P = 0.193N$ $P = 0.331N$ $P = 0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ (12%) $4/50$ (8%) $4/50$ (8%)Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Current rate $2/32$ (6%) $2/31$ (6%) $4/39$ (10%) $2/33$ (6%)		, ,			
Liver: Hepatocellular Adenoma, Hepatocellular Carcinoma, or HepatoblastomaOverall rate $23/47 (49\%)$ $28/50 (56\%)$ $22/50 (44\%)$ $28/50 (56\%)$ Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32 (56\%)$ $18/31 (58\%)$ $18/39 (46\%)$ $19/33 (58\%)$ First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Lung: Alveolar/bronchiolar CarcinomaOverall rate $4/49 (8\%)$ $2/50 (4\%)$ $1/50 (2\%)$ Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32 (3\%)$ $1/31 (3\%)$ $2/39 (5\%)$ $1/33 (3\%)$ First incidence (days) $639$ $639$ $735 (T)$ $735 (T)$ Poly-3 test $P=0.193N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49 (12\%)$ $4/50 (8\%)$ $4/50 (8\%)$ $Ajusted rate6/49 (12\%)4/50 (8\%)3/50 (6\%)Adjusted rate13.8\%9.1\%8.8\%6.5\%Cverall rate6/49 (12\%)4/50 (8\%)4/50 (8\%)3/50 (6\%)Adjusted rate13.8\%9.1\%8.8\%6.5\%Cverall rate6/49 (12\%)4/50 (8\%)4/50 (8\%)3/50 (6\%)Adveolar/bronchiolar Adenoma or CarcinomaCverall rate6/49 (12\%)4/50 (8\%)$					
Overall rate $23/47$ ( $49\%$ ) $28/50$ ( $56\%$ ) $22/50$ ( $44\%$ ) $28/50$ ( $56\%$ )Adjusted rate $52.7\%$ $60.0\%$ $46.4\%$ $58.1\%$ Terminal rate $18/32$ ( $56\%$ ) $18/31$ ( $58\%$ ) $18/39$ ( $46\%$ ) $19/33$ ( $58\%$ )First incidence (days) $610$ $567$ $543$ $527$ Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Lung: Alveolar/bronchiolar CarcinomaOverall rate $4/49$ ( $8\%$ ) $2/50$ ( $4\%$ ) $1/50$ ( $2\%$ )Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ ( $3\%$ ) $1/31$ ( $3\%$ ) $2/39$ ( $5\%$ ) $1/33$ ( $3\%$ )First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ ( $12\%$ ) $4/50$ ( $8\%$ ) $4/50$ ( $8\%$ ) $3/50$ ( $6\%$ )Adjusted rate $2/32$ ( $6\%$ ) $2/31$ ( $6\%$ ) $4/39$ ( $10\%$ ) $2/33$ ( $6\%$ )	Poly-3 test	P = 0.206	P = 0.158	P = 0.442	P = 0.132
Adjusted rate52.7%60.0%46.4%58.1%Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days)610567543527Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar CarcinomaOverall rateOverall rate4/49 (8%)2/50 (4%)2/50 (4%)1/50 (2%)Adjusted rate9.3%4.6%4.4%2.2%Terminal rate1/32 (3%)1/31 (3%)2/39 (5%)1/33 (3%)First incidence (days)639639735 (T)735 (T)Poly-3 testP= 0.193NP= 0.331NP= 0.311NP= 0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate6/49 (12%)4/50 (8%)4/50 (8%)3/50 (6%)Adjusted rate13.8%9.1%8.8%6.5%Terminal rate2/32 (6%)2/31 (6%)4/39 (10%)2/33 (6%)				00/50 (110/)	00/50 (500/)
Terminal rate18/32 (56%)18/31 (58%)18/39 (46%)19/33 (58%)First incidence (days) $610$ $567$ $543$ $527$ Poly-3 testP= 0.399P= 0.309P= 0.348NP= 0.377Lung: Alveolar/bronchiolar CarcinomaOverall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%)Adjusted rate9.3% $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 testP= 0.193NP= 0.331NP= 0.311NP= 0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ (12%) $4/50$ (8%) $4/50$ (8%) $3/50$ (6%)Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32$ (6%) $2/31$ (6%) $4/39$ (10%) $2/33$ (6%)		( )	· · ·	, ,	. ,
First incidence (days) Poly-3 test $610$ P=0.399 $567$ P=0.309 $543$ P=0.348N $527$ P=0.377Lung: Alveolar/bronchiolar Carcinoma $V$ $V$ $V$ $V$ $V$ Overall rate Adjusted rate $4/49$ (8%) 9.3% $2/50$ (4%) $4.6\%$ $1/50$ (2%) $2.2\%$ Adjusted rate Terminal rate $9.3\%$ $1/32$ (3%) $1/31$ (3%) $2.2/39$ (5%) $1/33$ (3%) $1/33$ (3%)First incidence (days) Poly-3 test $639$ P=0.193N $639$ P=0.331N $735$ (T) P=0.311N $735$ (T) P=0.161NLung: Alveolar/bronchiolar Adenoma or Carcinoma Overall rate Adjusted rate Terminal rate $6/49$ (12%) $13.8\%$ $4/50$ (8%) $9.1\%$ $4/50$ (8%) $8.8\%$ $3/50$ (6%) $6.5\%$ Terminal rate	5				
Poly-3 test $P=0.399$ $P=0.309$ $P=0.348N$ $P=0.377$ Lung: Alveolar/bronchiolar Carcinoma $V$ $V$ $V$ $V$ $V$ Overall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or Carcinoma $V$ $V$ $V$ $V$ Overall rate $6/49$ ( $12\%$ ) $4/50$ ( $8\%$ ) $4/50$ ( $8\%$ ) $3/50$ ( $6\%$ )Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32$ ( $6\%$ ) $2/31$ ( $6\%$ ) $4/39$ ( $10\%$ ) $2/33$ ( $6\%$ )		, ,		, ,	, ,
Lung: Alveolar/bronchiolar CarcinomaOverall rate $4/49 (8\%)$ $2/50 (4\%)$ $2/50 (4\%)$ $1/50 (2\%)$ Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32 (3\%)$ $1/31 (3\%)$ $2/39 (5\%)$ $1/33 (3\%)$ First incidence (days) $639$ $639$ $735 (T)$ $735 (T)$ Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49 (12\%)$ $4/50 (8\%)$ $4/50 (8\%)$ $3/50 (6\%)$ Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32 (6\%)$ $2/31 (6\%)$ $4/39 (10\%)$ $2/33 (6\%)$					
Overall rate $4/49$ (8%) $2/50$ (4%) $2/50$ (4%) $1/50$ (2%)Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ (12%) $4/50$ (8%) $4/50$ (8%) $3/50$ (6%)Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32$ (6%) $2/31$ (6%) $4/39$ (10%) $2/33$ (6%)	•				
Adjusted rate $9.3\%$ $4.6\%$ $4.4\%$ $2.2\%$ Terminal rate $1/32 (3\%)$ $1/31 (3\%)$ $2/39 (5\%)$ $1/33 (3\%)$ First incidence (days) $639$ $639$ $735 (T)$ $735 (T)$ Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49 (12\%)$ $4/50 (8\%)$ $4/50 (8\%)$ $3/50 (6\%)$ Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32 (6\%)$ $2/31 (6\%)$ $4/39 (10\%)$ $2/33 (6\%)$		1/10 (00/)	2/50 (40/)	2/50 (40/)	1/50 (9%)
Terminal rate $1/32$ (3%) $1/31$ (3%) $2/39$ (5%) $1/33$ (3%)First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ (12%) $4/50$ (8%) $4/50$ (8%) $3/50$ (6%)Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32$ (6%) $2/31$ (6%) $4/39$ (10%) $2/33$ (6%)		. ,	· · ·	· · ·	
First incidence (days) $639$ $639$ $735$ (T) $735$ (T)Poly-3 testP= 0.193NP= 0.331NP= 0.311NP= 0.161NLung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49$ (12%) $4/50$ (8%) $4/50$ (8%) $3/50$ (6%)Adjusted rate13.8% $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32$ (6%) $2/31$ (6%) $4/39$ (10%) $2/33$ (6%)					
Poly-3 test $P=0.193N$ $P=0.331N$ $P=0.311N$ $P=0.161N$ Lung: Alveolar/bronchiolar Adenoma or CarcinomaOverall rate $6/49 (12\%)$ $4/50 (8\%)$ $4/50 (8\%)$ $3/50 (6\%)$ Adjusted rate $13.8\%$ $9.1\%$ $8.8\%$ $6.5\%$ Terminal rate $2/32 (6\%)$ $2/31 (6\%)$ $4/39 (10\%)$ $2/33 (6\%)$		. ,			
Overall rate         6/49 (12%)         4/50 (8%)         4/50 (8%)         3/50 (6%)           Adjusted rate         13.8%         9.1%         8.8%         6.5%           Terminal rate         2/32 (6%)         2/31 (6%)         4/39 (10%)         2/33 (6%)					
Overall rate         6/49 (12%)         4/50 (8%)         4/50 (8%)         3/50 (6%)           Adjusted rate         13.8%         9.1%         8.8%         6.5%           Terminal rate         2/32 (6%)         2/31 (6%)         4/39 (10%)         2/33 (6%)	Lung: Alveolar/bronchiolar Adenoma or Carcino	ma			
Adjusted rate         13.8%         9.1%         8.8%         6.5%           Terminal rate         2/32 (6%)         2/31 (6%)         4/39 (10%)         2/33 (6%)			4/50 (8%)	4/50 (8%)	3/50 (6%)
Terminal rate         2/32 (6%)         2/31 (6%)         4/39 (10%)         2/33 (6%)		( )		· · /	
Poly-3 test $P = 0.248N$ $P = 0.360N$ $P = 0.338N$ $P = 0.215N$				, ,	

# Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

# Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Ovary: Cystadenoma				
Overall rate	0/48 (0%)	3/50 (6%)	1/48 (2%)	2/50 (4%)
Adjusted rate	0.0%	6.8%	2.3%	4.4%
Terminal rate	0/32 (0%)	1/31 (3%)	1/38 (3%)	2/33 (6%)
First incidence (days)	_	572	735 (T)	735 (T)
Poly-3 test	P=0.486	P = 0.125	P = 0.509	P=0.255
Pituitary Gland (Pars Distalis): Adenoma				
Overall rate	8/49 (16%)	13/49 (27%)	12/49 (24%)	12/49 (24%)
Adjusted rate	18.8%	29.8%	26.7%	26.2%
Terminal rate	6/32 (19%)	10/31 (32%)	11/39 (28%)	8/33 (24%)
First incidence (days)	709	615	709	672
Poly-3 test	P = 0.462	P = 0.171	P = 0.265	P=0.279
Pituitary Gland (Pars Distalis): Adenoma or C	arcinoma			
Overall rate	8/49 (16%)	13/49 (27%)	13/49 (27%)	12/49 (24%)
Adjusted rate	18.8%	29.8%	28.4%	26.2%
Terminal rate	6/32 (19%)	10/31 (32%)	11/39 (28%)	8/33 (24%)
First incidence (days)	709	615	477	672
Poly-3 test	P = 0.476	P = 0.171	P = 0.206	P=0.279
Skin (Subcutaneous Tissue): Fibrous Histiocyte	oma, Fibrosarcoma, or Sar	coma		
Overall rate	2/50 (4%)	5/50 (10%)	1/50 (2%)	3/50 (6%)
Adjusted rate	4.7%	11.3%	2.2%	6.5%
Ferminal rate	0/32 (0%)	3/31 (10%)	0/39 (0%)	1/33 (3%)
First incidence (days)	667	611	692	709
Poly-3 test	P = 0.578N	P = 0.228	P = 0.476N	P = 0.532
Spleen: Hemangiosarcoma				
Overall rate	3/49 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
Adjusted rate	7.1%	0.0%	0.0%	2.2%
Ferminal rate	2/32 (6%)	0/31 (0%)	0/39 (0%)	1/33 (3%)
First incidence (days)	709	—	—	735 (T)
Poly-3 test	P = 0.524 N	P = 0.115N	P = 0.106N	P=0.280N
Fhyroid Gland (Follicular Cell): Adenoma				
Overall rate	1/48 (2%)	4/50 (8%)	3/49 (6%)	2/50 (4%)
Adjusted rate	2.4%	9.2%	6.6%	4.4%
Cerminal rate	1/32 (3%)	3/31 (10%)	3/39 (8%)	2/33 (6%)
First incidence (days)	735 (T)	695	735 (T)	735 (T)
Poly-3 test	P=0.499N	P=0.187	P = 0.330	P = 0.527
Fhyroid Gland (Follicular Cell): Adenoma or (	Carcinoma			
Overall rate	1/48 (2%)	4/50 (8%)	4/49 (8%)	3/50 (6%)
Adjusted rate	2.4%	9.2%	8.8%	6.6%
Ferminal rate	1/32 (3%)	3/31 (10%)	4/39 (10%)	3/33 (9%)
First incidence (days)	735 (T)	695	735 (T)	735 (T)
Poly-3 test	P = 0.558	P=0.187	P = 0.200	P=0.334
Uterus: Stromal Polyp				
Overall rate	3/50 (6%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
Adjusted rate	7.0%	2.3%	2.2%	0.0%
Ferminal rate	2/32 (6%)	1/31 (3%)	1/39 (3%)	0/33 (0%)
First incidence (days)	709	735 (T)	735 (T)	_
Poly-3 test	P = 0.132N	P = 0.298N	P = 0.280N	P = 0.106N

# Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
All Organs: Hemangiosarcoma				
Overall rate	3/50 (6%)	1/50 (2%)	3/50 (6%)	1/50 (2%)
Adjusted rate	7.0%	2.3%	6.5%	2.2%
Terminal rate	2/32 (6%)	1/31 (3%)	2/39 (5%)	1/33 (3%)
First incidence (days)	709	735 (T)	618	735 (T)
Poly-3 test	P = 0.323N	P=0.298N	P = 0.625N	P=0.280N
All Organs: Hemangioma or Hemangiosarcoma				
Overall rate	3/50 (6%)	2/50 (4%)	4/50 (8%)	1/50 (2%)
Adjusted rate	7.0%	4.6%	8.7%	2.2%
Ferminal rate	2/32 (6%)	2/31 (6%)	3/39 (8%)	1/33 (3%)
First incidence (days)	709	735 (T)	618	735 (T)
Poly-3 test	P=0.236N	P = 0.492N	P = 0.543	P=0.280N
All Organs: Histiocytic Sarcoma				
Overall rate	2/50 (4%)	4/50 (8%)	2/50 (4%)	0/50 (0%)
Adjusted rate	4.7%	9.1%	4.3%	0.0%
Ferminal rate	2/32 (6%)	2/31 (6%)	1/39 (3%)	0/33 (0%)
First incidence (days)	735 (T)	615	628	_
Poly-3 test	P=0.077N	P = 0.354	P=0.664N	P=0.221N
All Organs: Malignant Lymphoma				
Overall rate	16/50 (32%)	9/50 (18%)	17/50 (34%)	19/50 (38%)
Adjusted rate	35.9%	20.4%	36.0%	40.7%
Ferminal rate	12/32 (38%)	7/31 (23%)	12/39 (31%)	14/33 (42%)
First incidence (days)	378	506	543	583
Poly-3 test	P=0.119	P = 0.079 N	P=0.582	P=0.398
All Organs: Benign Neoplasms				
Overall rate	29/50 (58%)	35/50 (70%)	33/50 (66%)	32/50 (64%)
Adjusted rate	65.0%	74.8%	70.8%	68.4%
Ferminal rate	21/32 (66%)	24/31 (77%)	30/39 (77%)	26/33 (79%)
First incidence (days)	449	572	543	596
Poly-3 test	P=0.490N	P=0.205	P = 0.351	P = 0.450
All Organs: Malignant Neoplasms				
Overall rate	29/50 (58%)	29/50 (58%)	30/50 (60%)	31/50 (62%)
Adjusted rate	60.9%	60.7%	60.8%	63.2%
Ferminal rate	15/32 (47%)	17/31 (55%)	20/39 (51%)	18/33 (55%)
First incidence (days)	322	506	477	527
Poly-3 test	P = 0.440	P = 0.577N	P = 0.581N	P = 0.489

#### Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ррт	2,000 ppm	8,000 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rate	43/50 (86%)	45/50 (90%)	44/50 (88%)	44/50 (88%)
Adjusted rate	87.7%	91.3%	89.2%	89.1%
Terminal rate	26/32 (81%)	28/31 (90%)	34/39 (87%)	29/33 (88%)
First incidence (days)	322	506	477	527
Poly-3 test	P=0.568N	P=0.397	P=0.534	P=0.541

(T)Terminal sacrifice

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, liver, lung, ovary, pituitary gland, spleen, and thyroid gland; for other tissues, denominator is number of animals necropsied.

Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

^e Not applicable; no neoplasms in animal group

## Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	13	16	6	13
Natural deaths	5	3	5	4
Survivors				
Terminal sacrifice	32	31	39	33
Animals examined microscopically	50	50	50	50
Alimentary System				
Intestine large, rectum	(45)	(45)	(47)	(48)
Artery, inflammation, chronic active	×/	()	()	1 (2%)
Intestine small, ileum	(46)	(48)	(46)	(47)
Inflammation, chronic active	x - /	x - 7	1 (2%)	
Liver	(47)	(50)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)		1 (2%)
Basophilic focus	4 (9%)	4 (8%)	2 (4%)	5 (10%)
Clear cell focus		4 (8%)	3 (6%)	4 (8%)
Cyst	1 (2%)			1 (2%)
Degeneration, fatty	2 (4%)	1 (2%)	5 (10%)	1 (2%)
Eosinophilic focus	17 (36%)	11 (22%)	12 (24%)	7 (14%)
Hematopoietic cell proliferation			1 (2%)	1 (2%)
Mixed cell focus				1 (2%)
Necrosis		2 (4%)	3 (6%)	1 (2%)
Tension lipidosis	1 (2%)	3 (6%)	1 (2%)	
Bile duct, hyperplasia			1 (2%)	
Centrilobular, necrosis			1 (2%)	3 (6%)
Mesentery	(7)	(8)	(8)	(10)
Artery, inflammation		1 (13%)		1 (10%)
Fat, inflammation, chronic active				1 (10%)
Fat, necrosis	7 (100%)	6 (75%)	6 (75%)	10 (100%)
Pancreas	(47)	(50)	(48)	(49)
Atrophy		0 ((2))		1 (2%)
Basophilic focus	1 (2%)	2 (4%)		1 (00/)
Lipomatosis	1 (2%)	1 (00/)		1 (2%)
Duct, cyst	1 (2%)	1 (2%)	(40)	(40)
Stomach, forestomach	(48)	(49)	(49)	(49)
Hyperplasia Inflammation, acuto	2 (4%)	4 (8%) 2 (4%)	1 (2%)	1 (2%)
Inflammation, acute	1 (2%)	2 (4%)	(48)	(49)
Stomach, glandular Necrosis	(46)	(48)	(48) 1 (2%)	(49)
			1 (2%)	1 (2%)
Artery, inflammation, chronic active Footh			(1)	(1)
Malformation			1 (100%)	1 (100%)
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	10 (20%)	10 (20%)	12 (24%)	8 (16%)
Mineralization	10 (20/0)	1 (2%)	1 (21/0)	0 (1070)

 a  Number of animals examined microscopically at the site and the number of animals with lesion

## Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm
Endocrine System				
Adrenal cortex	(49)	(50)	(49)	(50)
Hematopoietic cell proliferation	1 (2%)	(00)	1 (2%)	1 (2%)
Hyperplasia	3 (6%)	4 (8%)	3 (6%)	5 (10%)
Hypertrophy	3 (6%)	1 (2%)	4 (8%)	2 (4%)
Vacuolization cytoplasmic	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Adrenal medulla	(48)	(49)	(49)	(49)
Hyperplasia	(40)	3 (6%)	(43)	(43)
slets, pancreatic	(47)	(49)	(48)	(49)
		(49)	1 (2%)	3 (6%)
Hyperplasia Divitore gland	1 (2%)	(40)		( )
Pituitary gland	(49)	(49)	(49)	(49)
Pars distalis, hyperplasia	13 (27%)	15 (31%)	19 (39%)	14 (29%)
Thyroid gland	(48)	(50)	(49)	(50)
Follicular cell, hyperplasia	25 (52%)	16 (32%)	29 (59%)	30 (60%)
G <b>eneral Body System</b> None				
Genital System				
Ovary	(48)	(50)	(48)	(50)
	(40)	. ,	(40)	, ,
Angiectasis	19 (970/)	1 (2%)	11 (990/)	3 (6%) 8 (16%)
Cyst	13 (27%)	14 (28%)	11 (23%)	8 (16%)
Inflammation, suppurative	1 (2%)	(50)	(50)	(50)
Jterus	(49)	(50)	(50)	(50)
Angiectasis				1 (2%)
Hydrometra	6 (12%)	7 (14%)	3 (6%)	4 (8%)
Inflammation, suppurative		1 (2%)	1 (2%)	
Necrosis			1 (2%)	
Thrombosis			1 (2%)	
Endometrium, hyperplasia, cystic				1 (2%)
Hematopoietic System				
Bone marrow	(48)	(49)	(49)	(50)
Necrosis		1 (2%)		
Lymph node	(7)	(2)	(5)	(4)
Lumbar, hemorrhage	1 (14%)			
Lymph node, bronchial	(38)	(33)	(44)	(44)
Hyperplasia, plasma cell	1 (3%)	(00)	(**)	(11)
Lymph node, mandibular	(41)	(42)	(44)	(38)
Hyperplasia, lymphoid	1 (2%)	(16)	(11)	(00)
Infiltration cellular, mixed cell	1 (2/0)		1 (2%)	
	(46)	(19)	, ,	(40)
<i>Lymph node, mesenteric</i>	(46) (20()	(48) (40()	(47)	(49)
Angiectasis	1 (2%)	2 (4%)		1 (00/)
Infiltration cellular, plasma cell				1 (2%)
Infiltration cellular, mixed cell	()	( )	1 (2%)	()
Lymph node, mediastinal	(38)	(42)	(36)	(42)
Infiltration cellular, mixed cell			1 (3%)	
Spleen	(49)	(50)	(50)	(50)
Hematopoietic cell proliferation	4 (8%)	12 (24%)	6 (12%)	5 (10%)
Infarct				1 (2%)
Infiltration cellular, histiocyte		1 (2%)		

## Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Inhalation Study of Isobutene

	Chamber	Control	50	0 ppm	2,00	0 ppm	8,00	)0 ppm
ntegumentary System	(40)		(50)		(10)		(50)	
kin Inflammation, acute	(49)		(50)	(2%)	(49)		(50)	
Inflammation, chronic active	1	(2%)		(2%)			1	(2%)
<b>Ausculoskeletal System</b> Jone								
Vervous System								
Brain	(49)		(50)	(00.1)	(50)		(50)	
Inflammation, chronic active			1	(2%)				
Respiratory System							· ·	
Lung	(49)		(50)	(90/)	(50)		(50)	
Hemorrhage Infiltration cellular, histiocyte			1	(2%)	1	(2%)	1	(2%)
Inflammation, granulomatous					1	(270)		(2%)
Metaplasia, osseous			1	(2%)				. ,
Alveolar epithelium, hyperplasia		(8%)		(6%)		(6%)		(2%)
lose	(47)		(50)		(49)		(50)	(00)
Inflammation, chronic Inflammation, suppurative			1	(2%)	1	(2%)	1	(2%)
Olfactory epithelium, atrophy				(2%)	1	(270)		
Olfactory epithelium, degeneration, hyaline	17	(36%)		(38%)	24	(49%)	27	(54%)
Respiratory epithelium, degeneration, hyalin		(45%)		(78%)		(84%)		(96%)
Special Senses System								
Eye	(1)		(1)				(1)	
Degeneration	1	(100%)						
Cornea, metaplasia, squamous			1	(100%)				
Jrinary System								
Kidney	(49)		(50)		(49)		(50)	
Amyloid deposition	1	(2%)		(= = · · ·				
Cyst	4	(00/)		(2%)		(00/)		
Infarct Metaplasia, osseous		(2%)		(4%)		(2%) (4%)		
Metaplasia, osseous Mineralization	1	(2%)	1	(2%)		(4%)		
Nephropathy	13	(27%)	14	(28%)		(37%)	12	(24%)
Renal tubule, necrosis	10	· · · · ·		、 -···		(2%)	16	(
Jrinary bladder	(45)		(49)		(49)		(50)	
Artery, inflammation, chronic active							1	(2%)

# **APPENDIX E GENETIC TOXICOLOGY**

SALMONELLA TYPHIMURIUM MUTAGENICITY TEST PROTOCOL	188
MOUSE PERIPHERAL BLOOD MICRONUCLEUS TEST PROTOCOL	188
Results	189
TABLE E1         Mutagenicity of Isobutene in Salmonella typhimurium	190
TABLE E2         Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice	
Following Treatment with Isobutene by Inhalation for 14 Weeks	191

# **GENETIC TOXICOLOGY**

# SALMONELLA TYPHIMURIUM MUTAGENICITY TEST PROTOCOL

Because isobutene is a gas, it was tested in a desiccator (Zeiger *et al.*, 1992). The *Salmonella typhimurium* strains (TA97, TA98, TA100, and TA1535) and buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor 1254-induced male F344 rat or Syrian hamster liver) were incorporated into the top agar and poured onto minimal medium plates. The lids of the plates were slightly raised, and the plates were stacked in glass desiccator jars. The air was evacuated. A measured amount of isobutene was introduced, and air was allowed to enter until atmospheric pressure was reached. The desiccator was then sealed and placed in a  $37^{\circ}$  C incubator for 24 hours, after which time the desiccator was moved to a safety hood, the lid was opened, and the residual test gas was allowed to dissipate. The plates were removed from the desiccator and incubated at  $37^{\circ}$  C for an additional 24 hours. The concentration was expressed as moles of isobutene per desiccator.

Each trial consisted of triplicate plates of concurrent positive and negative controls and five doses of isobutene. The high dose of 0.027 mol/dessicator was limited by toxicity.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants that is not dose related, is not reproducible, or is not of sufficient magnitude to support a determination of mutagenicity. A negative response is obtained when no increase in revertant colonies is observed following chemical treatment. There is no minimum percentage or fold increase required for a chemical to be judged positive or weakly positive.

## **MOUSE PERIPHERAL BLOOD MICRONUCLEUS TEST PROTOCOL**

A detailed discussion of this assay is presented in MacGregor *et al.* (1990). At the end of the 14-week toxicity study, peripheral blood samples were obtained from male and female mice. Smears were immediately prepared and fixed in absolute methanol. The methanol-fixed slides were stained with acridine orange and coded. Slides were scanned to determine the frequency of micronuclei in 2,000 normochromatic erythrocytes (NCEs) in each of five male and five female mice per dose group.

The results were tabulated as the mean of the pooled results from all animals within a treatment group plus or minus the standard error of the mean. The frequency of micronucleated cells among NCEs was analyzed by a statistical software package that tested for increasing trend over exposure groups with a one-tailed Cochran-Armitage trend test, followed by pairwise comparisons between each exposed group and the control group (Margolin *et al.*, 1990). In the presence of excess binomial variation, as detected by a binomial dispersion test, the binomial variance of the Cochran-Armitage test was adjusted upward in proportion to the excess variation. In the micronucleus test, an individual trial is considered positive if the trend test P value is less than or equal to 0.025 or if the P value for any single exposed group is less than or equal to 0.025 divided by the number of exposure groups. A final call of positive for micronucleus induction is preferably based on reproducibly positive trials (as noted above). Ultimately, the final call is determined by the scientific staff after considering the results of statistical analyses, reproducibility of any effects observed, and the magnitudes of those effects.

# **R**ESULTS

Isobutene (0.001 to 0.027 mol/desiccator) was not mutagenic in *S. typhimurium* strain TA97, TA98, TA100, or TA1535, with or without induced rat or hamster liver S9 enzymes (Table E1). *In vivo*, no increase in the frequency of micronucleated NCEs was seen in peripheral blood samples from male or female mice administered isobutene via inhalation for 14 weeks (Table E2).

Strain	-			Revertan			
Con	centration		S9	+ ham	ster S9	+ rat	t <b>S9</b>
mol/dessic	ator)	Trial 1	Trial 2	<b>10</b> %	<b>30</b> %	10%	<b>30</b> %
ГА100	Air	110 ± 7.5	143 ± 14.3	$131 \pm 2.2$	$127 \pm 4.7$	$142~\pm~11.0$	141 ± 10.4
	0.001	$98 \pm 1.9$	$152 \pm 5.3$	$132~\pm~13.5$	$121~\pm~8.0$	$131 \pm 12.9$	$147 \pm 12.5$
	0.002	$100~\pm~4.0$	$151~\pm~11.0$	$128~\pm~11.6$	$114~\pm~8.6$	$142 \pm 1.9$	$124~\pm~9.1$
	0.007	$101~\pm~4.9$	$135 \pm 2.6$	$130 \pm 3.2$	$117 \pm 7.2$	$146~\pm~5.5$	$134~\pm~4.3$
	0.013	$81 \pm 1.9$	$124~\pm~11.9$	$112~\pm~11.8$	$87 \pm 4.7$	$117~\pm~10.6$	$95 \pm 0.9$
	0.027	$68 \pm 11.7$	$84~\pm~1.2$	$127~\pm~17.1$	$79~\pm~5.9$	$89~\pm~10.4$	$83~\pm~7.2$
Frial summai	ry	Negative	Negative	Negative	Negative	Negative	Negative
Positive cont	rol ^c	$432 \pm 11.8$	$383 \pm 12.4$	$332~\pm~15.3$	$859~\pm~31.9$	$914 \pm 55.4$	$583 \pm 11.5$
FA1535	Air	$10~\pm~2.6$	$8 \pm 1.5$	$12~\pm~0.9$	$22 \pm 4.2$	$15 \pm 1.2$	$14 \pm 3.2$
	0.001	$11 \pm 1.2$	$10 \pm 1.2$	$13 \pm 1.3$	$15 \pm 2.1$	$11 \pm 1.5$	$20 \pm 2.7$
	0.002	$15 \pm 2.0$	$14 \pm 2.3$	$10 \pm 2.0$	$16 \pm 0.9$	$13 \pm 1.9$	$20~\pm~3.9$
	0.007	$13 \pm 1.0$	$11 \pm 0.6$	$11 \pm 1.3$	$16 \pm 2.0$	$12 \pm 3.2$	$14 \pm 3.7$
	0.013	$10 \pm 1.8$	$14 \pm 0.9$	$13 \pm 1.7$	$16 \pm 1.3$	$13 \pm 3.0$	$16 \pm 1.9$
	0.027	$9~\pm~0.9$	$13 \pm 2.0$	$13 \pm 3.1$	$16 \pm 2.2$	$13~\pm~2.1$	$13~\pm~2.9$
rial summa	ry	Negative	Negative	Negative	Negative	Negative	Negative
ositive cont	rol	$359 \pm 14.5$	$340~\pm~8.8$	$63 \pm 4.8$	$129~\pm~5.7$	$164~\pm~9.6$	$121 \pm 11.6$
Г <b>А97</b>	Air	$153 \pm 7.3$	$153 \pm 3.3$	$134~\pm~5.5$	$185~\pm~13.0$	$155~\pm~5.2$	$212~\pm~5.0$
	0.001	$142~\pm~3.2$	$140 \pm 7.1$	$136~\pm~9.0$	$195 \pm 13.3$	$168~\pm~8.8$	$196 \pm 1.5$
	0.002	$139 \pm 2.7$	$139 \pm 6.8$	$157~\pm~16.1$	$194~\pm~11.6$	$170 \pm 7.6$	$205~\pm~6.1$
	0.007	$135~\pm~9.5$	$140 \pm 7.5$	$135 \pm 4.3$	$194 \pm 3.0$	$162 \pm 2.6$	$225 \pm 15.9$
	0.013	$134~\pm~4.3$	$155 \pm 7.6$	$137~\pm~8.0$	$175 \pm 5.5$	$147 \pm 8.0$	$209~\pm~16.8$
	0.027	$121~\pm~1.2$	$161~\pm~6.6$	$125~\pm~4.4$	$149~\pm~2.0$	$139~\pm~8.7$	$189 \pm 13.5$
Frial summar	ry	Negative	Negative	Negative	Negative	Negative	Negative
Positive cont	rol	$583 \pm 35.8$	$432~\pm~38.4$	$2,035 \pm 28.9$	$1,505 \pm 74.3$	$942~\pm~19.7$	$759 \pm 44.8$
ГА98	Air	$17 \pm 2.2$	$15 \pm 2.2$	$24~\pm~2.9$	$21 \pm 1.5$	$26~\pm~4.6$	$26~\pm~5.5$
	0.001	$19 \pm 1.5$	$13 \pm 2.3$	$19 \pm 1.0$	$23~\pm~2.9$	$17 \pm 0.6$	$25 \pm 1.2$
	0.002	$17 \pm 1.5$	$14 \pm 0.7$	$22 \pm 1.9$	$26 \pm 3.8$	$17 \pm 2.7$	$31 \pm 2.9$
	0.007	$15 \pm 0.7$	$14~\pm~0.9$	$26~\pm~3.8$	$20 \pm 1.2$	$20~\pm~2.0$	$29~\pm~4.6$
	0.013	$18 \pm 3.9$	$13 \pm 0.6$	$19 \pm 2.4$	$19 \pm 2.7$	$27 \pm 3.6$	$19 \pm 4.1$
	0.027	$11 \pm 1.5$	$10~\pm~1.0$	$18 \pm 2.6$	$14 \pm 1.5$	$23~\pm~0.3$	$15 \pm 1.5$
Trial summa	ry	Negative	Negative	Negative	Negative	Negative	Negative
Positive cont	rol	377 ± 14.1	$316 \pm 11.1$	$265 \pm 8.0$	$979 \pm 2.0$	$314 \pm 22.1$	$321 \pm 16.7$

#### TABLE E1 Mutagenicity of Isobutene in Salmonella typhimurium^a

Study was performed at Microbiological Associates, Inc. The detailed protocol is presented in Zeiger *et al.* (1992). Air was the control. Revertants are presented as mean  $\pm$  standard error from three plates. а

b

с The positive controls in the absence of metabolic activation were sodium azide (TA100 and TA1535), 9-aminoacridine (TA97), and 4-nitro-*o*-phenylenediamine (TA98). The positive control for metabolic activation with all strains was 2-aminoanthracene.

#### TABLE E2 Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice Following Treatment with Isobutene by Inhalation for 14 Weeks^a

Compound	Concentration (ppm)	Number of Mice with Erythrocytes Scored	Micronucleated NCEs/ 1,000 NCEs ^b	NCEs ^b (%)
Male				
Chamber Control		5	$1.10~\pm~0.37$	$97.20~\pm~0.38$
Isobutene	500 1,000 2,000 4,000 8,000	5 5 5 5 5	$\begin{array}{l} 1.40 \pm \ 0.33 \\ 1.70 \pm \ 0.12 \\ 1.70 \pm \ 0.20 \\ 1.60 \pm \ 0.33 \\ 2.00 \pm \ 0.47 \end{array}$ $P = 0.086^{C}$	$\begin{array}{r} 97.42 \pm 0.38 \\ 97.20 \pm 0.33 \\ 97.68 \pm 0.31 \\ 97.58 \pm 0.51 \\ 97.50 \pm 0.19 \end{array}$
Female				
Chamber Control		5	$0.80~\pm~0.20$	$97.38~\pm~0.15$
Isobutene	500 1,000 2,000 4,000 8,000	5 5 5 5 5	$\begin{array}{rrrr} 1.00 \pm \ 0.32 \\ 1.10 \pm \ 0.29 \\ 0.60 \pm \ 0.10 \\ 1.20 \pm \ 0.25 \\ 0.80 \pm \ 0.25 \end{array}$	$\begin{array}{r} 97.42 \pm 0.24 \\ 97.28 \pm 0.36 \\ 96.38 \pm 0.18 \\ 97.06 \pm 0.33 \\ 96.72 \pm 0.34 \end{array}$
			P=0.541	

а Analysis was performed at Environmental Health Research and Testing, Inc. The detailed protocol is presented in MacGregor *et al.* (1990). NCE= normochromatic erythrocyte

b

^b Mean ± standard error
 ^c Significance of micronucleated NCEs/1,000 NCEs tested by the one-tailed trend test, significant at P 0.025 (Margolin *et al.*, 1990)

# APPENDIX F HEMATOLOGY AND CLINICAL CHEMISTRY RESULTS

TABLE F1	Hematology and Clinical Chemistry Data for Rats in the 14-Week Inhalation Study	
	of Isobutene	194

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Male						
Hematology						
n	10	10	10	10	10	10
Automated hematocrit (%)						
Day 3	$41.6 \pm 0.3$	$41.8 \pm 0.4$	$41.5~\pm~0.5$	$41.5 \pm 0.7$	$42.0 \pm 0.5$	$42.1 \pm 0.5$
Day 23	$45.7 \pm 0.7$	$45.0~\pm~0.4$	$44.4~\pm~0.5$	$45.4~\pm~0.2$	$45.6~\pm~0.3$	$45.5~\pm~0.4$
Week 14	$45.8 \pm 0.4$	$45.4~\pm~0.3$	$44.9~\pm~0.3$	$45.4 \pm 0.4$	$45.8 \pm 0.4$	$45.1 \pm 0.4$
Manual hematocrit (%)						
Day 3	$42.5 \pm 0.3$	$42.6~\pm~0.4$	$42.8~\pm~0.4$	$42.2~\pm~0.6$	$43.3~{\pm}~0.4$	$43.4~\pm~0.4$
Day 23	$46.6 \pm 0.7$	$45.9 \pm 0.5$	$45.4 \pm 0.6$	$46.2 \pm 0.3$	$46.4 \pm 0.3$	$46.5 \pm 0.3$
Week 14	$46.3 \pm 0.4$	$46.8 \pm 0.9$	$45.5 \pm 0.3$	$45.9 \pm 0.4$	$46.6 \pm 0.3$	$46.0 \pm 0.3$
Hemoglobin (g/dL)	10.0 - 0.1	1010 - 010	10.0 - 0.0	10.0 - 0.1	10.0 ± 0.0	10.0 - 0.0
Day 3	$13.9 \pm 0.1$	$14.1 \pm 0.1$	$13.8 \pm 0.2$	$13.7 \pm 0.2$	$14.0~\pm~0.1$	$13.8 \pm 0.2$
Day 23	$16.0 \pm 0.1$ 16.0 ± 0.2	$15.7 \pm 0.2$	$15.6 \pm 0.2$	$15.8 \pm 0.1$	$15.7 \pm 0.1$	$15.8 \pm 0.1$
Week 14	$15.4 \pm 0.1$	$15.7 \pm 0.2$ $15.3 \pm 0.1$	$15.0 \pm 0.2$ $15.2 \pm 0.1$	$15.2 \pm 0.1$	$15.7 \pm 0.1$ $15.3 \pm 0.1$	$15.2 \pm 0.1$ $15.2 \pm 0.1$
Erythrocytes (10 ⁶ /µL)	10.1 - 0.1	10.0 - 0.1	10.2 - 0.1	10.2 - 0.1	10.0 ± 0.1	10.2 - 0.1
Day 3	$7.47 \pm 0.11$	$7.55 \pm 0.11$	$7.41 \pm 0.12$	$7.33 \pm 0.17$	$7.50 \pm 0.12$	$7.37 \pm 0.12$
Day 23	$8.64 \pm 0.11$	$8.55 \pm 0.12$	$8.34 \pm 0.11$	$8.50 \pm 0.09$	$8.51 \pm 0.06$	$8.56 \pm 0.09$
Week 14	$9.18 \pm 0.05$	$9.08 \pm 0.06$	$9.03 \pm 0.06$	$9.05 \pm 0.06$	$9.12 \pm 0.06$	$9.03 \pm 0.08$
Reticulocytes (10 ⁶ /µL)	$0.10 \pm 0.00$	5.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.12 ± 0.00	0.00 ± 0.00
Day 3	$0.24 \pm 0.05$	$0.17 \pm 0.03$	$0.18 \pm 0.03$	$0.12 \pm 0.02$	$0.16 \pm 0.05$	$0.27~\pm~0.03$
Day 23	$0.24 \pm 0.03$ $0.10 \pm 0.02^{b}$	$0.09 \pm 0.02^{\rm b}$	$0.10 \pm 0.03$ $0.07 \pm 0.02$	$0.12 \pm 0.02^{\rm b}$ $0.09 \pm 0.02^{\rm b}$	$0.10 \pm 0.03$ $0.13 \pm 0.03$	$0.12 \pm 0.03^{\rm b}$
Week 14	$0.10 \pm 0.02$ $0.07 \pm 0.01$	$0.05 \pm 0.02$ $0.05 \pm 0.01$	$0.07 \pm 0.02$ $0.06 \pm 0.01$	$0.03 \pm 0.02$ $0.07 \pm 0.01$	$0.15 \pm 0.05$ $0.06 \pm 0.01$	$0.12 \pm 0.02$ $0.06 \pm 0.01$
Nucleated erythrocytes (10 ³ /µI		$0.05 \pm 0.01$	$0.00 \pm 0.01$	$0.07 \pm 0.01$	$0.00 \pm 0.01$	$0.00 \pm 0.01$
Day 3	$0.11 \pm 0.03$	$0.07 \pm 0.02$	$0.08 \pm 0.03$	$0.09 \pm 0.03$	$0.11 \pm 0.04$	$0.14 \pm 0.05$
Day 23	$0.02 \pm 0.01$	$0.07 \pm 0.02$ $0.01 \pm 0.01$	$0.03 \pm 0.03$ $0.04 \pm 0.02$	$0.03 \pm 0.03$ $0.02 \pm 0.01$	$0.01 \pm 0.04$ $0.01 \pm 0.01$	$0.01 \pm 0.001$
Week 14	$0.02 \pm 0.01$ $0.03 \pm 0.01$	$0.01 \pm 0.01$ $0.03 \pm 0.02$	$0.04 \pm 0.02$ $0.04 \pm 0.02$	$0.02 \pm 0.01$ $0.02 \pm 0.01$	$0.01 \pm 0.01$ $0.03 \pm 0.02$	$0.01 \pm 0.01$ $0.02 \pm 0.02$
Mean cell volume (fL)	$0.05 \pm 0.01$	$0.05 \pm 0.02$	$0.04 \pm 0.02$	$0.02 \pm 0.01$	$0.05 \pm 0.02$	$0.02 \pm 0.02$
Day 3	$55.5 \pm 0.7$	$55.4 \pm 0.6$	$55.9 \pm 0.5$	$56.8 \pm 0.6$	$56.1 \pm 0.3$	$57.2 \pm 0.4$
Day 23	$53.3 \pm 0.7$ $52.8 \pm 0.4$	$53.4 \pm 0.0$ $52.6 \pm 0.4$	$53.9 \pm 0.3$ $53.2 \pm 0.4$	$53.3 \pm 0.0$	$50.1 \pm 0.3$ $53.5 \pm 0.4$	$57.2 \pm 0.4$ $53.1 \pm 0.5$
Week 14	$32.8 \pm 0.4$ $49.9 \pm 0.3$	$52.0 \pm 0.4$ $50.0 \pm 0.3$	$33.2 \pm 0.4$ $49.8 \pm 0.3$	$50.2 \pm 0.2$	$50.1 \pm 0.3$	$50.1 \pm 0.3$ 50.1 ± 0.4
	$49.9 \pm 0.3$	$50.0 \pm 0.3$	$49.8 \pm 0.3$	$30.2 \pm 0.2$	$30.1 \pm 0.3$	$50.1 \pm 0.4$
Mean cell hemoglobin (pg)	$18.6 \pm 0.1$	107.01	107.01	$18.7 \pm 0.2$	107.01	107.01
Day 3 Day 22		$18.7 \pm 0.1$	$18.7 \pm 0.1$	$18.7 \pm 0.2$ $18.6 \pm 0.2$	$\begin{array}{rrrr} 18.7 \pm \ 0.1 \\ 18.5 \pm \ 0.1 \end{array}$	$\begin{array}{rrrr} 18.7 \pm \ 0.1 \\ 18.5 \pm \ 0.1 \end{array}$
Day 23 Week 14	$\begin{array}{rrrr} 18.5 \pm \ 0.1 \\ 16.8 \pm \ 0.0 \end{array}$	$18.4 \pm 0.1$ $16.9 \pm 0.1$	$18.7 \pm 0.1$			
Week 14		$10.9 \pm 0.1$	$16.8~\pm~0.0$	$16.8 \pm 0.0$	$16.8 \pm 0.0$	$16.8 \pm 0.1$
Mean cell hemoglobin concent		226 + 01	$33.4 \pm 0.2$	220 . 0.2	$33.3 \pm 0.2$	297 0 1**
Day 3 Day 23	$33.4 \pm 0.2$ $35.1 \pm 0.2$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$33.4 \pm 0.2$ $35.1 \pm 0.1$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$33.3 \pm 0.2$ $34.5 \pm 0.2$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$
Day 23 Week 14	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$34.9 \pm 0.2$ $33.7 \pm 0.2$	$35.1 \pm 0.1$ $33.7 \pm 0.3$		$34.5 \pm 0.2$ $33.5 \pm 0.1$	$34.8 \pm 0.2$ $33.6 \pm 0.3$
	$33.1 \pm 0.2$	$33.7 \pm 0.2$	$33.7 \pm 0.3$	$33.5 \pm 0.1$	$33.3 \pm 0.1$	$33.0 \pm 0.3$
Platelets (10 ³ /µL)	099 4 . 95 1	979 0 . 90 0	97/ 0 40 1	Q15 7 , 14 4*	0266 . 220	951 0 14 0
Day 3	$922.4 \pm 25.1$	$878.9 \pm 26.9$	$874.8 \pm 43.1$	$815.7 \pm 14.4^*$	$836.6 \pm 33.9$	$851.0 \pm 14.6$
Day 23 Week 14	$680.2 \pm 19.2$	$672.0 \pm 13.6$	$669.8 \pm 14.2$	$646.3 \pm 24.1$	$681.5 \pm 17.9$	$642.8 \pm 30.8$
Week 14	$515.5 \pm 10.4$	$530.9 \pm 12.0$	$535.1 \pm 7.3$	$501.6 \pm 7.4$	$525.9 \pm 5.3$	$541.2 \pm 7.9$
Leukocytes (10 ³ /µL)	7 05 . 0 00	0 76 . 0 96	071 001	0 55 . 0 00	701 . 0.40	7 06 . 0.04
Day 3	$7.85 \pm 0.39$	$8.76 \pm 0.36$	$8.71 \pm 0.31$	$8.55 \pm 0.32$	$7.84 \pm 0.48$	$7.86 \pm 0.34$
Day 23	$5.56 \pm 0.55$	$6.12 \pm 0.18$	$5.85 \pm 0.35$	$6.08 \pm 0.45$	$5.87 \pm 0.45$	$6.61 \pm 0.35$
Week 14	$5.73 \pm 0.39$	$6.14~\pm~0.27$	$6.13 \pm 0.36$	$6.73 \pm 0.30$	$6.04 \pm 0.36$	$5.69 \pm 0.37$
Segmented neutrophils (10 ³ /µL		0.74 . 0.11	0.01 . 0.10	0.77 . 0.10	0.74 . 0.10	0.00 . 0.00
Day 3	$0.80 \pm 0.09$	$0.74 \pm 0.11$	$0.91 \pm 0.12$	$0.77 \pm 0.10$	$0.74 \pm 0.10$	$0.92 \pm 0.08$
Day 23	$0.82 \pm 0.14$	$0.90 \pm 0.09$	$0.78 \pm 0.07$	$0.83 \pm 0.07$	$0.73 \pm 0.07$	$0.84 \pm 0.10$
Week 14	$0.93 \pm 0.08$	$1.17 \pm 0.10$	$1.33 \pm 0.12$	$0.95 \pm 0.12$	$1.07~\pm~0.10$	$1.02~\pm~0.11$
Lymphocytes (10 ³ /µL)	0.04 0.04	<b>7</b> .00 0.07			0.07 0.11	0.04 0.5
Day 3	$6.81 \pm 0.34$	$7.88 \pm 0.35$	$7.74 \pm 0.26$	$7.72 \pm 0.24$	$6.87 \pm 0.44$	$6.81 \pm 0.31$
Day 23	$4.68 \pm 0.48$	$5.20 \pm 0.13$	$5.03 \pm 0.37$	$5.21 \pm 0.42$	$5.11 \pm 0.42$	$5.73 \pm 0.38$
Week 14	$4.70 \pm 0.35$	$4.86~\pm~0.24$	$4.70 \pm 0.30$	$5.71 \pm 0.25$	$4.93 \pm 0.34$	$4.59 \pm 0.32$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Male (continued)						
Hematology (continued)						
1	10	10	10	10	10	10
Monocytes (10 ³ /µL)						
Day 3	$0.20 \pm 0.05$	$0.12~\pm~0.04$	$0.06 \pm 0.03$	$0.02 \pm 0.01^{**}$	$0.15 \pm 0.04$	$0.12 \pm 0.03$
Day 23	$0.20 \pm 0.03$ $0.04 \pm 0.02$	$0.12 \pm 0.04$ $0.01 \pm 0.01$	$0.00 \pm 0.03$ $0.02 \pm 0.02$	$0.02 \pm 0.01$ $0.03 \pm 0.03$	$0.13 \pm 0.04$ $0.01 \pm 0.01$	$0.12 \pm 0.03$ $0.01 \pm 0.01$
Week 14	$0.04 \pm 0.02$ $0.06 \pm 0.02$	$0.01 \pm 0.01$ $0.05 \pm 0.02$	$0.02 \pm 0.02$ $0.06 \pm 0.02$	$0.03 \pm 0.03$ $0.04 \pm 0.02$	$0.01 \pm 0.01$ $0.03 \pm 0.01$	$0.01 \pm 0.01$ $0.05 \pm 0.02$
Eosinophils (10 ³ /µL)	$0.00 \pm 0.02$	0.00 ± 0.02	0.00 ± 0.02	0.04 ± 0.02	0.00 ± 0.01	0.00 ± 0.02
Day 3	$0.03 \pm 0.02$	$0.02~\pm~0.02$	$0.01 \pm 0.01$	$0.03 \pm 0.02$	$0.07~\pm~0.02$	$0.02~\pm~0.01$
Day 23	$0.03 \pm 0.01$	$0.01 \pm 0.01$	$0.01 \pm 0.01$ $0.02 \pm 0.01$	$0.00 \pm 0.02$ $0.00 \pm 0.00$	$0.02 \pm 0.01$	$0.02 \pm 0.01$ $0.03 \pm 0.01$
Week 14	$0.05 \pm 0.01$ $0.05 \pm 0.02$	$0.06 \pm 0.02$	$0.04 \pm 0.01$	$0.03 \pm 0.02$	$0.01 \pm 0.01$	$0.03 \pm 0.02$
	0.02					0.00
linical Chemistry						
l						
Day 3	10	10	10	10	9	10
Day 23	10	10	10	10	10	10
Week 14	10	10	10	10	10	10
Jrea nitrogen (mg/dL)						
Day 3	$12.7 \pm 0.7$	$14.2 \pm 0.6$	$12.3 \pm 0.4$	$11.1 \pm 0.5$	$11.9 \pm 0.6$	$11.5 \pm 0.5$
Day 23	$15.6 \pm 0.4$	$14.7 \pm 0.3$	$14.6 \pm 0.3$	$15.2 \pm 0.5$	$14.9 \pm 0.2$	$14.6 \pm 0.2$
Week 14	$20.6 \pm 0.7$	$19.7~\pm~0.6$	$18.8~\pm~0.7$	$20.4~\pm~0.7$	$19.6~\pm~0.8$	$19.2~\pm~0.6$
Creatinine (mg/dL)	0.01 0.05	0.00	0.50 0.00	0.47 0.00**	0.50 0.04*	0.51 0.00
Day 3	$0.61 \pm 0.05$	$0.62 \pm 0.02$	$0.56 \pm 0.03$	$0.47 \pm 0.02^{**}$	$0.53 \pm 0.04^{*}$	$0.51 \pm 0.02^{\circ}$
Day 23	$0.73 \pm 0.02$	$0.72 \pm 0.01$	$0.71 \pm 0.02$	$0.70 \pm 0.02$	$0.72 \pm 0.01$	$0.71 \pm 0.02$
Week 14	$0.86~\pm~0.02$	$0.88~\pm~0.02$	$0.89~\pm~0.01$	$0.86~\pm~0.02$	$0.86~\pm~0.02$	$0.84~\pm~0.02$
erum glucose (mg/dL) Day 3	$146 \pm 4$	$158 \pm 2$	$162 \pm 4$	$162 \pm 4^{*}$	$147 \pm 3$	$138 \pm 2$
Day 23	$140 \pm 4$ $157 \pm 4$	$158 \pm 2$ 156 ± 10	$102 \pm 4$ 157 ± 4	$102 \pm 4^{\circ}$ 150 ± 3	$147 \pm 3$ $153 \pm 2$	$130 \pm 2$ $155 \pm 5$
Week 14	$157 \pm 4$ $153 \pm 7$	$130 \pm 10$ 185 ± 12	$157 \pm 4$ 158 ± 5	$130 \pm 3$ $171 \pm 11$	$133 \pm 2$ 178 ± 13	$155 \pm 5$ $166 \pm 10$
otal protein (g/dL)	100 - 7	100 - 16	100 ± 0	1/1 - 11	110 - 10	100 ± 10
Day 3	$6.2 \pm 0.1$	$6.5 \pm 0.1$	$6.2 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.1 \pm 0.1$
Day 23	$6.8 \pm 0.1$	$6.6 \pm 0.1$	$6.7 \pm 0.1$	$6.8 \pm 0.1$	$6.7 \pm 0.1$	$6.6 \pm 0.1$
Week 14	$7.6 \pm 0.1$	$7.6 \pm 0.1$	$7.7 \pm 0.1$	$7.5 \pm 0.1$	$7.7 \pm 0.1$	$7.5 \pm 0.1$
lbumin (g/dL)						
Day 3	$5.0 \pm 0.1$	$5.3 \pm 0.1$	$5.1 \pm 0.1$	$4.8~{\pm}~0.1$	$4.9~\pm~0.1$	$5.0~\pm~0.1$
Day 23	$4.9~\pm~0.1$	$4.9~\pm~0.1$	$4.9 \pm 0.1$	$5.0~\pm~0.1$	$4.9~\pm~0.1$	$4.9~\pm~0.1$
Week 14	$4.8~\pm~0.1$	$4.9~\pm~0.1$	$4.9 \pm 0.1$	$4.8~\pm~0.1$	$4.8~\pm~0.1$	$4.8~\pm~0.1$
lobulin (g/dL)						
Day 3	$1.1 \pm 0.1$	$1.2~\pm~0.1$	$1.1 \pm 0.0$	$1.1 \pm 0.1$	$1.2~\pm~0.1$	$1.1~\pm~0.0$
Day 23	$1.9~\pm~0.1$	$1.7~\pm~0.1$	$1.8~\pm~0.1$	$1.8~\pm~0.1$	$1.8~\pm~0.1$	$1.7~\pm~0.1$
Week 14	$2.8~\pm~0.1$	$2.7~\pm~0.1$	$2.9~\pm~0.1$	$2.7~\pm~0.1$	$2.9~\pm~0.0$	$2.7~\pm~0.1$
/G ratio						
Day 3	$4.5~\pm~0.3$	$4.6~\pm~0.3$	$4.9~\pm~0.3$	$4.4~\pm~0.2$	$4.4~\pm~0.3$	$4.4~\pm~0.2$
Day 23	$2.7~\pm~0.2$	$2.9~\pm~0.2$	$2.9~\pm~0.2$	$2.8~\pm~0.1$	$2.8~\pm~0.2$	$3.0~\pm~0.2$
Week 14	$1.7 \pm 0.1$	$1.8 \pm 0.0$	$1.7 \pm 0.1$	$1.8 \pm 0.1$	$1.7 \pm 0.0$	$1.8~\pm~0.1$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Male (continued)						
Clinical Chemistry (continued)						
n						
Day 3	10	10	10	10	9	10
Day 23	10	10	10	10	10	10
Week 14	10	10	10	10	10	10
Alanine aminotransferase (IU/L)	)					
Day 3	$35 \pm 1$	$31 \pm 1$	$33 \pm 1$	$38 \pm 1$	$36 \pm 1^{c}$	$37 \pm 1$
Day 23	$34 \pm 1$	$34 \pm 1$	$33 \pm 1$	$37 \pm 3$	$32 \pm 1$	$33 \pm 1$
Week 14	$68 \pm 5$	$58 \pm 3$	$54 \pm 2$	$62 \pm 5$	$61 \pm 3$	$56 \pm 3$
Alkaline phosphatase (IU/L)						
Day 3	$674~\pm~59$	$764~\pm~34$	$755 \pm 35$	$791~\pm~29$	$748~\pm~32$	$726~\pm~40$
Day 23	$454 \pm 16$	$445 \pm 15$	$460 \pm 10$	$465 \pm 13$	$439 \pm 14$	$443 \pm 18$
Week 14	$371 \pm 18$	$377 \pm 9$	$363 \pm 8$	$361 \pm 11$	$330 \pm 13$	$364 \pm 11$
Creatine kinase (IU/L)	0.05 4.0	001 17	005 10	000 11	070 000	004 00
Day 3	$265 \pm 46$	$201 \pm 15$	$235 \pm 16$	$232 \pm 11$	$273 \pm 36^{\circ}$	$264 \pm 23$
Day 23 Wook 14	$\begin{array}{rrrr}199~\pm&22\\110~\pm&18\end{array}$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$196 \pm 24$ $103 \pm 11$	$242 \pm 31 \\ 103 \pm 12$	$\begin{array}{rrrr} 215 \pm & 19 \\ 96 \pm & 9 \end{array}$	$241 \pm 26 \\ 105 \pm 9$
Week 14 Sorbitol dehydrogenase (IU/L)	$110 \pm 18$	$111 \pm 18$	$103 \pm 11$	$103 \pm 12$	$90 \pm 9$	$105 \pm 9$
Day 3	$13 \pm 1$	$12 \pm 1$	$13 \pm 0$	$13 \pm 1$	$14 \pm 1$	$14 \pm 1$
Day 23	$13 \pm 1$ $12 \pm 0$	$12 \pm 1$ $12 \pm 1$	$13 \pm 0$ $12 \pm 1$	$13 \pm 1$ 14 ± 1	$14 \pm 1$ $12 \pm 0$	$14 \pm 1$ $11 \pm 0$
Week 14	$12 \pm 0$ $18 \pm 1$	$12 \pm 1$ 16 ± 1	$12 \pm 1$ $14 \pm 0^*$	$14 \pm 1$ 16 ± 1	$12 \pm 0$ $17 \pm 1$	$11 \pm 0$ $16 \pm 1$
Bile acids (µmol/L)	10 ± 1	10 ± 1	11 ± 0	10 - 1	17 ± 1	10 ± 1
Day 3	$25.8 \pm 2.0$	$22.6 \pm 2.5$	$23.2 \pm 1.8$	$22.3 \pm 1.0$	$22.6 \pm 1.0^{\circ}$	$22.6 \pm 0.9$
Day 23	$17.1 \pm 0.7$	$19.5 \pm 1.8$	$16.7 \pm 0.8$	$19.5 \pm 1.1$	$17.1 \pm 0.5$	$17.4 \pm 0.8$
Week 14	$23.4 \pm 2.1$	$27.7~\pm~3.2$	$21.3 \pm 1.5$	$27.1 \pm 4.8$	$30.2 \pm 3.9$	$25.0 \pm 1.6$
Female						
1	10	10	10	10	10	10
1	10	10	10	10	10	10
Hematology						
Automated hematocrit (%)						
Day 3	$45.1 \pm \ 0.6$	$44.9~\pm~0.7$	$43.9~\pm~0.7$	$46.2~\pm~0.4$	$46.3 \pm \ 0.8$	$45.7~\pm~0.6$
Day 23	$47.8 \pm \ 0.5$	$47.5~\pm~0.4$	$47.5~\pm~0.5$	$47.2~\pm~0.4$	$47.3~\pm~0.2$	$48.0 \pm \ 0.4$
Week 14	$44.9 \pm 0.5$	$45.4~\pm~0.3$	$45.6~\pm~0.3$	$45.3 \pm 0.4$	$45.2~\pm~0.1$	$45.6~\pm~0.4$
Manual hematocrit (%)	15 0 0 1		10.0	150 53		
Day 3	$45.2 \pm 0.4$	$44.8 \pm 0.5$	$43.6 \pm 0.6$	$45.8 \pm 0.2$	$45.4 \pm 0.6$	$45.2 \pm 0.4$
Day 23	$47.1 \pm 0.4$	$47.3 \pm 0.4$	$47.0 \pm 0.4$	$47.0 \pm 0.4$	$46.9 \pm 0.2$	$47.4 \pm 0.4$
Week 14 Jamoglahin (g/dL)	$45.3 \pm \ 0.4$	$45.7~\pm~0.3$	$46.2~\pm~0.3$	$45.4~\pm~0.4$	$45.6 \pm 0.2$	$45.8 \pm 0.3$
Hemoglobin (g/dL)	15 4 + 0.9	$15.1 \pm 0.2$	150 - 02	15 2 . 0 2	15 4 - 0.2	15.2 . 0.1
Day 3 Day 23	$\begin{array}{rrrr} 15.4 \pm \ 0.2 \\ 16.2 \pm \ 0.0 \end{array}$	$15.1 \pm 0.2$ $16.2 \pm 0.1$	$15.0 \pm 0.3$ $16.1 \pm 0.1$	$\begin{array}{rrrr} 15.2 \ \pm \ 0.2 \\ 16.0 \ \pm \ 0.1 \end{array}$	$\begin{array}{rrrr} 15.4 \pm \ 0.3 \\ 16.1 \pm \ 0.1 \end{array}$	$\begin{array}{rrr} 15.3 \pm \ 0.1 \\ 16.0 \pm \ 0.1 \end{array}$
Week 14	$16.2 \pm 0.0$ $15.3 \pm 0.2$	$16.2 \pm 0.1$ $15.5 \pm 0.1$	$16.1 \pm 0.1$ $15.5 \pm 0.1$	$16.0 \pm 0.1$ $15.4 \pm 0.1$	$16.1 \pm 0.1$ $15.4 \pm 0.1$	$16.0 \pm 0.1$ $15.5 \pm 0.1$
Erythrocytes (10 ⁶ /µL)	10.0 ± 0.4	10.0 - 0.1	10.0 ± 0.1	10.7 - 0.1	10.7 ± 0.1	$15.5 \pm 0.1$
Day 3	$8.15 \pm 0.11$	$7.96~\pm~0.12$	$7.94~\pm~0.15$	$8.09 \pm 0.08$	$8.23 \pm 0.17$	$8.12 \pm 0.11$
Day 23	$8.57 \pm 0.04$	$8.54 \pm 0.10$	$8.53 \pm 0.08$	$8.46 \pm 0.07$	$8.56 \pm 0.05$	$8.46 \pm 0.04$
Week 14	$8.41 \pm 0.09$	$8.50 \pm 0.05$	$8.58 \pm 0.05$	$8.49 \pm 0.06$	$8.47 \pm 0.03$	$8.50 \pm 0.05$
Reticulocytes (10 ⁶ /µL)						
Day 3	$0.16~\pm~0.03$	$0.22~\pm~0.03$	$0.20~\pm~0.02$	$0.20~\pm~0.03$	$0.18 \pm 0.02$	$0.15~\pm~0.03$
Day 23	$0.07~\pm~0.01$	$0.07~\pm~0.01$	$0.06~\pm~0.02$	$0.06~\pm~0.01$	$0.08~\pm~0.01$	$0.05~\pm~0.01$
Week 14	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Female (continued)						
1	10	10	10	10	10	10
Hematology (continued)						
Nucleated erythrocytes (10 ³ /µ)	L)					
Day 3	$0.05 \pm 0.02$	$0.05~\pm~0.02$	$0.06~\pm~0.02$	$0.06 \pm 0.03$	$0.04~\pm~0.02$	$0.07~\pm~0.04$
Day 23	$0.03 \pm 0.01$	$0.02 \pm 0.02$	$0.01 \pm 0.01$	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.00 \pm 0.00$
Week 14	$0.03 \pm 0.01$	$0.01 \pm 0.01$	$0.02 \pm 0.01$	$0.04 \pm 0.01$	$0.01 \pm 0.01$	$0.01 \pm 0.01$
Mean cell volume (fL)						
Day 3	$55.3 \pm 0.4$	$56.5 \pm 0.4$	$55.3 \pm 0.7$	$57.1 \pm 0.3^{*}$	$56.4 \pm 0.3$	$56.3 \pm 0.6$
Day 23	$56.0 \pm 0.4$	$55.6 \pm 0.5$	$55.7 \pm 0.4$	$55.9 \pm 0.4$	$55.3 \pm 0.3$	$56.4 \pm 0.3$
Week 14	$53.4 \pm 0.3$	$53.6 \pm 0.2$	$53.2 \pm 0.3$	$53.2 \pm 0.2$	$53.3 \pm 0.2$	$53.6 \pm 0.2$
Mean cell hemoglobin (pg)						
Day 3	$18.9 \pm 0.1$	$19.0 \pm 0.1$	$18.8 \pm 0.1$	$18.8 \pm 0.1$	$18.7 \pm 0.1$	$18.8 \pm 0.1$
Day 23	$18.9 \pm 0.1$ $18.9 \pm 0.1$	$19.0 \pm 0.1$ 19.0 ± 0.1	$18.9 \pm 0.1$	$18.9 \pm 0.1$	$18.8 \pm 0.1$	$10.0 \pm 0.1$ $19.0 \pm 0.1$
Week 14	$18.3 \pm 0.1$ $18.2 \pm 0.1$	$13.0 \pm 0.1$ $18.2 \pm 0.1$	$18.5 \pm 0.1$ $18.1 \pm 0.1$	$18.3 \pm 0.1$ $18.1 \pm 0.0$	$18.2 \pm 0.1$ 18.2 ± 0.1	$13.0 \pm 0.1$ $18.3 \pm 0.1$
Mean cell hemoglobin concent		10.2 - 0.1	10.1 ± 0.1	10.1 ± 0.0	10.2 - 0.1	10.5 ± 0.1
	$34.1 \pm 0.2$	$33.7 \pm 0.3$	$34.1 \pm 0.4$	$32.9 \pm 0.2^{*}$	$33.3 \pm 0.1$	$33.5 \pm 0.3$
Day 3 Day 23		$33.7 \pm 0.3$ $34.1 \pm 0.2$	$34.1 \pm 0.4$ $33.9 \pm 0.3$	$32.9 \pm 0.2^{*}$ $33.8 \pm 0.2$	$33.3 \pm 0.1$ $34.0 \pm 0.1$	$33.5 \pm 0.3$ $33.5 \pm 0.2$
Day 23	$34.0 \pm 0.3$					
Week 14 $(10^3 (1))$	$34.1 \pm 0.2$	$34.1 \pm 0.1$	$34.1~\pm~0.1$	$34.1~\pm~0.2$	$34.2 \pm 0.1$	$34.0 \pm 0.2$
Platelets (10 ³ /µL)	707 5 40.0	001 0 00 7	001.0 40.1	071 7 00 4	040 0 54 0	701 4 00 1
Day 3	$797.5 \pm 48.0$	$861.6 \pm 63.7$	$831.0 \pm 40.1$	$871.7 \pm 39.4$	$840.8 \pm 54.6$	$791.4 \pm 32.1$
Day 23	$705.0 \pm 21.4$	$675.0 \pm 30.5$	$754.5 \pm 35.2$	$721.4 \pm 20.5$	$707.4 \pm 11.4$	$745.5 \pm 19.9$
Week 14	$599.4 \pm 16.2$	$615.8~\pm~26.6$	$570.2~\pm~24.2$	$530.5 \pm 13.4^*$	$575.8 \pm 15.1$	$603.8 \pm 19.2$
Leukocytes (10 ³ /µL)						
Day 3	$8.24~\pm~0.39$	$8.61~\pm~0.25$	$8.45 \pm 0.38$	$8.90 \pm 0.28$	$9.94 \pm 0.54^*$	$9.34 \pm 0.43^*$
Day 23	$5.44~\pm~0.36$	$6.26~\pm~0.57$	$5.68 \pm 0.34$	$5.76 \pm 0.31$	$5.97 \pm 0.60$	$5.74~\pm~0.43$
Week 14	$6.71 \pm 0.14$	$6.95 \pm 0.27$	$6.92~\pm~0.45$	$6.95 \pm 0.20$	$7.26~\pm~0.39$	$6.43 \pm 0.40$
Segmented neutrophils (10 ³ /µl						
Day 3	$0.78 \pm 0.10$	$0.77 \pm 0.10$	$0.79 \pm 0.10$	$0.78 \pm 0.08$	$1.16 \pm 0.13$	$0.97~\pm~0.19$
Day 23	$0.72~\pm~0.08$	$0.76~\pm~0.12$	$0.76 \pm 0.08$	$0.76 \pm 0.09$	$0.99~\pm~0.12$	$0.81~\pm~0.09$
Week 14	$1.03 \pm 0.10$	$0.86~\pm~0.08$	$1.22~\pm~0.15$	$0.95~\pm~0.08$	$1.40~\pm~0.12$	$1.05~\pm~0.14$
Lymphocytes (10 ³ /µL)						
Day 3	$7.33 \pm 0.39$	$7.70~\pm~0.20$	$7.54 \pm 0.37$	$7.99~\pm~0.28$	$8.71 \pm 0.46$	$8.28~\pm~0.36$
Day 23	$4.65 \pm 0.33$	$5.42~\pm~0.49$	$4.81 \pm 0.31$	$4.95~\pm~0.33$	$4.90 \pm 0.52$	$4.87~\pm~0.49$
Week 14	$5.59 \pm 0.17$	$6.02~\pm~0.27$	$5.62~\pm~0.32$	$5.90 \pm 0.20$	$5.76 \pm 0.35$	$5.29~\pm~0.31$
Monocytes (10 ³ /µL)						
Day 3	$0.09 \pm 0.04$	$0.11 \pm 0.04$	$0.09 \pm 0.03$	$0.07 \pm 0.04$	$0.03 \pm 0.02$	$0.04 \pm 0.03$
Day 23	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.01 \pm 0.01$	$0.00 \pm 0.00$	$0.01 \pm 0.01$
Week 14	$0.02 \pm 0.01$ $0.04 \pm 0.02$	$0.02 \pm 0.01$ $0.03 \pm 0.02$	$0.02 \pm 0.01$ $0.04 \pm 0.02$	$0.01 \pm 0.01$ $0.05 \pm 0.02$	$0.05 \pm 0.02$	$0.01 \pm 0.01$ $0.03 \pm 0.01$
Eosinophils (10 ³ /µL)	0.01 - 0.06	0.00 - 0.02	0.01 - 0.0%	0.00 - 0.02	0.00 - 0.02	$0.00 \pm 0.01$
Day 3	$0.04~\pm~0.02$	$0.03~\pm~0.01$	$0.04 \pm 0.02$	$0.05~\pm~0.02$	$0.05 \pm 0.02$	$0.05~\pm~0.02$
Day 23	$0.04 \pm 0.02$ $0.05 \pm 0.02$	$0.05 \pm 0.01$ $0.06 \pm 0.02$	$0.04 \pm 0.02$ $0.07 \pm 0.02$	$0.03 \pm 0.02$ $0.03 \pm 0.01$	$0.03 \pm 0.02$ $0.07 \pm 0.02$	$0.03 \pm 0.02$ $0.03 \pm 0.01$
Week 14	$0.05 \pm 0.02$ $0.05 \pm 0.02$	$0.00 \pm 0.02$ $0.04 \pm 0.01$	$0.07 \pm 0.02$ $0.04 \pm 0.02$	$0.03 \pm 0.01$ $0.06 \pm 0.02$	$0.07 \pm 0.02$ $0.05 \pm 0.02$	$0.03 \pm 0.01$ $0.08 \pm 0.02$
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.00 ± 0.02	0.01 - 0.01	0.01 - 0.02	0.00 - 0.02	0.00 - 0.02	0.00 ± 0.02
Clinical Chemistry						
Iron nitrogon (mg/dI)						
Urea nitrogen (mg/dL)	10 9 . 1 1	19 4 . 0 5***	116.07**	1/1 / 0.9**	19 5 , 0 5**	120 0 . 0
Day 3	$18.3 \pm 1.1$	$13.4 \pm 0.5^{**}$	$14.6 \pm 0.7^{**}$	$14.1 \pm 0.3^{**}$	$13.5 \pm 0.5^{**}$	$12.9 \pm 0.5^{**}$
Day 23	$14.3 \pm 0.4$	$14.6 \pm 0.6$	$14.0 \pm 0.5$	$13.5 \pm 0.6$	$13.7 \pm 0.4$	$13.1 \pm 0.3$
Week 14	$19.4 \pm 1.0$	$20.0~\pm~0.7$	$20.0~\pm~0.8$	$19.2~\pm~1.1$	$19.7~\pm~0.5$	$19.0~\pm~0.8$
Creatinine (mg/dL)						
Day 3	$0.63~\pm~0.02$	$0.63 \pm 0.02$	$0.59 \pm 0.02$	$0.55 \pm 0.02^{**}$	$0.59 \pm 0.02^*$	$0.58 \pm 0.03^{*}$
Day 23	$0.76~\pm~0.02$	$0.84~\pm~0.02$	$0.77~\pm~0.03$	$0.76~\pm~0.02$	$0.77~\pm~0.02$	$0.75~\pm~0.02$
Week 14	$0.83 \pm 0.03$	$0.81 \pm 0.03$	$0.85 \pm 0.02$	$0.84~\pm~0.02$	$0.83~\pm~0.03$	$0.80~\pm~0.02$

Hematology and Clinical Chemistry Data for Rats in the 14-Week Inhalation Study of Isobutene

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Female (continued)						
n	10	10	10	10	10	10
Clinical Chemistry (continued)						
Serum glucose (mg/dL)						
Day 3	$124 \pm 4$	$136 \pm 6$	$141 \pm 9$	$128 \pm 3$	$127 \pm 4$	$122 \pm 4$
Day 23	$155 \pm 4$	$171 \pm 13$	$166 \pm 8$	$148 \pm 6$	$158 \pm 3$	$164 \pm 5$
Week 14	$164 \pm 5$	$169 \pm 11$	$176 \pm 10$	$170 \pm 7$	$167 \pm 4$	$169 \pm 5$
Total protein (g/dL)						
Day 3	$6.1 \pm 0.1$	$6.1 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.1 \pm 0.1$
Day 23	$6.5 \pm 0.1$	$6.6 \pm 0.1$	$6.5 \pm 0.1$	$6.4 \pm 0.1$	$6.5 \pm 0.1$	$6.6 \pm 0.1$
Week 14	$7.3 \pm 0.1$	$7.5 \pm 0.1$	$7.6 \pm 0.1$	$7.3 \pm 0.1$	$7.3 \pm 0.1$	$7.3 \pm 0.1$
Albumin (g/dL)						
Day 3	$5.4 \pm 0.1$	$5.7 \pm 0.1$	$5.5 \pm 0.1$	$5.5 \pm 0.0$	$5.4 \pm 0.1$	$5.3 \pm 0.1$
Day 23	$4.7 \pm 0.1$	$4.8 \pm 0.1$	$4.8 \pm 0.1$	$4.7 \pm 0.0$	$4.8 \pm 0.1$	$4.7 \pm 0.1$
Week 14	$5.1 \pm 0.1$	$5.2 \pm 0.1$	$5.1 \pm 0.1$	$5.1 \pm 0.1$	$5.0 \pm 0.1$	$5.0 \pm 0.1$
Globulin (g/dL)			011 = 011		010 = 011	010 = 011
Day 3	$0.7 \pm 0.1$	$0.5 \pm 0.1$	$0.5 \pm 0.1$	$0.5 \pm 0.0^{*}$	$0.6~\pm~0.1$	$0.8 \pm 0.1$
Day 23	$1.8 \pm 0.1$	$1.8 \pm 0.1$	$1.8 \pm 0.1$	$1.7 \pm 0.1$	$1.7 \pm 0.0$	$1.8 \pm 0.1$
Week 14	$2.2 \pm 0.1$	$2.3 \pm 0.1$	$2.5 \pm 0.1$	$2.3 \pm 0.1$	$2.4 \pm 0.1$	$2.3 \pm 0.1$
A/G ratio						
Day 3	$8.1 \pm 0.8$	$14.5 \pm 2.7^{b}$	$12.8 \pm 2.0$	$13.1 \pm 1.1$	$9.9 \pm 1.3$	$7.5 \pm 1.0$
Day 23	$2.7 \pm 0.1$	$2.6 \pm 0.1$	$2.7 \pm 0.1$	$2.9 \pm 0.1$	$2.8 \pm 0.1$	$2.6 \pm 0.1$
Week 14	$2.4 \pm 0.1$	$2.3 \pm 0.1$	$2.1 \pm 0.1$	$2.3 \pm 0.1$	$2.1 \pm 0.1$	$2.3 \pm 0.1$
Alanine aminotransferase (IU/I						
Day 3	$34 \pm 1$	$34 \pm 1$	$35 \pm 2$	$34 \pm 1$	$33 \pm 1$	$33 \pm 1$
Day 23	$30 \pm 1$	$34 \pm 3$	$30 \pm 1$	$29 \pm 1$	$29 \pm 1$	$30 \pm 1$ $30 \pm 1$
Week 14	$47 \pm 2$	$65 \pm 6^*$	$55 \pm 3$		$54 \pm 5$	$60 \pm 4$
Alkaline phosphatase (IU/L)						
Day 3	$583 \pm 22$	$577 \pm 21$	$569 \pm 32$	$539 \pm 20$	$486~\pm~18^*$	$554 \pm 26$
Day 23	$347 \pm 10$	$391 \pm 10^*$	$366 \pm 12$	$366 \pm 9$	$330 \pm 10$	$347 \pm 8$
Week 14	$307 \pm 15$	$328 \pm 11$	$369 \pm 14^*$	$317 \pm 15$	$321 \pm 12$	$306 \pm 13$
Creatine kinase (IU/L)		-			-	
Day 3	$204 \pm 16$	$222 \pm 12$	$210 \pm 24$	$198 \pm 18$	$205 \pm 26$	$277 \pm 36$
Day 23	$197 \pm 35$	$196 \pm 24$	$162 \pm 20$	$202 \pm 27$	$183 \pm 28$	$221 \pm 59$
Week 14	$100 \pm 9$	$122 \pm 20$	$102 \pm 12$ 112 ± 12	$139 \pm 17$	$130 \pm 100$ $134 \pm 14$	$146 \pm 13$
Sorbitol dehydrogenase (IU/L)		-			-	
Day 3	$16 \pm 0$	$16 \pm 1$	$14 \pm 1^{*}$	$14 \pm 0^{**}$	$15 \pm 1^{*}$	$14 \pm 1^{*}$
Day 23	$10 \pm 0$ $15 \pm 1$	$10 \pm 1$ $19 \pm 2$	$14 \pm 1$	$16 \pm 1$	10 = 1 $15 \pm 1$	$16 \pm 0$
Week 14	10 = 1 $14 \pm 1$	10 = 2 $17 \pm 1$	$17 \pm 1$	10 = 1 $17 \pm 1$	$15 \pm 1$ 15 ± 2	$10 \pm 0$ $17 \pm 1$
Bile acids (µmol/L)						
Day 3	$17.9 \pm 1.9$	$13.6~\pm~1.3$	$20.0 \pm 3.7$	$17.8 \pm 1.3$	$16.1 \pm 1.2$	$16.1 \pm 1.2$
Day 23	$14.6 \pm 0.7$	$21.7 \pm 5.7$	$18.0 \pm 2.0$	$14.7 \pm 1.1$	$14.2 \pm 0.6$	$16.6 \pm 1.4$
Week 14	$24.8 \pm 3.5$	$24.5 \pm 3.4$	$30.5 \pm 6.1$	$40.1 \pm 5.6$	$32.6 \pm 5.4$	$30.4 \pm 4.2$

* Significantly different (P<0.05) from the chamber control group by Dunn's or Shirley's test ** P<0.01 a Mean  $\pm$  standard error. Statistical tests were performed on unrounded data.

c = n = 8

b n=9

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Male						
Hematology						
n	10	10	10	10	10	10
Automated hematocrit (%)						
Day 3	$41.6 \pm 0.3$	$41.8 \pm 0.4$	$41.5~\pm~0.5$	$41.5 \pm 0.7$	$42.0 \pm 0.5$	$42.1 \pm 0.5$
Day 23	$45.7 \pm 0.7$	$45.0~\pm~0.4$	$44.4~\pm~0.5$	$45.4~\pm~0.2$	$45.6~\pm~0.3$	$45.5~\pm~0.4$
Week 14	$45.8 \pm 0.4$	$45.4~\pm~0.3$	$44.9~{\pm}~0.3$	$45.4 \pm 0.4$	$45.8 \pm 0.4$	$45.1 \pm 0.4$
Manual hematocrit (%)						
Day 3	$42.5 \pm 0.3$	$42.6~\pm~0.4$	$42.8~\pm~0.4$	$42.2~\pm~0.6$	$43.3~{\pm}~0.4$	$43.4~\pm~0.4$
Day 23	$46.6 \pm 0.7$	$45.9 \pm 0.5$	$45.4 \pm 0.6$	$46.2 \pm 0.3$	$46.4 \pm 0.3$	$46.5 \pm 0.3$
Week 14	$46.3 \pm 0.4$	$46.8 \pm 0.9$	$45.5 \pm 0.3$	$45.9 \pm 0.4$	$46.6 \pm 0.3$	$46.0 \pm 0.3$
Hemoglobin (g/dL)	10.0 - 0.1	1010 - 010	10.0 - 0.0	10.0 - 0.1	10.0 ± 0.0	10.0 - 0.0
Day 3	$13.9 \pm 0.1$	$14.1 \pm 0.1$	$13.8 \pm 0.2$	$13.7 \pm 0.2$	$14.0~\pm~0.1$	$13.8 \pm 0.2$
Day 23	$16.0 \pm 0.1$ 16.0 ± 0.2	$15.7 \pm 0.2$	$15.6 \pm 0.2$	$15.8 \pm 0.1$	$15.7 \pm 0.1$	$15.8 \pm 0.1$
Week 14	$15.4 \pm 0.1$	$15.7 \pm 0.2$ $15.3 \pm 0.1$	$15.0 \pm 0.2$ $15.2 \pm 0.1$	$15.2 \pm 0.1$	$15.7 \pm 0.1$ $15.3 \pm 0.1$	$15.2 \pm 0.1$ $15.2 \pm 0.1$
Erythrocytes (10 ⁶ /µL)	10.1 - 0.1	10.0 - 0.1	10.2 - 0.1	10.2 - 0.1	10.0 ± 0.1	10.2 - 0.1
Day 3	$7.47 \pm 0.11$	$7.55 \pm 0.11$	$7.41 \pm 0.12$	$7.33 \pm 0.17$	$7.50 \pm 0.12$	$7.37 \pm 0.12$
Day 23	$8.64 \pm 0.11$	$8.55 \pm 0.12$	$8.34 \pm 0.11$	$8.50 \pm 0.09$	$8.51 \pm 0.06$	$8.56 \pm 0.09$
Week 14	$9.18 \pm 0.05$	$9.08 \pm 0.06$	$9.03 \pm 0.06$	$9.05 \pm 0.06$	$9.12 \pm 0.06$	$9.03 \pm 0.08$
Reticulocytes (10 ⁶ /µL)	$0.10 \pm 0.00$	5.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.12 ± 0.00	0.00 ± 0.00
Day 3	$0.24 \pm 0.05$	$0.17 \pm 0.03$	$0.18 \pm 0.03$	$0.12 \pm 0.02$	$0.16 \pm 0.05$	$0.27~\pm~0.03$
Day 23	$0.24 \pm 0.03$ $0.10 \pm 0.02^{b}$	$0.09 \pm 0.02^{\rm b}$	$0.10 \pm 0.03$ $0.07 \pm 0.02$	$0.12 \pm 0.02^{\rm b}$ $0.09 \pm 0.02^{\rm b}$	$0.10 \pm 0.03$ $0.13 \pm 0.03$	$0.12 \pm 0.03^{b}$
Week 14	$0.10 \pm 0.02$ $0.07 \pm 0.01$	$0.05 \pm 0.02$ $0.05 \pm 0.01$	$0.07 \pm 0.02$ $0.06 \pm 0.01$	$0.03 \pm 0.02$ $0.07 \pm 0.01$	$0.15 \pm 0.05$ $0.06 \pm 0.01$	$0.12 \pm 0.02$ $0.06 \pm 0.01$
Nucleated erythrocytes (10 ³ /µI		$0.05 \pm 0.01$	$0.00 \pm 0.01$	$0.07 \pm 0.01$	$0.00 \pm 0.01$	$0.00 \pm 0.01$
Day 3	$0.11 \pm 0.03$	$0.07 \pm 0.02$	$0.08 \pm 0.03$	$0.09 \pm 0.03$	$0.11 \pm 0.04$	$0.14 \pm 0.05$
Day 23	$0.02 \pm 0.01$	$0.07 \pm 0.02$ $0.01 \pm 0.01$	$0.03 \pm 0.03$ $0.04 \pm 0.02$	$0.03 \pm 0.03$ $0.02 \pm 0.01$	$0.01 \pm 0.04$ $0.01 \pm 0.01$	$0.01 \pm 0.001$
Week 14	$0.02 \pm 0.01$ $0.03 \pm 0.01$	$0.01 \pm 0.01$ $0.03 \pm 0.02$	$0.04 \pm 0.02$ $0.04 \pm 0.02$	$0.02 \pm 0.01$ $0.02 \pm 0.01$	$0.01 \pm 0.01$ $0.03 \pm 0.02$	$0.01 \pm 0.01$ $0.02 \pm 0.02$
Mean cell volume (fL)	$0.05 \pm 0.01$	$0.05 \pm 0.02$	$0.04 \pm 0.02$	$0.02 \pm 0.01$	$0.05 \pm 0.02$	$0.02 \pm 0.02$
Day 3	$55.5 \pm 0.7$	$55.4 \pm 0.6$	$55.9 \pm 0.5$	$56.8 \pm 0.6$	$56.1 \pm 0.3$	$57.2 \pm 0.4$
Day 23	$53.3 \pm 0.7$ $52.8 \pm 0.4$	$53.4 \pm 0.0$ $52.6 \pm 0.4$	$53.9 \pm 0.3$ $53.2 \pm 0.4$	$53.3 \pm 0.0$	$50.1 \pm 0.3$ $53.5 \pm 0.4$	$57.2 \pm 0.4$ $53.1 \pm 0.5$
Week 14	$32.8 \pm 0.4$ $49.9 \pm 0.3$	$52.0 \pm 0.4$ $50.0 \pm 0.3$	$33.2 \pm 0.4$ $49.8 \pm 0.3$	$50.2 \pm 0.2$	$50.1 \pm 0.3$	$50.1 \pm 0.3$ 50.1 ± 0.4
	$49.9 \pm 0.3$	$50.0 \pm 0.3$	$49.8 \pm 0.3$	$30.2 \pm 0.2$	$30.1 \pm 0.3$	$50.1 \pm 0.4$
Mean cell hemoglobin (pg)	$18.6 \pm 0.1$	107.01	107.01	$18.7 \pm 0.2$	107.01	107.01
Day 3 Day 22		$18.7 \pm 0.1$	$18.7 \pm 0.1$	$18.7 \pm 0.2$ $18.6 \pm 0.2$	$\begin{array}{rrrr} 18.7 \pm \ 0.1 \\ 18.5 \pm \ 0.1 \end{array}$	$\begin{array}{rrrr} 18.7 \pm \ 0.1 \\ 18.5 \pm \ 0.1 \end{array}$
Day 23 Week 14	$\begin{array}{rrrr} 18.5 \pm \ 0.1 \\ 16.8 \pm \ 0.0 \end{array}$	$18.4 \pm 0.1$ $16.9 \pm 0.1$	$18.7 \pm 0.1$			
Week 14		$10.9 \pm 0.1$	$16.8~\pm~0.0$	$16.8 \pm 0.0$	$16.8 \pm 0.0$	$16.8 \pm 0.1$
Mean cell hemoglobin concent		226 + 01	$33.4 \pm 0.2$	220 . 0.2	$33.3 \pm 0.2$	297 . 0.1**
Day 3 Day 23	$33.4 \pm 0.2$ $35.1 \pm 0.2$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$33.4 \pm 0.2$ $35.1 \pm 0.1$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$33.3 \pm 0.2$ $34.5 \pm 0.2$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$
Day 23 Week 14	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$34.9 \pm 0.2$ $33.7 \pm 0.2$	$35.1 \pm 0.1$ $33.7 \pm 0.3$		$34.5 \pm 0.2$ $33.5 \pm 0.1$	$34.8 \pm 0.2$ $33.6 \pm 0.3$
	$33.1 \pm 0.2$	$33.7 \pm 0.2$	$33.7 \pm 0.3$	$33.5 \pm 0.1$	$33.3 \pm 0.1$	$33.0 \pm 0.3$
Platelets (10 ³ /µL)	099 4 . 95 1	979 0 . 90 0	971 0 40 1	Q15 7 , 14 4*	0266 . 220	951 0 14 0
Day 3	$922.4 \pm 25.1$	$878.9 \pm 26.9$	$874.8 \pm 43.1$	$815.7 \pm 14.4^*$	$836.6 \pm 33.9$	$851.0 \pm 14.6$
Day 23 Week 14	$680.2 \pm 19.2$	$672.0 \pm 13.6$	$669.8 \pm 14.2$	$646.3 \pm 24.1$	$681.5 \pm 17.9$	$642.8 \pm 30.8$
Week 14	$515.5 \pm 10.4$	$530.9 \pm 12.0$	$535.1 \pm 7.3$	$501.6 \pm 7.4$	$525.9 \pm 5.3$	$541.2 \pm 7.9$
Leukocytes (10 ³ /µL)	7 05 . 0 00	0 76 . 0 96	071 001	0 55 . 0 00	701 . 0.40	7 06 . 0.04
Day 3	$7.85 \pm 0.39$	$8.76 \pm 0.36$	$8.71 \pm 0.31$	$8.55 \pm 0.32$	$7.84 \pm 0.48$	$7.86 \pm 0.34$
Day 23	$5.56 \pm 0.55$	$6.12 \pm 0.18$	$5.85 \pm 0.35$	$6.08 \pm 0.45$	$5.87 \pm 0.45$	$6.61 \pm 0.35$
Week 14	$5.73 \pm 0.39$	$6.14~\pm~0.27$	$6.13 \pm 0.36$	$6.73 \pm 0.30$	$6.04 \pm 0.36$	$5.69 \pm 0.37$
Segmented neutrophils (10 ³ /µL		0.74 . 0.11	0.01 . 0.10	0.77 . 0.10	0.74 . 0.10	0.00 . 0.00
Day 3	$0.80 \pm 0.09$	$0.74 \pm 0.11$	$0.91 \pm 0.12$	$0.77 \pm 0.10$	$0.74 \pm 0.10$	$0.92 \pm 0.08$
Day 23	$0.82 \pm 0.14$	$0.90 \pm 0.09$	$0.78 \pm 0.07$	$0.83 \pm 0.07$	$0.73 \pm 0.07$	$0.84 \pm 0.10$
Week 14	$0.93 \pm 0.08$	$1.17 \pm 0.10$	$1.33 \pm 0.12$	$0.95 \pm 0.12$	$1.07~\pm~0.10$	$1.02~\pm~0.11$
Lymphocytes (10 ³ /µL)	0.04 0.04	<b>7</b> .00 0.07			0.07 0.11	0.04 0.5
Day 3	$6.81 \pm 0.34$	$7.88 \pm 0.35$	$7.74 \pm 0.26$	$7.72 \pm 0.24$	$6.87 \pm 0.44$	$6.81 \pm 0.31$
Day 23	$4.68 \pm 0.48$	$5.20 \pm 0.13$	$5.03 \pm 0.37$	$5.21 \pm 0.42$	$5.11 \pm 0.42$	$5.73 \pm 0.38$
Week 14	$4.70 \pm 0.35$	$4.86~\pm~0.24$	$4.70 \pm 0.30$	$5.71 \pm 0.25$	$4.93 \pm 0.34$	$4.59 \pm 0.32$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Male (continued)						
Hematology (continued)						
1	10	10	10	10	10	10
Monocytes (10 ³ /µL)						
Day 3	$0.20 \pm 0.05$	$0.12~\pm~0.04$	$0.06 \pm 0.03$	$0.02 \pm 0.01^{**}$	$0.15 \pm 0.04$	$0.12 \pm 0.03$
Day 23	$0.20 \pm 0.03$ $0.04 \pm 0.02$	$0.12 \pm 0.04$ $0.01 \pm 0.01$	$0.00 \pm 0.03$ $0.02 \pm 0.02$	$0.02 \pm 0.01$ $0.03 \pm 0.03$	$0.13 \pm 0.04$ $0.01 \pm 0.01$	$0.12 \pm 0.03$ $0.01 \pm 0.01$
Week 14	$0.04 \pm 0.02$ $0.06 \pm 0.02$	$0.01 \pm 0.01$ $0.05 \pm 0.02$	$0.02 \pm 0.02$ $0.06 \pm 0.02$	$0.03 \pm 0.03$ $0.04 \pm 0.02$	$0.01 \pm 0.01$ $0.03 \pm 0.01$	$0.01 \pm 0.01$ $0.05 \pm 0.02$
Eosinophils (10 ³ /µL)	$0.00 \pm 0.02$	0.00 ± 0.02	0.00 ± 0.02	0.04 ± 0.02	0.00 ± 0.01	0.00 ± 0.02
Day 3	$0.03 \pm 0.02$	$0.02~\pm~0.02$	$0.01 \pm 0.01$	$0.03 \pm 0.02$	$0.07~\pm~0.02$	$0.02~\pm~0.01$
Day 23	$0.03 \pm 0.01$	$0.01 \pm 0.01$	$0.01 \pm 0.01$ $0.02 \pm 0.01$	$0.00 \pm 0.02$ $0.00 \pm 0.00$	$0.02 \pm 0.01$	$0.02 \pm 0.01$ $0.03 \pm 0.01$
Week 14	$0.05 \pm 0.01$ $0.05 \pm 0.02$	$0.06 \pm 0.02$	$0.04 \pm 0.01$	$0.03 \pm 0.02$	$0.01 \pm 0.01$	$0.03 \pm 0.02$
	0.02					0.00
linical Chemistry						
l						
Day 3	10	10	10	10	9	10
Day 23	10	10	10	10	10	10
Week 14	10	10	10	10	10	10
Jrea nitrogen (mg/dL)						
Day 3	$12.7 \pm 0.7$	$14.2 \pm 0.6$	$12.3 \pm 0.4$	$11.1 \pm 0.5$	$11.9 \pm 0.6$	$11.5 \pm 0.5$
Day 23	$15.6 \pm 0.4$	$14.7 \pm 0.3$	$14.6 \pm 0.3$	$15.2 \pm 0.5$	$14.9 \pm 0.2$	$14.6 \pm 0.2$
Week 14	$20.6 \pm 0.7$	$19.7~\pm~0.6$	$18.8~\pm~0.7$	$20.4~\pm~0.7$	$19.6~\pm~0.8$	$19.2~\pm~0.6$
Creatinine (mg/dL)	0.01 0.05	0.00	0.50 0.00	0.47 0.00**	0.50 0.04*	0.51 0.00
Day 3	$0.61 \pm 0.05$	$0.62 \pm 0.02$	$0.56 \pm 0.03$	$0.47 \pm 0.02^{**}$	$0.53 \pm 0.04^{*}$	$0.51 \pm 0.02^{\circ}$
Day 23	$0.73 \pm 0.02$	$0.72 \pm 0.01$	$0.71 \pm 0.02$	$0.70 \pm 0.02$	$0.72 \pm 0.01$	$0.71 \pm 0.02$
Week 14	$0.86~\pm~0.02$	$0.88~\pm~0.02$	$0.89~\pm~0.01$	$0.86~\pm~0.02$	$0.86~\pm~0.02$	$0.84~\pm~0.02$
erum glucose (mg/dL) Day 3	$146 \pm 4$	$158 \pm 2$	$162 \pm 4$	$162 \pm 4^{*}$	$147 \pm 3$	$138 \pm 2$
Day 23	$140 \pm 4$ $157 \pm 4$	$158 \pm 2$ 156 ± 10	$102 \pm 4$ 157 ± 4	$102 \pm 4^{\circ}$ 150 ± 3	$147 \pm 3$ $153 \pm 2$	$130 \pm 2$ $155 \pm 5$
Week 14	$157 \pm 4$ $153 \pm 7$	$130 \pm 10$ 185 ± 12	$157 \pm 4$ 158 ± 5	$130 \pm 3$ $171 \pm 11$	$133 \pm 2$ 178 ± 13	$155 \pm 5$ $166 \pm 10$
otal protein (g/dL)	100 - 7	100 - 16	100 ± 0	1/1 - 11	110 - 10	100 ± 10
Day 3	$6.2 \pm 0.1$	$6.5 \pm 0.1$	$6.2 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.1 \pm 0.1$
Day 23	$6.8 \pm 0.1$	$6.6 \pm 0.1$	$6.7 \pm 0.1$	$6.8 \pm 0.1$	$6.7 \pm 0.1$	$6.6 \pm 0.1$
Week 14	$7.6 \pm 0.1$	$7.6 \pm 0.1$	$7.7 \pm 0.1$	$7.5 \pm 0.1$	$7.7 \pm 0.1$	$7.5 \pm 0.1$
lbumin (g/dL)						
Day 3	$5.0~\pm~0.1$	$5.3 \pm 0.1$	$5.1 \pm 0.1$	$4.8~\pm~0.1$	$4.9~\pm~0.1$	$5.0~\pm~0.1$
Day 23	$4.9~\pm~0.1$	$4.9~\pm~0.1$	$4.9 \pm 0.1$	$5.0~\pm~0.1$	$4.9~\pm~0.1$	$4.9~\pm~0.1$
Week 14	$4.8~\pm~0.1$	$4.9~\pm~0.1$	$4.9~\pm~0.1$	$4.8~\pm~0.1$	$4.8~\pm~0.1$	$4.8~\pm~0.1$
lobulin (g/dL)						
Day 3	$1.1 \pm 0.1$	$1.2~\pm~0.1$	$1.1 \pm 0.0$	$1.1 \pm 0.1$	$1.2~\pm~0.1$	$1.1~\pm~0.0$
Day 23	$1.9~\pm~0.1$	$1.7~\pm~0.1$	$1.8~\pm~0.1$	$1.8~\pm~0.1$	$1.8~\pm~0.1$	$1.7~\pm~0.1$
Week 14	$2.8~\pm~0.1$	$2.7~\pm~0.1$	$2.9~\pm~0.1$	$2.7~\pm~0.1$	$2.9~\pm~0.0$	$2.7~\pm~0.1$
/G ratio						
Day 3	$4.5~\pm~0.3$	$4.6~\pm~0.3$	$4.9~\pm~0.3$	$4.4~\pm~0.2$	$4.4~\pm~0.3$	$4.4~\pm~0.2$
Day 23	$2.7~\pm~0.2$	$2.9~\pm~0.2$	$2.9~\pm~0.2$	$2.8~\pm~0.1$	$2.8~\pm~0.2$	$3.0~\pm~0.2$
Week 14	$1.7 \pm 0.1$	$1.8 \pm 0.0$	$1.7 \pm 0.1$	$1.8 \pm 0.1$	$1.7 \pm 0.0$	$1.8~\pm~0.1$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
<b>Male</b> (continued)						
Clinical Chemistry (continued)						
n						
Day 3	10	10	10	10	9	10
Day 23	10	10	10	10	10	10
Week 14	10	10	10	10	10	10
Alanine aminotransferase (IU/L)	)					
Day 3	$35 \pm 1$	$31 \pm 1$	$33 \pm 1$	$38 \pm 1$	$36 \pm 1^{c}$	$37 \pm 1$
Day 23	$34 \pm 1$	$34 \pm 1$	$33 \pm 1$	$37 \pm 3$	$32 \pm 1$	$33 \pm 1$
Week 14	$68 \pm 5$	$58 \pm 3$	$54 \pm 2$	$62 \pm 5$	$61 \pm 3$	$56 \pm 3$
Alkaline phosphatase (IU/L)						
Day 3	$674 \pm 59$	$764~\pm~34$	$755 \pm 35$	$791~\pm~29$	$748 \pm 32$	$726~\pm~40$
Day 23	$454 \pm 16$	$445 \pm 15$	$460 \pm 10$	$465 \pm 13$	$439 \pm 14$	$443 \pm 18$
Week 14	$371 \pm 18$	$377 \pm 9$	$363 \pm 8$	$361 \pm 11$	$330 \pm 13$	$364 \pm 11$
Creatine kinase (IU/L)	0.05 4.0	001 17	005 10	000 11	070 000	004 00
Day 3	$265 \pm 46$	$201 \pm 15$	$235 \pm 16$	$232 \pm 11$	$273 \pm 36^{\circ}$	$264 \pm 23$
Day 23 Wook 14	$\begin{array}{rrrr}199~\pm&22\\110~\pm&18\end{array}$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$196 \pm 24$ $103 \pm 11$	$242 \pm 31 \\ 103 \pm 12$	$\begin{array}{rrrr} 215 \pm & 19 \\ 96 \pm & 9 \end{array}$	$241 \pm 26 \\ 105 \pm 9$
Week 14 Sorbitol dehydrogenase (IU/L)	$110 \pm 18$	$111 \pm 18$	$103 \pm 11$	$103 \pm 12$	$90 \pm 9$	$105 \pm 9$
Day 3	$13 \pm 1$	$12 \pm 1$	$13 \pm 0$	$13 \pm 1$	$14 \pm 1$	$14 \pm 1$
Day 23	$13 \pm 1$ $12 \pm 0$	$12 \pm 1$ $12 \pm 1$	$13 \pm 0$ $12 \pm 1$	$13 \pm 1$ 14 ± 1	$14 \pm 1$ $12 \pm 0$	$14 \pm 1$ $11 \pm 0$
Week 14	$12 \pm 0$ $18 \pm 1$	$12 \pm 1$ 16 ± 1	$12 \pm 1$ $14 \pm 0^*$	$14 \pm 1$ 16 ± 1	$12 \pm 0$ $17 \pm 1$	$11 \pm 0$ $16 \pm 1$
Bile acids (µmol/L)	10 ± 1	10 ± 1	11 ± 0	10 - 1	17 ± 1	10 ± 1
Day 3	$25.8 \pm 2.0$	$22.6 \pm 2.5$	$23.2 \pm 1.8$	$22.3 \pm 1.0$	$22.6 \pm 1.0^{\circ}$	$22.6 \pm 0.9$
Day 23	$17.1 \pm 0.7$	$19.5 \pm 1.8$	$16.7 \pm 0.8$	$19.5 \pm 1.1$	$17.1 \pm 0.5$	$17.4 \pm 0.8$
Week 14	$23.4 \pm 2.1$	$27.7~\pm~3.2$	$21.3 \pm 1.5$	$27.1 \pm 4.8$	$30.2 \pm 3.9$	$25.0 \pm 1.6$
Female						
1	10	10	10	10	10	10
1	10	10	10	10	10	10
Hematology						
Automated hematocrit (%)						
Day 3	$45.1 \pm \ 0.6$	$44.9~\pm~0.7$	$43.9~\pm~0.7$	$46.2~\pm~0.4$	$46.3 \pm \ 0.8$	$45.7~\pm~0.6$
Day 23	$47.8 \pm \ 0.5$	$47.5~\pm~0.4$	$47.5~\pm~0.5$	$47.2~\pm~0.4$	$47.3~\pm~0.2$	$48.0 \pm \ 0.4$
Week 14	$44.9 \pm 0.5$	$45.4~\pm~0.3$	$45.6~\pm~0.3$	$45.3 \pm 0.4$	$45.2~\pm~0.1$	$45.6 \pm 0.4$
Manual hematocrit (%)	15 0 0 1		10.0	150 53		
Day 3	$45.2 \pm 0.4$	$44.8 \pm 0.5$	$43.6 \pm 0.6$	$45.8 \pm 0.2$	$45.4 \pm 0.6$	$45.2 \pm 0.4$
Day 23	$47.1 \pm 0.4$	$47.3 \pm 0.4$	$47.0 \pm 0.4$	$47.0 \pm 0.4$	$46.9 \pm 0.2$	$47.4 \pm 0.4$
Week 14 Jamoglahin (g/dL)	$45.3 \pm \ 0.4$	$45.7~\pm~0.3$	$46.2~\pm~0.3$	$45.4~\pm~0.4$	$45.6 \pm 0.2$	$45.8 \pm 0.3$
Hemoglobin (g/dL)	15 4 + 0.9	$15.1 \pm 0.2$	150 - 02	15 2 . 0 2	15 4 - 0.2	15.2 . 0.1
Day 3 Day 23	$\begin{array}{rrrr} 15.4 \pm \ 0.2 \\ 16.2 \pm \ 0.0 \end{array}$	$15.1 \pm 0.2$ $16.2 \pm 0.1$	$15.0 \pm 0.3$ $16.1 \pm 0.1$	$\begin{array}{rrrr} 15.2 \ \pm \ 0.2 \\ 16.0 \ \pm \ 0.1 \end{array}$	$\begin{array}{rrrr} 15.4 \pm \ 0.3 \\ 16.1 \pm \ 0.1 \end{array}$	$\begin{array}{rrr} 15.3 \pm \ 0.1 \\ 16.0 \pm \ 0.1 \end{array}$
Week 14	$16.2 \pm 0.0$ $15.3 \pm 0.2$	$16.2 \pm 0.1$ $15.5 \pm 0.1$	$16.1 \pm 0.1$ $15.5 \pm 0.1$	$16.0 \pm 0.1$ $15.4 \pm 0.1$	$16.1 \pm 0.1$ $15.4 \pm 0.1$	$16.0 \pm 0.1$ $15.5 \pm 0.1$
Erythrocytes (10 ⁶ /µL)	10.0 ± 0.4	10.0 - 0.1	10.0 ± 0.1	10.7 - 0.1	10.7 ± 0.1	$15.5 \pm 0.1$
Day 3	$8.15 \pm 0.11$	$7.96~\pm~0.12$	$7.94~\pm~0.15$	$8.09 \pm 0.08$	$8.23 \pm 0.17$	$8.12 \pm 0.11$
Day 23	$8.57 \pm 0.04$	$8.54 \pm 0.10$	$8.53 \pm 0.08$	$8.46 \pm 0.07$	$8.56 \pm 0.05$	$8.46 \pm 0.04$
Week 14	$8.41 \pm 0.09$	$8.50 \pm 0.05$	$8.58 \pm 0.05$	$8.49 \pm 0.06$	$8.47 \pm 0.03$	$8.50 \pm 0.05$
Reticulocytes (10 ⁶ /µL)						
Day 3	$0.16~\pm~0.03$	$0.22~\pm~0.03$	$0.20~\pm~0.02$	$0.20~\pm~0.03$	$0.18 \pm 0.02$	$0.15~\pm~0.03$
Day 23	$0.07~\pm~0.01$	$0.07~\pm~0.01$	$0.06~\pm~0.02$	$0.06~\pm~0.01$	$0.08~\pm~0.01$	$0.05~\pm~0.01$
Week 14	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$	$0.05~\pm~0.01$

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Female (continued)						
1	10	10	10	10	10	10
Hematology (continued)						
Nucleated erythrocytes (10 ³ /µ)	L)					
Day 3	$0.05 \pm 0.02$	$0.05~\pm~0.02$	$0.06~\pm~0.02$	$0.06 \pm 0.03$	$0.04~\pm~0.02$	$0.07~\pm~0.04$
Day 23	$0.03 \pm 0.01$	$0.02 \pm 0.02$	$0.01 \pm 0.01$	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.00 \pm 0.00$
Week 14	$0.03 \pm 0.01$	$0.01 \pm 0.01$	$0.02 \pm 0.01$	$0.04 \pm 0.01$	$0.01 \pm 0.01$	$0.01 \pm 0.01$
Mean cell volume (fL)						
Day 3	$55.3 \pm 0.4$	$56.5~\pm~0.4$	$55.3 \pm 0.7$	$57.1 \pm 0.3^{*}$	$56.4 \pm 0.3$	$56.3 \pm 0.6$
Day 23	$56.0 \pm 0.4$	$55.6 \pm 0.5$	$55.7 \pm 0.4$	$55.9 \pm 0.4$	$55.3 \pm 0.3$	$56.4 \pm 0.3$
Week 14	$53.4 \pm 0.3$	$53.6 \pm 0.2$	$53.2 \pm 0.3$	$53.2 \pm 0.2$	$53.3 \pm 0.2$	$53.6 \pm 0.2$
Mean cell hemoglobin (pg)						
Day 3	$18.9 \pm 0.1$	$19.0 \pm 0.1$	$18.8 \pm 0.1$	$18.8 \pm 0.1$	$18.7 \pm 0.1$	$18.8 \pm 0.1$
Day 23	$18.9 \pm 0.1$ $18.9 \pm 0.1$	$19.0 \pm 0.1$ 19.0 ± 0.1	$18.9 \pm 0.1$	$18.9 \pm 0.1$	$18.8 \pm 0.1$	$10.0 \pm 0.1$ $19.0 \pm 0.1$
Week 14	$18.3 \pm 0.1$ $18.2 \pm 0.1$	$13.0 \pm 0.1$ $18.2 \pm 0.1$	$18.5 \pm 0.1$ $18.1 \pm 0.1$	$18.3 \pm 0.1$ $18.1 \pm 0.0$	$18.2 \pm 0.1$ 18.2 ± 0.1	$13.0 \pm 0.1$ $18.3 \pm 0.1$
Mean cell hemoglobin concent		10.2 - 0.1	10.1 ± 0.1	10.1 ± 0.0	10.2 - 0.1	10.0 ± 0.1
	$34.1 \pm 0.2$	$33.7 \pm 0.3$	$34.1 \pm 0.4$	$32.9 \pm 0.2^{*}$	$33.3 \pm 0.1$	$33.5 \pm 0.3$
Day 3 Day 23		$33.7 \pm 0.3$ $34.1 \pm 0.2$	$34.1 \pm 0.4$ $33.9 \pm 0.3$	$32.9 \pm 0.2^{*}$ $33.8 \pm 0.2$	$33.3 \pm 0.1$ $34.0 \pm 0.1$	$33.5 \pm 0.3$ $33.5 \pm 0.2$
Day 23	$34.0 \pm 0.3$					
Week 14 $(10^3 (1))$	$34.1 \pm 0.2$	$34.1 \pm 0.1$	$34.1~\pm~0.1$	$34.1~\pm~0.2$	$34.2 \pm 0.1$	$34.0 \pm 0.2$
Platelets (10 ³ /µL)	707 5 40.0	001 0 00 7	001.0 40.1	071 7 00 4	040 0 54 0	701 4 00 1
Day 3	$797.5 \pm 48.0$	$861.6 \pm 63.7$	$831.0 \pm 40.1$	$871.7 \pm 39.4$	$840.8 \pm 54.6$	$791.4 \pm 32.1$
Day 23	$705.0 \pm 21.4$	$675.0 \pm 30.5$	$754.5 \pm 35.2$	$721.4 \pm 20.5$	$707.4 \pm 11.4$	$745.5 \pm 19.9$
Week 14	$599.4 \pm 16.2$	$615.8~\pm~26.6$	$570.2~\pm~24.2$	$530.5 \pm 13.4^*$	$575.8 \pm 15.1$	$603.8 \pm 19.2$
Leukocytes (10 ³ /µL)						
Day 3	$8.24~\pm~0.39$	$8.61~\pm~0.25$	$8.45 \pm 0.38$	$8.90 \pm 0.28$	$9.94 \pm 0.54^*$	$9.34 \pm 0.43^*$
Day 23	$5.44~\pm~0.36$	$6.26~\pm~0.57$	$5.68 \pm 0.34$	$5.76 \pm 0.31$	$5.97 \pm 0.60$	$5.74~\pm~0.43$
Week 14	$6.71 \pm 0.14$	$6.95 \pm 0.27$	$6.92~\pm~0.45$	$6.95 \pm 0.20$	$7.26~\pm~0.39$	$6.43~\pm~0.40$
Segmented neutrophils (10 ³ /µl						
Day 3	$0.78 \pm 0.10$	$0.77 \pm 0.10$	$0.79 \pm 0.10$	$0.78 \pm 0.08$	$1.16 \pm 0.13$	$0.97~\pm~0.19$
Day 23	$0.72~\pm~0.08$	$0.76~\pm~0.12$	$0.76~\pm~0.08$	$0.76 \pm 0.09$	$0.99~\pm~0.12$	$0.81~\pm~0.09$
Week 14	$1.03 \pm 0.10$	$0.86~\pm~0.08$	$1.22~\pm~0.15$	$0.95~\pm~0.08$	$1.40~\pm~0.12$	$1.05~\pm~0.14$
Lymphocytes (10 ³ /µL)						
Day 3	$7.33 \pm 0.39$	$7.70~\pm~0.20$	$7.54 \pm 0.37$	$7.99~\pm~0.28$	$8.71 \pm 0.46$	$8.28~\pm~0.36$
Day 23	$4.65 \pm 0.33$	$5.42~\pm~0.49$	$4.81 \pm 0.31$	$4.95~\pm~0.33$	$4.90 \pm 0.52$	$4.87~\pm~0.49$
Week 14	$5.59 \pm 0.17$	$6.02~\pm~0.27$	$5.62 \pm 0.32$	$5.90 \pm 0.20$	$5.76 \pm 0.35$	$5.29~\pm~0.31$
Monocytes (10 ³ /µL)						
Day 3	$0.09 \pm 0.04$	$0.11 \pm 0.04$	$0.09 \pm 0.03$	$0.07 \pm 0.04$	$0.03 \pm 0.02$	$0.04 \pm 0.03$
Day 23	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.02 \pm 0.01$	$0.01 \pm 0.01$	$0.00 \pm 0.00$	$0.01 \pm 0.01$
Week 14	$0.02 \pm 0.01$ $0.04 \pm 0.02$	$0.02 \pm 0.01$ $0.03 \pm 0.02$	$0.02 \pm 0.01$ $0.04 \pm 0.02$	$0.01 \pm 0.01$ $0.05 \pm 0.02$	$0.05 \pm 0.02$	$0.01 \pm 0.01$ $0.03 \pm 0.01$
Eosinophils (10 ³ /µL)	0.01 - 0.0%	0.00 - 0.02	0.01 - 0.02	0.00 - 0.02	0.00 - 0.02	$0.00 \pm 0.01$
Day 3	$0.04~\pm~0.02$	$0.03~\pm~0.01$	$0.04 \pm 0.02$	$0.05~\pm~0.02$	$0.05 \pm 0.02$	$0.05~\pm~0.02$
Day 23	$0.04 \pm 0.02$ $0.05 \pm 0.02$	$0.05 \pm 0.01$ $0.06 \pm 0.02$	$0.04 \pm 0.02$ $0.07 \pm 0.02$	$0.03 \pm 0.02$ $0.03 \pm 0.01$	$0.03 \pm 0.02$ $0.07 \pm 0.02$	$0.03 \pm 0.02$ $0.03 \pm 0.01$
Week 14	$0.05 \pm 0.02$ $0.05 \pm 0.02$	$0.00 \pm 0.02$ $0.04 \pm 0.01$	$0.07 \pm 0.02$ $0.04 \pm 0.02$	$0.03 \pm 0.01$ $0.06 \pm 0.02$	$0.07 \pm 0.02$ $0.05 \pm 0.02$	$0.03 \pm 0.01$ $0.08 \pm 0.02$
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.00 ± 0.02	0.01 - 0.01	0.01 - 0.02	0.00 - 0.02	0.00 - 0.02	0.00 ± 0.02
Clinical Chemistry						
Iron nitrogon (mg/dI)						
Urea nitrogen (mg/dL)	10 9 . 1 1	19 4 . 0 5***	116.07**	1/1 / 0.9**	19 5 , 0 5**	120 0 . 0
Day 3	$18.3 \pm 1.1$	$13.4 \pm 0.5^{**}$	$14.6 \pm 0.7^{**}$	$14.1 \pm 0.3^{**}$	$13.5 \pm 0.5^{**}$	$12.9 \pm 0.5^{**}$
Day 23	$14.3 \pm 0.4$	$14.6 \pm 0.6$	$14.0 \pm 0.5$	$13.5 \pm 0.6$	$13.7 \pm 0.4$	$13.1 \pm 0.3$
Week 14	$19.4 \pm 1.0$	$20.0~\pm~0.7$	$20.0~\pm~0.8$	$19.2~\pm~1.1$	$19.7~\pm~0.5$	$19.0~\pm~0.8$
Creatinine (mg/dL)						
Day 3	$0.63~\pm~0.02$	$0.63 \pm 0.02$	$0.59 \pm 0.02$	$0.55 \pm 0.02^{**}$	$0.59 \pm 0.02^*$	$0.58 \pm 0.03^{*}$
Day 23	$0.76~\pm~0.02$	$0.84~\pm~0.02$	$0.77~\pm~0.03$	$0.76~\pm~0.02$	$0.77~\pm~0.02$	$0.75~\pm~0.02$
Week 14	$0.83 \pm 0.03$	$0.81 \pm 0.03$	$0.85 \pm 0.02$	$0.84~\pm~0.02$	$0.83~\pm~0.03$	$0.80~\pm~0.02$

Hematology and Clinical Chemistry Data for Rats in the 14-Week Inhalation Study of Isobutene

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
Female (continued)						
n	10	10	10	10	10	10
Clinical Chemistry (continued)						
Serum glucose (mg/dL)						
Day 3	$124 \pm 4$	$136 \pm 6$	$141 \pm 9$	$128 \pm 3$	$127 \pm 4$	$122 \pm 4$
Day 23	$155 \pm 4$	$171 \pm 13$	$166 \pm 8$	$148 \pm 6$	$158 \pm 3$	$164 \pm 5$
Week 14	$164 \pm 5$	$169 \pm 11$	$176 \pm 10$	$170 \pm 7$	$167 \pm 4$	$169 \pm 5$
Total protein (g/dL)						
Day 3	$6.1 \pm 0.1$	$6.1 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.0 \pm 0.1$	$6.1 \pm 0.1$
Day 23	$6.5 \pm 0.1$	$6.6 \pm 0.1$	$6.5 \pm 0.1$	$6.4 \pm 0.1$	$6.5 \pm 0.1$	$6.6 \pm 0.1$
Week 14	$7.3 \pm 0.1$	$7.5 \pm 0.1$	$7.6 \pm 0.1$	$7.3 \pm 0.1$	$7.3 \pm 0.1$	$7.3 \pm 0.1$
Albumin (g/dL)						
Day 3	$5.4 \pm 0.1$	$5.7 \pm 0.1$	$5.5 \pm 0.1$	$5.5 \pm 0.0$	$5.4 \pm 0.1$	$5.3 \pm 0.1$
Day 23	$4.7 \pm 0.1$	$4.8 \pm 0.1$	$4.8 \pm 0.1$	$4.7 \pm 0.0$	$4.8 \pm 0.1$	$4.7 \pm 0.1$
Week 14	$5.1 \pm 0.1$	$5.2 \pm 0.1$	$5.1 \pm 0.1$	$5.1 \pm 0.1$	$5.0 \pm 0.1$	$5.0 \pm 0.1$
Globulin (g/dL)			011 = 011		010 = 011	010 = 011
Day 3	$0.7 \pm 0.1$	$0.5 \pm 0.1$	$0.5 \pm 0.1$	$0.5 \pm 0.0^{*}$	$0.6 \pm 0.1$	$0.8 \pm 0.1$
Day 23	$1.8 \pm 0.1$	$1.8 \pm 0.1$	$1.8 \pm 0.1$	$1.7 \pm 0.1$	$1.7 \pm 0.0$	$1.8 \pm 0.1$
Week 14	$2.2 \pm 0.1$	$2.3 \pm 0.1$	$2.5 \pm 0.1$	$2.3 \pm 0.1$	$2.4 \pm 0.1$	$2.3 \pm 0.1$
A/G ratio						
Day 3	$8.1 \pm 0.8$	$14.5 \pm 2.7^{b}$	$12.8 \pm 2.0$	$13.1 \pm 1.1$	$9.9 \pm 1.3$	$7.5 \pm 1.0$
Day 23	$2.7 \pm 0.1$	$2.6 \pm 0.1$	$2.7 \pm 0.1$	$2.9 \pm 0.1$	$2.8 \pm 0.1$	$2.6 \pm 0.1$
Week 14	$2.4 \pm 0.1$	$2.3 \pm 0.1$	$2.1 \pm 0.1$	$2.3 \pm 0.1$	$2.1 \pm 0.1$	$2.3 \pm 0.1$
Alanine aminotransferase (IU/I						
Day 3	$34 \pm 1$	$34 \pm 1$	$35 \pm 2$	$34 \pm 1$	$33 \pm 1$	$33 \pm 1$
Day 23	$30 \pm 1$	$34 \pm 3$	$30 \pm 1$	$29 \pm 1$	$29 \pm 1$	$30 \pm 1$ $30 \pm 1$
Week 14	$47 \pm 2$	$65 \pm 6^*$	$55 \pm 3$		$54 \pm 5$	$60 \pm 4$
Alkaline phosphatase (IU/L)						
Day 3	$583 \pm 22$	$577 \pm 21$	$569 \pm 32$	$539 \pm 20$	$486~\pm~18^*$	$554 \pm 26$
Day 23	$347 \pm 10$	$391 \pm 10^*$	$366 \pm 12$	$366 \pm 9$	$330 \pm 10$	$347 \pm 8$
Week 14	$307 \pm 15$	$328 \pm 11$	$369 \pm 14^*$	$317 \pm 15$	$321 \pm 12$	$306 \pm 13$
Creatine kinase (IU/L)		-			-	
Day 3	$204 \pm 16$	$222 \pm 12$	$210 \pm 24$	$198 \pm 18$	$205 \pm 26$	$277 \pm 36$
Day 23	$197 \pm 35$	$196 \pm 24$	$162 \pm 20$	$202 \pm 27$	$183 \pm 28$	$221 \pm 59$
Week 14	$100 \pm 9$	$122 \pm 20$	$102 \pm 12$ 112 ± 12	$139 \pm 17$	$130 \pm 100$ $134 \pm 14$	$146 \pm 13$
Sorbitol dehydrogenase (IU/L)		-			-	
Day 3	$16 \pm 0$	$16 \pm 1$	$14 \pm 1^{*}$	$14 \pm 0^{**}$	$15 \pm 1^{*}$	$14 \pm 1^{*}$
Day 23	$10 \pm 0$ $15 \pm 1$	$10 \pm 1$ $19 \pm 2$	$14 \pm 1$	$16 \pm 1$	10 = 1 $15 \pm 1$	$16 \pm 0$
Week 14	10 = 1 $14 \pm 1$	10 = 2 $17 \pm 1$	$17 \pm 1$ 17 ± 1	10 = 1 $17 \pm 1$	$15 \pm 1$ 15 ± 2	$10 \pm 0$ $17 \pm 1$
Bile acids (µmol/L)						
Day 3	$17.9 \pm 1.9$	$13.6~\pm~1.3$	$20.0 \pm 3.7$	$17.8 \pm 1.3$	$16.1 \pm 1.2$	$16.1 \pm 1.2$
Day 23	$14.6 \pm 0.7$	$21.7 \pm 5.7$	$18.0 \pm 2.0$	$14.7 \pm 1.1$	$14.2 \pm 0.6$	$16.6 \pm 1.4$
Week 14	$24.8 \pm 3.5$	$24.5 \pm 3.4$	$30.5 \pm 6.1$	$40.1 \pm 5.6$	$32.6 \pm 5.4$	$30.4 \pm 4.2$

* Significantly different (P<0.05) from the chamber control group by Dunn's or Shirley's test ** P<0.01 a Mean  $\pm$  standard error. Statistical tests were performed on unrounded data.

c = n = 8

b n=9

# APPENDIX G ORGAN WEIGHTS AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
in the 14-Week Inhalation Study of Isobutene	200
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
in the 14-Week Inhalation Study of Isobutene	201
	in the 14-Week Inhalation Study of Isobutene

#### TABLE G1

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
n	10	10	10	10	10	10
Male						
Necropsy body wt	$359~\pm~8$	$367 \pm \ 6$	$365~\pm~8$	$364 \pm 6$	$362 \pm 7$	$366 \pm 6$
Heart						
Absolute	$0.993 \pm 0.022$	$1.040 \pm 0.021$	$1.090 \pm 0.026^{*}$	$1.031 \pm 0.017$	$1.033 \pm 0.015$	$1.050 \pm 0.025$
Relative	$2.77 \pm 0.05$	$2.83~\pm~0.02$	$2.99 \pm 0.06^{*}$	$2.84~\pm~0.05$	$2.86~\pm~0.06$	$2.87~{\pm}~0.06$
R. Kidney						
Absolute	$1.116 \pm 0.019$	$1.191 \pm 0.028$	$1.187 \pm 0.030$	$1.182 \pm 0.021$	$1.219 \pm 0.030^{**}$	$1.231 \pm 0.024^{**}$
Relative	$3.12~\pm~0.04$	$3.24 \pm 0.04^{*}$	$3.25 \pm 0.03^{*}$	$3.25 \pm 0.06^{*}$	$3.36 \pm 0.05^{**}$	$3.36 \pm 0.04^{**}$
Liver						
Absolute	$12.073 \pm 0.484$	$12.419 \pm 0.279$	$12.377 \pm 0.301$	$12.348 \pm 0.291$	$12.438 \pm 0.323$	$12.461 \pm 0.364$
Relative	$33.58 \pm 0.66$	$33.81 \pm 0.53$	$33.93 \pm 0.29$	$33.91 \pm 0.45$	$34.31 \pm 0.43$	$33.98 \pm 0.59$
Lung						
Absolute	$1.649 \pm 0.074$	$1.625 \pm 0.040$	$1.728 \pm 0.039$	$1.677 \pm 0.055$	$1.666 \pm 0.036$	$1.785 \pm 0.057$
Relative	$4.60 \pm 0.17$	$4.43 \pm 0.10$	$4.75 \pm 0.14$	$4.62 \pm 0.17$	$4.61 \pm 0.10$	$4.89 \pm 0.20$
R. Testis						
Absolute	$1.416 \pm 0.031$	$1.412 \pm 0.026$	$1.417 \pm 0.025$	$1.412 \pm 0.011$	$1.419 \pm 0.016$	$1.445 \pm 0.011$
Relative	$3.96 \pm 0.07$	$3.84~\pm~0.03$	$3.89~{\pm}~0.06$	$3.89 \pm 0.07$	$3.93 \pm 0.06$	$3.95 \pm 0.06$
Гhymus						
Absolute	$0.324 \pm 0.015$	$0.314 \pm 0.017$	$0.319 \pm 0.010$	$0.332 \pm 0.014$	$0.296 \pm 0.021$	$0.309 \pm 0.014$
Relative	$0.91 \pm 0.05$	$0.86~\pm~0.05$	$0.88~\pm~0.03$	$0.91 \pm 0.04$	$0.82 \pm 0.06$	$0.84 \pm \ 0.04$
Female						
Necropsy body wt	$207~\pm~4$	$202~\pm~2$	$215~\pm~5$	$213~\pm~5$	$208~\pm~4$	$217~\pm~6$
Heart						
Absolute	$0.669 \pm 0.014$	$0.655 \ \pm \ 0.010$	$0.710 \pm 0.017$	$0.689 \ \pm \ 0.016$	$0.680 \pm 0.010$	$0.719 \pm 0.015$
Relative	$3.23~\pm~0.05$	$3.24~\pm~0.04$	$3.30~\pm~0.06$	$3.23~\pm~0.04$	$3.27~\pm~0.06$	$3.32~\pm~0.05$
R. Kidney						
Absolute	$0.682~\pm~0.023$	$0.669 \ \pm \ 0.012$	$0.746 \ \pm \ 0.017$	$0.696 \ \pm \ 0.018$	$0.645 \ \pm \ 0.045$	$0.725 \pm 0.017$
Relative	$3.29~\pm~0.10$	$3.31~\pm~0.07$	$3.47~\pm~0.05$	$3.27~\pm~0.06$	$3.09~\pm~0.21$	$3.35~\pm~0.04$
Liver						
Absolute	$6.101 \pm 0.129$	$6.450 \ \pm \ 0.133$	$7.267 \pm 0.193^{**}$	$6.875 \pm 0.257^{**}$	$6.673 \pm 0.211^{**}$	$7.006 \pm 0.248^{**}$
Relative	$29.45~\pm~0.51$	$31.92 \pm 0.65^*$	$33.75 \pm 0.64^{**}$	$32.20 \pm 0.73^*$	$32.01 \pm 0.65^*$	$32.27 \pm 0.53^*$
Lung						
Absolute	$1.116 \pm 0.034$	$1.014 \pm 0.030$	$1.162 \pm 0.069$	$1.182 \pm 0.058$	$1.173 \pm 0.057$	$1.222 \pm 0.045$
Relative	$5.38 \pm 0.13$	$5.01~\pm~0.11$	$5.38~{\pm}~0.25$	$5.55~\pm~0.25$	$5.64~\pm~0.27$	$5.67 \pm 0.28$
Thymus						
Absolute	$0.235 \ \pm \ 0.012$	$0.245 \ \pm \ 0.007$	$0.250 \pm 0.014$	$0.236 \pm 0.011$	$0.243 \pm 0.015$	$0.246 \pm 0.009$
Relative	$1.14~\pm~0.06$	$1.21~\pm~0.03$	$1.16 \pm 0.05$	$1.10 \pm 0.03$	$1.16 \pm 0.06$	$1.14 \pm 0.03$

	_				
Organ Weights and	Organ-Weight-to	.Rodv-Weight Rati	os for Rats in the	14-Week Inhalation	Study of Isobutene ^a
organ weights and		Duy Wight Rad	of the man of the second second	11 WCCK Innanation	Study of ISObutche

* Significantly different (P≤0.05) from the chamber control group by Williams' or Dunnett's test
 ** P≤0.01

 a Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error).

#### TABLE G2

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 14-Week Inhalation Study of Isobutene^a

	Chamber Control	500 ppm	1,000 ppm	2,000 ppm	4,000 ppm	8,000 ppm
n	10	10	10	10	10	10
Male						
Necropsy body wt	$37.8 \pm 1.4$	$38.2 \pm 0.8$	$39.8~\pm~0.8$	$38.0 \pm \ 0.9$	$37.5 \pm \ 0.6$	$37.8 \pm 1.1$
Heart						
Absolute	$0.164 \pm 0.005$	$0.169 \pm 0.004$	$0.164 \pm 0.005$	$0.165 \pm \ 0.005$	$0.166 \pm 0.005$	$0.160 \pm 0.004$
Relative	$4.38 \pm 0.16$	$4.43~\pm~0.09$	$4.15~\pm~0.17$	$4.35~\pm~0.08$	$4.41~\pm~0.09$	$4.25~\pm~0.10$
R. Kidney						
Absolute	$0.309 \pm \ 0.012$	$0.340 \ \pm \ 0.008$	$0.345 \pm 0.010^{*}$	$0.339 \pm 0.007$	$0.336 \pm 0.007$	$0.345 \pm 0.008^{*}$
Relative	$8.26 \pm 0.38$	$8.91~\pm~0.16$	$8.70~\pm~0.27$	$8.97 \pm 0.24$	$8.95 \pm 0.12$	$9.15 \pm 0.17^*$
Liver						
Absolute	$1.747 \pm 0.076$	$1.800 \pm 0.034$	$1.819 \pm 0.043$	$1.794 \pm 0.046$	$1.764 \pm 0.034$	$1.815 \pm 0.054$
Relative	$46.21 \pm 0.72$	$47.23 \pm 0.96$	$45.80 \pm 0.81$	$47.29 \pm 0.61$	$47.00 \pm 0.58$	$48.04 \pm 0.67$
Lung						
Absolute	$0.228 \pm 0.007$	$0.228 \pm 0.016$	$0.232 \pm 0.007$	$0.239 \pm 0.004$	$0.244 \pm 0.006$	$0.238 \pm 0.004$
Relative	$6.09 \pm 0.21$	$5.97~\pm~0.38$	$5.85 \pm 0.19$	$6.33 \pm 0.17$	$6.51 \pm 0.15$	$6.34 \pm 0.19$
R. Testis						
Absolute	$0.121 \pm 0.002$	$0.125 \pm 0.002$	$0.123 \pm 0.003$	$0.124 \pm 0.002$	$0.127 \pm 0.003$	$0.109 \pm 0.010$
Relative	$3.25 \pm 0.12$	$3.27 \pm 0.04$	$3.11 \pm 0.11$	$3.28 \pm 0.08$	$3.38 \pm 0.06$	$2.91 \pm 0.27$
Thymus						
Absolute	$0.037 \pm 0.003$	$0.037 \pm 0.002$	$0.037 \pm 0.003$	$0.040 \pm 0.002$	$0.041 \pm 0.002$	$0.036 \pm 0.003$
Relative	$0.99 \pm 0.09$	$0.97~\pm~0.05$	$0.94~\pm~0.08$	$1.04~\pm~0.04$	$1.10~\pm~0.04$	$0.95~\pm~0.08$
Female						
Necropsy body wt	$33.8~\pm~0.7$	$32.6 \pm 0.9$	$35.6~\pm~1.2$	$34.8~\pm~0.9$	$33.8 \pm 1.0$	$33.9 \pm \ 0.8$
Heart						
Absolute	$0.134 \pm 0.003$	$0.138 \pm 0.002$	$0.142 \pm 0.003$	$0.140 \pm 0.003$	$0.135 \pm 0.002$	$0.137 \pm 0.003$
Relative	$3.98 \pm 0.10$	$4.25~\pm~0.10$	$4.02~\pm~0.13$	$4.04~\pm~0.09$	$4.02~\pm~0.10$	$4.05~\pm~0.10$
R. Kidney						
Absolute	$0.198 \pm \ 0.004$	$0.226~\pm~0.005^{**}$	$0.226~\pm~0.006^{**}$	$0.222~\pm~0.005^{**}$	$0.226~\pm~0.005^{**}$	$0.234 \pm 0.003^{**}$
Relative	$5.89 \pm 0.19$	$6.95 \pm 0.19^{**}$	$6.38 \pm 0.12^{**}$	$6.40 \pm 0.13^{**}$	$6.72 \pm 0.16^{**}$	$6.93 \pm 0.13^{**}$
Liver						
Absolute	$1.603 \pm \ 0.036$	$1.622 \pm 0.038$	$1.697 \pm 0.050$	$1.694 \pm 0.047$	$1.659 \pm 0.050$	$1.665 \pm 0.040$
Relative	$47.48 \pm \ 0.59$	$49.80 \pm 0.91$	$47.85 \pm 0.76$	$48.72 \pm 0.59$	$49.14 \pm 0.89$	$49.11 \pm 0.45$
Lung						
Absolute	$0.232 \ \pm \ 0.007$	$0.233 \ \pm \ 0.005$	$0.247 \pm 0.007$	$0.248 \pm 0.005$	$0.233 \pm 0.007$	$0.236 \pm 0.004$
Relative	$6.88 \pm 0.20$	$7.17~\pm~0.20$	$6.97~\pm~0.14$	$7.15 \pm 0.13$	$6.90 \pm 0.11$	$6.99 \pm 0.18$
Гhymus						
Absolute	$0.054 \pm \ 0.002$	$0.055 \ \pm \ 0.003$	$0.062 \pm 0.006$	$0.057 \pm 0.002$	$0.054 \pm 0.004$	$0.055 \pm 0.003$
Relative	$1.60 \pm 0.07$	$1.68 \pm 0.08$	$1.71 \pm 0.10$	$1.65 \pm 0.07$	$1.60 \pm 0.09$	$1.62 \pm 0.06$

* Significantly different (P $\le$ 0.05) from the chamber control group by Williams' or Dunnett's test ** P $\le$ 0.01

^a Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error).

# APPENDIX H REPRODUCTIVE TISSUE EVALUATIONS AND ESTROUS CYCLE CHARACTERIZATION

TABLE H1	Summary of Reproductive Tissue Evaluations for Male Rats	
	in the 14-Week Inhalation Study of Isobutene	204
TABLE H2	Summary of Estrous Cycle Characterization for Female Rats	
	in the 14-Week Inhalation Study of Isobutene	204
TABLE H3	Summary of Reproductive Tissue Evaluations for Male Mice	
	in the 14-Week Inhalation Study of Isobutene	205
TABLE H4	Summary of Estrous Cycle Characterization for Female Mice	
	in the 14-Week Inhalation Study of Isobutene	205

	Chamber Control	2,000 ppm	4,000 ppm	8,000 ppm
n	10	10	10	10
Weights (g)				
Necropsy body wt	$358 \pm 8$	$364 \pm 6$	$362 \pm 7$	$366 \pm 6$
L. cauda epididymis	$0.1742 \pm 0.0063$	$0.1906 \pm 0.0020$	$0.1838 \pm 0.0065$	$0.1936 \pm 0.0046^*$
L. epididymis	$0.4650 \pm 0.0067$	$0.4758 \pm 0.0040$	$0.4601 \pm 0.0107$	$0.4780 \pm 0.0067$
L. testis	$1.4802 \pm 0.0260$	$1.4905 \pm \ 0.0079$	$1.4913 \pm \ 0.0304$	$1.5185 \pm \ 0.0211$
Spermatid measurements				
Spermatid heads (10 ⁷ /g testis)	$9.89 \pm 0.34$	$10.11 \pm 0.40$	$9.95 \pm 0.28$	$9.97 \pm 0.22$
Spermatid heads (10 ⁷ /testis)	$14.63 \pm 0.54$	$15.07 \pm 0.62$	$14.82 \pm 0.44$	$15.15 \pm 0.43$
Spermatid count				
$(\text{mean}/10^{-4} \text{ mL suspension})$	$73.13~\pm~2.68$	$75.35 \pm \ 3.09$	$74.08~\pm~2.18$	$75.75 \pm 2.13$
Epididymal spermatozoal measurement	S			
Motility (%)	$91.15 \pm 3.18$	$89.32 \pm 2.01$	$88.04 \pm 1.97$	$86.53 \pm 1.90^*$
Concentration				50100 - 1100
$(10^{6}/\text{g cauda epididymal tissue})$	$886 \pm 55$	$836 \pm 39$	$819 \pm 66$	$840 \pm 39$

#### TABLE H1

Summary of Reproductive	Tissue Evaluations for	r Male Rats in the 14-Week	Inhalation Study of Isobutene ^a

* Significantly different (P<0.05) from the chamber control group by Shirley's test (motility) or by Dunnett's test (left caudal weights)

^a Data are presented as mean  $\pm$  standard error. Differences from the chamber control group are not significant by Dunnett's test (body weights) or Dunn's test (spermatid measurements and epididymal spermatozoal measurements).

TABLE H2
Summary of Estrous Cycle Characterization for Female Rats in the 14-Week Inhalation Study of Isobutene ^a

	Chamber Control	2,000 ppm	4,000 ppm	8,000 ppm
n	10	10	10	10
Necropsy body wt (g)	$207 \pm 4$	$213 \pm 5$	$208 \pm 4$	$217 \pm 6$
Estrous cycle length (days)	$4.70 \pm 0.15$	$4.80~\pm~0.13$	$4.80~\pm~0.11$	$4.80~\pm~0.08$
Estrous stages (% of cycle)				
Diestrus	40.0	38.3	38.3	39.2
Proestrus	17.5	18.3	18.3	13.3
Estrus	20.8	20.8	25.0	24.2
Metestrus	20.8	20.8	18.3	21.7
Uncertain diagnoses	0.8	1.7	0.0	1.7

^a Necropsy body weight and estrous cycle length data are presented as mean  $\pm$  standard error. Differences from the chamber control group are not significant by Dunnett's test (body weights) or Dunn's test (estrous cycle length). By multivariate analysis of variance, exposed females do not differ significantly from the chamber control females in the relative length of time spent in the estrous stages.

Chamber Control	2,000 ppm	4,000 ppm	8,000 ppm
10	10	10	10
$37.8 \pm 1.4$	$38.0 \pm 0.9$	$37.5 \pm 0.6$	$37.8 \pm 1.1$
$0.0167 \pm 0.0011$	$0.0187 \pm 0.0014$	$0.0196 \pm 0.0007$	$0.0173 \pm 0.0009$
$0.0436 \pm 0.0016$	$0.0485 \pm 0.0015$	$0.0462 \pm 0.0017$	$0.0426 \pm 0.0022$
$0.1165 \pm \ 0.0020$	$0.1191 \ \pm \ 0.0010$	$0.1201 \ \pm \ 0.0018$	$0.1038 \pm \ 0.0093$
$18.17 \pm 0.54$	$17.49 \pm 0.53$	$18.21 \pm 0.90$	$15.32 \pm 1.80$
$2.12~\pm~0.08$	$2.09 \pm 0.07$	$2.18~\pm~0.10$	$1.73~\pm~0.20$
$66.20 \pm 2.39$	$65.15 \pm 2.30$	$68.23 \pm 3.22$	$53.95 \pm 6.29$
ts			
$79.31 \pm 2.74$	$77.65 \pm \ 1.94$	$76.94 \pm \ 1.53$	$76.07 \pm \ 1.38^{b}$
$1,261 \pm 142^{b}$	$1,534 \pm 151$	$1,225 \pm 88^{b}$	$1,444 \pm 228$
	$10$ $37.8 \pm 1.4$ $0.0167 \pm 0.0011$ $0.0436 \pm 0.0016$ $0.1165 \pm 0.0020$ $18.17 \pm 0.54$ $2.12 \pm 0.08$ $66.20 \pm 2.39$ $79.31 \pm 2.74$	10       10 $37.8 \pm 1.4$ $38.0 \pm 0.9$ $0.0167 \pm 0.0011$ $0.0187 \pm 0.0014$ $0.0436 \pm 0.0016$ $0.0485 \pm 0.0015$ $0.1165 \pm 0.0020$ $0.1191 \pm 0.0010$ $18.17 \pm 0.54$ $17.49 \pm 0.53$ $2.12 \pm 0.08$ $2.09 \pm 0.07$ $66.20 \pm 2.39$ $65.15 \pm 2.30$ ts $79.31 \pm 2.74$ $77.65 \pm 1.94$	10       10       10       10 $37.8 \pm 1.4$ $38.0 \pm 0.9$ $37.5 \pm 0.6$ $0.0167 \pm 0.0011$ $0.0187 \pm 0.0014$ $0.0196 \pm 0.0007$ $0.0436 \pm 0.0016$ $0.0485 \pm 0.0015$ $0.0462 \pm 0.0017$ $0.1165 \pm 0.0020$ $0.1191 \pm 0.0010$ $0.1201 \pm 0.0018$ 18.17 \pm 0.54       17.49 \pm 0.53       18.21 \pm 0.90 $2.12 \pm 0.08$ $2.09 \pm 0.07$ $2.18 \pm 0.10$ $66.20 \pm 2.39$ $65.15 \pm 2.30$ $68.23 \pm 3.22$ ts       79.31 \pm 2.74 $77.65 \pm 1.94$ $76.94 \pm 1.53$

#### TABLE H3

Summary of Reproduct	ive Tissue Evaluations for	r Male Mice in the 14-Week	Inhalation Study of Isobutene ^a

^a Data are presented as mean ± standard error. Differences from the chamber control group are not significant by Dunnett's test (body and tissue weights) or Dunn's test (spermatid and epididymal spermatozoal measurements).

^b n=9

# TABLE H4 Summary of Estrous Cycle Characterization for Female Mice in the 14-Week Inhalation Study of Isobutene^a

	Chamber Control	2,000 ppm	4,000 ppm	8,000 ppm
n	10	10	10	10
Necropsy body wt (g)	$33.8 \pm 0.7$	$34.8 \pm 0.9$	$33.8 \pm 1.0$	$33.9 \pm 0.8$
Estrous cycle length (days) Estrous stages ^c (% of cycle)	$4.50 \pm 0.15$	$\begin{array}{rrr} 34.8 \pm \ 0.9 \\ 4.11 \ \pm \ 0.07^b \end{array}$	$\begin{array}{rrr} 33.8 \pm \ 1.0 \\ 4.56 \pm \ 0.13^b \end{array}$	$4.20 \pm 0.11$
Diestrus	27.5	34.2	39.2	33.3
Proestrus	16.7	21.7	19.2	20.0
Estrus	37.5	25.8	24.2	29.2
Metestrus	17.5	18.3	17.5	15.0
Uncertain diagnoses	0.8	0.0	0.0	2.5

^a Necropsy body weight and estrous cycle length data are presented as mean  $\pm$  standard error. Differences from the chamber control group are not significant by Dunnett's test (body weights) or Dunn's test (estrous cycle length).

^b Estrous cycle was longer than 12 days or unclear in 1 of 10 animals.

^c Evidence shows that females exposed to 2,000 or 4,000 ppm differ significantly (Wilk's Criterion, P≤0.05) from the chamber control females in the relative length of time spent in the estrous stages. Exposed females spent more time in diestrus and less time in estrus than chamber control females.

# APPENDIX I 2-HYDROXYISOBUTYRIC ACID — BIOMARKER OF EXPOSURE

TABLE I1	Urinary Biomarker Data for Rats in the 2-Year Inhalation Study of Isobutene	208
TABLE I2	Urinary Biomarker Data for Mice in the 2-Year Inhalation Study of Isobutene	209

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm	Trend P Value ^a
n	5	10	10	10	
Male					
Urine excretion (g)					
6 Months	$11.04 \pm 1.67^{b}$	$9.08 \pm 0.46$	$9.46 \pm 0.94$	$8.80 \pm 0.70$	NS ^c
12 Months	$6.83 \pm 0.91$	$7.39 \pm 0.69$	$7.61 \pm 0.95$	$6.93 \pm 0.44$	NS
18 Months	$8.96 \pm 0.69$	$9.85 \pm 1.11$	$12.11 \pm 1.17$	$9.56 \pm 0.73$	NS
Urine creatinine (μg/g urine)					
6 Months	$934.0 \pm 90.3$	$1,073.0 \pm 54.5$	$1,083.0 \pm 79.5$	$1,131.0 \pm 79.7$	NS
12 Months	$1,114.0 \pm 95.7$	$1,240.0 \pm 100.1$	$1,164.0 \pm 83.2$	$1,279.0 \pm 61.4$	NS
18 Months	$1,044.0 \pm 84.5$	$989.0 \pm 83.5$	$869.0 \pm 60.9$	$1,011.0 \pm 44.2$	NS
Urine HIBA/urine (mg/total sam	ple)				
6 Months	d	$5.040 \pm 0.128$	$12.859 \pm 0.273^{**}$	$19.920 \pm 0.379^{**}$	$P \leq 0.01$
12 Months	_	$5.353 \pm 0.203$	$15.857 \pm 0.643^{**}$	$24.746 \pm 1.352^{**}$	P≤0.01
18 Months	_	$4.059 \pm 0.243$	$12.551 \pm 1.650^{**}$	$23.693 \pm 1.132^{**}$	P≤0.01
Urine HIBA/creatinine (µg/µg)					
6 Months	_	$0.530 \pm 0.010$	$1.348 \pm 0.035^{**}$	$2.103 \pm 0.057^{**}$	$P \leq 0.01$
12 Months	_	$0.630 \pm 0.020$	$1.959 \pm 0.114^{**}$	$2.843 \pm 0.070^{**}$	$P \leq 0.01$
18 Months	_	$0.457 \pm 0.018$	$1.211 \pm 0.079^{**}$	$2.526 \pm 0.065^{**}$	$P \leq 0.01$
Urine HIBA/creatinine/isobutene	e (ng/µg/ppm)				
6 Months		$1.060 \pm 0.020$	$0.674 \pm 0.017^{**}$	$0.263 \pm 0.007^{**}$	$P \leq 0.01$
12 Months	_	$1.260 \pm 0.041$	$0.979 \pm 0.057^{**}$	$0.355 \pm 0.009^{**}$	$P \leq 0.01$
18 Months	_	$0.914 \ \pm \ 0.035$	$0.606 \pm 0.040^{**}$	$0.316~\pm~0.008^{**}$	$P{\leq}0.01$
Female					
Urine excretion (g)					
6 Months	$6.70 \pm 1.06$	$8.13 \pm 1.37$	$9.65 \pm 1.47$	$6.26 \pm 0.71$	NS
12 Months	$6.30 \pm 0.61$	$9.99 \pm 3.67$	$9.71 \pm 3.76$	$5.95 \pm 0.86$	NS
18 Months	$6.44 \pm 0.24$	$7.06 \pm 0.73$	$9.82 \pm 3.33$	$7.72 \pm 0.64$	NS
Urine creatinine (µg/g urine)	0.11 ± 0.51	1.00 ± 0.10	0.00 ± 0.00	1.10 2 0.01	110
6 Months	$652.0 \pm 62.2$	$733.0 \pm 121.5$	$593.0 \pm 88.6$	$693.0 \pm 64.6$	NS
12 Months	$754.0 \pm 65.2$	$787.0 \pm 112.1$	$752.0 \pm 91.1$	$846.0 \pm 74.7$	NS
18 Months	$708.0 \pm 30.1$	$652.0 \pm 51.7$	$707.0 \pm 83.2$	$731.0 \pm 60.7$	NS
Urine HIBA/urine (mg/total sam					
6 Months		$3.317 \pm 0.146$	$6.203 \pm 0.248^{**}$	$8.657 \pm 0.788^{**}$	P≤0.01
12 Months	_	$3.328 \pm 0.265$	$8.541 \pm 0.495^{**}$	$13.356 \pm 0.920^{**}$	P≤0.01
18 Months	_	$2.684 \pm 0.340$	$8.431 \pm 0.780^{**}$	$15.450 \pm 0.747^{**}$	P≤0.01
Urine HIBA/creatinine (µg/µg)					
6 Months	_	$0.731 \pm 0.025$	$1.347 \pm 0.075^{**}$	$2.064 \pm 0.060^{**}$	$P \leq 0.01$
12 Months	_	$0.672 \pm 0.041$	$1.831 \pm 0.123^{**}$	$2.916 \pm 0.122^{**}$	P≤0.01
18 Months	_	$0.564 \pm 0.066$	$1.825 \pm 0.122^{**}$	$2.932 \pm 0.222^{**}$	P≤0.01
Urine HIBA/creatinine/isobutene	e (ng/µg/ppm)				
6 Months	—	$1.462 \pm 0.050$	$0.674 \pm 0.037^{**}$	$0.258 \pm 0.008^{**}$	$P \leq 0.01$
12 Months	_	$1.344 \pm 0.082$	$0.916 \pm 0.061^{**}$	$0.365 \pm 0.015^{**}$	$P \leq 0.01$
		$1.128 \pm 0.131$			P≤0.01

### TABLE I1

Urinary Biomarker Data for Rats in the 2-Year Inhalation Study of Isobutene

** Significantly different (P $\le$ 0.01) from the 500 ppm group by Dunnett's test a The trend was assessed by linear regression analysis. b Mean  $\pm$  standard error. HIBA= 2-hydroxyisobutyric acid c Not significant d Sample measurement less than limit of quantitation

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm	Trend P Value ^a
Male					
n					
6 Months	5	10	10	9	
12 Months	5	9	7	8	
18 Months	5	10	9	10	
Jrine excretion (g)					
6 Months	$1.34 \pm 0.18^{b}$	$1.31~\pm~0.23$	$1.15~\pm~0.18$	$1.71~\pm~0.33$	NS ^c
12 Months	$1.64~\pm~0.26$	$2.05~\pm~0.10$	$3.62~\pm~1.22$	$1.80~\pm~0.22$	NS
18 Months	$1.49 \pm 0.37$	$1.84~\pm~0.22$	$1.97 \pm 0.32$	$1.84~\pm~0.25$	NS
Jrine creatinine (µg/g urine)			,		
6 Months	$314.0 \pm 34.9$	$302.0~\pm~17.0$	$337.5 \pm 19.6^{d}$	$282.2~\pm~18.4$	NS
12 Months	$244.0~\pm~21.8$	$270.0~\pm~25.4$	$220.0~\pm~35.8$	$220.0~\pm~29.5$	NS
18 Months	$230.0~\pm~40.4$	$252.0~\pm~11.1$	$242.2~\pm~26.2$	$214.0 \ \pm \ 21.9$	NS
Jrine HIBA/urine (mg/total sample					
6 Months	e	$1.075 \pm 0.174$	$3.224 \pm 0.654^*$	$6.169 \pm 1.265^{**}$	$P{\leq}0.01$
12 Months	_	$2.046 \ \pm \ 0.079$	$7.336 \pm 0.334^{**}$	$10.971 \pm 1.757^{**}$	$P{\leq}0.01$
18 Months	_	$1.629 \pm 0.134$	$6.079 \pm 0.903^{**}$	$11.277 \pm 1.497^{**}$	$P \leq 0.01$
Jrine HIBA/creatinine (µg/µg)			L		
6 Months	_	$2.832~\pm~0.222$	$8.665 \pm 1.565^{**d}$	$13.298 \pm 1.640^{**}$	$P \leq 0.01$
12 Months	_	$3.971 \pm 0.343$	$14.226 \pm 1.689^{**}$	$26.269 \pm 2.839^{**}$	$P \leq 0.01$
18 Months	_	$4.159 \pm 0.749$	$11.882 \pm 0.833^{**}$	$25.888 \pm 2.127^{**}$	$P \leq 0.01$
Jrine HIBA/creatinine/isobutene (	ng/µg/ppm)		d		
6 Months	_	$5.664 \pm 0.444$	$4.333 \pm 0.782^{d}$	$1.662 \pm 0.205^{**}$	$P \le 0.01$
12 Months	_	$7.942 \pm 0.687$	$7.113 \pm 0.844$	$3.284 \pm 0.355^{**}$	$P \leq 0.01$
18 Months	—	$8.318 \pm 1.498$	$5.941 \pm 0.416$	$3.236 \pm 0.266^{**}$	$P \leq 0.01$
Female					
1					
6 Months	5	10	9	10	
12 Months	5	10	10	10	
18 Months	5	10	10	10	
Jrine excretion (g)		4 4 7 0 4 0	4 00 0 40	4.4.4 0.4.7	NG
6 Months	$1.47 \pm 0.14$	$1.17 \pm 0.12$	$1.39 \pm 0.13$	$1.14 \pm 0.17$	NS
12 Months	$1.66 \pm 0.17$	$1.62 \pm 0.11$	$2.96 \pm 1.21$	$1.44 \pm 0.08$	NS
18 Months	$1.60~\pm~0.13$	$1.70 \pm 0.15$	$1.81~\pm~0.23$	$1.55 \pm 0.10$	NS
Jrine creatinine (µg/g urine)	004.0 10.0	001.0 00.4	001 1 00 0	ara a aq	NG
6 Months	$294.0 \pm 18.6$	$331.0 \pm 33.4$	$331.1 \pm 30.2$	$352.2 \pm 28.7^{f}$	NS
12 Months	$278.0 \pm 22.0$	$217.0 \pm 9.3$	$235.0 \pm 23.2$	$274.0 \pm 11.1$	NS NS
18 Months	$264.0 \pm 16.3$	$208.0 \pm 15.5$	$246.0~\pm~20.9$	$241.0 \pm 10.6$	NS
Jrine HIBA/urine (mg/total sample	e)	1 270 - 0 120	5 441 + 0 446**	5 9/2 + 0 0/1**	D / ባ በሮ
6 Months	_	$1.370 \pm 0.130$ 1.640 $\pm$ 0.078	$5.441 \pm 0.446^{**}$	$5.843 \pm 0.841^{**}$	P≤0.05
12 Months	—	$1.640 \pm 0.078$	$5.894 \pm 0.475^{**}$	$8.294 \pm 0.779^{**}$	P≤0.01
18 Months	—	$1.668 \pm 0.137$	$6.349 \pm 0.292^{**}$	$8.524 \pm 0.743^{**}$	$P{\leq}0.01$
Jrine HIBA/creatinine (µg/µg)		1 017 0 590	19 9/1 ± 0.659**	$15.977 \pm 1.361^{**f}$	D 20 01
6 Months	_	$4.017 \pm 0.529$	$12.341 \pm 0.653^{**}$	$15.977 \pm 1.361^{***}$ 21.375 ± 2.187**	P≤0.01
12 Months	_	$4.830 \pm 0.266$	$12.989 \pm 1.389^{**}$ 15 808 $\pm$ 1 205**	$21.375 \pm 2.187^{**}$ $22.758 \pm 1.859^{**}$	P≤0.01 P<0.01
18 Months	_	$4.983 \pm 0.345$	$15.898 \pm 1.205^{**}$	$22.130 \pm 1.039^{-1}$	$P \le 0.01$

# TABLE I2 Urinary Biomarker Data for Mice in the 2-Year Inhalation Study of Isobutene

	Chamber Control	500 ppm	2,000 ppm	8,000 ppm	Trend P Value
Female (continued)					
n					
6 Months	5	10	9	10	
12 Months	5	10	10	10	
18 Months	5	10	10	10	
Urine HIBA/creatinine/isobu	itene (ng/µg/ppm)				
6 Months		$8.034 \pm 1.057$	$6.171 \pm 0.326^{d}$	$1.997 \pm 0.170^{**f}$	$P \leq 0.01$
12 Months	_	$9.660 \pm 0.532$	$6.495 \pm 0.695^{**}$	$2.672 \pm 0.273^{**}$	$P \leq 0.01$
18 Months	—	$9.966 \pm 0.691$	$7.949 \pm 0.603$	$2.845 \pm \ 0.232^{**}$	$P{\leq}0.01$

### TABLE I2

Urinary Biomarker Data for Mice in the 2-Year Inhalation Study of Isobutene

* Significantly different (P $\le$ 0.05) from the 500 ppm group by Dunnett's test ** P $\le$ 0.01

а

The trend was assessed by linear regression analysis. Mean  $\pm$  standard error. HIBA= 2-hydroxyisobutyric acid Not significant b

с

d n= 8

Sample measurement less than limit of quantitation n=9e

f

# APPENDIX J CHEMICAL CHARACTERIZATION AND GENERATION OF CHAMBER CONCENTRATIONS

PROCUREME	NT AND CHARACTERIZATION OF ISOBUTENE	212
VAPOR GENE	RATION AND EXPOSURE SYSTEM	213
VAPOR CONC	CENTRATION MONITORING	214
CHAMBER AT	IMOSPHERE CHARACTERIZATION	214
FIGURE J1	Infrared Absorption Spectrum of Isobutene	216
FIGURE J2	Nuclear Magnetic Resonance Spectrum of Isobutene	217
FIGURE J3	Schematic of Generation and Delivery System	218
FIGURE J4	14-Week Inhalation Suite	219
FIGURE J5	2-Year Inhalation Suite	220
TABLE J1	Summary of Chamber Concentrations in the 14-Week Inhalation Studies of Isobutene	221
TABLE J2	Summary of Chamber Concentrations in the 2-Year Inhalation Studies of Isobutene	221

# CHEMICAL CHARACTERIZATION AND GENERATION OF CHAMBER CONCENTRATIONS

### **PROCUREMENT AND CHARACTERIZATION OF ISOBUTENE**

Isobutene was manufactured by Exxon, Inc. (Baytown, TX), supplied by Specialty Gas Concepts (La Porte, TX) and shipped through Norco (Kennewick, WA) in two lots (SGC051091ECA and SGC020594ECA). Lot SGC051091ECA was used during the 14-week and 2-year studies, and lot SGC020594ECA was used during the 2-year studies. Identity, purity, and stability analyses were conducted by the study laboratory, Battelle Pacific Northwest Laboratories (Richland, WA). Reports on analyses performed in support of the isobutene studies are on file at the National Institute of Environmental Health Sciences.

The chemical, a colorless vapor at room temperature, was identified as isobutene by infrared and nuclear magnetic resonance spectroscopy. The infrared spectrum was consistent with a literature spectrum (*Aldrich*, 1985) of isobutene. Both spectra were consistent with those expected for the structure of isobutene and with those of a reference standard supplied by Matheson Gas Products (East Rutherford, NJ) at a stated purity of 99.9%. The infrared and nuclear magnetic spectra are presented in Figures J1 and J2.

The initial purity of each lot was determined with gas chromatography/flame ionization detection (GC/FID). Two systems were used for initial purity determinations on each lot:

- A) Al₂O₃/KCl PLOT column (10 M  $\times$  0.53 mm), with an oven temperature program of 45° C for 5 minutes, then 45° to 180° C at 20° C per minute and held for 1 minute, using a nitrogen carrier gas at a flow rate of 30 mL/minute,
- B) DB-624 fused silica column (30 M  $\times$  0.53 mm) with a 3 µm film thickness, with an oven temperature program of -15° C for 10 minutes, then -15° to 100° C at 20° C per minute and held for 1 minute, and a nitrogen carrier gas at a flow rate of 5 to 15 mL/minute, and
- C)  $Al_2O_3/Na_2SO_4$  PLOT column (50 M  $\times$  0.53 mm), with an oven temperature program of 130° C for 5 minutes to 190° C (no hold time) at 10° C/minute using nitrogen as a carrier gas at a flow rate of 30 mL/minute.

Major peak comparisons with GC/FID indicated a relative purity of 100.0% by system A and 100.6% by system B for lot SGC051091ECA relative to the reference standard. For lot SGC020594ECA, gas chromatographic peak comparison indicated a relative purity of 98.7% by system C and and 98.5% by system A. The overall purity of lot SGC051091ECA was determined to be greater than 99%, and the overall purity of lot SGC020594ECA was greater than 98%.

Additional analyses of each lot were performed with gas chromatography/mass spectrometry (GC/MS) to identify and quantify the impurities indicated by the manufacturer or by GC/FID. The gas chromatograph system included a flame ionization detector, an  $RT_X$  volatile fused silica column (60 M × 0.32 mm with 1.5 µm film thickness) with a nitrogen carrier gas at a flow rate of 1.7 mL per minute and an oven temperature program of  $-15^{\circ}$  C for 12 minutes, then  $-15^{\circ}$  to  $150^{\circ}$  C at  $15^{\circ}$  C per minute and held for 3 minutes. The mass spectrum pattern of the major peak was consistent with isobutene. The following impurities were detected for lot SGC051091ECA (concentrations were estimated): propane/propene, 42 ppm; isobutane, 140 ppm; 1,3-butadiene, 6 ppm; *trans*-2-butene, 213 ppm; and *cis*-2-butene, 286 ppm. Butane and *n*-butene coeluted with the major peak and were not quantified. Lot SGC020594ECA contained an estimated 11 ppm propane/propene, 339 ppm isobutane, 15 ppm *trans*-2-butene, 11 ppm *cis*-2-butene, and no 1,3-butadiene. Samples from each cylinder of each lot of isobutene were analyzed for 1,3-butadiene

before the cylinder was used for exposure by GC/MS with the same system but with an isothermal oven temperature of  $-15^{\circ}$  C. All cylinders used in the 14-week studies contained less than 50 ppm 1,3-butadiene, well within the maximum limit of 100 ppm; the maximum concentration detected in cylinders used in the 2-year studies was 15 ppm. Cylinders used in the 14-week studies were also screened individually for other impurities; results indicated less than 1% impurities by peak area.

In a 4-day pilot study, the stability of isobutene was monitored in grab-bag samples taken from the distribution manifold at the beginning and the end of 6-hour generation periods until approximately 94% of the cylinder was exhausted. Isobutene in the distribution manifold was assumed to be of equivalent purity to that in the cylinder headspace because no dilution flow was present. Samples were analyzed using GC/FID with a column as in system B (14-week studies) or a column as in system C (2-year studies) and using modified temperature programs. The results from samples taken over 8 test generation days showed no significant enhancement of any volatile impurities, and no additional impurities were detected with relative areas of 0.1% or greater relative to isobutene. Based on these results, approximately 90% of the contents of each cylinder were used during the 14-week and 2-year studies.

During the studies, the bulk chemical was stored in its original shipping cylinders at approximately  $22^{\circ}$  C. Stability was monitored throughout the studies by the study laboratory with GC/FID by system A. No degradation of the bulk chemical was detected.

### VAPOR GENERATION AND EXPOSURE SYSTEM

Diagrams of the isobutene generation and delivery system used in the 14-week and 2-year studies are shown in Figure J3. Because isobutene is a vapor at room temperature, it was distributed under regulated pressure, and the chemical flow rate to each chamber was monitored and adjusted individually. Isobutene was delivered directly from the cylinder. Two cylinders of isobutene were connected in parallel to the exposure system; one supplied isobutene for exposures while the other cylinder was available if the first did not maintain sufficient gas pressure in the distribution manifold. Warm circulating-water blankets surrounding the cylinders provided additional heat to replace the heat lost due to isobutene vaporization. The manifold pressure was regulated to approximately 7 psi with a two-stage regulator on the cylinder. The gas passed through a filter via a main on/off pneumatic valve, operated either manually or by computer, and then was distributed by a manifold to five (14-week studies) or six (2-year studies) pairs of metering valves with corresponding flow meters. Isobutene was delivered to each exposure chamber through these flow meters via three-way solenoid valves located at the chamber end of the vapor delivery line. Each three-way valve was controlled either manually or by computer; when the valve to a chamber was closed, the vapor was routed to the exposure system exhaust.

Isobutene vapor was diluted with conditioned air as it was injected into the chamber inlet duct. The concentration in each chamber was controlled by manually adjusting the individual chamber metering valves. The generation system was purged with nitrogen at the end of the exposure day.

Stainless-steel chambers (Hazleton H-2000[®]) manufactured by Lab Products, Inc. (Harford Systems Division, Aberdeen, MD) were used throughout the studies. The total volume of each chamber was 2.3 m³; the active mixing volume of each chamber was 1.7 m³. The chamber was designed by the study laboratory so that uniform vapor concentrations could be maintained through the chamber when catch pans were in place. Diagrams of the inhalation suites are shown in Figures J4 and J5.

### VAPOR CONCENTRATION MONITORING

Chamber concentrations of isobutene were monitored during both studies by an on-line GC/FID with a column as in system A and a modified temperature program. Samples were drawn from each chamber, the

exposure room, and the on-line standard approximately every 20 minutes during exposures by a computercontrolled, 12-port stream select valve.

The on-line GC/FID was calibrated by direct analysis of volumetrically prepared gas-bag standards during the 14-week studies and against validated, commercially prepared, certified standards for the 2-year studies. Calibrations were performed approximately once a month or if drift occurred in the value of the on-line standard. An on-line standard of isobutene in nitrogen was used to monitor instrument drift before the start of each exposure day and once during each monitoring cycle. Standard exposure and chamber samples were taken in triplicate. A Teflon[®] line was coupled directly to the calibration port of the on-line monitor stream select valve.

Summaries of the chamber concentrations for the 14-week and 2-year studies are presented in Tables J1 and J2.

### **CHAMBER ATMOSPHERE CHARACTERIZATION**

The times for the exposure concentration to build up to 90% of the final exposure concentration ( $T_{90}$ ) and to decay to 10% of the exposure concentration ( $T_{10}$ ) were measured. In all studies,  $T_{90}$  and  $T_{10}$  were measured in all exposure chambers with and without animals present. At a chamber air flow rate of 15 air changes per hour, the theoretical value for both  $T_{90}$  and  $T_{10}$  was calculated to be 12.5 minutes. The actual chamber air flow rates were maintained at 12 to 18 changes per hour during all studies.

In the 14-week studies, without animals present,  $T_{90}$  values and  $T_{10}$  values ranged from 8 to 9 minutes for rats and mice. With animals present,  $T_{90}$  values ranged from 9 to 10 minutes for rats and mice;  $T_{10}$  values ranged from 9 to 11 minutes for rats and mice. In the 2-year studies, without animals present,  $T_{90}$  values ranged from 11 to 15 minutes for rats and from 9 to 13 minutes for mice;  $T_{10}$  values ranged from 8 to 10 minutes for rats and from 6 to 9 minutes for mice. With animals present,  $T_{90}$  values ranged from 9 to 12 minutes for rats and from 9 to 11 minutes for mice;  $T_{10}$  values ranged from 9 to 12 minutes for rats and from 9 to 11 minutes for mice. The  $T_{90}$  values ranged from 9 to 12 minutes for rats and from 10 to 11 minutes for mice. The  $T_{90}$  value selected for all studies was 12 minutes.


Vapor concentration uniformity in the exposure chambers without animals present was measured before each of the studies began. Concentration uniformity with animals present was measured during the first week of the 14-week rat study and at approximately 90-day intervals during the 2-year studies. Vapor concentration was measured using the on-line GC/FID with the automatic 12-port sample valve disabled to allow continuous monitoring from a single input line. Samples were taken from several positions in each chamber without animals and from two positions with animals present. Chamber concentration uniformity was maintained throughout the studies.

During the 14-week and 2-year studies, the persistence of isobutene after exposure ceased was monitored by GC/FID in the 8,000 ppm chambers with animals present. Persistence in the chambers with no animals present was tested before the 14-week and 2-year studies began. Without animals present, the concentration fell to less than 1% of the target concentration within 19 minutes for the 14-week studies and 2-year rat study; for the 2-year mouse study, the concentration fell to less than 1% of the target concentration within animals present, the concentration decreased to less than 1% within 22 minutes. In the 14-week studies with animals present, the concentration decreased to less than 1% of the target concentration within 24 minutes (rat chamber) or 25 minutes (mouse chamber).

Before and during the 14-week and 2-year studies, the stability of isobutene in the 500 and 8,000 ppm chambers was analyzed with the on-line GC/FID within the first and last hours of the exposure day. Additionally, samples from the 500 and 8,000 ppm chambers were collected with a syringe and transferred to a gas sample bag; these samples and samples collected directly from the distribution manifold were

analyzed by an off-line GC/FID with a DB-624 column (14-week studies) or GC/FID with an  $Al_2O_3/Na_2SO_4$ PLOT column (2-year studies) within the first and last hours of the exposure day. Mixed standard gas bags containing equivalent concentrations of each of the expected volatile contaminants (propene, propane, isobutane, 1-butene, 1,3-butadiene, n-butane, trans-2-butene, and cis-2-butene) were volumetrically prepared in addition to an isobutene reference standard gas bag. During the 14-week study analyses, butene was the only contaminant completely unresolved from isobutene on both GC/FIDs. One unidentified impurity with a concentration of 0.14% relative to the concentration of isobutene was detected by the offline GC/FID at the beginning of the exposure period in the 8,000 ppm chamber before the 14-week studies began; this impurity was not detected at the end of the exposure period. An unidentified impurity was also detected in the 500 ppm chamber with a relative concentration of 0.12% at the beginning of exposure and 0.04% at the end of the exposure period. No other impurities were detected with relative areas of 0.1% or greater during the 14-week studies, although several volatile impurities were present in the 500 and 8,000 ppm chambers and the distribution manifold at concentrations of less than 0.1% relative to the isobutene concentrations. No impurities with concentrations of 0.1% or greater relative to the isobutene concentration were detected by the on-line or off-line GC/FID before the 2-year studies began. During the 2-year studies, the on-line GC/FID detected an unidentified impurity at the beginning of the exposure period in the 500 ppm rat and mouse chambers at relative concentrations of 0.6% and 0.7%, respectively, and at the end of the exposure period in the 500 ppm mouse chamber with a relative concentration of less than 1%. No other impurities with concentrations of 0.1% or greater relative to the isobutene concentrations were identified during the 2-year studies by either GC/FID.

Relative concentrations of 1,3-butadiene remained well below 100 ppm. The results from these stability studies indicated that isobutene was stable under the conditions used to generate and transport it to the exposure chambers and that no significant enhancement of impurities was detected in the distribution manifold or the exposure chambers over the course of a typical exposure day.



Wavenumber (cm⁻¹)

FIGURE J1 Infrared Absorption Spectrum of Isobutene




FIGURE J2 Nuclear Magnetic Resonance Spectrum of Isobutene




FIGURE J3 Schematic of Generation and Delivery System




FIGURE J4 14-Week Inhalation Suite




FIGURE J5 2 Year Inhalation Suite

Target Concentration (ppm)	Total Number of Readings	Average Concentration ^a (ppm)
Rat Chambers		
500	1,176	$495~\pm~16$
1,000	1,183	$1,010 \pm 35$
2,000	1,185	$1,990 \pm 61$
4,000	1,185	$4,010 \pm 130$
8,000	1,184	$7,970~\pm~585$
Mouse Chambers		
500	1,193	$495~\pm~16$
1,000	1,201	$1,010 \pm 35$
2,000	1,203	$1,990 \pm 62$
4,000	1,203	$4,010 \pm 130$
8,000	1,202	$7,980 \pm 582$

### TABLE J1

Summary of Chamber Concentrations in the 14-Week Inhalation Studies of Isobutene

 a  Mean  $\pm$  standard deviation

TABLE J2
Summary of Chamber Concentrations in the 2-Year Inhalation Studies of Isobutene

Target Concentration (ppm)	Total Number of Readings	Average Concentration ^a (ppm)
Rat Chambers		
500	7,467	$497~\pm~21$
2,000	7,521	$1,990 \pm 72$
8,000	7,550	$7,940~\pm~313$
Mouse Chambers		
500	7,476	$498~\pm~20$
2,000	7,430	$1,990 \pm 74$
8,000	7,536	$7,960 \pm 283$

 a  Mean  $\pm$  standard deviation

# APPENDIX K INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH-07 RAT AND MOUSE RATION

TABLE K1	Ingredients of NIH-07 Rat and Mouse Ration	224
TABLE K2	Vitamins and Minerals in NIH-07 Rat and Mouse Ration	224
TABLE K3	Nutrient Composition of NIH-07 Rat and Mouse Ration	225
TABLE K4	Contaminant Levels in NIH-07 Rat and Mouse Ration	226

Ingredients ^b	Percent by Weight	
Ground #2 yellow shelled corn Ground hard winter wheat Soybean meal (49% protein) Fish meal (60% protein)	24.50 23.00 12.00 10.00	
Wheat middlings Dried skim milk Alfalfa meal (dehydrated, 17% protein)	10.00 5.00 4.00	
Corn gluten meal (60% protein) Soy oil Dried brewer's yeast Dry molasses	3.00 2.50 2.00 1.50	
Dicalcium phosphate Ground limestone Salt Premixes (vitamin and mineral)	1.25 0.50 0.50 0.25	

### TABLE K1 Ingredients of NIH-07 Rat and Mouse Ration^a

^a NCI, 1976; NIH, 1978

^b Ingredients were ground to pass through a U.S. Standard Screen No. 16 before being mixed.

#### Amount Source Vitamins 5,500,000 IU Stabilized vitamin A palmitate or acetate А $D_3$ $K_3$ d- $\alpha$ -Tocopheryl acetate 4,600,000 IU D-activated animal sterol 2.8 g 20,000 IU Menadione 560.0 g Choline Choline chloride 2.2 g 30.0 g Folic acid Niacin 18.0 g d-Pantothenic acid d-Calcium pantothenate 3.4 g 10.0 g Riboflavin Thiamine Thiamine mononitrate $4,000\;\mu \bar{g}$ $B_{12}$ Pyridoxine 1.7 g Pyridoxine hydrochloride Biotin 140.0 mg *d*-Biotin Minerals 120.0 g Iron sulfate Iron 60.0 g Manganese Manganous oxide Zinc 16.0 g Zinc oxide Copper 4.0 g Copper sulfate Calcium iodate Iodine 1.4 g Cobalt 0.4 g Cobalt carbonate

# TABLE K2 Vitamins and Minerals in NIH-07 Rat and Mouse Ration^a

^a Per ton (2,000 lb) of finished product

# TABLE K3 Nutrient Composition of NIH-07 Rat and Mouse Ration

Nutrient	Mean ± Standard Deviation	Range	Number of Samples
Protein (% by weight)	$22.91 \pm 0.48$	22.1) 23.6	24
Crude fat (% by weight)	$5.34 \pm 0.18$	5.00) 5.80	24
Crude fiber (% by weight)	$3.12\pm0.29$	2.60 4.00	24
Ash (% by weight)	$6.23\pm0.16$	5.72) 6.54	24
Amino Acids (% of total diet)			
Arginine	$1.273 \pm 0.083$	1.100) 1.390	12
Cystine	$0.307 \pm 0.068$	0.181) 0.400	12
Glycine	$1.152 \pm 0.051$	1.060) 1.220	12
Histidine	$0.581 \pm 0.029$	0.531) 0.630	12
Isoleucine	$0.913 \pm 0.034$	0.867) 0.965	12
Leucine	$1.969 \pm 0.053$	1.850) 2.040	12
Lysine	$1.269 \pm 0.050$	1.200) 1.370	12
Methionine	$0.436 \pm 0.104$	0.306) 0.699	12
Phenylalanine	$0.999 \pm 0.114$	0.665) 1.110	12
Threonine	$0.899 \pm 0.059$	0.824) 0.985	12
Tryptophan	$0.216 \pm 0.146$	0.107) 0.671	12
Tyrosine	$0.690 \pm 0.091$	0.564) 0.794	12
Valine	$1.079\pm0.057$	0.962) 1.170	12
Essential Fatty Acids (% of total diet)			
Linoleic	$2.389 \pm 0.223$	1.830) 2.570	11
Linolenic	$0.273\pm0.034$	0.210) 0.320	11
Vitamins	0.000 540	r rras a aaa	
Vitamin A (IU/kg)	$6,802 \pm 546$	5,550) 8,800	24
Vitamin D (IU/kg)	$4,450 \pm 1,382$	3,000) 6,300	4
α-Tocopherol (ppm)	$35.24 \pm 8.58$	22.5) 48.9	12
Thiamine (ppm)	$16.87 \pm 3.66$	13.0) 26.0	23
Riboflavin (ppm)	$7.78 \pm 0.899$	6.10) 9.00	12
Niacin (ppm)	$98.73 \pm 23.21$	65.0) 150.0	12
Pantothenic acid (ppm)	$32.94 \pm 8.92$	23.0) 59.2	12
Pyridoxine (ppm)	$9.28 \pm 2.49$	5.60) 14.0	12
Folic acid (ppm)	$2.56 \pm 0.70$	1.80) 3.70	12
Biotin (ppm)	$0.265 \pm 0.046$	0.190) 0.354	12
Vitamin B ₁₂ (ppb)	$41.6 \pm 18.6$	10.6) 65.0	12
Choline (ppm)	$2,955\pm382$	2,300) 3,430	11
Minerals	1.15 0.00	1.002.4.07	<u>.</u>
Calcium (%)	$1.15 \pm 0.06$	1.03) 1.27	24
Phosphorus (%)	$0.89 \pm 0.02$	0.84) 0.95	24
Potassium (%)	$0.886 \pm 0.059$	0.772) 0.971	10
Chloride (%)	$0.531 \pm 0.082$	0.380) 0.635	10
Sodium (%)	$0.316 \pm 0.031$	0.258) 0.370	12
Magnesium (%)	$0.165 \pm 0.010$	0.148) 0.180	12
Sulfur (%)	$0.266 \pm 0.060$	0.208) 0.420	11
Iron (ppm)	$348.0 \pm 83.7$	255.0) 523.0	12
Manganese (ppm)	$93.27 \pm 5.62$	81.7) 102.0	12
Zinc (ppm)	$59.42 \pm 9.73$	46.1) 81.6	12
Copper (ppm)	$11.63 \pm 2.46$	8.09) 15.4	12
Iodine (ppm)	$3.49 \pm 1.14$	1.52) 5.83	11
Chromium (ppm)	$1.57 \pm 0.53$	0.60) 2.09	12
Cobalt (ppm)	$0.81 \pm 0.27$	0.49) 1.23	8

	Mean ± Standard			
	<b>Deviation</b> ^b	Range	Number of Samples	
Contaminants				
Arsenic (ppm)	$0.52\pm0.17$	0.10) 0.80	24	
Cadmium (ppm)	$0.04\pm0.01$	0.04) 0.06	24	
Lead (ppm)	$0.24\pm0.06$	0.20) 0.40	24	
Mercury (ppm)	< 0.02		24	
Selenium (ppm)	$0.34\pm0.10$	0.10) 0.50	24	
Aflatoxins (ppb)	< 5.0		24	
Nitrate nitrogen (ppm) ^C	$7.76\pm2.61$	2.90) 14.0	24	
Nitrite nitrogen (ppm) ^C	$1.37\pm0.89$	0.30) 3.50	24	
BHA (ppm) ^a	$1.32 \pm 1.88$	0.05) 10.0	24	
BHT (ppm) ^d	$1.68 \pm 1.14$	0.18) 5.0	24	
Aerobic plate count (CFU/g)	$121,708 \pm 126,261$	20,000 ) 460,000	24	
Coliform (MPN/g)	$136\pm569$	3) 2,800	24	
Escherichia coli (MPN/g)	$6\pm3.5$	3) 10	24	
Salmonella (MPN/g)	Negative		24	
Total nitrosoamines (ppb) ^e	$12.15 \pm 4.09$	4.0) 23.0	24	
N-Nitrosodimethylamine (ppb) ^e	$10.41 \pm 3.86$	3.0) 21.0	24	
N-Nitrosopyrrolidine (ppb) ^e	$1.74\pm0.79$	1.0) 4.0	24	
esticides (ppm)				
α-BHC	< 0.01		24	
β-BHC	< 0.02		24	
γ-BHC	< 0.01		24	
δ-BHC	< 0.01		24	
Heptachlor	< 0.01		24	
Aldrin	< 0.01		24	
Heptachlor epoxide	< 0.01		24	
DDE	< 0.01		24	
DDD	< 0.01		24	
DDT	< 0.01		24	
HCB	< 0.01		24	
Mirex	< 0.01		24	
Methoxychlor	< 0.05		24	
Dieldrin	< 0.01		24	
Endrin	< 0.01		24	
Telodrin	< 0.01 < 0.05		24 24	
Chlordane				
Toxaphene Estimated PCPs	< 0.10		24 24	
Estimated PCBs Ronnel	< 0.20 < 0.01		24 24	
	< 0.01		24 24	
Ethion			24 24	
Trithion Diazinon	< 0.05 < 0.10		24 24	
	< 0.10 < 0.02		24 24	
Methyl parathion	< 0.02 < 0.02		24 24	
Ethyl parathion Malathion	< 0.02 $0.13 \pm 0.16$	0.02 0.02	24 24	
Endosulfan I	$0.13 \pm 0.16$ < 0.01	0.02) 0.83	24 24	
Endosulfan II	< 0.01		24 24	
Endosulfan sulfate	< 0.01		24 24	

### TABLE K4 Contaminant Levels in NIH-07 Rat and Mouse Ration^a

CFU= colony-forming units; MPN= most probable number; BHC= hexachlorocyclohexane or benzene hexachloride For values less than the limit of detection, the detection limit is given as the mean. Sources of contamination: alfalfa, grains, and fish meal Sources of contamination: soy oil and fish meal All values were corrected for percent recovery. а

b

с

d

e

# APPENDIX L SENTINEL ANIMAL PROGRAM

METHODS	 228
RESULTS	 229

# SENTINEL ANIMAL PROGRAM

### **METHODS**

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Serum samples were collected from randomly selected rats and mice during the 2-year studies. Blood from each animal was collected and allowed to clot, and the serum was separated. The samples were processed appropriately and sent to Microbiological Associates, Inc. (Bethesda, MD), for determination of antibody titers. The laboratory serology methods and viral agents for which testing was performed are tabulated below; the times at which blood was collected during the studies are also listed.

### **Method and Test**

### **Time of Analysis**

### RATS

ELISA Mycoplasma arthritidis Mycoplasma pulmonis PVM (pneumonia virus of mice) RCV/SDA (rat coronavirus/ sialodacryoadenitis virus) Sendai

Immunofluorescence Assay *M. arthritidis* 

Hemagglutination Inhibition H-1 (Toolan's H-1 virus) KRV (Kilham rat virus) Study terminationStudy termination6, 12, and 18 months, study termination6, 12, and 18 months, study termination6, 12, and 18 months, study termination

Study termination

6, 12, and 18 months, study termination

6, 12, and 18 months, study termination

#### Method and Test

### MICE

#### **ELISA** Ectromelia virus 6, 12, and 18 months, study termination EDIM (epizootic diarrhea of infant mice) 6, 12, and 18 months, study termination GDVII (mouse encephalomyelitis virus) 6, 12, and 18 months, study termination 6, 12, and 18 months, study termination LCM (lymphocytic choriomeningitis virus) Mouse adenoma virus-FL 6, 12, and 18 months, study termination MHV (mouse hepatitis virus) 6, 12, and 18 months, study termination Study termination M. arthriditis M. pulmonis Study termination 6, 12, and 18 months, study termination PVM **Reovirus 3** 6, 12, and 18 months, study termination 6, 12, and 18 months, study termination Sendai Immunofluorescence Assay EDIM 12 months M. arthriditis Study termination **Reovirus 3** 18 months, study termination Hemagglutination Inhibition K (papovavirus) 6, 12, and 18 months, study termination MVM (minute virus of mice) 6, 12, and 18 months, study termination 6, 12, and 18 months, study termination Polyoma virus

### RESULTS

Four rats and six mice had positive titers for *M. arthritidis*. Further evaluation of samples positive for immunoblot and Western blot procedures indicated that the positive titers may have been due to cross reaction with antibodies of nonpathogenic *Mycoplasma* or other agents. There were no clinical findings or histopathologic changes of *M. arthritidis* infection in animals with positive titers. Accordingly, *M. arthritidis*-positive titers were considered false positives.